Cancer in Queensland€¦ · and nursing homes throughout Queensland. The work of all people concerned is appreciated and grateful thanks are extended to them for their continued

Cancer in Queensland

1982-2013

Incidence, Mortality, Survival and Prevalence

st

at

is

ti

ca

l

ta

bl

es

Cancer in Queensland Incidence, Mortality, Survival and Prevalence – 1982 to 2013 1


CANCER IN QUEENSLAND

1982 to 2013

Incidence, Mortality, Survival and Prevalence

Statistical Tables

Queensland Cancer Registry

Cancer Council Queensland

November 2015

2 Cancer in Queensland Incidence, Mortality, Survival and Prevalence – 1982 to 2013


Contents Page

Acknowledgements 2

Members of the Queensland Cancer Registry 4

Introduction 5

Establishment of the Cancer Registry 5Aims of the Registry 5Notification and Sources of Data 5Classification and Coding 5Coverage of the Registry 6Structure of this Report 6Publication of Reports 7Abbreviations 7

Tables

1a. Leading 20 Cancer Sites for 2013 (Counts), Incidence, Males, 1982-2013 8

1b. Leading 20 Cancer Sites for 2013 (Counts), Mortality, Males, 1982-2013 8

1c. Leading 20 Cancer Sites for 2013 (Counts), Incidence, Females, 1982-2013 9

1d. Leading 20 Cancer Sites for 2013 (Counts), Mortality, Females, 1982-2013 9

2. Cancer Incidence and Mortality (Counts) by Site and Sex, Queensland, 1982-2013 10-16

3. Cancer Incidence and Mortality (Age Standardised Rates (World)/100,000) bySite and Sex, Queensland, 1982–2013 17-23

4. Cancer Incidence and Mortality (Age Standardised Rates (Australia 2001)/100,000) by Site and Sex, Queensland, 1982–2013 24-30

5. Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2013 31-46

6. Limited Duration (5 year and 25 year) Cancer Prevalence by Site, Sex and Age Group, 47-52Queensland, 2013

7. Relative Survival by Site, Sex and Year after diagnosis, Queensland, 2009-2013 53-56

8. Conditional 5-year Relative Survival by Site, Sex and Years after diagnosis, Queensland, 2004-2013 57-60

Appendices

Appendix 1: Guidelines for Release of Information, Queensland Cancer Registry 61-62Appendix 2: Queensland Cancer Registry Notification Form 63Appendix 3: Cancer Reporting Definitions and Calculation of Statistics 64-66Appendix 4: Age Distribution of Standard Populations 67Appendix 5: Indices of Data Quality 68-69


Acknowledgements

This report has been made possible by the co-operation of staff of hospitals, pathology laboratories and nursing homes throughout Queensland. The work of all people concerned is appreciated and grateful thanks are extended to them for their continued support in notifying cancer cases.

Thanks are due also to the Registrar of Births, Deaths and Marriages and to members of the medical profession who provided additional information to improve the accuracy of Registry data.

We acknowledge and thank the Queensland Cancer Control and Analysis Team at Queensland Health, and the Cancer Research Centre at Cancer Council Queensland for their advice and support.

Finally, acknowledgement is made of the work of the members of staff of the Queensland Cancer Registry. The Registry staff work tirelessly to ensure the quality of the data is of the highest standard. This publication would not have been possible without their support and dedication.

Published by Cancer Council Queensland, November 2015© The State of Queensland, Queensland Health, 2015

Queensland Cancer RegistryCancer Council QueenslandLocked Bag No 1450Spring Hill Q 4004

Telephone (07) 3634 5333Facsimile (07) 3259 8590E-mail [email protected] www.cancerqld.org.au

ISSN: 1323 - 8760



Contents Page

Acknowledgements 2

Members of the Queensland Cancer Registry 4

Introduction 5

Establishment of the Cancer Registry 5Aims of the Registry 5Notification and Sources of Data 5Classification and Coding 5Coverage of the Registry 6Structure of this Report 6Publication of Reports 7Abbreviations 7

Tables

1a. Leading 20 Cancer Sites for 2013 (Counts), Incidence, Males, 1982-2013 8

1b. Leading 20 Cancer Sites for 2013 (Counts), Mortality, Males, 1982-2013 8

1c. Leading 20 Cancer Sites for 2013 (Counts), Incidence, Females, 1982-2013 9

1d. Leading 20 Cancer Sites for 2013 (Counts), Mortality, Females, 1982-2013 9

2. Cancer Incidence and Mortality (Counts) by Site and Sex, Queensland, 1982-2013 10-16

3. Cancer Incidence and Mortality (Age Standardised Rates (World)/100,000) bySite and Sex, Queensland, 1982–2013 17-23

4. Cancer Incidence and Mortality (Age Standardised Rates (Australia 2001)/100,000) by Site and Sex, Queensland, 1982–2013 24-30

5. Cancer Incidence and Mortality by Site, Sex and Age Group, Queensland, 2013 31-46

6. Limited Duration (5 year and 25 year) Cancer Prevalence by Site, Sex and Age Group, 47-52Queensland, 2013

7. Relative Survival by Site, Sex and Year after diagnosis, Queensland, 2009-2013 53-56

8. Conditional 5-year Relative Survival by Site, Sex and Years after diagnosis, Queensland, 2004-2013 57-60

Appendices

Appendix 1: Guidelines for Release of Information, Queensland Cancer Registry 61-62Appendix 2: Queensland Cancer Registry Notification Form 63Appendix 3: Cancer Reporting Definitions and Calculation of Statistics 64-66Appendix 4: Age Distribution of Standard Populations 67Appendix 5: Indices of Data Quality 68-69


Acknowledgements

This report has been made possible by the co-operation of staff of hospitals, pathology laboratories and nursing homes throughout Queensland. The work of all people concerned is appreciated and grateful thanks are extended to them for their continued support in notifying cancer cases.

Thanks are due also to the Registrar of Births, Deaths and Marriages and to members of the medical profession who provided additional information to improve the accuracy of Registry data.

We acknowledge and thank the Queensland Cancer Control and Analysis Team at Queensland Health, and the Cancer Research Centre at Cancer Council Queensland for their advice and support.

Finally, acknowledgement is made of the work of the members of staff of the Queensland Cancer Registry. The Registry staff work tirelessly to ensure the quality of the data is of the highest standard. This publication would not have been possible without their support and dedication.

Published by Cancer Council Queensland, November 2015© The State of Queensland, Queensland Health, 2015

Queensland Cancer RegistryCancer Council QueenslandLocked Bag No 1450Spring Hill Q 4004

Telephone (07) 3634 5333Facsimile (07) 3259 8590E-mail [email protected] www.cancerqld.org.au

ISSN: 1323 - 8760



Members of the Queensland Cancer Registry

Prof Joanne Aitken DirectorCarly Scott RegistrarPeta Gordon Assistant RegistrarGeorgina Novak Coding Educator

Anthony ArmstrongEmma DownMark FosterNikkitia GolobicBelinda GritschDanica JongLachlan ManahanKara MortonKim Neri (Melanoma Data Manager)Caroline ReimersBronwyn RossbergKathy TempertonKira Ward



INTRODUCTION

Establishment of the Cancer RegistryThe Queensland Cancer Registry operates under the Public Health Act 2005, to receive information on cancer in Queensland. The Registry is population-based and maintains a register of all cases of cancer diagnosed in Queensland since the beginning of 1982. It was established in response to the need for state-wide information on cancer expressed by community and state organisations such as the Queensland Institute of Medical Research and Cancer Council Queensland (formally Queensland Cancer Fund).

Cancer Council Queensland currently manages the processing operations of the Registry for Queensland Health (since October 2000).

Aims of the RegistryThe main aim of the Queensland Cancer Registry is to collect data to describe the nature and extent of cancer in Queensland. This can be combined with related data to assist in the control and prevention of cancer. To this end, Queensland Cancer Registry data are available for use:• in research projects on the causes, treatment and prevention of cancer, • in the planning and assessment of cancer treatment and prevention services, • in monitoring survival times of cancer patients, and • for the education of health professionals and members of the general public.

Notification and Sources of DataNotification of cancer is a statutory requirement for all public and private hospitals, nursing homes and pathology services. Notifications are received for all persons with cancer separated from public and private hospitals and nursing homes. Queensland pathology laboratories provide copies of pathology reports for cancer specimens. Data on all persons who die of cancer or cancer patients who die of other diseases are abstracted from the mortality files of the Registrar of Births, Deaths and Marriages and linked to hospital and pathology data.

Classification and CodingThe Queensland Cancer Registry codes the site and the histology of the cancers to the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). Prior to July 2004, the primary site of cancer was coded to the International Classification of Diseases for Oncology, 2nd edition (ICD-O-2).

The change to ICD-O-3 was in response to an Australasian Association of Cancer Registries (AACR) recommendation. At present, cancer registries in Australia use this specialist oncology classification. Hospitals code patient separation records using International Classification of Diseases, 10th Revision, Australian Modification (ICD-10-AM). The Australian Bureau of Statistics codes deaths from 1999 using ICD-10. The variety of classifications employed and a desire to publish categories that are comparable with other states has meant that for the purposes of this publication ICD-O-3 codes have been mapped to the equivalent ICD-10-AM structure.

All sub-descriptions of cancer sites and morphologies are included on an electronic reference file that is readily accessible to coders on-line. This means that:• a greater degree of detail may be recorded by coders,• the search process has improved (by using wild cards),• the inclusion of the additional coded detail makes it easier to code with certainty,• it may assist future conversions by having more detail available.

In addition, the Registry links sites and morphologies through the use of morphology families based on those published by the International Agency for Research on Cancer (IARC Technical Report No. 19). This means we are able to validate our code combinations more thoroughly and investigate any that appear unusual or unlikely.


Members of the Queensland Cancer Registry

Prof Joanne Aitken DirectorCarly Scott RegistrarPeta Gordon Assistant RegistrarGeorgina Novak Coding Educator

Anthony ArmstrongEmma DownMark FosterNikkitia GolobicBelinda GritschDanica JongLachlan ManahanKara MortonKim Neri (Melanoma Data Manager)Caroline ReimersBronwyn RossbergKathy TempertonKira Ward



Coverage of the RegistryAll primary cancers (ICD-O-3 rubrics C00-C80) with either a malignant, uncertain or in-situ behaviour are registered, excluding basal and squamous cell carcinoma of skin (C44, M805-M811). Basal and squamous cell carcinomas of skin are not registered by the Queensland Cancer Registry (nor most other registries) as many are treated in doctor’s surgeries using destructive techniques that preclude histological confirmation.Benign brain tumours are registered.

Structure of this ReportThe information contained in this publication is intended to give a summary of cancer statistics in Queensland from the inception of the Registry (1982 to 2013) and a brief outline of the Queensland Cancer Registry. Incidence and mortality data have been aggregated for the earlier years of 1982-1986, 1987-1991, 1992-1996and 1997-2001 with the average being displayed in the tables. In addition to incidence and mortality statistics, the latest estimates for prevalence, relative survival and conditional survival are provided in the report.

The data presented in this report include only invasive primary cancers (behaviour = 3, site C000-C809) other than basal and squamous cell carcinomas of skin (C44, M805-M811).

The annual report publications prior to 2004 were based on the ICD-O-2 topography and morphology codes. Due to the change in coding systems to ICD-O-3, the data in this report are not comparable to publications prior to 2004.

The main coding changes from ICD-O-2 to ICD-O-3 that impact on the incidence and mortality counts and rates are:

- Myeloproliferative disorders and myelodysplastic syndromes. Coding of malignant status has changed from uncertain behaviour to invasive cancer. These are now included in the report.

- Ovarian tumours of borderline malignancy and pilocytic astrocytoma cancers of the brain. Coding of malignant status has changed from invasive cancer to uncertain behaviour. These are no longer included.

- In addition, the morphology codes for lymphoma and leukaemias have changed significantly. Although the malignant status of these neoplasms has not altered, many of the morphology codes have been merged together and new codes have been added.

As in previous reports, in an effort to publish data that is comparable with historical and other data sources, ICD-O-3 codes have been mapped to the equivalent ICD-10-AM structure.

This means that the following cancer types: mesothelioma, Kaposi sarcoma, lymphoma and other neoplasms of haematopoietic and reticuloendothelial systems, are tabulated as separate categories and excluded from the organ in which these diseases were diagnosed. The remaining sites retain their ICD-O-3 site code. Some are grouped for the purposes of preserving comparability with previous reports or where the numbers are very small.

M905 MesotheliomaM914 Kaposi SarcomaM959,M967-M972 Non-Hodgkin LymphomaM965-M966 Hodgkin LymphomaM974 - M976 Other Neoplasms Of Lymphatic & Haematopoietic TissueM973 Myeloma / Plasma Cell TumoursM980 Unspecified LeukaemiaM994 Other Specified LeukaemiaM982 - M983 Lymphoid LeukaemiaM984 - M993 Myeloid LeukaemiaM998 Myelodysplastic DiseasesC44, M872-M879 MelanomaM995 – M996 Chronic Myeloproliferative Diseases

Details of cancer reporting definitions and calculation of statistics are included in Appendix 3. More detailed statistics are available on request and are also available through Queensland Cancer Statistics Online (www.cancerqld.org.au/qcsol). See Appendix 1 for details.



Publication of ReportsIt should be noted that despite intensive efforts to ensure the completeness of incidence and mortality data before publication, the counts and rates for a given time period change by a small percentage over time. The Registry may continue to receive notifications for cases already counted in incidence and the diagnosis date or diagnosis may be amended as a result of this later notification. Reports for previously uncounted cases diagnosed in a particular year may continue to arrive at the Registry for some years after the incidence for that year has been published. The database is therefore continually being updated and the quality of data improved across the entire period of cancer reporting.

The incidence and mortality data reported in this publication are the 1982 to 2013 statistics as they stood in November 2015. Future publications and requests for data may not exactly correspond to the figures in this report as they will reflect subsequent revisions to the data.

AbbreviationsASR Age Standardised Rate. See Appendix 3 - Cancer reporting definitions and calculation of

statistics.Cum Rate Cumulative Rate. See Appendix 3 - Cancer reporting definitions and calculation of statistics.Cum Risk Cumulative Risk. See Appendix 3 - Cancer reporting definitions and calculation of statistics.n.a. Not applicableICD-O-3 International Classification of Diseases, Oncology, 3rd Edition95% CI 95% Confidence Interval


Coverage of the RegistryAll primary cancers (ICD-O-3 rubrics C00-C80) with either a malignant, uncertain or in-situ behaviour are registered, excluding basal and squamous cell carcinoma of skin (C44, M805-M811). Basal and squamous cell carcinomas of skin are not registered by the Queensland Cancer Registry (nor most other registries) as many are treated in doctor’s surgeries using destructive techniques that preclude histological confirmation.Benign brain tumours are registered.

Structure of this ReportThe information contained in this publication is intended to give a summary of cancer statistics in Queensland from the inception of the Registry (1982 to 2013) and a brief outline of the Queensland Cancer Registry. Incidence and mortality data have been aggregated for the earlier years of 1982-1986, 1987-1991, 1992-1996and 1997-2001 with the average being displayed in the tables. In addition to incidence and mortality statistics, the latest estimates for prevalence, relative survival and conditional survival are provided in the report.

The data presented in this report include only invasive primary cancers (behaviour = 3, site C000-C809) other than basal and squamous cell carcinomas of skin (C44, M805-M811).

The annual report publications prior to 2004 were based on the ICD-O-2 topography and morphology codes. Due to the change in coding systems to ICD-O-3, the data in this report are not comparable to publications prior to 2004.

The main coding changes from ICD-O-2 to ICD-O-3 that impact on the incidence and mortality counts and rates are:

- Myeloproliferative disorders and myelodysplastic syndromes. Coding of malignant status has changed from uncertain behaviour to invasive cancer. These are now included in the report.

- Ovarian tumours of borderline malignancy and pilocytic astrocytoma cancers of the brain. Coding of malignant status has changed from invasive cancer to uncertain behaviour. These are no longer included.

- In addition, the morphology codes for lymphoma and leukaemias have changed significantly. Although the malignant status of these neoplasms has not altered, many of the morphology codes have been merged together and new codes have been added.

As in previous reports, in an effort to publish data that is comparable with historical and other data sources, ICD-O-3 codes have been mapped to the equivalent ICD-10-AM structure.

This means that the following cancer types: mesothelioma, Kaposi sarcoma, lymphoma and other neoplasms of haematopoietic and reticuloendothelial systems, are tabulated as separate categories and excluded from the organ in which these diseases were diagnosed. The remaining sites retain their ICD-O-3 site code. Some are grouped for the purposes of preserving comparability with previous reports or where the numbers are very small.

M905 MesotheliomaM914 Kaposi SarcomaM959,M967-M972 Non-Hodgkin LymphomaM965-M966 Hodgkin LymphomaM974 - M976 Other Neoplasms Of Lymphatic & Haematopoietic TissueM973 Myeloma / Plasma Cell TumoursM980 Unspecified LeukaemiaM994 Other Specified LeukaemiaM982 - M983 Lymphoid LeukaemiaM984 - M993 Myeloid LeukaemiaM998 Myelodysplastic DiseasesC44, M872-M879 MelanomaM995 – M996 Chronic Myeloproliferative Diseases

Details of cancer reporting definitions and calculation of statistics are included in Appendix 3. More detailed statistics are available on request and are also available through Queensland Cancer Statistics Online (www.cancerqld.org.au/qcsol). See Appendix 1 for details.


Tabl

e 1

a. L

eadi

ng 2

0 C

ance

r Si

tes

for

20

13

(C

ount

s), I

ncid

ence

, Mal

es, Q

ueen

slan

d, 1

98

2 -

20

13

ICD

-O3/

SITE

1982

-198

619

87-1

991

1992

-199

619

97-2

001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

TOTA

L M

ALI

GN

AN

T N

EOP

LASM

S (C

00-C

80)

4761

.459

58.2

7887

.890

8710

026

1054

711

040

1152

312

235

1287

113

374

1357

413

642

1428

414

723

1474

8

C61

PRO

STAT

E

739.

610

28.0

1812

.418

2522

8027

3330

6930

6534

0737

6539

4740

7437

9540

5341

4740

64C4

4,M

872-

M87

9 M

ELAN

OM

A

52

5.4

752.

096

2.4

1256

1465

1434

1313

1563

1467

1575

1743

1759

1822

1908

1998

2140

C33,

C34

TRAC

HEA

AN

D B

RO

NCH

US

& L

UN

G

81

0.0

892.

295

3.4

1064

1065

1058

1139

1166

1282

1231

1315

1234

1330

1332

1356

1364

C18

COLO

N

413.

054

0.8

613.

477

379

780

188

389

693

210

0097

298

799

610

6910

7098

2M

959,

M96

7-M

972

NO

N-H

OD

GKI

N L

YMPH

OM

A

139.

618

1.6

243.

631

134

937

336

939

441

443

146

446

750

553

459

958

1C1

9,C2

0 R

ECTO

SIG

MO

ID J

UN

CTIO

N A

ND

REC

TUM

20

8.4

265.

437

7.2

438

475

473

560

538

544

560

587

542

581

593

587

587

C64-

C66,

C68

KID

NEY

AN

D O

THER

REN

AL T

RAC

T

126.

615

6.2

221.

027

325

929

930

034

839

540

434

142

740

047

250

049

2C6

7 BL

ADD

ER

27

4.0

303.

835

7.8

399

368

374

364

382

393

321

327

334

358

356

366

375

C26,

C39,

C76,

C77,

C80

OTH

ER &

ILL

-DEF

INED

SIT

ES A

ND

UN

KNO

WN

PR

IMAR

Y SI

TE

18

3.0

215.

826

2.4

276

296

268

289

286

294

306

347

353

341

342

329

375

C25

PAN

CREA

S

100.

811

6.4

140.

617

416

820

219

919

124

425

924

223

628

526

127

226

6C1

6 ST

OM

ACH

179.

018

7.6

199.

421

321

222

823

422

024

420

623

021

823

522

724

924

4M

982-

M98

3 LY

MPH

OID

LEU

KAEM

IA

81.8

85.6

120.

215

416

917

417

817

519

921

422

418

221

922

922

721

9C1

5 O

ESO

PHAG

US

54.2

80.0

110.

013

214

114

214

214

816

717

516

117

919

720

922

617

7C2

2 LI

VER

& I

NTR

AHEP

ATIC

BIL

E D

UCT

S

26.4

42.8

63.0

8490

100

9813

214

216

517

517

317

717

921

222

0M

973

MYE

LOM

A/PL

ASM

A CE

LL T

UM

OU

RS

52

.663

.676

.211

711

111

611

312

613

714

316

516

215

417

319

419

9C0

0 LI

P

102.

615

6.6

204.

218

118

516

314

415

419

114

212

515

616

518

017

818

2M

998

MYE

LOD

YSPL

ASTI

C D

ISEA

SES

3.8

11.4

27.0

8711

914

513

513

514

015

815

813

816

916

216

615

6C7

0-C7

2 BR

AIN

, MEN

ING

ES A

ND

OTH

ER C

ENTR

AL N

ERVO

US

SYST

EM

80.2

96.6

115.

213

914

214

316

817

017

416

718

120

517

719

816

417

0C0

1,C0

2 TO

NG

UE

41.0

49.6

58.0

6270

6388

8565

8810

810

412

211

612

415

2C7

3 TH

YRO

ID G

LAN

D

18.8

22.2

33.6

5567

9074

8794

113

113

119

120

142

124

151

Tabl

e 1

b. L

eadi

ng 2

0 C

ance

r Si

tes

for

20

13

(C

ount

s), M

orta

lity,

Mal

es, Q

ueen

slan

d, 1

98

2 -

20

13

ICD

-O3/

SITE

1982

-198

619

87-1

991

1992

-199

619

97-2

001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

TOTA

L M

ALI

GN

AN

T N

EOP

LASM

S (C

00-C

80)

2271

.427

22.2

3240

.036

1538

5038

6240

6740

6041

3643

9744

4144

5646

9146

7248

5250

50

C33,

C34

TRAC

HEA

AN

D B

RO

NCH

US

& L

UN

G

66

5.0

734.

881

0.8

864

899

880

954

941

1009

1030

1047

1003

1029

1031

1047

1130

C61

PRO

STAT

E

231.

032

4.8

452.

647

050

352

656

953

255

459

559

256

064

663

765

963

6C1

8 CO

LON

19

2.2

239.

224

6.4

301

320

271

305

325

332

307

299

347

335

319

342

353

C25

PAN

CREA

S

90.8

101.

012

9.6

148

162

175

184

166

177

245

227

193

240

242

233

242

C26,

C39,

C76,

C77,

C80

OTH

ER &

ILL

-DEF

INED

SIT

ES A

ND

UN

KNO

WN

PR

IMAR

Y SI

TE

14

7.6

166.

019

7.2

204

219

189

198

209

212

194

216

250

209

249

218

252

C44,

M87

2-M

879

MEL

ANO

MA

68.0

92.6

119.

813

713

217

918

818

314

319

519

017

321

522

321

328

7C1

9,C2

0 R

ECTO

SIG

MO

ID J

UN

CTIO

N A

ND

REC

TUM

92

.212

2.8

161.

417

414

318

116

319

918

320

918

721

718

418

020

722

4C1

6 ST

OM

ACH

139.

813

5.6

142.

615

517

215

815

715

314

815

415

615

115

817

617

516

7C1

5 O

ESO

PHAG

US

45.8

61.4

87.4

9210

911

312

310

612

812

712

712

713

713

315

514

9C6

4-C6

6,C6

8 KI

DN

EY A

ND

OTH

ER R

ENAL

TR

ACT

53

.665

.284

.892

9210

210

210

110

412

010

512

211

813

915

213

8C2

2 LI

VER

& I

NTR

AHEP

ATIC

BIL

E D

UCT

S

20.6

34.2

47.4

6182

8067

9110

510

714

113

412

913

014

316

8C6

7 BL

ADD

ER

67

.277

.296

.610

812

311

510

911

512

613

112

415

313

714

714

315

5C7

0-C7

2 BR

AIN

, MEN

ING

ES A

ND

OTH

ER C

ENTR

AL N

ERVO

US

SYST

EM

62.8

73.6

82.8

111

114

117

128

127

142

125

146

147

146

151

140

142

M90

5 M

ESO

THEL

IOM

A

17

.030

.044

.266

7298

8375

8411

110

595

113

104

130

105

M95

9,M

967-

M97

2 N

ON

-HO

DG

KIN

LYM

PHO

MA

67

.685

.411

0.4

131

134

132

132

101

127

102

125

128

143

148

125

156

M99

8 M

YELO

DYS

PLAS

TIC

DIS

EASE

S

2.

43.

67.

422

4637

4856

4657

7249

6861

8969

M98

4-M

993

MYE

LOID

LEU

KAEM

IA

54

.461

.873

.075

7471

7860

6889

7977

7681

8481

M97

3 M

YELO

MA/

PLAS

MA

CELL

TU

MO

UR

S

27.6

46.0

43.0

6469

6070

6656

6986

6975

8072

73M

982-

M98

3 LY

MPH

OID

LEU

KAEM

IA

28.2

31.0

46.0

4748

4941

4946

4342

4346

4458

52C0

1,C0

2 TO

NG

UE

16.8

21.6

23.0

2631

2539

3623

2128

4139

3643

49

8 C

ance

r in

Que

ensl

and

Inci

denc

e, M

orta

lity,

Sur

viva

l and

Pre

vale

nce

- 19

82 to

201

3


Tabl

e 1

c. L

eadi

ng 2

0 C

ance

r Si

tes

for

20

13

(C

ount

s), I

ncid

ence

, Fem

ales

, Que

ensl

and,

19

82

- 2

01

3

ICD

-O3/

SITE

1982

-198

619

87-1

991

1992

-199

619

97-2

001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

TOTA

L M

ALI

GN

AN

T N

EOP

LASM

S (C

00-C

80)

3915

.448

44.4

6096

.674

7782

7379

7085

0089

9792

6993

6599

0710

347

1054

910

597

1125

111

587

C50

BREA

ST

91

7.0

1215

.815

61.6

2038

2237

2216

2294

2424

2529

2477

2768

2819

2918

2925

3143

3272

C44,

M87

2-M

879

MEL

ANO

MA

499.

862

7.4

738.

092

710

9510

1510

4411

2210

1611

2011

8412

5112

6413

6214

2815

09C1

8 CO

LON

44

3.4

500.

262

4.0

721

783

759

749

853

900

891

971

966

991

966

918

977

C33,

C34

TRAC

HEA

AN

D B

RO

NCH

US

& L

UN

G

20

3.8

279.

236

1.6

474

585

528

650

650

673

708

767

876

847

807

840

906

C54

COR

PUS

UTE

RI

14

6.0

162.

621

4.4

270

310

309

331

351

338

374

405

405

439

431

476

504

M95

9,M

967-

M97

2 N

ON

-HO

DG

KIN

LYM

PHO

MA

12

4.4

160.

019

9.4

256

261

267

302

345

350

342

329

370

342

377

419

452

C73

THYR

OID

GLA

ND

46

.862

.610

4.8

160

206

214

242

277

287

355

326

356

397

343

359

415

C19,

C20

REC

TOSI

GM

OID

JU

NCT

ION

AN

D R

ECTU

M

141.

416

9.0

224.

825

829

431

032

230

734

933

633

229

433

731

535

234

0C5

6 O

VAR

Y

14

5.2

163.

219

8.2

206

225

190

221

231

239

228

230

257

255

267

282

273

C64-

C66,

C68

KID

NEY

AN

D O

THER

REN

AL T

RAC

T

82.2

113.

014

7.0

172

187

180

192

178

230

209

240

269

258

259

276

259

C26,

C39,

C76,

C77,

C80

OTH

ER &

ILL

-DEF

INED

SIT

ES A

ND

UN

KNO

WN

PR

IMAR

Y SI

TE

14

9.6

168.

822

2.8

249

246

213

244

254

269

285

264

265

249

222

263

308

C25

PAN

CREA

S

77.2

99.6

121.

215

416

417

218

419

119

119

521

621

021

425

526

022

2C5

3 CE

RVI

X U

TER

I

190.

820

1.2

197.

817

415

215

814

618

118

514

615

116

518

517

220

718

7C7

0-C7

2 BR

AIN

, MEN

ING

ES A

ND

OTH

ER C

ENTR

AL N

ERVO

US

SYST

EM

64.4

76.8

89.6

107

101

104

8712

511

011

311

214

313

614

115

212

6M

973

MYE

LOM

A/PL

ASM

A CE

LL T

UM

OU

RS

44

.045

.262

.689

8288

9787

100

9996

141

110

9914

612

9M

982-

M98

3 LY

MPH

OID

LEU

KAEM

IA

47.4

59.6

89.8

111

131

120

100

111

139

115

159

136

136

137

136

130

C16

STO

MAC

H

93

.486

.210

8.8

107

120

9510

611

710

211

712

011

210

310

912

710

9C6

7 BL

ADD

ER

86

.696

.411

7.6

127

138

109

129

104

120

115

109

133

119

120

124

126

M98

4-M

993

MYE

LOID

LEU

KAEM

IA

55

.265

.484

.284

7684

8980

9595

102

111

106

108

120

100

M99

8 M

YELO

DYS

PLAS

TIC

DIS

EASE

S

2.

48.

419

.857

101

8197

8095

9883

9010

410

191

100

Tabl

e 1

d. L

eadi

ng 2

0 C

ance

r Si

tes

for

20

13

(C

ount

s), M

orta

lity,

Fem

ales

, Que

ensl

and,

19

82

- 2

01

3

ICD

-O3/

SITE

1982

-198

619

87-1

991

1992

-199

619

97-2

001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

TOTA

L M

ALI

GN

AN

T N

EOP

LASM

S (C

00-C

80)

1596

.818

98.2

2275

.425

8028

3327

6829

2930

5829

4931

0131

6432

0033

1133

4335

0636

01

C33,

C34

TRAC

HEA

AN

D B

RO

NCH

US

& L

UN

G

15

9.4

201.

828

0.2

364

461

425

489

538

531

557

524

621

628

623

659

644

C50

BREA

ST

29

0.0

344.

841

2.6

427

432

455

450

475

427

493

491

444

475

502

512

553

C18

COLO

N

211.

823

7.6

241.

827

930

627

627

027

727

932

331

332

536

336

132

434

3C2

5 PA

NCR

EAS

69

.685

.411

0.0

134

139

148

171

185

173

168

185

186

189

215

220

210

C26,

C39,

C76,

C77,

C80

OTH

ER &

ILL

-DEF

INED

SIT

ES A

ND

UN

KNO

WN

PR

IMAR

Y SI

TE

11

8.8

133.

417

4.4

198

219

173

182

188

199

195

204

184

187

158

201

213

C56

OVA

RY

90.8

94.8

111.

211

013

213

412

613

913

213

515

014

415

015

615

416

4C7

0-C7

2 BR

AIN

, MEN

ING

ES A

ND

OTH

ER C

ENTR

AL N

ERVO

US

SYST

EM

45.4

60.4

70.0

8195

8775

7986

8289

106

9296

110

126

C19,

C20

REC

TOSI

GM

OID

JU

NCT

ION

AN

D R

ECTU

M

62.8

70.6

88.2

9910

811

712

711

095

124

117

103

110

110

110

104

C44,

M87

2-M

879

MEL

ANO

MA

39.8

48.6

56.2

6964

8078

7882

8789

8110

293

9610

3C6

4-C6

6,C6

8 KI

DN

EY A

ND

OTH

ER R

ENAL

TR

ACT

36

.453

.261

.666

7166

7969

7158

8076

7781

9173

C54

COR

PUS

UTE

RI

29

.033

.441

.649

5852

6772

6471

6469

6160

8873

M95

9,M

967-

M97

2 N

ON

-HO

DG

KIN

LYM

PHO

MA

55

.072

.691

.210

712

610

310

610

296

9593

8689

9680

100

C67

BLAD

DER

26.0

30.8

40.0

4546

4862

4950

5062

6351

4574

54C1

6 ST

OM

ACH

73.0

67.8

73.0

7167

8283

8560

8578

8475

7768

62C2

2 LI

VER

& I

NTR

AHEP

ATIC

BIL

E D

UCT

S

7.2

13.6

18.0

2729

3236

4640

3248

4251

5167

87M

973

MYE

LOM

A/PL

ASM

A CE

LL T

UM

OU

RS

26

.231

.241

.444

4754

5955

4654

5047

6863

6557

C23,

C24

GAL

LBLA

DD

ER A

ND

OTH

ER &

UN

SPEC

IFIE

D P

ARTS

OF

BILI

ARY

TRAC

T

31

.442

.445

.644

4447

4558

3755

4255

5859

6363

M98

4-M

993

MYE

LOID

LEU

KAEM

IA

41

.446

.458

.254

4657

5446

5852

5252

6277

5467

C15

OES

OPH

AGU

S

25

.032

.039

.445

4743

5061

4457

4456

4147

5076

C53

CER

VIX

UTE

RI

48

.253

.055

.251

3639

4742

5735

5146

5147

4847

9 C

ance

r in

Que

ensl

and

Inci

denc

e, M

orta

lity,

Sur

viva

l and

Pre

vale

nce

- 19

82 to

201

3


ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Incidence M 102.6 156.6 204.2 181.4 185 163 144 154 191 142 125 156 165 180 178 182F 20.6 40.6 54.8 65.8 84 57 48 49 48 47 37 48 60 50 44 65P 123.2 197.2 259.0 247.2 269 220 192 203 239 189 162 204 225 230 222 247

Mortality M 1.8 2.6 3.4 4.0 6 3 10 9 1 2 4 4 2 3 1 3F 0.6 0.8 0.4 1.2 1 3 1 2 1 3 0 1 2 1 3 1P 2.4 3.4 3.8 5.2 7 6 11 11 2 5 4 5 4 4 4 4

Incidence M 269.2 288.2 338.8 360.2 358 375 427 447 452 493 484 509 538 525 536 566F 73.2 95.0 114.8 120.0 117 125 134 160 161 164 173 158 185 180 176 199P 342.4 383.2 453.6 480.2 475 500 561 607 613 657 657 667 723 705 712 765

Mortality M 98.8 122.4 134.4 137.8 154 156 173 186 170 155 179 186 206 186 203 192F 28.0 37.0 38.2 44.8 58 52 44 62 40 51 52 56 61 51 64 52P 126.8 159.4 172.6 182.6 212 208 217 248 210 206 231 242 267 237 267 244

Incidence M 41.0 49.6 58.0 61.6 70 63 88 85 65 88 108 104 122 116 124 152F 15.0 22.0 25.0 32.2 27 36 32 37 28 51 48 43 48 51 51 51P 56.0 71.6 83.0 93.8 97 99 120 122 93 139 156 147 170 167 175 203

Mortality M 16.8 21.6 23.0 26.4 31 25 39 36 23 21 28 41 39 36 43 49F 4.6 9.4 9.0 12.0 13 14 14 15 11 12 10 11 11 13 24 19P 21.4 31.0 32.0 38.4 44 39 53 51 34 33 38 52 50 49 67 68

Incidence M 3.2 3.2 7.4 6.4 4 10 11 13 7 12 14 23 17 17 24 14F 3.4 2.6 4.2 5.4 6 8 8 7 14 8 13 12 9 12 8 12P 6.6 5.8 11.6 11.8 10 18 19 20 21 20 27 35 26 29 32 26

Mortality M 0.6 1.2 3.0 1.8 4 4 4 6 3 3 7 1 5 7 4 9F 0.8 1.2 0.8 2.8 3 1 2 3 1 7 3 2 3 4 6 2P 1.4 2.4 3.8 4.6 7 5 6 9 4 10 10 3 8 11 10 11

Incidence M 20.2 17.4 21.4 24.0 17 19 19 28 22 27 25 34 37 33 23 22F 7.0 7.2 7.4 10.0 9 12 6 20 8 8 8 8 11 13 6 17P 27.2 24.6 28.8 34.0 26 31 25 48 30 35 33 42 48 46 29 39

Mortality M 6.8 6.6 9.0 9.4 6 9 9 12 8 10 11 8 9 12 15 5F 2.0 1.4 2.2 3.0 4 3 2 7 2 4 2 7 4 4 2 2P 8.8 8.0 11.2 12.4 10 12 11 19 10 14 13 15 13 16 17 7

Incidence M 25.4 24.0 22.6 25.0 34 24 29 41 34 44 37 33 29 35 32 40F 9.2 14.8 19.8 16.2 12 18 20 18 28 20 22 23 30 28 26 23P 34.6 38.8 42.4 41.2 46 42 49 59 62 64 59 56 59 63 58 63

Mortality M 9.2 8.4 10.6 7.6 8 8 13 15 16 14 18 17 9 17 20 16F 3.2 6.2 6.0 5.4 6 9 6 10 8 5 6 10 6 8 10 10P 12.4 14.6 16.6 13.0 14 17 19 25 24 19 24 27 15 25 30 26

Incidence M 15.2 17.6 23.4 31.0 31 34 36 34 55 41 39 32 48 44 25 36F 9.0 10.4 17.4 16.4 18 17 20 24 26 29 27 16 21 23 22 32P 24.2 28.0 40.8 47.4 49 51 56 58 81 70 66 48 69 67 47 68

Mortality M 4.2 6.2 6.6 6.8 13 10 5 14 17 7 17 9 11 8 9 9F 1.6 3.0 3.8 3.8 7 6 1 5 1 3 7 4 6 4 2 3P 5.8 9.2 10.4 10.6 20 16 6 19 18 10 24 13 17 12 11 12

Incidence M 29.0 24.8 36.0 43.2 47 55 56 63 73 87 85 86 89 102 118 111F 7.6 9.4 8.6 11.2 15 13 14 17 14 18 19 17 18 20 29 23P 36.6 34.2 44.6 54.4 62 68 70 80 87 105 104 103 107 122 147 134

Mortality M 13.6 14.2 17.6 17.2 23 22 21 23 24 24 24 31 29 26 17 31F 4.2 4.2 3.8 5.0 5 5 7 6 3 6 4 8 7 5 6 5P 17.8 18.4 21.4 22.2 28 27 28 29 27 30 28 39 36 31 23 36

Incidence M 10.8 8.8 12.2 11.8 10 9 9 16 12 12 12 14 17 13 16 13F 3.6 4.0 5.8 3.2 2 2 5 3 9 3 4 5 3 4 6 6P 14.4 12.8 18.0 15.0 12 11 14 19 21 15 16 19 20 17 22 19

Mortality M 6.6 5.6 7.8 6.8 2 2 3 7 6 5 7 6 4 3 7 8F 2.4 2.0 2.4 3.0 1 2 0 2 3 2 3 0 3 2 0 1P 9.0 7.6 10.2 9.8 3 4 3 9 9 7 10 6 7 5 7 9

Table 2. Cancer Incidence and Mortality (Counts) by Site and Sex, Queensland, 1982 - 2013

C11 NASOPHARYNX

C09,C10 TONSIL AND OROPHARYNX

C07,C08 PAROTID AND OTHER & UNSPECIFIED MAJOR SALIVARY GLANDS

C05,C06 PALATE AND OTHER & UNSPECIFIED PARTS OF MOUTH

C04 FLOOR OF MOUTH

C03 GUM

C01,C02 TONGUE

C01-C14, C30-C32 HEAD AND NECK

C00 LIP

10 Cancer in Queensland Incidence, Mortality, Survival and Prevalence - 1982 to 2013


ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 21.2 28.2 30.8 30.6 22 24 34 28 24 36 27 37 41 34 31 41F 3.0 4.2 4.4 4.8 7 2 6 8 6 4 4 4 10 6 4 9P 24.2 32.4 35.2 35.4 29 26 40 36 30 40 31 41 51 40 35 50

Mortality M 10.6 17.2 17.0 18.8 23 22 17 14 22 18 14 18 27 24 28 17F 2.2 1.4 2.2 3.2 7 0 3 5 3 4 3 3 5 1 4 2P 12.8 18.6 19.2 22.0 30 22 20 19 25 22 17 21 32 25 32 19

Incidence M 7.0 10.2 11.4 14.2 13 21 12 22 21 25 11 24 14 14 17 14F 1.4 3.4 2.6 5.0 4 2 2 5 4 0 2 3 6 4 3 2P 8.4 13.6 14.0 19.2 17 23 14 27 25 25 13 27 20 18 20 16

Mortality M 3.2 6.0 6.2 7.0 5 9 10 16 12 11 8 7 18 13 7 11F 0.6 1.2 1.8 2.4 2 2 1 1 3 1 2 4 7 2 1 1P 3.8 7.2 8.0 9.4 7 11 11 17 15 12 10 11 25 15 8 12

Incidence M 54.2 80.0 110.0 131.8 141 142 142 148 167 175 161 179 197 209 226 177F 30.4 45.0 52.4 62.8 48 68 77 58 69 75 66 68 69 73 72 68P 84.6 125.0 162.4 194.6 189 210 219 206 236 250 227 247 266 282 298 245

Mortality M 45.8 61.4 87.4 92.0 109 113 123 106 128 127 127 127 137 133 155 149F 25.0 32.0 39.4 45.2 47 43 50 61 44 57 44 56 41 47 50 76P 70.8 93.4 126.8 137.2 156 156 173 167 172 184 171 183 178 180 205 225

Incidence M 179.0 187.6 199.4 213.4 212 228 234 220 244 206 230 218 235 227 249 244F 93.4 86.2 108.8 106.8 120 95 106 117 102 117 120 112 103 109 127 109P 272.4 273.8 308.2 320.2 332 323 340 337 346 323 350 330 338 336 376 353

Mortality M 139.8 135.6 142.6 155.2 172 158 157 153 148 154 156 151 158 176 175 167F 73.0 67.8 73.0 71.4 67 82 83 85 60 85 78 84 75 77 68 62P 212.8 203.4 215.6 226.6 239 240 240 238 208 239 234 235 233 253 243 229

Incidence M 11.4 15.0 20.0 31.8 31 30 33 48 41 54 47 71 61 61 86 82F 10.4 12.6 14.6 21.8 25 24 32 42 37 38 36 35 51 52 47 52P 21.8 27.6 34.6 53.6 56 54 65 90 78 92 83 106 112 113 133 134

Mortality M 5.6 7.8 8.2 12.6 12 13 10 16 14 18 16 24 26 28 20 27F 5.0 6.8 8.0 10.0 11 9 7 10 17 17 16 9 10 13 14 18P 10.6 14.6 16.2 22.6 23 22 17 26 31 35 32 33 36 41 34 45

Incidence M 622.6 808.2 993.8 1217.4 1280 1277 1452 1440 1487 1574 1563 1540 1585 1674 1670 1582F 586.4 671.2 851.6 983.4 1092 1078 1080 1176 1267 1236 1317 1267 1341 1298 1296 1330P 1209.0 1479.4 1845.4 2200.8 2372 2355 2532 2616 2754 2810 2880 2807 2926 2972 2966 2912

Mortality M 284.6 363.8 408.6 478.2 464 457 473 526 519 520 491 567 525 500 554 581F 275.0 308.8 330.4 380.8 416 396 401 388 379 451 433 430 475 474 441 451P 559.6 672.6 739.0 859.0 880 853 874 914 898 971 924 997 1000 974 995 1032

Incidence M 413.0 540.8 613.4 773.4 797 801 883 896 932 1000 972 987 996 1069 1070 982F 443.4 500.2 624.0 721.0 783 759 749 853 900 891 971 966 991 966 918 977P 856.4 1041.0 1237.4 1494.4 1580 1560 1632 1749 1832 1891 1943 1953 1987 2035 1988 1959

Mortality M 192.2 239.2 246.4 301.2 320 271 305 325 332 307 299 347 335 319 342 353F 211.8 237.6 241.8 279.4 306 276 270 277 279 323 313 325 363 361 324 343P 404.0 476.8 488.2 580.6 626 547 575 602 611 630 612 672 698 680 666 696

Incidence M 208.4 265.4 377.2 438.2 475 473 560 538 544 560 587 542 581 593 587 587F 141.4 169.0 224.8 258.2 294 310 322 307 349 336 332 294 337 315 352 340P 349.8 434.4 602.0 696.4 769 783 882 845 893 896 919 836 918 908 939 927

Mortality M 92.2 122.8 161.4 174.4 143 181 163 199 183 209 187 217 184 180 207 224F 62.8 70.6 88.2 99.2 108 117 127 110 95 124 117 103 110 110 110 104P 155.0 193.4 249.6 273.6 251 298 290 309 278 333 304 320 294 290 317 328

Incidence M 6.4 10.0 18.6 18.2 25 23 26 35 27 28 21 34 27 33 35 32F 10.6 16.2 18.0 20.8 34 38 30 43 55 31 49 32 41 56 56 46P 17.0 26.2 36.6 39.0 59 61 56 78 82 59 70 66 68 89 91 78

Mortality M 2.0 3.2 5.0 5.8 5 11 11 10 12 19 11 9 14 7 12 14F 4.4 6.0 4.6 6.2 6 11 10 7 10 13 12 13 16 14 13 11P 6.4 9.2 9.6 12.0 11 22 21 17 22 32 23 22 30 21 25 25

C16 STOMACH

C15 OESOPHAGUS

C14 OTHER & ILL-DEFINED SITES IN LIP,ORAL CAVITY & PHARYNX

C12,C13 PYRIFORM SINUS AND HYPOPHARYNX

C21 ANUS & ANAL CANAL

C19,C20 RECTOSIGMOID JUNCTION AND RECTUM

C18 COLON

C18-C20,C218 COLORECTAL

C17 SMALL INTESTINE



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 26.4 42.8 63.0 84.4 90 100 98 132 142 165 175 173 177 179 212 220F 11.4 18.0 22.6 36.6 34 37 52 56 51 54 63 62 76 74 86 98P 37.8 60.8 85.6 121.0 124 137 150 188 193 219 238 235 253 253 298 318

Mortality M 20.6 34.2 47.4 60.6 82 80 67 91 105 107 141 134 129 130 143 168F 7.2 13.6 18.0 27.4 29 32 36 46 40 32 48 42 51 51 67 87P 27.8 47.8 65.4 88.0 111 112 103 137 145 139 189 176 180 181 210 255

Incidence M 23.2 30.2 38.4 47.0 55 47 47 51 45 63 55 70 63 60 69 65F 41.0 51.6 56.6 56.0 64 58 59 67 69 57 62 68 69 72 90 78P 64.2 81.8 95.0 103.0 119 105 106 118 114 120 117 138 132 132 159 143

Mortality M 19.4 22.4 24.4 32.0 36 43 34 40 32 39 34 39 55 39 50 49F 31.4 42.4 45.6 44.0 44 47 45 58 37 55 42 55 58 59 63 63P 50.8 64.8 70.0 76.0 80 90 79 98 69 94 76 94 113 98 113 112

Incidence M 100.8 116.4 140.6 174.0 168 202 199 191 244 259 242 236 285 261 272 266F 77.2 99.6 121.2 154.4 164 172 184 191 191 195 216 210 214 255 260 222P 178.0 216.0 261.8 328.4 332 374 383 382 435 454 458 446 499 516 532 488

Mortality M 90.8 101.0 129.6 148.0 162 175 184 166 177 245 227 193 240 242 233 242F 69.6 85.4 110.0 133.8 139 148 171 185 173 168 185 186 189 215 220 210P 160.4 186.4 239.6 281.8 301 323 355 351 350 413 412 379 429 457 453 452

Incidence M 10.2 10.8 14.8 13.2 9 12 19 16 17 12 19 15 21 18 15 15F 6.0 7.2 6.8 6.6 6 6 8 11 9 9 13 8 10 9 14 13P 16.2 18.0 21.6 19.8 15 18 27 27 26 21 32 23 31 27 29 28

Mortality M 4.2 5.4 7.0 6.0 6 4 7 7 5 4 5 6 9 11 5 5F 2.4 3.4 3.0 1.8 3 3 5 3 1 2 5 4 2 4 2 4P 6.6 8.8 10.0 7.8 9 7 12 10 6 6 10 10 11 15 7 9

Incidence M 86.0 93.6 100.8 99.2 101 104 114 101 122 109 107 107 103 99 111 108F 8.0 9.8 12.8 9.0 11 9 13 10 15 14 13 19 19 10 7 11P 94.0 103.4 113.6 108.2 112 113 127 111 137 123 120 126 122 109 118 119

Mortality M 23.0 30.0 26.6 30.0 33 41 45 36 34 38 40 42 46 29 48 32F 4.0 3.6 3.2 2.4 7 7 3 5 4 5 7 3 7 4 7 3P 27.0 33.6 29.8 32.4 40 48 48 41 38 43 47 45 53 33 55 35

Incidence M 810.0 892.2 953.4 1064.0 1065 1058 1139 1166 1282 1231 1315 1234 1330 1332 1356 1364F 203.8 279.2 361.6 474.2 585 528 650 650 673 708 767 876 847 807 840 906P 1013.8 1171.4 1315.0 1538.2 1650 1586 1789 1816 1955 1939 2082 2110 2177 2139 2196 2270

Mortality M 665.0 734.8 810.8 863.6 899 880 954 941 1009 1030 1047 1003 1029 1031 1047 1130F 159.4 201.8 280.2 364.2 461 425 489 538 531 557 524 621 628 623 659 644P 824.4 936.6 1091.0 1227.8 1360 1305 1443 1479 1540 1587 1571 1624 1657 1654 1706 1774

Incidence M 4.6 6.2 7.6 9.8 15 11 7 7 7 10 8 14 19 10 8 13F 3.2 3.6 4.0 4.4 7 7 8 7 7 5 6 9 5 8 6 12P 7.8 9.8 11.6 14.2 22 18 15 14 14 15 14 23 24 18 14 25

Mortality M 3.8 2.2 2.0 4.2 5 3 5 3 1 8 1 6 12 5 5 4F 2.2 2.4 2.2 2.2 3 1 3 4 4 1 4 3 3 2 4 3P 6.0 4.6 4.2 6.4 8 4 8 7 5 9 5 9 15 7 9 7

Incidence M 13.8 20.4 19.2 18.8 30 23 18 17 31 29 19 18 27 30 22 29F 7.4 12.0 13.0 16.2 19 11 27 19 12 14 23 14 16 21 12 16P 21.2 32.4 32.2 35.0 49 34 45 36 43 43 42 32 43 51 34 45

Mortality M 5.8 8.2 8.0 8.2 10 7 11 6 4 18 5 11 10 10 11 10F 3.8 4.0 4.4 5.2 4 7 4 2 9 11 9 2 5 1 10 6P 9.6 12.2 12.4 13.4 14 14 15 8 13 29 14 13 15 11 21 16

Incidence M 525.4 752.0 962.4 1256.4 1465 1434 1313 1563 1467 1575 1743 1759 1822 1908 1998 2140F 499.8 627.4 738.0 926.6 1095 1015 1044 1122 1016 1120 1184 1251 1264 1362 1428 1509P 1025.2 1379.4 1700.4 2183.0 2560 2449 2357 2685 2483 2695 2927 3010 3086 3270 3426 3649

Mortality M 68.0 92.6 119.8 137.2 132 179 188 183 143 195 190 173 215 223 213 287F 39.8 48.6 56.2 69.4 64 80 78 78 82 87 89 81 102 93 96 103P 107.8 141.2 176.0 206.6 196 259 266 261 225 282 279 254 317 316 309 390

C33,C34 TRACHEA AND BRONCHUS & LUNG

C32 LARYNX

C44, M872-M879 MELANOMA

C40,C41 BONES,JOINTS & ARTICULAR CARTILAGES

C37, C38 THYMUS,HEART,MEDIASTINUM & PLEURA

C30,C31 NASAL CAVITY & MIDDLE EAR AND ACCESSORY SINUSES

C25 PANCREAS

C23,C24 GALLBLADDER AND OTHER & UNSPECIFIED PARTS OF BILIARY TRACT

C22 LIVER & INTRAHEPATIC BILE DUCTS



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 15.4 31.0 47.6 54.2 76 66 80 75 74 115 131 144 123 130 144 150F 8.0 17.2 22.4 35.6 45 35 39 51 49 59 44 66 66 69 80 83P 23.4 48.2 70.0 89.8 121 101 119 126 123 174 175 210 189 199 224 233

Mortality M 1.4 4.8 8.2 11.0 13 9 21 23 14 24 24 26 26 22 27 41F 0.2 1.2 2.4 7.0 11 6 0 12 7 8 12 6 15 12 10 20P 1.6 6.0 10.6 18.0 24 15 21 35 21 32 36 32 41 34 37 61

Incidence M 21.0 35.6 49.4 79.2 90 91 89 90 107 113 101 109 120 121 138 110F 1.8 5.6 7.4 13.8 23 14 17 20 24 16 23 32 28 21 33 25P 22.8 41.2 56.8 93.0 113 105 106 110 131 129 124 141 148 142 171 135

Mortality M 17.0 30.0 44.2 66.4 72 98 83 75 84 111 105 95 113 104 130 105F 1.6 4.0 6.4 9.6 20 17 13 18 18 17 24 23 25 24 27 24P 18.6 34.0 50.6 76.0 92 115 96 93 102 128 129 118 138 128 157 129

Incidence M 1.0 9.4 12.4 5.6 7 1 6 3 4 9 7 6 8 9 6 3F 0.0 0.6 0.8 0.4 0 0 1 2 0 1 1 2 1 0 0 2P 1.0 10.0 13.2 6.0 7 1 7 5 4 10 8 8 9 9 6 5

Mortality M 0.4 0.6 0.6 0.2 0 2 0 0 1 0 0 0 1 1 0 0F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 0.4 0.6 0.6 0.2 0 2 0 0 1 0 0 0 1 1 0 0

Incidence M 28.8 31.6 37.4 47.8 59 52 57 50 50 43 49 50 58 67 70 71F 22.2 22.2 33.2 37.2 35 28 41 64 41 37 36 48 37 55 57 47P 51.0 53.8 70.6 85.0 94 80 98 114 91 80 85 98 95 122 127 118

Mortality M 11.2 10.8 13.0 13.2 23 19 19 24 27 13 17 22 19 17 35 22F 9.4 8.6 12.0 13.4 8 13 13 22 24 15 11 9 20 15 19 25P 20.6 19.4 25.0 26.6 31 32 32 46 51 28 28 31 39 32 54 47

Incidence M 3.2 4.4 4.0 6.8 8 7 7 7 12 17 4 14 12 14 16 12F 6.0 4.4 8.6 23.4 23 32 30 31 43 45 34 42 27 33 31 30P 9.2 8.8 12.6 30.2 31 39 37 38 55 62 38 56 39 47 47 42

Mortality M 3.0 3.4 1.6 4.6 6 4 3 4 2 7 7 6 11 1 7 9F 3.0 4.0 3.4 9.8 18 15 17 18 27 29 28 25 29 27 30 26P 6.0 7.4 5.0 14.4 24 19 20 22 29 36 35 31 40 28 37 35

Incidence M 9.4 10.6 11.2 15.4 14 13 28 21 23 24 16 25 24 14 27 28F 917.0 1215.8 1561.6 2038.2 2237 2216 2294 2424 2529 2477 2768 2819 2918 2925 3143 3272P 926.4 1226.4 1572.8 2053.6 2251 2229 2322 2445 2552 2501 2784 2844 2942 2939 3170 3300

Mortality M 2.8 2.4 4.0 2.6 0 2 6 4 3 2 3 3 5 3 7 6F 290.0 344.8 412.6 427.0 432 455 450 475 427 493 491 444 475 502 512 553P 292.8 347.2 416.6 429.6 432 457 456 479 430 495 494 447 480 505 519 559

Incidence M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 530.8 578.8 668.2 718.0 758 718 792 858 855 853 877 929 1002 986 1095 1087P 530.8 578.8 668.2 718.0 758 718 792 858 855 853 877 929 1002 986 1095 1087

Mortality M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 181.4 198.0 225.0 231.6 246 242 275 297 285 271 300 292 302 306 336 336P 181.4 198.0 225.0 231.6 246 242 275 297 285 271 300 292 302 306 336 336

Incidence M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 26.4 28.6 34.0 37.0 40 32 40 38 49 48 49 51 60 60 80 62P 26.4 28.6 34.0 37.0 40 32 40 38 49 48 49 51 60 60 80 62

Mortality M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 5.4 8.2 8.4 8.0 11 4 17 11 11 13 16 15 16 17 20 20P 5.4 8.2 8.4 8.0 11 4 17 11 11 13 16 15 16 17 20 20

Incidence M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 190.8 201.2 197.8 173.6 152 158 146 181 185 146 151 165 185 172 207 187P 190.8 201.2 197.8 173.6 152 158 146 181 185 146 151 165 185 172 207 187

Mortality M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 48.2 53.0 55.2 51.2 36 39 47 42 57 35 51 46 51 47 48 47P 48.2 53.0 55.2 51.2 36 39 47 42 57 35 51 46 51 47 48 47

M905 MESOTHELIOMA

C44 OTHER SKIN (EXCL BCC/SCC)

C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVES

M914 KAPOSI SARCOMA

C53 CERVIX UTERI

C51 VULVA

C51-C58 GYNAECOLOGICAL

C50 BREAST

C48 RETROPERITONEUM & PERITONEUM



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 146.0 162.6 214.4 269.6 310 309 331 351 338 374 405 405 439 431 476 504P 146.0 162.6 214.4 269.6 310 309 331 351 338 374 405 405 439 431 476 504

Mortality M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 29.0 33.4 41.6 48.8 58 52 67 72 64 71 64 69 61 60 88 73P 29.0 33.4 41.6 48.8 58 52 67 72 64 71 64 69 61 60 88 73

Incidence M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 145.2 163.2 198.2 205.8 225 190 221 231 239 228 230 257 255 267 282 273P 145.2 163.2 198.2 205.8 225 190 221 231 239 228 230 257 255 267 282 273

Mortality M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 90.8 94.8 111.2 110.2 132 134 126 139 132 135 150 144 150 156 154 164P 90.8 94.8 111.2 110.2 132 134 126 139 132 135 150 144 150 156 154 164

Incidence M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 22.4 23.2 23.8 32.0 31 29 54 57 44 57 42 51 63 56 50 61P 22.4 23.2 23.8 32.0 31 29 54 57 44 57 42 51 63 56 50 61

Mortality M 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0F 8.0 8.6 8.6 13.4 9 13 18 33 21 17 19 18 24 26 26 32P 8.0 8.6 8.6 13.4 9 13 18 33 21 17 19 18 24 26 26 32

Incidence M 739.6 1028.0 1812.4 1824.6 2280 2733 3069 3065 3407 3765 3947 4074 3795 4053 4147 4064F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 739.6 1028.0 1812.4 1824.6 2280 2733 3069 3065 3407 3765 3947 4074 3795 4053 4147 4064

Mortality M 231.0 324.8 452.6 469.8 503 526 569 532 554 595 592 560 646 637 659 636F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 231.0 324.8 452.6 469.8 503 526 569 532 554 595 592 560 646 637 659 636

Incidence M 60.6 61.2 94.2 100.8 134 115 115 135 137 117 152 159 142 153 142 150F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 60.6 61.2 94.2 100.8 134 115 115 135 137 117 152 159 142 153 142 150

Mortality M 7.4 5.2 5.0 3.8 2 5 6 5 3 4 2 3 5 2 6 2F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 7.4 5.2 5.0 3.8 2 5 6 5 3 4 2 3 5 2 6 2

Incidence M 10.4 11.8 15.6 17.8 18 17 18 12 14 24 24 19 15 25 38 26F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 10.4 11.8 15.6 17.8 18 17 18 12 14 24 24 19 15 25 38 26

Mortality M 2.0 3.2 3.2 3.6 3 2 3 7 3 3 5 8 3 6 9 8F 0.0 0.0 0.0 0.0 0 0 0 0 0 0 0 0 0 0 0 0P 2.0 3.2 3.2 3.6 3 2 3 7 3 3 5 8 3 6 9 8

Incidence M 126.6 156.2 221.0 272.8 259 299 300 348 395 404 341 427 400 472 500 492F 82.2 113.0 147.0 172.0 187 180 192 178 230 209 240 269 258 259 276 259P 208.8 269.2 368.0 444.8 446 479 492 526 625 613 581 696 658 731 776 751

Mortality M 53.6 65.2 84.8 92.4 92 102 102 101 104 120 105 122 118 139 152 138F 36.4 53.2 61.6 66.4 71 66 79 69 71 58 80 76 77 81 91 73P 90.0 118.4 146.4 158.8 163 168 181 170 175 178 185 198 195 220 243 211

Incidence M 274.0 303.8 357.8 398.8 368 374 364 382 393 321 327 334 358 356 366 375F 86.6 96.4 117.6 127.0 138 109 129 104 120 115 109 133 119 120 124 126P 360.6 400.2 475.4 525.8 506 483 493 486 513 436 436 467 477 476 490 501

Mortality M 67.2 77.2 96.6 107.6 123 115 109 115 126 131 124 153 137 147 143 155F 26.0 30.8 40.0 44.6 46 48 62 49 50 50 62 63 51 45 74 54P 93.2 108.0 136.6 152.2 169 163 171 164 176 181 186 216 188 192 217 209

Incidence M 16.0 21.8 34.0 34.2 32 44 23 37 45 25 41 33 34 33 31 53F 9.4 16.6 20.4 19.8 20 24 27 27 28 32 26 19 24 22 24 28P 25.4 38.4 54.4 54.0 52 68 50 64 73 57 67 52 58 55 55 81

Mortality M 2.8 4.8 3.6 5.4 6 5 8 8 4 8 8 5 11 4 4 11F 1.8 2.6 5.4 3.6 1 3 6 6 1 5 7 10 10 5 10 10P 4.6 7.4 9.0 9.0 7 8 14 14 5 13 15 15 21 9 14 21

C69 EYE & ADNEXA

C67 BLADDER

C64-C66,C68 KIDNEY AND OTHER RENAL TRACT

C60,C63 PENIS AND OTHER & UNSPECIFIED MALE GENITAL ORGANS

C62 TESTIS

C61 PROSTATE GLAND

C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANS

C56 OVARY

C54 CORPUS UTERI



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 80.2 96.6 115.2 138.6 142 143 168 170 174 167 181 205 177 198 164 170F 64.4 76.8 89.6 107.2 101 104 87 125 110 113 112 143 136 141 152 126P 144.6 173.4 204.8 245.8 243 247 255 295 284 280 293 348 313 339 316 296

Mortality M 62.8 73.6 82.8 110.6 114 117 128 127 142 125 146 147 146 151 140 142F 45.4 60.4 70.0 80.8 95 87 75 79 86 82 89 106 92 96 110 126P 108.2 134.0 152.8 191.4 209 204 203 206 228 207 235 253 238 247 250 268

Incidence M 18.8 22.2 33.6 55.4 67 90 74 87 94 113 113 119 120 142 124 151F 46.8 62.6 104.8 160.2 206 214 242 277 287 355 326 356 397 343 359 415P 65.6 84.8 138.4 215.6 273 304 316 364 381 468 439 475 517 485 483 566

Mortality M 3.2 6.2 5.4 5.8 10 6 7 12 15 9 8 11 10 9 15 9F 4.6 5.0 5.6 5.6 5 10 12 8 12 7 11 18 12 11 13 6P 7.8 11.2 11.0 11.4 15 16 19 20 27 16 19 29 22 20 28 15

Incidence M 3.4 5.6 8.2 8.4 4 8 5 6 10 5 9 11 3 6 12 8F 2.8 6.4 6.4 7.4 9 8 12 7 10 9 17 5 10 7 11 7P 6.2 12.0 14.6 15.8 13 16 17 13 20 14 26 16 13 13 23 15

Mortality M 3.0 2.2 3.8 3.2 4 6 2 4 2 6 0 1 5 4 2 2F 0.8 3.4 3.6 3.6 7 4 6 4 7 3 5 9 2 4 3 6P 3.8 5.6 7.4 6.8 11 10 8 8 9 9 5 10 7 8 5 8

Incidence M 183.0 215.8 262.4 276.0 296 268 289 286 294 306 347 353 341 342 329 375F 149.6 168.8 222.8 249.2 246 213 244 254 269 285 264 265 249 222 263 308P 332.6 384.6 485.2 525.2 542 481 533 540 563 591 611 618 590 564 592 683

Mortality M 147.6 166.0 197.2 203.8 219 189 198 209 212 194 216 250 209 249 218 252F 118.8 133.4 174.4 198.0 219 173 182 188 199 195 204 184 187 158 201 213P 266.4 299.4 371.6 401.8 438 362 380 397 411 389 420 434 396 407 419 465

Incidence M 169.2 212.6 275.6 346.0 393 415 396 440 466 480 515 512 566 588 657 643F 140.4 183.2 226.0 286.4 292 302 335 381 398 382 359 423 384 444 475 506P 309.6 395.8 501.6 632.4 685 717 731 821 864 862 874 935 950 1032 1132 1149

Mortality M 78.6 93.2 116.8 138.2 142 139 140 108 138 113 128 135 149 156 133 166F 60.6 78.0 95.6 110.6 132 105 111 108 102 97 96 95 91 108 81 108P 139.2 171.2 212.4 248.8 274 244 251 216 240 210 224 230 240 264 214 274

Incidence M 29.6 31.0 32.0 35.2 44 42 27 46 52 49 51 45 61 54 58 62F 16.0 23.2 26.6 30.6 31 35 33 36 48 40 30 53 42 67 56 54P 45.6 54.2 58.6 65.8 75 77 60 82 100 89 81 98 103 121 114 116

Mortality M 11.0 7.8 6.4 7.2 8 7 8 7 11 11 3 7 6 8 8 10F 5.6 5.4 4.4 3.6 6 2 5 6 6 2 3 9 2 12 1 8P 16.6 13.2 10.8 10.8 14 9 13 13 17 13 6 16 8 20 9 18

Incidence M 139.6 181.6 243.6 310.8 349 373 369 394 414 431 464 467 505 534 599 581F 124.4 160.0 199.4 255.8 261 267 302 345 350 342 329 370 342 377 419 452P 264.0 341.6 443.0 566.6 610 640 671 739 764 773 793 837 847 911 1018 1033

Mortality M 67.6 85.4 110.4 131.0 134 132 132 101 127 102 125 128 143 148 125 156F 55.0 72.6 91.2 107.0 126 103 106 102 96 95 93 86 89 96 80 100P 122.6 158.0 201.6 238.0 260 235 238 203 223 197 218 214 232 244 205 256

Incidence M 169.0 187.6 256.4 296.8 334 331 334 328 346 406 465 385 425 456 438 432F 111.8 133.6 184.8 209.8 230 220 214 216 263 240 300 278 272 286 284 262P 280.8 321.2 441.2 506.6 564 551 548 544 609 646 765 663 697 742 722 694

Mortality M 88.8 101.2 127.8 132.8 141 129 131 134 131 149 142 149 166 150 164 153F 63.0 74.0 94.2 95.4 88 96 116 79 102 90 99 97 101 116 103 119P 151.8 175.2 222.0 228.2 229 225 247 213 233 239 241 246 267 266 267 272

Incidence M 81.8 85.6 120.2 154.4 169 174 178 175 199 214 224 182 219 229 227 219F 47.4 59.6 89.8 111.0 131 120 100 111 139 115 159 136 136 137 136 130P 129.2 145.2 210.0 265.4 300 294 278 286 338 329 383 318 355 366 363 349

Mortality M 28.2 31.0 46.0 47.0 48 49 41 49 46 43 42 43 46 44 58 52F 16.8 21.8 29.0 33.8 33 30 49 22 30 28 33 27 30 28 36 35P 45.0 52.8 75.0 80.8 81 79 90 71 76 71 75 70 76 72 94 87

C26, C39,C76,C77,C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITE

C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDS

C73 THYROID GLAND

C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEM

M982-M983 LYMPHOID LEUKAEMIA

M980-M994 ALL LEUKAEMIAS

M959,M967-M972 NON-HODGKIN LYMPHOMA

M965-M966 HODGKIN LYMPHOMA

M959-M972 ALL LYMPHOMAS



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 74.6 86.6 108.0 110.2 124 123 110 103 100 124 165 139 137 157 150 142F 55.2 65.4 84.2 84.0 76 84 89 80 95 95 102 111 106 108 120 100P 129.8 152.0 192.2 194.2 200 207 199 183 195 219 267 250 243 265 270 242

Mortality M 54.4 61.8 73.0 75.0 74 71 78 60 68 89 79 77 76 81 84 81F 41.4 46.4 58.2 54.4 46 57 54 46 58 52 52 52 62 77 54 67P 95.8 108.2 131.2 129.4 120 128 132 106 126 141 131 129 138 158 138 148

Incidence M 5.4 7.2 18.8 27.4 39 32 42 47 44 60 74 57 61 63 58 64F 2.8 2.4 3.8 9.4 20 13 20 23 23 24 34 25 26 39 23 26P 8.2 9.6 22.6 36.8 59 45 62 70 67 84 108 82 87 102 81 90

Mortality M 1.4 2.0 3.8 7.4 16 8 11 23 16 12 20 23 38 19 21 17F 0.6 0.8 1.6 2.8 8 6 9 9 9 6 13 15 8 11 11 13P 2.0 2.8 5.4 10.2 24 14 20 32 25 18 33 38 46 30 32 30

Incidence M 7.2 8.2 9.4 4.8 2 2 4 3 3 8 2 7 8 7 3 7F 6.4 6.2 7.0 5.4 3 3 5 2 6 6 5 6 4 2 5 6P 13.6 14.4 16.4 10.2 5 5 9 5 9 14 7 13 12 9 8 13

Mortality M 4.8 6.4 5.0 3.4 3 1 1 2 1 5 1 6 6 6 1 3F 4.2 5.0 5.4 4.4 1 3 4 2 5 4 1 3 1 0 2 4P 9.0 11.4 10.4 7.8 4 4 5 4 6 9 2 9 7 6 3 7

Incidence M 52.6 63.6 76.2 116.6 111 116 113 126 137 143 165 162 154 173 194 199F 44.0 45.2 62.6 89.4 82 88 97 87 100 99 96 141 110 99 146 129P 96.6 108.8 138.8 206.0 193 204 210 213 237 242 261 303 264 272 340 328

Mortality M 27.6 46.0 43.0 64.2 69 60 70 66 56 69 86 69 75 80 72 73F 26.2 31.2 41.4 44.2 47 54 59 55 46 54 50 47 68 63 65 57P 53.8 77.2 84.4 108.4 116 114 129 121 102 123 136 116 143 143 137 130

Incidence M 3.8 11.4 27.0 87.0 119 145 135 135 140 158 158 138 169 162 166 156F 2.4 8.4 19.8 57.4 101 81 97 80 95 98 83 90 104 101 91 100P 6.2 19.8 46.8 144.4 220 226 232 215 235 256 241 228 273 263 257 256

Mortality M 2.4 3.6 7.4 22.2 46 37 48 56 46 57 72 49 68 61 89 69F 1.0 2.0 4.8 15.0 30 25 24 37 43 33 49 38 29 38 40 40P 3.4 5.6 12.2 37.2 76 62 72 93 89 90 121 87 97 99 129 109

Incidence M 23.6 31.4 65.8 91.8 89 95 88 103 91 114 89 88 67 85 101 124F 20.0 31.4 60.2 73.0 56 71 76 62 72 83 77 79 71 63 84 69P 43.6 62.8 126.0 164.8 145 166 164 165 163 197 166 167 138 148 185 193

Mortality M 5.0 6.0 6.8 13.4 15 12 16 11 8 21 23 14 12 12 20 26F 1.8 5.8 6.4 9.8 6 14 9 8 18 9 12 16 9 12 14 20P 6.8 11.8 13.2 23.2 21 26 25 19 26 30 35 30 21 24 34 46

Incidence M 3.4 2.2 4.2 9.4 14 14 12 4 6 12 8 7 8 8 9 7F 2.0 1.2 3.2 5.6 11 9 12 8 6 5 10 5 8 1 9 8P 5.4 3.4 7.4 15.0 25 23 24 12 12 17 18 12 16 9 18 15

Mortality M 1.0 1.4 0.8 3.4 0 5 3 1 2 3 4 4 4 5 3 6F 0.8 1.0 0.4 0.8 3 2 2 1 2 1 1 5 2 2 2 1P 1.8 2.4 1.2 4.2 3 7 5 2 4 4 5 9 6 7 5 7

Incidence M 4761.4 5958.2 7887.8 9086.8 10026 10547 11040 11523 12235 12871 13374 13574 13642 14284 14723 14748F 3915.4 4844.4 6096.6 7476.6 8273 7970 8500 8997 9269 9365 9907 10347 10549 10597 11251 11587P 8676.8 10802.6 13984.4 16563.4 18299 18517 19540 20520 21504 22236 23281 23921 24191 24881 25974 26335

Mortality M 2271.4 2722.2 3240.0 3615.0 3850 3862 4067 4060 4136 4397 4441 4456 4691 4672 4852 5050F 1596.8 1898.2 2275.4 2580.4 2833 2768 2929 3058 2949 3101 3164 3200 3311 3343 3506 3601P 3868.2 4620.4 5515.4 6195.4 6683 6630 6996 7118 7085 7498 7605 7656 8002 8015 8358 8651

M980 UNSPECIFIED LEUKAEMIA

TOTAL MALIGNANT NEOPLASMS (C00-C80)

M974-M976 OTHER NEOPLASMS OF LYMPHATIC & HAEMATOPOIETIC TISSUE

M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASES

M998 MYELODYSPLASTIC DISEASES

M973 MYELOMA/PLASMA CELL TUMOURS

M994 OTHER SPECIFIED LEUKAEMIA

M984-M993 MYELOID LEUKAEMIA



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Incidence M 7.3 9.7 10.6 8.1 7.5 6.6 5.5 5.7 6.9 5.1 4.3 5.2 5.4 5.7 5.3 5.4F 1.3 2.1 2.3 2.4 3.1 2.0 1.6 1.5 1.5 1.4 1.1 1.3 1.6 1.2 1.2 1.5P 4.3 5.8 6.4 5.2 5.3 4.3 3.5 3.5 4.1 3.2 2.7 3.2 3.5 3.5 3.2 3.4

Mortality M 0.1 0.2 0.2 0.2 0.3 0.1 0.3 0.3 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1F 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0P 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1

Incidence M 19.4 18.0 18.0 16.2 14.4 14.6 16.0 16.4 15.6 16.9 15.9 16.3 17.1 15.7 15.9 16.2F 4.7 5.3 5.5 4.9 4.5 4.4 4.8 5.5 5.5 5.4 5.1 4.8 5.5 5.0 5.2 5.7P 11.8 11.5 11.6 10.5 9.4 9.5 10.3 10.9 10.5 11.1 10.5 10.5 11.2 10.3 10.5 10.8

Mortality M 6.9 7.4 7.0 5.9 6.2 5.7 6.4 6.4 5.5 5.0 5.5 5.5 5.9 5.2 5.4 4.9F 1.6 1.8 1.6 1.6 1.9 1.5 1.3 1.9 1.2 1.3 1.3 1.5 1.5 1.3 1.4 1.1P 4.1 4.5 4.2 3.7 4.0 3.5 3.8 4.1 3.3 3.1 3.4 3.5 3.6 3.2 3.4 2.9

Incidence M 3.0 3.1 3.2 2.8 2.8 2.5 3.5 3.2 2.2 3.1 3.7 3.4 4.1 3.7 3.9 4.4F 0.9 1.2 1.2 1.3 1.0 1.2 1.1 1.3 0.9 1.7 1.4 1.3 1.5 1.4 1.4 1.5P 1.9 2.1 2.2 2.0 1.9 1.8 2.3 2.3 1.6 2.4 2.6 2.3 2.8 2.5 2.6 3.0

Mortality M 1.2 1.3 1.2 1.1 1.3 0.9 1.5 1.3 0.8 0.7 0.9 1.3 1.2 1.1 1.2 1.4F 0.2 0.5 0.4 0.4 0.4 0.4 0.4 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.5 0.4P 0.7 0.9 0.8 0.8 0.9 0.7 0.9 0.9 0.6 0.5 0.6 0.8 0.7 0.7 0.8 0.9

Incidence M 0.2 0.2 0.4 0.3 0.2 0.4 0.4 0.5 0.2 0.4 0.4 0.7 0.5 0.4 0.6 0.4F 0.2 0.1 0.2 0.2 0.3 0.2 0.2 0.2 0.4 0.2 0.4 0.3 0.2 0.3 0.3 0.2P 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.3 0.4 0.3 0.4 0.5 0.4 0.4 0.4 0.3

Mortality M 0.0 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.2F 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.0P 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1

Incidence M 1.5 1.1 1.1 1.1 0.7 0.7 0.8 1.1 0.8 0.9 0.8 1.1 1.2 1.0 0.7 0.7F 0.4 0.4 0.4 0.4 0.3 0.5 0.3 0.7 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.5P 1.0 0.8 0.8 0.8 0.5 0.6 0.5 0.9 0.5 0.6 0.5 0.7 0.8 0.7 0.4 0.6

Mortality M 0.5 0.4 0.5 0.4 0.2 0.3 0.3 0.4 0.3 0.3 0.4 0.2 0.3 0.4 0.4 0.1F 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.0P 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1

Incidence M 1.9 1.5 1.2 1.1 1.4 1.0 1.1 1.6 1.2 1.5 1.3 0.9 0.9 1.0 0.9 1.2F 0.5 0.8 0.9 0.6 0.4 0.6 0.7 0.6 1.0 0.6 0.6 0.7 0.9 0.8 0.7 0.5P 1.2 1.2 1.1 0.9 0.9 0.8 0.9 1.1 1.1 1.0 0.9 0.8 0.9 0.9 0.8 0.9

Mortality M 0.6 0.5 0.5 0.3 0.4 0.3 0.5 0.5 0.5 0.4 0.6 0.5 0.3 0.5 0.6 0.4F 0.2 0.3 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.1 0.1 0.2 0.1 0.2 0.3 0.2P 0.4 0.4 0.4 0.2 0.3 0.3 0.3 0.4 0.4 0.3 0.3 0.4 0.2 0.3 0.4 0.3

Incidence M 1.1 1.1 1.2 1.3 1.2 1.2 1.2 1.1 1.8 1.4 1.3 1.0 1.4 1.2 0.7 0.9F 0.6 0.6 0.8 0.6 0.7 0.7 0.8 0.7 1.0 0.9 0.8 0.6 0.6 0.7 0.7 1.0P 0.8 0.8 1.0 1.0 0.9 0.9 0.9 0.9 1.3 1.1 1.0 0.8 1.0 1.0 0.7 0.9

Mortality M 0.3 0.3 0.3 0.3 0.5 0.4 0.1 0.5 0.4 0.2 0.4 0.3 0.3 0.2 0.2 0.2F 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.1P 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.1

Incidence M 2.2 1.6 2.0 2.0 1.9 2.2 2.2 2.4 2.8 3.1 3.0 2.9 2.9 3.3 3.6 3.4F 0.5 0.5 0.4 0.5 0.6 0.5 0.5 0.6 0.5 0.6 0.6 0.6 0.5 0.6 0.9 0.7P 1.3 1.0 1.2 1.3 1.2 1.4 1.3 1.5 1.6 1.8 1.8 1.7 1.7 2.0 2.2 2.1

Mortality M 1.0 0.9 1.0 0.8 1.0 0.8 0.8 0.8 0.8 0.8 0.8 1.0 0.9 0.8 0.5 0.8F 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.3 0.2 0.1 0.2 0.1P 0.6 0.6 0.6 0.5 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.6 0.6 0.4 0.3 0.5

Incidence M 0.8 0.5 0.6 0.6 0.5 0.4 0.4 0.6 0.4 0.5 0.4 0.6 0.7 0.4 0.6 0.4F 0.3 0.2 0.3 0.1 0.1 0.1 0.2 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.2 0.2P 0.5 0.4 0.5 0.4 0.3 0.2 0.3 0.4 0.4 0.3 0.3 0.4 0.4 0.3 0.4 0.3

Mortality M 0.5 0.3 0.4 0.3 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2F 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0P 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Table 3. Cancer Incidence and Mortality (ASR (World)/100,000) by Site and Sex, Queensland, 1982 - 2013

C00 LIP


C01,C02 TONGUE

C11 NASOPHARYNX

C03 GUM

C04 FLOOR OF MOUTH






ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 1.5 1.8 1.7 1.3 0.8 0.9 1.2 1.0 0.8 1.2 0.8 1.2 1.2 0.9 0.9 1.1F 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.3 0.2 0.2 0.1 0.1 0.3 0.1 0.1 0.2P 0.8 1.0 0.9 0.8 0.6 0.5 0.7 0.6 0.5 0.7 0.4 0.6 0.7 0.5 0.5 0.6

Mortality M 0.7 1.1 0.9 0.8 0.9 0.8 0.6 0.4 0.7 0.5 0.4 0.5 0.8 0.6 0.7 0.4F 0.1 0.1 0.1 0.1 0.3 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0P 0.4 0.6 0.5 0.5 0.6 0.4 0.4 0.3 0.4 0.3 0.2 0.3 0.4 0.3 0.4 0.2

Incidence M 0.5 0.6 0.6 0.6 0.5 0.8 0.5 0.8 0.7 0.8 0.3 0.8 0.4 0.4 0.5 0.4F 0.1 0.2 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.0P 0.3 0.4 0.3 0.4 0.3 0.4 0.3 0.5 0.4 0.4 0.2 0.4 0.3 0.2 0.3 0.2

Mortality M 0.2 0.4 0.3 0.3 0.2 0.3 0.3 0.6 0.4 0.4 0.3 0.2 0.5 0.3 0.2 0.3F 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.0 0.0P 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.2 0.1 0.2

Incidence M 3.7 4.7 5.6 5.5 5.4 5.0 5.0 4.9 5.4 5.5 4.9 5.4 5.7 5.6 6.2 4.7F 1.6 2.0 2.1 2.1 1.5 1.8 2.2 1.5 1.8 2.1 1.5 1.6 1.7 1.7 1.5 1.4P 2.6 3.3 3.8 3.7 3.4 3.4 3.6 3.1 3.5 3.8 3.2 3.5 3.7 3.6 3.8 3.0

Mortality M 3.1 3.6 4.4 3.7 4.1 3.9 4.3 3.4 4.0 3.9 3.7 3.7 3.9 3.6 4.0 3.9F 1.3 1.4 1.5 1.4 1.1 1.2 1.3 1.5 1.1 1.3 0.9 1.2 0.9 1.0 1.0 1.4P 2.2 2.5 2.9 2.5 2.5 2.5 2.7 2.4 2.5 2.6 2.3 2.4 2.4 2.3 2.5 2.6

Incidence M 12.0 10.5 9.6 8.7 7.6 8.2 7.8 7.2 7.6 6.2 6.9 6.5 6.6 6.2 6.6 6.2F 4.8 3.9 4.1 3.8 3.6 2.9 3.0 3.4 2.7 3.1 3.2 2.8 2.3 2.6 2.8 2.7P 8.1 6.9 6.7 6.0 5.5 5.4 5.2 5.2 5.1 4.6 5.0 4.6 4.4 4.3 4.7 4.4

Mortality M 9.3 7.5 6.8 6.2 6.1 5.4 5.3 4.7 4.4 4.5 4.4 4.3 4.4 4.8 4.5 4.2F 3.6 3.0 2.6 2.3 1.9 2.3 2.3 2.1 1.5 2.2 1.9 2.0 1.7 1.6 1.3 1.2P 6.2 4.9 4.6 4.1 3.9 3.8 3.7 3.3 2.9 3.3 3.1 3.1 3.0 3.2 2.9 2.6

Incidence M 0.8 0.9 1.0 1.4 1.2 1.2 1.2 1.7 1.5 1.7 1.6 2.2 1.8 1.7 2.6 2.1F 0.6 0.7 0.7 0.9 0.8 0.9 1.0 1.4 1.1 1.2 1.1 1.0 1.5 1.5 1.3 1.4P 0.7 0.8 0.8 1.1 1.0 1.0 1.1 1.5 1.3 1.4 1.3 1.6 1.6 1.6 1.9 1.7

Mortality M 0.4 0.4 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.6 0.4 0.7 0.8 0.7 0.5 0.7F 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.5 0.5 0.3 0.2 0.3 0.3 0.4 0.3P 0.3 0.4 0.4 0.4 0.4 0.4 0.3 0.4 0.5 0.5 0.4 0.4 0.5 0.5 0.5 0.5

Incidence M 42.8 47.4 50.3 51.6 48.3 46.4 51.1 48.4 48.9 50.5 47.9 45.3 45.6 46.0 44.0 41.4F 34.7 33.4 36.9 35.9 35.8 34.7 33.4 34.5 37.0 35.0 36.3 32.9 34.1 31.4 30.8 31.5P 38.5 40.0 43.3 43.5 41.9 40.3 42.0 41.4 42.8 42.6 42.0 38.9 39.8 38.5 37.2 36.4

Mortality M 19.3 20.9 20.0 19.8 17.0 16.1 15.7 16.9 16.0 15.4 13.9 15.6 14.1 12.6 13.7 13.8F 15.3 14.3 13.1 12.7 12.1 11.5 11.3 9.9 9.5 10.9 10.0 9.8 10.4 10.1 9.1 9.0P 17.1 17.4 16.3 16.1 14.6 13.7 13.4 13.3 12.6 13.1 11.9 12.6 12.2 11.3 11.3 11.3

Incidence M 28.3 31.7 30.8 32.3 29.6 28.4 30.4 29.4 30.2 31.4 29.1 28.3 28.1 28.6 27.5 25.4F 26.2 24.6 26.6 25.8 25.2 23.6 22.4 24.5 25.6 24.6 26.0 24.2 24.4 22.4 20.9 22.1P 27.1 28.0 28.6 29.0 27.3 25.8 26.2 26.8 27.9 27.9 27.5 26.2 26.2 25.4 24.1 23.8

Mortality M 13.0 13.7 12.0 12.2 11.7 9.3 10.0 10.2 10.2 8.7 8.3 9.4 8.9 7.7 8.3 8.2F 11.9 11.0 9.4 9.1 8.8 7.8 7.3 7.2 6.9 7.6 7.1 7.0 7.8 7.5 6.5 6.7P 12.4 12.2 10.6 10.6 10.2 8.5 8.6 8.6 8.4 8.1 7.7 8.2 8.3 7.6 7.4 7.4

Incidence M 14.4 15.6 19.3 19.0 18.4 17.9 20.4 18.9 18.4 18.6 18.7 16.6 17.2 17.1 16.1 15.6F 8.4 8.6 10.2 9.9 10.1 10.7 10.6 9.5 10.8 10.1 9.9 8.5 9.3 8.5 9.2 9.0P 11.2 11.9 14.5 14.4 14.1 14.2 15.5 14.2 14.5 14.3 14.2 12.5 13.2 12.7 12.5 12.2

Mortality M 6.2 7.2 8.0 7.4 5.3 6.7 5.6 6.7 5.7 6.6 5.4 6.2 5.0 4.9 5.3 5.5F 3.5 3.3 3.6 3.5 3.3 3.6 3.8 2.7 2.4 3.2 2.8 2.7 2.6 2.5 2.5 2.2P 4.7 5.1 5.7 5.4 4.3 5.1 4.6 4.7 4.0 4.8 4.1 4.4 3.8 3.6 3.8 3.8

Incidence M 0.5 0.6 1.0 0.8 1.0 0.8 0.9 1.2 1.0 0.9 0.7 1.0 0.9 0.9 1.0 0.9F 0.6 0.8 0.8 0.8 1.2 1.4 1.0 1.4 1.8 1.0 1.4 1.0 1.2 1.6 1.5 1.3P 0.5 0.7 0.9 0.8 1.1 1.1 1.0 1.3 1.4 1.0 1.1 1.0 1.1 1.3 1.2 1.1

Mortality M 0.1 0.2 0.3 0.3 0.2 0.4 0.4 0.3 0.3 0.6 0.4 0.2 0.4 0.2 0.4 0.4F 0.3 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.4 0.4 0.3 0.2P 0.2 0.2 0.2 0.2 0.2 0.4 0.3 0.3 0.3 0.5 0.3 0.3 0.4 0.3 0.3 0.3



C15 OESOPHAGUS

C16 STOMACH

C17 SMALL INTESTINE


C18 COLON





ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 1.9 2.6 3.2 3.7 3.5 3.6 3.5 4.8 4.7 5.3 5.4 5.2 5.3 5.2 6.0 6.1F 0.7 1.0 1.0 1.4 1.2 1.2 1.7 1.7 1.6 1.5 1.9 1.6 2.0 2.0 2.3 2.4P 1.3 1.8 2.1 2.5 2.4 2.4 2.6 3.2 3.2 3.4 3.6 3.3 3.7 3.5 4.1 4.2

Mortality M 1.5 2.0 2.4 2.6 3.0 2.9 2.4 3.2 3.5 3.4 4.2 4.0 3.7 3.7 3.8 4.3F 0.4 0.7 0.7 0.9 1.0 0.9 1.1 1.4 1.1 0.9 1.3 0.9 1.2 1.2 1.6 2.0P 0.9 1.3 1.5 1.7 1.9 1.9 1.7 2.2 2.3 2.1 2.6 2.4 2.4 2.4 2.7 3.1

Incidence M 1.6 1.7 1.9 2.0 2.0 1.6 1.6 1.7 1.4 1.9 1.6 2.0 1.7 1.6 1.8 1.7F 2.2 2.3 2.3 1.8 1.9 1.8 1.6 1.8 1.8 1.5 1.6 1.6 1.7 1.5 2.0 1.6P 1.9 2.1 2.1 1.9 2.0 1.7 1.6 1.8 1.6 1.7 1.5 1.8 1.7 1.5 1.9 1.7

Mortality M 1.3 1.3 1.2 1.3 1.3 1.5 1.2 1.3 1.0 1.1 0.9 1.0 1.5 1.1 1.2 1.2F 1.7 1.9 1.8 1.3 1.2 1.4 1.2 1.4 1.0 1.3 1.0 1.3 1.4 1.1 1.3 1.2P 1.5 1.6 1.5 1.3 1.3 1.4 1.2 1.4 1.0 1.2 1.0 1.1 1.4 1.1 1.3 1.2

Incidence M 6.8 6.6 6.9 7.1 6.1 7.1 6.9 6.3 8.0 7.8 7.4 6.9 8.0 7.2 7.1 6.7F 4.2 4.7 4.7 5.0 5.0 5.0 5.3 4.9 5.0 4.9 5.3 5.0 4.9 5.8 5.8 4.9P 5.4 5.6 5.8 6.1 5.5 6.0 6.1 5.6 6.5 6.3 6.4 6.0 6.4 6.5 6.4 5.8

Mortality M 6.0 5.8 6.3 6.0 5.9 5.9 6.2 5.6 5.7 7.4 6.8 5.6 6.6 6.6 5.8 5.9F 3.7 3.9 4.2 4.2 4.0 4.2 4.7 4.8 4.3 4.2 4.4 4.4 4.1 4.4 4.7 4.4P 4.8 4.8 5.2 5.1 5.0 5.0 5.4 5.2 5.0 5.8 5.6 5.0 5.3 5.5 5.2 5.1

Incidence M 0.7 0.7 0.7 0.6 0.5 0.5 0.8 0.6 0.6 0.4 0.6 0.5 0.7 0.5 0.4 0.4F 0.4 0.4 0.3 0.3 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.4 0.4P 0.5 0.5 0.5 0.4 0.3 0.3 0.5 0.4 0.5 0.4 0.5 0.3 0.5 0.4 0.4 0.4

Mortality M 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.1 0.1F 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.1P 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1

Incidence M 6.2 5.8 5.3 4.4 4.0 4.1 4.1 3.6 4.1 3.6 3.4 3.3 3.1 2.8 3.0 3.0F 0.5 0.6 0.6 0.4 0.4 0.3 0.4 0.4 0.5 0.4 0.4 0.5 0.5 0.3 0.2 0.3P 3.2 3.1 2.9 2.3 2.2 2.2 2.2 1.9 2.3 2.0 1.8 1.9 1.8 1.5 1.6 1.6

Mortality M 1.6 1.8 1.4 1.2 1.3 1.5 1.7 1.2 1.0 1.1 1.2 1.2 1.2 0.8 1.2 0.8F 0.2 0.2 0.2 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1P 0.8 0.9 0.7 0.6 0.8 0.8 0.9 0.6 0.6 0.6 0.7 0.6 0.6 0.4 0.7 0.4

Incidence M 55.4 51.9 47.3 44.1 38.8 37.2 38.9 39.1 40.5 37.8 38.5 35.5 36.7 35.2 34.5 34.2F 13.0 15.0 16.7 18.4 20.4 17.5 20.4 20.7 20.4 20.9 21.8 23.9 22.2 21.3 20.9 21.8P 32.7 32.2 31.1 30.6 29.1 26.8 29.3 29.5 30.0 29.0 29.7 29.3 29.1 27.8 27.4 27.7

Mortality M 44.9 42.2 39.6 35.4 32.2 30.4 31.7 30.8 30.9 31.2 30.5 27.9 27.9 26.7 26.2 27.1F 9.9 10.5 12.5 13.9 15.6 13.4 14.3 16.2 15.8 15.9 14.2 16.3 16.0 15.2 15.6 14.6P 26.0 25.2 25.1 24.0 23.4 21.4 22.6 23.1 22.9 23.2 22.0 21.7 21.6 20.7 20.6 20.5

Incidence M 0.4 0.4 0.4 0.5 0.7 0.5 0.3 0.3 0.3 0.4 0.3 0.6 0.7 0.3 0.3 0.4F 0.2 0.2 0.2 0.2 0.3 0.4 0.3 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.1 0.4P 0.3 0.3 0.3 0.3 0.5 0.4 0.3 0.3 0.3 0.3 0.3 0.5 0.4 0.3 0.2 0.4

Mortality M 0.3 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.0 0.3 0.0 0.2 0.4 0.1 0.1 0.1F 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1P 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1

Incidence M 1.0 1.3 1.2 1.0 1.4 1.3 1.0 0.8 1.5 1.3 0.8 0.7 1.1 1.3 1.0 1.1F 0.5 0.8 0.8 0.9 1.1 0.5 1.3 0.7 0.6 0.6 1.0 0.6 0.7 0.8 0.5 0.5P 0.8 1.1 1.0 0.9 1.3 0.9 1.1 0.8 1.0 1.0 0.9 0.7 0.9 1.1 0.8 0.8

Mortality M 0.4 0.5 0.5 0.4 0.5 0.4 0.6 0.3 0.2 0.8 0.2 0.4 0.4 0.4 0.4 0.4F 0.2 0.2 0.3 0.2 0.2 0.4 0.2 0.1 0.3 0.5 0.2 0.1 0.2 0.1 0.3 0.3P 0.3 0.4 0.4 0.3 0.3 0.4 0.4 0.2 0.2 0.7 0.2 0.2 0.3 0.2 0.3 0.3

Incidence M 37.5 46.2 50.3 56.7 60.0 55.7 49.8 57.3 51.5 53.7 57.6 57.1 56.2 58.1 58.3 60.6F 35.2 37.3 37.9 41.7 44.9 40.7 39.7 42.0 35.6 39.0 40.6 41.2 40.7 42.3 42.6 44.8P 35.9 41.4 43.7 48.9 52.1 47.9 44.4 49.2 43.2 46.0 48.7 48.8 48.1 50.0 50.1 52.4

Mortality M 4.7 5.5 5.9 5.9 5.0 6.5 6.3 6.1 4.4 5.7 5.5 5.0 5.9 5.9 5.3 7.0F 2.6 2.5 2.5 2.6 2.1 2.5 2.4 2.6 2.6 2.6 2.4 2.3 2.8 2.3 2.3 2.4P 3.6 4.0 4.1 4.2 3.5 4.4 4.2 4.2 3.4 4.0 3.9 3.5 4.3 4.0 3.7 4.6



C25 PANCREAS


C32 LARYNX







ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 1.1 1.8 2.4 2.1 2.6 2.4 2.6 2.5 2.3 3.3 3.9 3.9 3.2 3.4 3.6 3.6F 0.5 0.8 1.0 1.2 1.5 1.2 1.1 1.6 1.5 1.7 1.1 1.5 1.4 1.5 1.7 1.9P 0.7 1.3 1.6 1.6 2.0 1.7 1.8 2.0 1.9 2.4 2.4 2.6 2.3 2.4 2.6 2.7

Mortality M 0.1 0.2 0.4 0.4 0.4 0.3 0.6 0.7 0.3 0.7 0.7 0.6 0.6 0.5 0.6 0.9F 0.0 0.0 0.1 0.2 0.3 0.2 0.0 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.3P 0.0 0.1 0.2 0.3 0.4 0.2 0.3 0.4 0.2 0.4 0.4 0.4 0.4 0.4 0.4 0.6

Incidence M 1.5 2.1 2.5 3.4 3.2 3.1 3.0 2.8 3.5 3.4 3.0 3.0 3.1 3.0 3.3 2.6F 0.1 0.3 0.3 0.5 0.7 0.5 0.5 0.5 0.8 0.5 0.6 0.8 0.8 0.5 0.8 0.6P 0.7 1.1 1.4 1.9 1.9 1.7 1.7 1.6 2.1 1.9 1.7 1.9 1.8 1.7 2.0 1.5

Mortality M 1.2 1.7 2.2 2.8 2.6 3.1 2.6 2.5 2.6 3.2 3.1 2.7 2.9 2.5 3.0 2.3F 0.1 0.2 0.3 0.3 0.6 0.5 0.4 0.4 0.5 0.5 0.6 0.6 0.6 0.6 0.6 0.5P 0.6 0.9 1.2 1.5 1.6 1.7 1.5 1.4 1.5 1.8 1.8 1.6 1.7 1.5 1.7 1.3

Incidence M 0.1 0.6 0.7 0.3 0.3 0.1 0.3 0.1 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.1F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1P 0.0 0.3 0.4 0.1 0.2 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1

Mortality M 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Incidence M 2.1 1.9 2.0 2.3 2.6 2.3 2.3 2.0 1.9 1.5 2.0 1.6 2.0 2.2 2.4 2.1F 1.5 1.3 1.6 1.7 1.5 1.1 1.7 2.8 1.8 1.5 1.4 1.9 1.3 1.7 1.7 1.6P 1.8 1.6 1.8 2.0 2.1 1.7 2.0 2.3 1.8 1.5 1.7 1.7 1.7 1.9 2.0 1.8

Mortality M 0.8 0.6 0.7 0.6 0.9 0.8 0.6 0.9 1.1 0.5 0.5 0.7 0.6 0.5 1.0 0.6F 0.7 0.5 0.5 0.5 0.3 0.5 0.5 0.7 0.9 0.6 0.4 0.3 0.6 0.4 0.5 0.6P 0.7 0.5 0.6 0.6 0.6 0.7 0.5 0.8 1.0 0.5 0.5 0.5 0.6 0.4 0.7 0.6

Incidence M 0.2 0.3 0.2 0.3 0.4 0.3 0.3 0.3 0.5 0.6 0.1 0.5 0.4 0.5 0.5 0.4F 0.4 0.2 0.4 0.9 0.8 1.1 1.1 1.1 1.4 1.4 1.0 1.4 0.9 1.0 1.0 0.9P 0.3 0.3 0.3 0.6 0.6 0.7 0.7 0.7 1.0 1.0 0.6 0.9 0.7 0.7 0.8 0.6

Mortality M 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.0 0.2 0.3F 0.2 0.2 0.1 0.3 0.5 0.6 0.6 0.6 0.8 0.8 0.8 0.7 0.8 0.7 0.9 0.6P 0.2 0.2 0.1 0.3 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.5 0.6 0.4 0.5 0.4

Incidence M 0.7 0.6 0.6 0.6 0.6 0.5 1.0 0.7 0.8 0.7 0.5 0.7 0.7 0.4 0.7 0.7F 61.1 69.7 77.5 88.2 89.8 85.0 84.9 87.1 88.8 83.4 91.1 89.9 91.3 87.9 92.6 93.7P 31.6 35.9 39.5 44.8 45.6 43.2 43.3 44.4 45.2 42.5 46.3 45.8 46.5 44.7 47.3 47.9

Mortality M 0.2 0.1 0.2 0.1 0.0 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1F 18.2 18.6 18.6 16.5 15.0 15.2 14.8 14.9 13.1 13.9 14.1 12.2 12.6 12.6 13.5 12.8P 9.6 9.7 9.7 8.5 7.7 7.9 7.7 7.7 6.7 7.2 7.3 6.3 6.6 6.5 7.0 6.7

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 35.5 32.8 32.7 30.3 29.3 26.7 28.3 30.2 29.3 27.9 28.2 28.5 30.2 29.2 31.6 30.5P 18.1 16.8 16.6 15.4 14.9 13.6 14.4 15.3 14.8 14.2 14.3 14.5 15.3 14.8 16.1 15.5

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 11.2 10.2 9.9 8.4 8.2 7.7 8.7 8.7 8.2 7.7 8.0 7.6 7.3 7.5 7.9 7.4P 5.9 5.4 5.2 4.4 4.2 4.0 4.5 4.5 4.3 4.0 4.1 3.9 3.8 3.9 4.1 3.9

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 1.5 1.3 1.4 1.4 1.3 0.9 1.4 1.1 1.4 1.4 1.4 1.4 1.7 1.6 2.1 1.5P 0.8 0.7 0.7 0.7 0.7 0.5 0.7 0.6 0.7 0.7 0.7 0.7 0.9 0.8 1.1 0.8

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 0.2 0.3 0.3 0.2 0.3 0.1 0.4 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.4 0.3P 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 13.4 11.9 10.2 8.0 6.3 6.4 5.9 7.2 7.3 5.4 5.6 6.0 6.6 6.2 7.0 6.4P 6.7 6.0 5.1 4.0 3.2 3.3 3.0 3.6 3.7 2.7 2.8 3.0 3.3 3.1 3.5 3.2

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 3.2 2.8 2.6 2.1 1.2 1.3 1.7 1.5 1.8 1.1 1.6 1.5 1.5 1.4 1.3 1.3P 1.6 1.4 1.3 1.1 0.6 0.6 0.9 0.8 0.9 0.6 0.8 0.7 0.8 0.7 0.7 0.6

M905 MESOTHELIOMA

M914 KAPOSI SARCOMA



C50 BREAST



C51 VULVA

C53 CERVIX UTERI



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 9.6 9.2 10.4 11.2 11.9 11.4 11.8 12.1 11.3 12.1 12.9 12.3 13.1 12.6 13.5 13.6P 5.0 4.7 5.3 5.7 6.0 5.8 5.9 6.1 5.7 6.1 6.5 6.2 6.6 6.4 6.8 6.9

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 1.7 1.6 1.7 1.7 1.9 1.6 2.0 2.0 1.8 2.0 1.7 1.7 1.3 1.5 2.0 1.6P 0.9 0.8 0.9 0.9 1.0 0.8 1.0 1.1 0.9 1.0 0.9 0.9 0.7 0.8 1.0 0.8

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 9.7 9.2 9.7 8.5 8.5 7.1 7.4 8.0 7.8 7.3 7.0 7.3 7.2 7.4 7.9 7.5P 5.0 4.7 4.9 4.3 4.3 3.6 3.8 4.1 4.0 3.7 3.6 3.8 3.7 3.8 4.0 3.8

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 5.7 5.1 5.0 4.0 4.5 4.3 4.2 4.0 3.8 3.8 3.9 3.6 3.5 3.6 3.6 3.6P 3.0 2.6 2.6 2.1 2.3 2.2 2.1 2.1 2.0 2.0 2.0 1.9 1.8 1.9 1.9 1.9

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 1.4 1.3 1.1 1.2 1.2 0.9 1.9 1.9 1.5 1.8 1.3 1.6 1.7 1.4 1.2 1.4P 0.7 0.7 0.6 0.6 0.6 0.5 1.0 1.0 0.8 0.9 0.7 0.8 0.9 0.7 0.6 0.7

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 0.4 0.4 0.3 0.4 0.3 0.4 0.5 0.9 0.6 0.3 0.5 0.5 0.6 0.6 0.5 0.6P 0.2 0.2 0.2 0.2 0.1 0.2 0.3 0.5 0.3 0.2 0.3 0.2 0.3 0.3 0.3 0.3

Incidence M 47.4 55.4 85.1 74.1 85.1 98.4 108.7 105.0 113.7 122.0 123.5 124.9 112.5 115.6 115.4 108.9F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 20.6 24.4 39.0 34.9 40.8 47.4 52.8 51.1 55.6 59.8 60.5 61.4 55.2 56.9 56.8 53.5

Mortality M 14.5 17.1 19.9 16.7 16.0 15.9 16.7 14.7 14.6 15.1 14.5 13.3 14.7 14.2 13.9 12.9F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 6.0 7.1 8.4 7.2 7.0 6.9 7.3 6.5 6.5 6.7 6.4 5.9 6.5 6.4 6.2 5.7

Incidence M 4.3 3.9 5.2 5.3 7.0 5.5 5.6 6.3 6.3 5.2 6.7 6.8 6.0 6.4 5.9 6.0F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 2.2 2.0 2.6 2.6 3.5 2.7 2.8 3.2 3.1 2.6 3.3 3.4 3.0 3.2 3.0 3.0

Mortality M 0.5 0.3 0.3 0.2 0.1 0.2 0.3 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.1F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.3 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0

Incidence M 0.7 0.7 0.8 0.7 0.7 0.6 0.6 0.4 0.5 0.7 0.8 0.6 0.4 0.7 1.1 0.7F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.3 0.3 0.4 0.4 0.4 0.3 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.4 0.5 0.3

Mortality M 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1

Incidence M 8.9 9.4 11.3 11.9 9.8 11.1 11.0 12.3 13.1 13.0 10.9 13.2 11.9 13.7 14.1 14.1F 5.2 6.1 6.6 6.6 6.4 5.8 6.3 5.5 7.1 6.3 7.0 7.8 7.2 6.8 7.2 7.0P 7.0 7.7 8.9 9.2 8.1 8.4 8.6 8.8 10.0 9.5 8.9 10.5 9.4 10.2 10.6 10.5

Mortality M 3.7 3.8 4.2 3.8 3.3 3.6 3.5 3.3 3.3 3.5 3.0 3.3 3.1 3.7 3.8 3.3F 2.1 2.7 2.4 2.1 2.1 1.8 2.0 1.6 1.8 1.4 1.8 1.7 1.9 1.7 1.6 1.4P 2.8 3.2 3.3 2.9 2.7 2.7 2.7 2.4 2.5 2.4 2.4 2.5 2.4 2.7 2.7 2.3

Incidence M 18.3 17.2 17.3 15.7 13.2 12.7 11.9 12.0 11.7 9.6 9.1 8.8 9.2 8.7 8.9 8.7F 4.9 4.7 4.7 4.2 4.0 3.2 3.5 2.8 3.0 2.7 2.5 2.9 2.7 2.5 2.5 2.5P 11.0 10.4 10.5 9.5 8.2 7.7 7.4 7.1 7.1 6.0 5.6 5.6 5.7 5.4 5.5 5.5

Mortality M 4.3 4.3 4.4 4.1 4.0 3.8 3.3 3.4 3.7 3.5 3.3 3.9 3.3 3.4 3.1 3.2F 1.3 1.2 1.4 1.2 1.1 1.2 1.3 1.1 1.1 1.1 1.4 1.2 0.8 0.8 1.3 1.0P 2.6 2.5 2.7 2.5 2.4 2.3 2.2 2.1 2.3 2.2 2.3 2.4 1.9 2.0 2.1 2.0

Incidence M 1.2 1.3 1.8 1.6 1.3 1.8 0.9 1.5 1.7 1.1 1.6 1.1 1.0 1.1 1.0 1.6F 0.7 1.0 1.1 1.0 0.8 0.9 0.9 1.0 1.1 1.2 1.2 0.6 0.6 0.7 0.8 0.9P 1.0 1.1 1.4 1.3 1.0 1.3 0.9 1.2 1.4 1.1 1.4 0.9 0.8 0.9 0.9 1.2

Mortality M 0.2 0.3 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.3 0.2 0.4 0.1 0.1 0.3F 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.0 0.2 0.2 0.3 0.2 0.1 0.2 0.3P 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.1 0.2 0.3


C61 PROSTATE GLAND

C62 TESTIS



C54 CORPUS UTERI

C56 OVARY

C67 BLADDER

C69 EYE & ADNEXA



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 6.0 6.2 6.5 6.7 6.4 6.0 7.1 7.0 7.0 6.5 6.9 7.4 6.2 6.8 5.5 5.4F 4.6 4.7 4.6 4.9 4.4 4.2 3.5 4.6 4.0 4.3 4.0 5.1 4.6 4.6 4.8 3.8P 5.3 5.4 5.6 5.8 5.4 5.1 5.3 5.8 5.5 5.4 5.4 6.2 5.4 5.7 5.1 4.6

Mortality M 4.7 4.6 4.5 5.1 4.8 4.7 5.2 4.8 5.2 4.5 5.1 5.2 4.9 4.5 4.2 4.2F 3.1 3.6 3.5 3.4 3.7 3.3 2.9 2.7 3.0 2.9 2.7 3.4 2.9 3.2 3.0 3.3P 3.9 4.1 4.0 4.3 4.2 4.0 4.0 3.8 4.1 3.7 3.9 4.3 3.9 3.8 3.6 3.7

Incidence M 1.4 1.4 1.8 2.6 3.0 3.6 2.8 3.4 3.6 4.2 4.1 4.1 4.1 4.9 4.1 4.8F 3.2 3.9 5.6 7.6 8.9 9.2 10.2 11.5 11.4 14.0 12.4 13.2 14.2 12.0 12.4 13.8P 2.3 2.6 3.7 5.1 6.0 6.4 6.5 7.5 7.5 9.1 8.2 8.7 9.1 8.5 8.3 9.3

Mortality M 0.2 0.4 0.3 0.2 0.4 0.3 0.2 0.4 0.5 0.3 0.2 0.3 0.3 0.2 0.4 0.3F 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.3 0.4 0.2 0.3 0.3 0.1P 0.2 0.3 0.2 0.2 0.3 0.2 0.3 0.3 0.4 0.2 0.2 0.4 0.3 0.2 0.3 0.2

Incidence M 0.3 0.4 0.6 0.6 0.2 0.5 0.2 0.4 0.6 0.3 0.5 0.6 0.1 0.3 0.6 0.5F 0.2 0.5 0.4 0.4 0.5 0.3 0.6 0.3 0.4 0.4 0.7 0.2 0.5 0.4 0.4 0.3P 0.3 0.5 0.5 0.5 0.4 0.4 0.4 0.4 0.5 0.4 0.6 0.4 0.3 0.4 0.5 0.4

Mortality M 0.3 0.2 0.3 0.2 0.2 0.4 0.1 0.2 0.1 0.3 0.0 0.0 0.2 0.2 0.1 0.1F 0.1 0.3 0.2 0.2 0.4 0.2 0.2 0.2 0.3 0.1 0.1 0.3 0.1 0.1 0.2 0.2P 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1

Incidence M 12.4 12.3 12.8 11.2 10.8 9.4 9.8 9.0 9.3 9.3 9.9 9.9 9.3 8.8 8.2 8.9F 8.1 7.8 8.8 8.0 6.8 6.0 6.5 6.5 6.3 6.6 6.1 5.8 5.5 4.5 5.3 6.2P 10.1 9.9 10.7 9.5 8.8 7.6 8.1 7.7 7.8 8.0 7.9 7.8 7.3 6.5 6.7 7.5

Mortality M 9.9 9.4 9.5 8.1 7.8 6.6 6.5 6.4 6.3 5.6 6.1 6.7 5.4 6.2 5.4 5.5F 6.4 6.0 6.7 6.2 5.7 4.6 4.6 4.4 4.4 4.1 4.3 3.6 3.9 3.0 3.8 3.8P 8.0 7.6 8.0 7.1 6.8 5.5 5.5 5.4 5.4 4.9 5.2 5.1 4.6 4.5 4.6 4.5

Incidence M 12.0 12.8 14.5 15.5 15.7 16.4 15.2 16.3 16.8 16.4 17.1 16.6 17.9 18.0 19.3 18.5F 8.7 9.8 10.5 11.7 11.2 10.6 11.3 12.5 13.6 11.9 11.0 12.7 11.3 13.0 12.9 13.6P 10.3 11.2 12.4 13.5 13.3 13.4 13.3 14.4 15.1 14.1 14.0 14.5 14.5 15.5 16.0 16.0

Mortality M 5.5 5.5 5.8 5.7 5.1 4.9 4.6 3.2 4.4 3.5 3.4 3.7 3.9 3.9 3.2 4.0F 3.5 3.5 3.6 3.7 4.1 3.0 3.2 2.7 2.3 2.3 2.1 2.0 1.9 2.3 1.6 1.9P 4.4 4.5 4.7 4.6 4.5 3.9 3.8 2.9 3.4 2.9 2.7 2.8 2.9 3.0 2.4 2.9

Incidence M 2.1 2.0 1.8 1.9 2.2 2.0 1.2 2.3 2.4 2.1 2.2 1.9 2.3 2.1 2.3 2.4F 1.1 1.4 1.6 1.7 1.8 1.5 1.6 1.7 2.5 1.7 1.3 2.3 1.7 2.8 2.1 2.0P 1.6 1.7 1.7 1.8 2.0 1.8 1.4 2.0 2.4 1.9 1.7 2.1 2.0 2.5 2.2 2.2

Mortality M 0.7 0.4 0.3 0.3 0.4 0.3 0.3 0.2 0.4 0.4 0.1 0.2 0.2 0.3 0.2 0.3F 0.4 0.3 0.2 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.1 0.2 0.1 0.2 0.0 0.2P 0.5 0.3 0.3 0.2 0.3 0.2 0.2 0.2 0.4 0.3 0.1 0.2 0.1 0.3 0.1 0.2

Incidence M 9.9 10.9 12.6 13.6 13.5 14.4 14.0 14.0 14.3 14.3 14.9 14.7 15.6 15.9 17.0 16.1F 7.7 8.3 8.9 10.0 9.5 9.1 9.7 10.8 11.2 10.2 9.7 10.4 9.6 10.2 10.8 11.6P 8.7 9.5 10.7 11.7 11.3 11.7 11.9 12.4 12.7 12.1 12.2 12.5 12.5 13.0 13.8 13.8

Mortality M 4.8 5.0 5.5 5.4 4.7 4.6 4.3 3.0 4.0 3.0 3.3 3.5 3.8 3.7 3.0 3.7F 3.1 3.3 3.4 3.6 3.9 2.9 2.9 2.5 2.0 2.2 2.0 1.8 1.9 2.0 1.6 1.7P 3.9 4.1 4.4 4.4 4.2 3.7 3.6 2.7 3.0 2.6 2.6 2.6 2.7 2.8 2.2 2.6

Incidence M 12.2 11.5 13.7 13.6 13.5 13.4 13.4 12.0 12.4 14.5 15.3 12.7 13.4 14.2 13.1 12.9F 7.0 7.4 8.8 8.7 9.0 8.8 7.7 7.9 9.4 8.1 9.8 8.6 8.1 8.2 8.2 7.7P 9.4 9.3 11.1 11.1 11.1 11.0 10.5 9.8 10.8 11.2 12.4 10.6 10.7 11.1 10.6 10.2

Mortality M 6.2 6.0 6.5 5.6 5.3 4.9 4.6 4.5 3.9 4.3 4.1 4.0 4.5 4.0 4.3 3.5F 3.6 3.8 3.9 3.4 2.7 3.0 3.4 2.2 2.4 2.6 2.5 2.6 2.5 2.5 2.2 2.6P 4.8 4.8 5.1 4.4 3.9 3.9 3.9 3.3 3.1 3.4 3.2 3.2 3.4 3.2 3.2 3.0

Incidence M 6.2 5.6 6.8 7.4 7.1 7.3 7.5 6.6 7.3 8.1 7.8 6.3 7.3 7.6 7.1 7.1F 3.2 3.5 4.7 4.8 5.4 5.1 3.8 4.3 5.5 4.3 5.7 4.4 4.4 4.4 4.1 4.3P 4.6 4.5 5.7 6.1 6.2 6.2 5.6 5.4 6.3 6.2 6.7 5.3 5.8 6.0 5.6 5.6

Mortality M 2.0 1.9 2.4 2.1 1.9 2.0 1.6 1.6 1.4 1.3 1.3 1.2 1.2 1.2 1.7 1.2F 1.0 1.1 1.3 1.2 1.0 0.9 1.4 0.6 0.6 0.8 0.8 0.8 0.7 0.6 0.9 0.8P 1.5 1.5 1.8 1.6 1.5 1.4 1.4 1.1 1.0 1.0 1.1 1.0 0.9 0.9 1.3 1.0






C73 THYROID GLAND






ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 5.1 5.0 5.5 4.9 5.0 4.9 4.3 3.7 3.6 4.4 5.4 4.7 4.3 4.6 4.5 4.1F 3.3 3.6 3.7 3.5 2.9 3.3 3.3 2.9 3.1 3.1 3.2 3.6 3.1 2.9 3.4 2.8P 4.1 4.2 4.6 4.1 3.9 4.0 3.8 3.3 3.3 3.7 4.2 4.1 3.7 3.7 3.9 3.5

Mortality M 3.7 3.6 3.6 3.0 2.8 2.5 2.7 2.1 2.1 2.6 2.3 2.1 2.2 2.2 2.1 1.9F 2.4 2.4 2.3 2.0 1.5 1.8 1.7 1.3 1.4 1.6 1.4 1.4 1.6 1.7 1.1 1.5P 3.0 2.9 2.9 2.5 2.1 2.1 2.1 1.7 1.8 2.0 1.8 1.7 1.9 1.9 1.6 1.7

Incidence M 0.4 0.4 0.9 1.1 1.3 1.1 1.5 1.5 1.4 1.8 2.0 1.5 1.6 1.7 1.4 1.5F 0.2 0.1 0.2 0.3 0.6 0.3 0.5 0.6 0.6 0.6 0.8 0.5 0.6 0.7 0.5 0.5P 0.3 0.3 0.5 0.7 0.9 0.7 1.0 1.0 1.0 1.1 1.4 1.0 1.1 1.2 0.9 1.0

Mortality M 0.1 0.1 0.2 0.3 0.5 0.3 0.3 0.7 0.4 0.3 0.5 0.6 1.0 0.4 0.5 0.4F 0.0 0.0 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.3 0.3 0.2 0.2 0.2 0.2P 0.1 0.1 0.1 0.2 0.3 0.3 0.3 0.4 0.3 0.2 0.4 0.4 0.5 0.3 0.3 0.3

Incidence M 0.5 0.5 0.4 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.2 0.2 0.2 0.1 0.2F 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.0 0.1 0.2 0.1P 0.4 0.4 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1

Mortality M 0.3 0.4 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.2 0.0 0.1F 0.2 0.2 0.2 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1P 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1

Incidence M 3.5 3.7 3.7 4.8 4.0 4.0 3.7 4.2 4.3 4.4 5.0 4.8 4.4 4.6 5.3 5.1F 2.5 2.1 2.6 3.3 2.5 2.6 3.0 2.6 2.8 2.8 2.7 3.8 2.9 2.5 3.5 2.9P 3.0 2.9 3.0 4.0 3.2 3.2 3.3 3.3 3.5 3.5 3.8 4.2 3.6 3.5 4.4 4.0

Mortality M 1.9 2.6 2.0 2.5 2.3 1.8 2.2 2.0 1.6 1.9 2.3 1.8 1.9 2.1 1.7 1.7F 1.4 1.4 1.5 1.4 1.4 1.4 1.6 1.5 1.2 1.3 1.1 1.1 1.4 1.3 1.3 1.1P 1.6 1.9 1.7 1.9 1.8 1.5 1.9 1.7 1.4 1.6 1.7 1.4 1.6 1.7 1.5 1.4

Incidence M 0.2 0.7 1.3 3.3 4.0 4.7 4.0 3.8 4.0 4.4 4.2 3.4 4.2 3.9 3.8 3.4F 0.1 0.4 0.7 1.8 2.8 2.0 2.5 1.8 2.2 2.3 1.7 2.1 2.2 1.9 1.9 1.9P 0.2 0.5 1.0 2.4 3.3 3.2 3.1 2.7 3.0 3.2 2.9 2.7 3.1 2.8 2.8 2.6

Mortality M 0.1 0.2 0.3 0.8 1.4 1.2 1.3 1.6 1.1 1.4 1.8 1.2 1.5 1.4 1.9 1.4F 0.1 0.1 0.2 0.4 0.7 0.5 0.5 0.9 0.9 0.6 0.9 0.7 0.5 0.6 0.7 0.6P 0.1 0.1 0.2 0.6 1.0 0.8 0.8 1.2 1.0 1.0 1.3 0.9 1.0 1.0 1.2 1.0

Incidence M 1.7 1.8 3.3 3.9 3.6 3.5 3.3 3.5 3.0 3.7 3.0 2.7 2.0 2.5 3.1 3.3F 1.1 1.5 2.5 2.8 2.1 2.4 2.7 1.9 2.3 2.5 2.3 2.3 2.0 1.7 2.3 1.8P 1.4 1.6 2.9 3.4 2.8 3.0 3.0 2.6 2.6 3.1 2.6 2.5 2.0 2.1 2.7 2.6

Mortality M 0.3 0.3 0.3 0.5 0.5 0.4 0.5 0.3 0.2 0.6 0.5 0.4 0.3 0.3 0.5 0.6F 0.1 0.2 0.2 0.3 0.1 0.4 0.2 0.2 0.4 0.2 0.2 0.3 0.2 0.2 0.3 0.3P 0.2 0.3 0.2 0.4 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.2 0.3 0.4 0.4

Incidence M 0.3 0.1 0.2 0.4 0.5 0.4 0.5 0.1 0.2 0.4 0.2 0.2 0.2 0.2 0.2 0.2F 0.1 0.1 0.2 0.2 0.3 0.3 0.4 0.2 0.2 0.2 0.3 0.1 0.3 0.0 0.2 0.3P 0.2 0.1 0.2 0.3 0.4 0.4 0.4 0.2 0.2 0.3 0.3 0.2 0.2 0.1 0.2 0.2

Mortality M 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1F 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0P 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Incidence M 327.2 348.6 395.3 388.2 386.2 390.5 397.2 401.4 411.4 420.4 422.3 417.3 405.2 411.1 410.4 400.1F 250.0 264.8 286.5 304.0 308.2 286.7 293.7 303.4 303.8 297.0 306.7 308.8 307.8 299.0 309.7 313.4P 282.5 300.5 334.9 341.9 343.7 335.1 342.6 349.6 354.9 356.1 362.1 360.8 354.4 353.0 358.2 355.0

Mortality M 153.5 155.5 157.1 146.3 138.2 133.4 134.7 129.7 126.2 129.6 126.0 122.8 125.2 119.9 119.2 119.4F 93.5 94.0 95.0 90.6 89.0 84.6 85.9 85.7 81.0 82.4 80.3 79.4 79.6 77.3 79.5 77.0P 120.1 121.2 122.8 116.0 111.5 106.9 108.2 106.1 101.7 104.2 101.4 99.3 100.6 97.0 97.8 96.6











ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Incidence M 9.9 13.4 15.3 11.6 10.8 8.9 7.9 8.4 9.8 7.0 6.1 7.3 7.6 7.9 7.7 7.7F 1.9 3.2 3.7 3.8 4.5 2.9 2.4 2.4 2.3 2.1 1.7 2.1 2.5 2.0 1.8 2.5P 5.8 8.1 9.2 7.6 7.6 5.9 5.0 5.3 5.9 4.5 3.8 4.6 5.0 4.9 4.6 5.1

Mortality M 0.3 0.2 0.3 0.3 0.4 0.2 0.6 0.6 0.0 0.1 0.2 0.2 0.1 0.1 0.0 0.1F 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0P 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Incidence M 26.8 25.1 25.4 23.0 20.3 20.7 23.0 23.1 23.0 23.9 22.9 23.2 23.8 22.7 22.5 23.0F 6.7 7.6 7.8 7.1 6.3 6.5 6.7 7.7 7.6 7.4 7.7 6.9 7.9 7.4 7.1 7.9P 16.3 15.9 16.2 14.8 13.1 13.4 14.6 15.2 15.0 15.4 15.1 14.8 15.7 14.8 14.6 15.2

Mortality M 10.3 11.1 10.4 9.2 9.1 8.9 9.5 9.8 8.9 7.8 8.7 9.0 9.6 8.2 8.6 8.1F 2.5 2.9 2.6 2.6 3.1 2.6 2.2 2.9 1.8 2.2 2.2 2.4 2.6 2.0 2.4 1.8P 6.1 6.7 6.3 5.7 6.0 5.6 5.7 6.3 5.2 4.9 5.4 5.5 5.9 5.0 5.4 4.8

Incidence M 4.0 4.4 4.3 3.9 4.0 3.4 4.5 4.2 3.3 4.1 5.1 4.6 5.3 5.0 5.1 6.2F 1.4 1.8 1.7 1.9 1.5 1.8 1.6 1.8 1.3 2.3 2.2 1.9 2.0 2.1 2.0 2.0P 2.7 3.0 3.0 2.9 2.7 2.6 3.1 3.0 2.3 3.2 3.6 3.2 3.6 3.6 3.6 4.0

Mortality M 1.7 1.9 1.7 1.7 1.8 1.4 2.1 1.8 1.1 1.0 1.4 2.0 1.7 1.5 1.8 2.0F 0.4 0.7 0.6 0.7 0.7 0.7 0.7 0.7 0.5 0.5 0.5 0.5 0.5 0.5 0.9 0.7P 1.0 1.3 1.2 1.2 1.2 1.1 1.4 1.3 0.8 0.8 0.9 1.2 1.1 1.0 1.4 1.3

Incidence M 0.3 0.3 0.6 0.4 0.2 0.6 0.7 0.7 0.4 0.6 0.7 1.1 0.8 0.8 1.1 0.6F 0.3 0.2 0.3 0.3 0.3 0.4 0.4 0.3 0.7 0.4 0.6 0.5 0.4 0.5 0.3 0.4P 0.3 0.2 0.4 0.4 0.3 0.5 0.5 0.5 0.5 0.5 0.6 0.8 0.6 0.6 0.7 0.5

Mortality M 0.1 0.1 0.3 0.1 0.2 0.3 0.2 0.3 0.2 0.1 0.4 0.1 0.2 0.3 0.2 0.4F 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.2 0.1P 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.2

Incidence M 1.9 1.5 1.5 1.5 0.9 1.1 1.0 1.4 1.0 1.3 1.2 1.5 1.6 1.3 0.9 0.8F 0.6 0.6 0.5 0.6 0.5 0.6 0.3 1.0 0.4 0.3 0.3 0.3 0.5 0.5 0.2 0.7P 1.3 1.0 1.0 1.0 0.7 0.8 0.7 1.2 0.7 0.8 0.8 0.9 1.0 0.9 0.6 0.7

Mortality M 0.7 0.6 0.7 0.6 0.3 0.5 0.5 0.6 0.4 0.5 0.5 0.4 0.4 0.5 0.6 0.2F 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.3 0.1 0.2 0.1 0.3 0.2 0.1 0.1 0.1P 0.4 0.3 0.4 0.4 0.3 0.3 0.3 0.5 0.2 0.3 0.3 0.4 0.3 0.3 0.3 0.1

Incidence M 2.5 2.1 1.7 1.6 1.9 1.3 1.6 2.1 1.7 2.2 1.7 1.5 1.3 1.5 1.4 1.6F 0.8 1.2 1.3 1.0 0.6 0.9 1.0 0.9 1.3 0.9 1.0 1.0 1.3 1.1 1.0 0.9P 1.7 1.6 1.5 1.3 1.3 1.1 1.3 1.5 1.5 1.5 1.4 1.2 1.3 1.3 1.2 1.3

Mortality M 0.9 0.8 0.8 0.5 0.4 0.4 0.7 0.8 0.8 0.7 0.9 0.8 0.4 0.7 0.8 0.7F 0.3 0.5 0.4 0.3 0.3 0.4 0.3 0.5 0.4 0.2 0.3 0.5 0.3 0.3 0.4 0.3P 0.6 0.6 0.6 0.4 0.4 0.5 0.5 0.6 0.6 0.5 0.6 0.6 0.3 0.5 0.6 0.5

Incidence M 1.8 1.7 1.9 2.1 1.9 2.0 2.2 2.0 3.0 2.1 2.0 1.5 2.3 2.0 1.0 1.6F 0.8 0.8 1.1 1.0 1.0 0.9 1.0 1.1 1.3 1.3 1.2 0.7 0.9 0.9 0.9 1.3P 1.2 1.2 1.5 1.5 1.4 1.4 1.5 1.5 2.0 1.7 1.5 1.1 1.6 1.4 1.0 1.4

Mortality M 0.5 0.7 0.6 0.5 0.9 0.6 0.3 0.9 1.1 0.4 0.9 0.5 0.6 0.4 0.4 0.4F 0.2 0.2 0.3 0.2 0.3 0.3 0.1 0.2 0.0 0.1 0.3 0.2 0.3 0.2 0.1 0.1P 0.3 0.4 0.4 0.3 0.6 0.4 0.2 0.5 0.5 0.2 0.6 0.3 0.4 0.3 0.2 0.2

Incidence M 2.8 2.1 2.7 2.7 2.6 2.9 2.9 3.2 3.6 4.1 3.9 3.8 3.8 4.3 4.9 4.4F 0.7 0.7 0.6 0.7 0.8 0.7 0.7 0.8 0.7 0.8 0.8 0.8 0.8 0.8 1.2 0.9P 1.7 1.4 1.6 1.7 1.7 1.8 1.8 2.0 2.1 2.4 2.3 2.3 2.3 2.5 3.0 2.7

Mortality M 1.4 1.2 1.3 1.1 1.3 1.2 1.1 1.2 1.2 1.2 1.1 1.4 1.2 1.1 0.7 1.3F 0.4 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.1 0.3 0.2 0.3 0.3 0.2 0.2 0.2P 0.9 0.7 0.8 0.7 0.8 0.7 0.7 0.7 0.7 0.7 0.6 0.9 0.8 0.7 0.5 0.7

Incidence M 1.1 0.8 0.9 0.7 0.6 0.5 0.5 0.8 0.6 0.6 0.6 0.6 0.8 0.6 0.7 0.5F 0.3 0.3 0.4 0.2 0.1 0.1 0.3 0.1 0.4 0.2 0.2 0.2 0.1 0.2 0.3 0.3P 0.7 0.5 0.6 0.5 0.3 0.3 0.4 0.5 0.5 0.4 0.4 0.4 0.5 0.4 0.5 0.4

Mortality M 0.7 0.5 0.6 0.4 0.1 0.1 0.2 0.4 0.3 0.2 0.4 0.3 0.2 0.2 0.3 0.3F 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0P 0.4 0.3 0.4 0.3 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2

Table 4. Cancer Incidence and Mortality (ASR (Aust 2001)/100,000) by Site and Sex, Queensland, 1982 - 2013

C00 LIP


C01,C02 TONGUE

C11 NASOPHARYNX

C03 GUM

C04 FLOOR OF MOUTH






ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 2.1 2.5 2.3 2.0 1.2 1.3 1.8 1.5 1.2 1.8 1.2 1.7 1.8 1.4 1.3 1.6F 0.3 0.3 0.3 0.3 0.4 0.1 0.3 0.4 0.3 0.2 0.2 0.2 0.4 0.3 0.2 0.4P 1.1 1.3 1.3 1.1 0.8 0.7 1.0 0.9 0.7 0.9 0.7 0.9 1.1 0.8 0.7 1.0

Mortality M 1.1 1.6 1.3 1.3 1.4 1.2 0.9 0.8 1.1 0.9 0.7 0.9 1.3 1.0 1.2 0.7F 0.2 0.1 0.2 0.2 0.4 0.0 0.2 0.3 0.1 0.2 0.1 0.1 0.2 0.0 0.2 0.1P 0.6 0.8 0.7 0.7 0.8 0.6 0.5 0.5 0.6 0.5 0.4 0.5 0.7 0.5 0.7 0.4

Incidence M 0.7 0.9 0.8 0.9 0.7 1.2 0.6 1.2 1.0 1.2 0.5 1.1 0.6 0.6 0.7 0.5F 0.1 0.3 0.2 0.3 0.2 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.2 0.1 0.1 0.1P 0.4 0.6 0.5 0.6 0.5 0.6 0.4 0.7 0.6 0.6 0.3 0.6 0.4 0.4 0.4 0.3

Mortality M 0.3 0.6 0.5 0.5 0.3 0.5 0.6 0.9 0.6 0.5 0.4 0.3 0.8 0.6 0.3 0.5F 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.3 0.1 0.0 0.0P 0.2 0.3 0.3 0.3 0.2 0.3 0.3 0.4 0.4 0.3 0.2 0.2 0.5 0.3 0.2 0.2

Incidence M 5.7 7.4 8.7 9.0 8.6 8.3 8.0 8.2 8.9 8.9 8.0 8.4 8.9 9.4 9.6 7.2F 2.8 3.5 3.5 3.6 2.5 3.4 3.8 2.8 3.3 3.5 2.8 2.9 2.8 3.1 2.7 2.5P 4.2 5.4 6.0 6.1 5.4 5.8 5.8 5.3 5.9 6.0 5.3 5.5 5.7 6.1 6.1 4.8

Mortality M 4.9 5.7 7.1 6.4 7.0 6.6 7.0 5.9 7.0 6.6 6.4 6.2 6.3 5.9 6.8 6.1F 2.3 2.5 2.6 2.6 2.4 2.1 2.4 2.8 2.0 2.7 1.9 2.3 1.6 1.9 2.0 2.7P 3.6 4.0 4.7 4.3 4.5 4.3 4.6 4.3 4.3 4.5 4.0 4.2 3.8 3.8 4.2 4.4

Incidence M 20.7 18.8 16.4 15.0 13.2 13.7 13.8 12.1 13.2 10.8 11.5 10.4 11.1 10.4 10.9 10.3F 8.8 6.8 7.3 6.2 6.2 4.9 5.2 5.7 4.7 5.2 5.2 4.8 4.2 4.4 4.9 4.2P 14.0 12.0 11.4 10.1 9.4 8.9 9.1 8.7 8.7 7.7 8.2 7.5 7.5 7.2 7.8 7.1

Mortality M 16.7 14.2 12.1 11.2 10.7 9.7 9.3 8.7 8.2 8.2 8.0 7.5 7.6 8.1 7.7 7.2F 6.9 5.4 4.9 4.1 3.4 4.1 4.1 3.9 2.7 3.9 3.4 3.5 3.0 3.1 2.5 2.3P 11.1 9.1 8.1 7.2 6.8 6.6 6.4 6.1 5.2 5.8 5.5 5.4 5.1 5.4 5.0 4.6

Incidence M 1.2 1.3 1.5 2.1 1.9 1.7 1.8 2.6 2.1 2.7 2.2 3.4 2.8 2.8 3.8 3.4F 1.0 1.0 1.0 1.3 1.3 1.3 1.6 2.1 1.8 1.8 1.7 1.6 2.2 2.2 1.9 2.0P 1.1 1.2 1.2 1.7 1.6 1.5 1.7 2.3 1.9 2.2 1.9 2.4 2.5 2.4 2.8 2.6

Mortality M 0.6 0.7 0.7 0.9 0.7 0.8 0.5 0.9 0.8 0.9 0.8 1.2 1.2 1.3 0.8 1.2F 0.5 0.6 0.5 0.6 0.6 0.5 0.4 0.5 0.8 0.8 0.7 0.4 0.5 0.5 0.5 0.7P 0.5 0.6 0.6 0.7 0.6 0.6 0.5 0.7 0.8 0.8 0.8 0.8 0.8 0.9 0.7 0.9

Incidence M 68.1 75.3 78.7 81.9 77.9 75.0 81.8 78.5 78.7 79.5 76.8 74.4 73.5 76.2 73.2 67.5F 54.6 53.1 58.1 57.5 58.0 55.7 53.9 57.0 59.9 56.6 58.5 55.0 56.3 52.8 50.9 51.2P 60.6 63.2 67.6 69.0 67.3 64.7 67.1 67.3 68.9 67.5 67.2 64.2 64.6 64.0 61.5 59.1

Mortality M 32.8 35.4 34.3 33.5 28.9 27.6 28.0 29.9 28.5 27.2 25.3 28.2 25.3 23.7 25.3 25.5F 25.7 24.6 22.4 21.9 21.7 19.9 19.7 18.3 17.5 20.0 18.4 17.9 19.0 18.7 16.8 16.6P 28.8 29.4 27.7 27.2 25.2 23.6 23.4 23.7 22.5 23.4 21.7 22.8 22.1 21.0 20.8 20.8

Incidence M 45.4 50.5 49.2 52.8 48.9 47.8 50.8 49.8 49.8 51.2 48.5 48.4 46.8 49.2 47.3 42.4F 41.3 39.5 42.5 42.0 41.6 39.2 37.3 41.3 42.6 40.9 43.0 41.9 41.6 39.2 35.8 37.4P 43.1 44.5 45.5 47.0 45.0 43.1 43.6 45.2 46.0 45.8 45.6 44.9 44.2 44.0 41.3 40.0

Mortality M 22.1 23.2 20.9 21.4 20.1 16.7 18.2 18.7 18.4 16.4 15.4 17.5 16.3 15.4 15.8 15.7F 19.8 19.0 16.4 16.0 15.9 13.9 13.2 13.1 13.0 14.4 13.4 13.5 14.5 14.2 12.3 12.8P 20.8 20.9 18.3 18.5 17.9 15.1 15.5 15.6 15.4 15.3 14.4 15.4 15.5 14.7 13.9 14.1

Incidence M 22.5 24.6 29.3 28.8 28.5 27.0 30.5 28.4 28.3 27.5 28.1 25.5 26.3 26.4 25.3 24.6F 13.1 13.4 15.4 15.2 15.7 16.0 16.1 14.9 16.5 15.2 14.9 12.8 14.1 12.9 14.0 13.3P 17.3 18.5 21.9 21.7 21.7 21.3 23.1 21.5 22.2 21.2 21.2 18.9 20.0 19.4 19.3 18.6

Mortality M 10.6 12.0 13.3 11.9 8.7 10.6 9.5 11.0 9.8 10.6 9.6 10.6 8.7 8.2 9.2 9.7F 5.9 5.6 6.0 5.8 5.6 5.9 6.3 5.2 4.3 5.4 4.9 4.3 4.4 4.4 4.3 3.8P 8.0 8.4 9.3 8.6 7.2 8.2 7.7 8.0 6.9 7.9 7.1 7.2 6.5 6.2 6.6 6.6

Incidence M 0.7 0.9 1.4 1.1 1.5 1.3 1.4 2.0 1.4 1.5 1.0 1.6 1.1 1.4 1.5 1.3F 1.0 1.3 1.2 1.2 1.8 2.0 1.5 2.1 2.6 1.4 2.1 1.4 1.7 2.2 2.2 1.8P 0.9 1.1 1.3 1.2 1.7 1.7 1.5 2.0 2.0 1.4 1.6 1.5 1.4 1.8 1.8 1.5

Mortality M 0.2 0.3 0.4 0.4 0.3 0.7 0.7 0.5 0.7 1.0 0.6 0.4 0.6 0.3 0.5 0.6F 0.4 0.5 0.3 0.4 0.3 0.6 0.5 0.3 0.5 0.6 0.5 0.6 0.6 0.6 0.5 0.4P 0.3 0.4 0.4 0.4 0.3 0.6 0.6 0.4 0.6 0.8 0.5 0.5 0.7 0.4 0.5 0.5



C15 OESOPHAGUS

C16 STOMACH

C17 SMALL INTESTINE


C18 COLON





ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 2.7 3.8 4.9 5.6 5.3 5.8 5.4 7.0 7.3 8.3 8.7 8.2 7.9 8.1 9.2 9.1F 1.1 1.4 1.5 2.1 1.8 1.9 2.5 2.7 2.5 2.5 2.8 2.7 3.1 3.1 3.4 3.7P 1.8 2.5 3.1 3.8 3.5 3.7 3.9 4.8 4.8 5.2 5.6 5.3 5.4 5.5 6.2 6.3

Mortality M 2.1 3.1 3.7 4.1 5.0 4.6 3.8 4.9 5.6 5.4 7.2 6.5 5.9 5.9 6.3 7.1F 0.7 1.1 1.2 1.6 1.5 1.6 1.8 2.2 1.8 1.4 2.1 1.8 2.0 2.0 2.6 3.3P 1.4 2.0 2.4 2.8 3.1 3.1 2.7 3.5 3.6 3.3 4.4 4.0 3.9 3.9 4.4 5.1

Incidence M 2.8 2.8 3.1 3.2 3.4 3.0 2.7 2.8 2.4 3.2 2.9 3.5 2.9 2.7 3.1 2.7F 3.8 4.2 3.8 3.2 3.3 2.9 2.8 3.2 3.1 2.5 2.7 2.9 2.9 2.8 3.4 2.9P 3.3 3.6 3.5 3.3 3.4 2.9 2.8 3.0 2.8 2.9 2.7 3.2 2.9 2.8 3.3 2.8

Mortality M 2.4 2.2 2.0 2.3 2.3 2.6 2.0 2.3 1.8 2.1 1.9 2.1 2.7 1.8 2.3 2.1F 2.9 3.4 3.1 2.5 2.2 2.4 2.2 2.7 1.6 2.4 1.8 2.3 2.4 2.3 2.5 2.3P 2.6 2.9 2.6 2.4 2.3 2.5 2.1 2.5 1.7 2.3 1.8 2.1 2.5 2.1 2.4 2.2

Incidence M 11.3 11.0 11.3 12.0 10.3 12.0 11.4 10.5 13.0 13.4 11.9 11.3 13.3 11.8 11.9 11.5F 7.1 7.8 8.2 8.9 8.6 8.7 9.0 8.8 8.7 8.6 9.4 9.0 9.0 10.3 10.1 8.2P 9.0 9.3 9.7 10.4 9.4 10.3 10.1 9.7 10.8 11.0 10.7 10.1 11.1 11.1 11.0 9.8

Mortality M 10.2 9.6 10.6 10.3 10.0 10.4 10.5 9.1 9.6 12.7 11.2 9.4 11.4 10.8 10.6 10.5F 6.4 6.7 7.4 7.7 7.2 7.4 8.4 8.6 7.9 7.5 7.9 7.8 7.8 8.7 8.7 7.7P 8.1 8.0 8.9 9.0 8.6 8.8 9.4 9.0 8.7 10.0 9.5 8.6 9.5 9.8 9.5 9.0

Incidence M 1.0 0.9 1.1 0.9 0.5 0.7 1.1 0.9 0.8 0.6 0.9 0.7 0.9 0.8 0.7 0.6F 0.5 0.6 0.5 0.4 0.3 0.3 0.4 0.5 0.4 0.5 0.6 0.3 0.4 0.4 0.5 0.5P 0.8 0.7 0.8 0.6 0.4 0.5 0.7 0.7 0.6 0.5 0.7 0.5 0.6 0.6 0.6 0.6

Mortality M 0.5 0.5 0.5 0.4 0.4 0.2 0.4 0.4 0.2 0.2 0.2 0.3 0.4 0.5 0.2 0.2F 0.2 0.3 0.2 0.1 0.1 0.2 0.2 0.2 0.0 0.1 0.2 0.2 0.1 0.1 0.1 0.1P 0.3 0.4 0.4 0.2 0.3 0.2 0.3 0.3 0.1 0.1 0.2 0.2 0.2 0.3 0.2 0.2

Incidence M 8.5 8.1 7.6 6.4 5.7 5.8 6.2 5.3 6.4 5.3 5.1 4.9 4.7 4.3 4.7 4.5F 0.7 0.8 0.9 0.5 0.6 0.5 0.7 0.5 0.7 0.6 0.6 0.8 0.8 0.4 0.3 0.5P 4.4 4.2 4.1 3.3 3.1 3.0 3.3 2.8 3.4 2.9 2.7 2.8 2.7 2.3 2.4 2.4

Mortality M 2.5 2.7 2.2 2.1 2.0 2.4 2.6 1.9 1.8 2.1 2.0 2.1 2.3 1.4 2.1 1.4F 0.3 0.3 0.2 0.1 0.4 0.4 0.2 0.2 0.2 0.2 0.3 0.1 0.3 0.2 0.2 0.1P 1.3 1.4 1.1 1.0 1.1 1.3 1.3 1.0 1.0 1.1 1.1 1.0 1.2 0.7 1.1 0.7

Incidence M 85.9 81.9 75.0 72.3 65.3 62.8 64.4 63.8 68.4 63.5 66.0 59.7 62.5 60.6 59.6 57.7F 18.5 21.8 24.7 28.1 31.5 27.6 32.6 31.6 31.4 32.6 33.9 37.8 35.3 32.8 33.1 34.6P 48.7 48.7 47.5 48.2 46.9 43.6 47.3 46.6 48.5 46.8 48.6 47.7 47.8 45.4 45.4 45.2

Mortality M 72.0 68.7 64.9 59.5 55.8 52.9 55.2 52.1 54.4 53.5 53.0 49.7 48.7 47.5 46.3 48.6F 14.4 15.7 19.1 21.5 24.8 22.0 24.3 26.1 24.9 25.5 23.2 26.5 26.3 24.9 25.7 24.5P 39.9 39.2 39.6 38.6 38.8 36.0 38.4 38.0 38.4 38.4 36.8 36.9 36.5 35.3 35.2 35.5

Incidence M 0.4 0.5 0.5 0.6 0.9 0.6 0.4 0.4 0.4 0.5 0.4 0.6 0.9 0.5 0.3 0.5F 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.3 0.3 0.2 0.3 0.4 0.2 0.4 0.2 0.5P 0.3 0.4 0.4 0.4 0.6 0.5 0.4 0.4 0.3 0.3 0.3 0.5 0.5 0.4 0.3 0.5

Mortality M 0.3 0.2 0.2 0.3 0.3 0.2 0.3 0.1 0.1 0.4 0.1 0.3 0.6 0.2 0.2 0.2F 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.0 0.2 0.1 0.1 0.1 0.1 0.1P 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.3 0.2 0.2 0.1

Incidence M 1.2 1.6 1.3 1.1 1.7 1.3 1.0 0.9 1.6 1.5 0.9 0.9 1.2 1.4 1.0 1.2F 0.6 0.9 0.8 0.9 1.0 0.6 1.4 0.9 0.6 0.7 1.1 0.6 0.7 0.9 0.5 0.6P 0.9 1.2 1.0 1.0 1.3 0.9 1.2 0.9 1.1 1.1 1.0 0.7 1.0 1.1 0.7 0.9

Mortality M 0.5 0.7 0.5 0.5 0.6 0.4 0.6 0.3 0.2 0.9 0.2 0.6 0.5 0.5 0.5 0.4F 0.3 0.3 0.3 0.3 0.2 0.4 0.2 0.1 0.4 0.5 0.4 0.1 0.2 0.0 0.4 0.2P 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.2 0.3 0.7 0.3 0.3 0.3 0.2 0.4 0.3

Incidence M 51.2 63.0 70.5 79.9 85.7 80.8 72.2 83.5 76.4 78.7 85.0 83.5 84.0 84.8 87.0 89.8F 44.6 48.3 49.1 54.4 59.3 53.3 53.1 55.7 48.8 52.6 54.1 55.9 54.4 57.4 58.4 60.9P 47.1 54.8 58.7 66.1 71.4 65.9 61.8 68.5 61.5 64.6 68.3 68.6 68.1 70.2 71.8 74.6

Mortality M 7.1 8.4 9.5 9.3 8.3 10.8 10.9 10.2 7.9 10.5 9.7 8.5 10.5 10.4 9.9 12.4F 3.7 3.8 3.8 4.0 3.4 4.1 3.9 3.7 3.8 3.9 3.9 3.5 4.2 3.7 3.6 3.9P 5.3 5.9 6.4 6.4 5.6 7.1 7.0 6.7 5.6 6.8 6.6 5.8 7.1 6.7 6.4 7.8



C25 PANCREAS


C32 LARYNX







ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 1.7 3.0 3.9 3.9 5.0 4.0 5.0 4.4 4.1 6.2 6.7 7.4 6.0 6.2 6.6 6.7F 0.8 1.3 1.5 2.0 2.4 1.8 1.9 2.5 2.3 2.6 1.9 2.8 2.7 2.7 3.0 3.2P 1.2 2.1 2.6 2.8 3.5 2.8 3.2 3.3 3.1 4.2 4.1 4.9 4.2 4.3 4.7 4.8

Mortality M 0.2 0.5 0.7 0.9 0.9 0.6 1.3 1.4 0.8 1.4 1.3 1.3 1.4 1.1 1.2 1.8F 0.0 0.1 0.2 0.4 0.6 0.3 0.0 0.6 0.3 0.3 0.4 0.2 0.6 0.5 0.3 0.7P 0.1 0.3 0.4 0.6 0.7 0.4 0.6 0.9 0.5 0.8 0.8 0.7 0.9 0.8 0.8 1.2

Incidence M 2.2 3.3 3.8 5.4 5.6 5.5 5.1 5.0 5.6 5.8 5.2 5.4 5.9 5.6 6.1 4.9F 0.2 0.4 0.5 0.8 1.2 0.7 0.9 1.0 1.1 0.7 1.1 1.4 1.2 0.8 1.3 1.0P 1.1 1.7 2.0 2.9 3.2 2.9 2.8 2.8 3.2 3.1 3.0 3.2 3.3 3.0 3.5 2.8

Mortality M 1.8 2.7 3.5 4.6 4.5 6.0 4.9 4.1 4.6 5.9 5.3 4.6 5.6 4.9 6.0 4.7F 0.1 0.3 0.4 0.6 1.1 0.9 0.7 0.9 0.9 0.7 1.1 1.1 1.0 1.0 1.0 0.9P 0.9 1.4 1.8 2.4 2.6 3.2 2.6 2.4 2.6 3.1 3.0 2.7 3.1 2.8 3.3 2.6

Incidence M 0.1 0.7 0.8 0.4 0.4 0.1 0.3 0.2 0.2 0.5 0.4 0.3 0.4 0.4 0.3 0.1F 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1P 0.1 0.4 0.4 0.2 0.2 0.0 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.1

Mortality M 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Incidence M 2.7 2.8 2.8 3.0 3.3 2.9 3.1 2.6 2.6 2.1 2.3 2.4 2.7 3.1 3.1 3.1F 2.0 1.7 2.2 2.2 1.9 1.4 2.1 3.2 2.0 1.8 1.6 2.1 1.5 2.3 2.4 1.8P 2.4 2.2 2.5 2.6 2.6 2.1 2.6 2.9 2.2 1.9 2.0 2.2 2.1 2.6 2.7 2.4

Mortality M 1.1 1.0 1.0 0.9 1.4 1.2 1.1 1.3 1.3 0.6 0.9 1.1 0.9 0.8 1.6 1.0F 0.9 0.7 0.8 0.8 0.4 0.7 0.6 1.0 1.2 0.7 0.5 0.4 0.9 0.6 0.7 0.9P 1.0 0.8 0.9 0.8 0.9 0.9 0.8 1.2 1.3 0.7 0.7 0.7 0.9 0.7 1.1 1.0

Incidence M 0.4 0.4 0.3 0.5 0.4 0.4 0.4 0.4 0.6 0.8 0.2 0.7 0.5 0.6 0.7 0.5F 0.5 0.4 0.6 1.4 1.2 1.6 1.5 1.5 2.1 2.1 1.5 1.9 1.1 1.4 1.2 1.1P 0.5 0.4 0.5 0.9 0.9 1.0 1.0 1.0 1.4 1.5 0.9 1.3 0.8 1.0 1.0 0.8

Mortality M 0.3 0.3 0.1 0.3 0.3 0.2 0.2 0.2 0.1 0.4 0.4 0.3 0.5 0.1 0.3 0.4F 0.3 0.3 0.2 0.6 0.9 0.8 0.9 0.9 1.3 1.3 1.3 1.1 1.3 1.1 1.2 1.0P 0.3 0.3 0.2 0.5 0.7 0.5 0.5 0.6 0.7 0.9 0.8 0.7 0.9 0.6 0.8 0.7

Incidence M 1.0 0.9 0.9 1.0 0.8 0.8 1.5 1.1 1.2 1.3 0.8 1.2 1.1 0.6 1.1 1.2F 86.7 98.1 108.0 121.3 121.1 115.7 115.7 119.1 120.5 114.4 124.4 123.1 124.4 121.2 127.2 129.5P 46.1 51.7 56.4 62.9 62.3 59.6 60.0 61.5 62.1 59.2 64.1 63.6 64.1 62.4 65.7 66.9

Mortality M 0.4 0.3 0.3 0.2 0.0 0.1 0.3 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.3 0.3F 27.2 27.8 28.4 25.1 22.8 23.3 22.2 22.7 19.8 21.9 21.6 18.8 19.4 19.9 20.1 20.7P 14.9 15.1 15.4 13.4 12.1 12.4 12.0 12.1 10.5 11.7 11.4 10.0 10.4 10.6 10.6 11.1

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 48.1 45.3 45.5 42.4 41.0 37.4 40.0 42.2 40.8 39.2 39.4 40.3 42.7 40.8 43.9 42.5P 25.1 23.7 23.7 22.0 21.2 19.4 20.7 21.8 21.0 20.2 20.3 20.8 22.0 21.0 22.6 21.9

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 16.7 15.7 15.3 13.5 13.0 12.5 13.6 14.3 13.2 12.1 13.1 12.3 12.3 12.3 13.2 12.5P 9.0 8.5 8.3 7.3 6.9 6.7 7.2 7.7 7.0 6.4 7.0 6.6 6.6 6.5 7.0 6.7

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 2.5 2.2 2.3 2.2 2.1 1.6 2.0 1.8 2.3 2.2 2.2 2.1 2.5 2.5 3.1 2.3P 1.4 1.3 1.3 1.2 1.1 0.9 1.0 1.0 1.2 1.2 1.1 1.1 1.3 1.3 1.6 1.2

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 0.5 0.7 0.6 0.5 0.6 0.2 0.8 0.5 0.5 0.5 0.7 0.6 0.6 0.6 0.8 0.7P 0.3 0.4 0.3 0.3 0.3 0.1 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4 0.4

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 17.0 15.4 13.1 10.1 8.2 8.4 7.6 9.1 9.1 6.9 7.1 7.6 8.3 7.6 9.0 8.0P 8.6 7.9 6.7 5.2 4.2 4.3 3.9 4.6 4.6 3.5 3.6 3.9 4.2 3.8 4.6 4.1

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 4.5 4.2 3.7 3.0 1.9 2.1 2.4 2.1 2.6 1.6 2.3 2.0 2.1 1.9 2.0 1.8P 2.4 2.3 2.0 1.6 1.0 1.1 1.2 1.1 1.4 0.8 1.2 1.0 1.1 1.0 1.0 0.9

M905 MESOTHELIOMA

M914 KAPOSI SARCOMA



C50 BREAST



C51 VULVA

C53 CERVIX UTERI



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 13.3 13.0 14.9 16.1 16.8 16.1 16.7 17.2 16.0 17.1 18.0 17.4 18.6 17.5 18.8 19.1P 7.0 6.8 7.8 8.4 8.7 8.3 8.6 8.8 8.2 8.7 9.2 8.9 9.5 8.9 9.6 9.8

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 2.6 2.6 2.8 2.8 3.1 2.7 3.3 3.5 3.0 3.2 2.8 3.0 2.4 2.5 3.5 2.7P 1.4 1.5 1.6 1.6 1.6 1.4 1.8 1.9 1.6 1.7 1.5 1.6 1.3 1.3 1.8 1.5

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 13.3 12.9 13.5 12.2 12.1 10.0 11.0 11.3 11.3 10.4 10.2 10.9 10.6 11.0 11.1 10.8P 7.0 6.8 7.1 6.4 6.3 5.1 5.8 5.9 5.9 5.4 5.3 5.7 5.6 5.7 5.8 5.6

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 8.4 7.5 7.6 6.5 7.0 6.9 6.3 6.7 6.1 6.0 6.4 6.0 6.1 6.2 6.0 6.1P 4.5 4.0 4.1 3.5 3.7 3.7 3.3 3.6 3.3 3.2 3.5 3.2 3.3 3.3 3.2 3.3

Incidence M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 2.1 1.9 1.6 1.9 1.7 1.5 2.7 2.8 2.1 2.6 1.9 2.3 2.7 2.2 1.9 2.3P 1.1 1.0 0.9 1.0 0.9 0.8 1.4 1.5 1.1 1.3 1.0 1.2 1.4 1.2 1.0 1.2

Mortality M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0F 0.8 0.7 0.6 0.8 0.5 0.6 0.9 1.6 1.0 0.7 0.8 0.8 1.0 1.0 1.0 1.1P 0.4 0.4 0.3 0.4 0.2 0.4 0.5 0.9 0.5 0.4 0.4 0.4 0.5 0.6 0.5 0.6

Incidence M 92.3 106.2 151.8 128.0 140.5 160.6 171.3 164.4 174.5 185.4 188.1 186.1 168.3 173.6 170.8 162.8F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 38.2 44.6 66.4 57.6 64.8 74.7 80.7 77.7 83.3 88.7 90.1 89.7 80.9 83.9 82.7 78.7

Mortality M 31.8 37.3 43.5 37.3 35.2 35.4 37.2 32.8 33.1 34.3 32.9 30.2 33.9 31.8 32.0 29.6F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 12.5 14.8 17.5 15.3 14.6 14.8 15.5 14.0 14.1 14.5 14.1 13.0 14.5 13.8 13.8 12.7

Incidence M 4.9 4.3 5.8 5.8 7.4 6.3 6.1 7.0 7.0 5.9 7.4 7.5 6.6 7.1 6.4 6.7F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 2.5 2.2 2.9 2.9 3.7 3.1 3.0 3.5 3.5 2.9 3.7 3.7 3.3 3.5 3.2 3.3

Mortality M 0.7 0.4 0.3 0.2 0.1 0.3 0.3 0.3 0.2 0.2 0.1 0.1 0.2 0.1 0.3 0.1F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.3 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0

Incidence M 1.1 1.1 1.2 1.2 1.1 1.0 1.0 0.7 0.8 1.3 1.2 0.9 0.7 1.1 1.7 1.1F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.5 0.5 0.6 0.6 0.5 0.5 0.5 0.3 0.4 0.6 0.6 0.4 0.3 0.5 0.8 0.5

Mortality M 0.2 0.3 0.3 0.3 0.2 0.1 0.2 0.5 0.2 0.2 0.3 0.4 0.1 0.3 0.4 0.4F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0P 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2

Incidence M 13.2 14.2 17.1 17.9 15.5 17.1 16.5 18.5 20.9 20.4 16.5 19.9 18.6 21.1 21.7 20.6F 7.4 8.9 9.9 10.1 10.0 9.3 9.9 8.6 10.8 9.5 10.5 11.6 10.8 10.5 10.9 10.0P 10.1 11.2 13.2 13.8 12.6 13.1 13.0 13.4 15.5 14.7 13.4 15.6 14.5 15.5 16.1 15.1

Mortality M 5.8 6.2 6.8 6.4 5.8 6.0 5.9 5.8 5.6 6.4 5.4 6.1 5.7 6.4 6.8 6.1F 3.3 4.2 4.1 3.8 3.8 3.3 3.9 3.2 3.2 2.6 3.3 3.2 3.0 3.2 3.3 2.6P 4.4 5.1 5.4 5.0 4.7 4.6 4.9 4.4 4.4 4.4 4.3 4.5 4.2 4.7 5.0 4.2

Incidence M 31.1 29.6 29.7 28.5 23.9 22.9 21.7 21.9 21.7 17.2 17.0 17.2 17.6 17.1 16.5 16.6F 8.0 7.6 7.9 7.3 7.3 5.5 6.3 5.0 5.6 5.1 4.6 5.6 4.7 4.7 4.7 4.6P 18.1 17.1 17.5 16.7 14.5 13.4 13.2 12.5 12.8 10.7 10.3 10.8 10.5 10.3 10.1 10.1

Mortality M 8.6 8.7 9.1 8.2 8.5 7.6 6.8 7.0 7.1 7.3 6.8 8.0 7.1 7.2 6.9 7.1F 2.4 2.4 2.7 2.5 2.3 2.4 2.9 2.3 2.2 2.2 2.7 2.6 1.9 1.7 2.7 1.9P 5.0 4.9 5.2 4.9 4.9 4.6 4.7 4.3 4.4 4.5 4.5 4.9 4.2 4.1 4.5 4.2

Incidence M 1.5 1.9 2.6 2.1 1.9 2.5 1.2 2.0 2.3 1.2 1.8 1.5 1.6 1.5 1.3 2.1F 0.8 1.3 1.3 1.2 1.1 1.2 1.4 1.4 1.4 1.5 1.2 0.8 1.0 0.9 0.9 1.1P 1.1 1.6 1.9 1.6 1.5 1.8 1.3 1.6 1.8 1.3 1.5 1.2 1.3 1.2 1.1 1.6

Mortality M 0.3 0.4 0.3 0.3 0.4 0.3 0.4 0.5 0.2 0.4 0.4 0.2 0.5 0.1 0.2 0.4F 0.2 0.2 0.4 0.2 0.1 0.2 0.3 0.3 0.0 0.2 0.3 0.4 0.4 0.2 0.4 0.4P 0.2 0.3 0.3 0.3 0.2 0.2 0.4 0.3 0.1 0.3 0.3 0.3 0.5 0.2 0.3 0.4


C61 PROSTATE GLAND

C62 TESTIS



C54 CORPUS UTERI

C56 OVARY

C67 BLADDER

C69 EYE & ADNEXA



ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 7.3 8.0 8.2 8.7 8.1 8.0 9.0 8.8 8.8 8.2 8.7 9.5 7.9 8.9 7.1 7.1F 5.6 5.8 6.0 6.3 5.5 5.5 4.4 6.3 5.2 5.4 5.1 6.3 5.9 6.0 6.2 5.0P 6.4 6.8 7.0 7.4 6.8 6.7 6.6 7.5 7.0 6.8 6.9 7.9 6.9 7.4 6.6 6.0

Mortality M 5.9 6.2 6.1 7.0 6.6 6.6 6.9 6.6 7.2 6.1 6.9 6.9 6.5 6.7 5.9 5.8F 4.0 4.6 4.7 4.8 5.1 4.5 3.8 4.0 4.1 3.8 4.0 4.6 3.9 4.1 4.4 4.9P 5.0 5.3 5.4 5.9 5.8 5.5 5.3 5.2 5.6 5.0 5.5 5.7 5.2 5.3 5.1 5.3

Incidence M 1.7 1.9 2.4 3.4 3.7 4.9 3.9 4.5 4.8 5.5 5.3 5.5 5.4 6.3 5.3 6.3F 4.0 4.8 6.9 9.4 11.2 11.3 12.5 14.0 14.1 17.1 15.3 16.1 17.8 14.9 15.5 17.1P 2.9 3.3 4.6 6.4 7.5 8.1 8.2 9.2 9.5 11.3 10.3 10.8 11.6 10.6 10.4 11.8

Mortality M 0.4 0.7 0.4 0.4 0.6 0.3 0.4 0.6 0.8 0.5 0.4 0.5 0.5 0.4 0.6 0.4F 0.4 0.4 0.4 0.3 0.3 0.5 0.6 0.3 0.5 0.3 0.5 0.7 0.5 0.5 0.5 0.2P 0.4 0.5 0.4 0.4 0.4 0.4 0.5 0.5 0.7 0.4 0.4 0.7 0.5 0.4 0.6 0.3

Incidence M 0.3 0.4 0.5 0.5 0.2 0.4 0.3 0.3 0.5 0.2 0.4 0.5 0.1 0.3 0.5 0.3F 0.2 0.5 0.4 0.4 0.5 0.4 0.6 0.4 0.5 0.4 0.8 0.2 0.4 0.3 0.5 0.3P 0.3 0.4 0.5 0.5 0.4 0.4 0.4 0.3 0.5 0.3 0.6 0.4 0.3 0.3 0.5 0.3

Mortality M 0.3 0.2 0.3 0.2 0.2 0.3 0.1 0.2 0.1 0.3 0.0 0.1 0.2 0.2 0.1 0.1F 0.1 0.2 0.2 0.2 0.4 0.2 0.3 0.2 0.4 0.1 0.2 0.4 0.1 0.2 0.1 0.2P 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.1 0.2

Incidence M 21.2 20.8 21.8 19.5 18.5 16.6 16.8 16.4 16.1 16.0 18.0 17.6 16.5 16.1 14.9 16.6F 13.8 13.4 14.9 14.3 12.6 10.6 11.9 11.7 11.9 12.4 11.1 10.9 9.9 8.4 9.9 11.4P 16.9 16.7 18.0 16.7 15.5 13.3 14.2 13.9 14.0 14.2 14.3 14.0 13.0 11.9 12.2 13.7

Mortality M 17.1 16.1 16.6 14.6 14.0 11.9 11.9 12.2 12.0 10.4 11.3 12.8 10.3 11.9 10.0 11.6F 10.9 10.6 11.7 11.3 11.1 8.6 8.7 8.6 8.7 8.2 8.5 7.4 7.5 5.9 7.3 7.8P 13.6 13.1 13.9 12.8 12.6 10.1 10.2 10.3 10.3 9.3 9.9 9.8 8.8 8.6 8.5 9.3

Incidence M 16.8 18.7 20.6 22.6 23.7 23.8 21.7 23.5 24.2 24.3 25.4 24.2 25.9 26.4 28.7 27.2F 12.6 14.2 15.1 16.8 15.6 15.6 16.8 18.6 19.0 17.5 16.0 18.5 16.4 18.5 19.3 20.0P 14.6 16.2 17.7 19.5 19.2 19.4 19.2 20.9 21.3 20.7 20.5 21.1 21.0 22.2 23.7 23.4

Mortality M 8.3 8.8 9.5 9.6 9.2 8.5 8.2 6.5 7.7 6.1 6.8 6.9 7.4 7.5 6.0 7.2F 5.6 6.1 6.4 6.4 6.9 5.3 5.4 5.1 4.6 4.3 4.1 4.0 3.6 4.4 3.2 3.9P 6.8 7.3 7.8 7.9 7.8 6.8 6.7 5.7 6.1 5.1 5.3 5.4 5.3 5.8 4.5 5.5

Incidence M 2.5 2.3 2.1 2.1 2.5 2.4 1.4 2.3 2.7 2.4 2.4 2.1 2.8 2.3 2.5 2.6F 1.3 1.6 1.6 1.8 1.7 1.9 1.7 1.8 2.4 2.0 1.4 2.4 1.9 3.0 2.4 2.3P 1.9 2.0 1.9 1.9 2.1 2.1 1.6 2.1 2.5 2.2 1.9 2.3 2.3 2.7 2.5 2.5

Mortality M 1.1 0.7 0.4 0.5 0.5 0.4 0.5 0.4 0.6 0.6 0.2 0.3 0.3 0.3 0.4 0.4F 0.5 0.4 0.3 0.2 0.3 0.1 0.3 0.3 0.3 0.1 0.1 0.4 0.1 0.5 0.0 0.3P 0.8 0.5 0.4 0.3 0.4 0.3 0.3 0.4 0.4 0.3 0.1 0.4 0.2 0.4 0.2 0.4

Incidence M 14.3 16.4 18.5 20.6 21.2 21.4 20.2 21.1 21.5 21.9 23.0 22.1 23.1 24.0 26.2 24.6F 11.3 12.5 13.4 15.0 13.9 13.8 15.0 16.7 16.5 15.6 14.6 16.1 14.5 15.5 16.9 17.7P 12.7 14.2 15.8 17.6 17.2 17.4 17.6 18.8 18.8 18.5 18.6 18.9 18.7 19.6 21.3 20.9

Mortality M 7.3 8.0 9.0 9.1 8.7 8.0 7.8 6.0 7.1 5.5 6.6 6.6 7.1 7.1 5.7 6.8F 5.0 5.7 6.1 6.2 6.6 5.2 5.2 4.8 4.3 4.2 4.0 3.6 3.6 3.9 3.2 3.6P 6.0 6.8 7.4 7.5 7.4 6.5 6.4 5.3 5.6 4.8 5.1 5.0 5.1 5.4 4.3 5.1

Incidence M 18.0 17.5 20.0 19.7 20.5 19.3 18.8 17.8 18.0 20.5 23.2 18.7 19.7 20.6 19.3 18.4F 9.9 10.2 12.3 12.2 12.3 11.2 10.8 10.5 12.5 11.0 13.5 12.1 11.5 11.6 11.4 10.2P 13.4 13.3 15.8 15.7 15.9 14.9 14.5 13.9 15.1 15.5 18.0 15.1 15.4 15.9 15.1 14.1

Mortality M 9.9 10.0 10.6 9.4 8.9 7.8 7.9 7.9 7.4 8.0 7.5 7.6 8.2 7.1 7.5 6.8F 5.6 5.7 6.3 5.4 4.6 4.9 5.7 3.7 4.7 4.1 4.2 4.2 4.1 4.6 4.0 4.5P 7.4 7.5 8.2 7.2 6.5 6.2 6.7 5.6 5.9 5.8 5.7 5.7 5.9 5.7 5.6 5.5

Incidence M 8.2 7.5 9.2 10.0 10.1 10.0 9.9 9.3 10.3 10.5 10.9 8.6 9.8 10.0 9.9 9.1F 4.1 4.5 6.0 6.4 7.0 6.1 5.0 5.4 6.7 5.4 7.1 5.9 5.7 5.6 5.5 5.0P 6.0 5.9 7.4 8.2 8.4 7.9 7.3 7.3 8.3 7.8 8.9 7.1 7.7 7.8 7.6 7.0

Mortality M 2.9 3.0 3.8 3.3 3.0 3.0 2.6 2.8 2.7 2.4 2.2 2.1 2.3 2.1 2.7 2.3F 1.5 1.7 1.9 1.9 1.7 1.5 2.4 1.0 1.3 1.3 1.4 1.2 1.2 1.1 1.4 1.3P 2.1 2.2 2.7 2.5 2.3 2.2 2.4 1.9 1.9 1.8 1.7 1.6 1.7 1.5 2.0 1.8






C73 THYROID GLAND






ICD-O3/SITE Sex 82-86 87-91 92-96 97-01 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013


Incidence M 8.3 8.4 8.5 7.4 7.5 7.2 6.2 5.7 5.2 6.3 8.3 6.8 6.4 7.3 6.6 6.0F 4.9 5.0 5.6 4.9 4.1 4.3 4.5 3.9 4.6 4.4 4.6 4.9 4.6 4.5 4.9 4.0P 6.3 6.4 6.9 6.0 5.6 5.6 5.3 4.7 4.9 5.3 6.3 5.8 5.4 5.7 5.7 4.9

Mortality M 6.2 6.2 6.0 5.3 4.6 4.3 4.6 3.5 3.8 4.7 4.2 3.9 3.7 3.8 3.8 3.6F 3.6 3.6 3.9 3.1 2.4 3.0 2.7 2.1 2.7 2.4 2.2 2.3 2.6 3.1 2.2 2.6P 4.7 4.7 4.8 4.1 3.4 3.5 3.6 2.7 3.2 3.4 3.1 3.0 3.0 3.4 2.9 3.0

Incidence M 0.6 0.7 1.5 2.0 2.7 1.9 2.5 2.7 2.4 3.3 3.9 3.0 3.0 3.0 2.7 2.9F 0.3 0.2 0.2 0.5 1.0 0.6 1.0 1.1 1.0 1.0 1.5 1.0 1.1 1.5 0.9 1.0P 0.4 0.4 0.8 1.2 1.7 1.2 1.7 1.8 1.7 2.1 2.5 1.9 2.0 2.2 1.7 1.9

Mortality M 0.2 0.2 0.3 0.6 1.1 0.5 0.7 1.4 1.0 0.7 1.1 1.2 1.9 1.0 1.0 0.8F 0.1 0.1 0.1 0.2 0.4 0.3 0.4 0.4 0.4 0.2 0.6 0.7 0.3 0.4 0.4 0.4P 0.1 0.1 0.2 0.3 0.7 0.4 0.5 0.8 0.7 0.5 0.8 0.9 1.0 0.6 0.7 0.6

Incidence M 0.9 0.8 0.8 0.3 0.1 0.1 0.2 0.1 0.2 0.4 0.1 0.4 0.4 0.3 0.1 0.3F 0.6 0.5 0.5 0.3 0.1 0.1 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.2 0.2P 0.7 0.6 0.6 0.3 0.1 0.1 0.2 0.1 0.2 0.3 0.2 0.3 0.3 0.2 0.2 0.3

Mortality M 0.7 0.6 0.5 0.3 0.2 0.1 0.1 0.1 0.1 0.3 0.0 0.3 0.3 0.3 0.0 0.1F 0.4 0.4 0.4 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.0 0.0 0.1 0.2P 0.5 0.5 0.4 0.3 0.1 0.1 0.1 0.1 0.2 0.2 0.0 0.2 0.2 0.1 0.1 0.1

Incidence M 6.0 6.2 6.6 8.0 7.0 7.1 6.5 7.0 7.3 7.4 8.1 7.8 7.2 7.9 8.3 8.3F 4.0 3.6 4.3 5.2 4.4 4.5 4.7 4.2 4.6 4.5 4.3 6.1 4.6 4.1 5.8 4.8P 4.9 4.7 5.2 6.5 5.5 5.6 5.5 5.4 5.9 5.8 6.1 6.9 5.8 5.8 7.0 6.5

Mortality M 3.3 4.6 3.9 4.6 4.5 4.0 4.2 4.0 3.1 3.7 4.6 3.5 3.8 3.8 3.3 3.2F 2.4 2.4 2.8 2.5 2.5 2.7 2.9 2.7 2.2 2.4 2.2 1.9 2.8 2.5 2.4 2.1P 2.8 3.3 3.2 3.5 3.4 3.2 3.5 3.2 2.6 3.0 3.3 2.6 3.2 3.1 2.8 2.6

Incidence M 0.5 1.0 2.4 6.6 8.1 9.4 8.5 8.3 8.0 8.8 8.5 7.4 8.4 7.8 7.7 7.1F 0.2 0.6 1.3 3.3 5.2 4.0 4.7 3.6 4.2 4.3 3.6 3.7 4.2 3.8 3.5 3.6P 0.3 0.8 1.8 4.6 6.4 6.3 6.3 5.6 5.9 6.2 5.8 5.3 6.1 5.6 5.3 5.2

Mortality M 0.3 0.4 0.6 1.8 3.3 2.6 3.2 3.6 2.7 3.3 4.0 2.7 3.6 3.0 4.3 3.2F 0.1 0.2 0.3 0.8 1.5 1.2 1.1 1.7 1.9 1.4 2.0 1.5 1.2 1.4 1.5 1.4P 0.2 0.3 0.5 1.2 2.2 1.8 2.0 2.4 2.2 2.2 2.8 2.0 2.2 2.1 2.7 2.2

Incidence M 2.5 3.0 5.3 6.2 5.2 5.5 4.7 5.7 4.7 5.9 4.3 4.3 3.1 3.9 4.2 5.3F 1.7 2.5 4.0 4.3 3.0 3.7 3.8 2.9 3.4 3.8 3.4 3.4 3.0 2.6 3.5 2.7P 2.1 2.7 4.6 5.1 4.1 4.5 4.3 4.2 4.0 4.8 3.9 3.8 3.0 3.2 3.9 3.9

Mortality M 0.6 0.6 0.6 1.1 1.0 0.8 1.0 0.7 0.5 1.1 1.4 0.7 0.6 0.6 0.9 1.2F 0.1 0.5 0.4 0.5 0.3 0.7 0.4 0.4 0.8 0.4 0.5 0.6 0.3 0.4 0.5 0.7P 0.3 0.5 0.5 0.8 0.6 0.7 0.7 0.5 0.7 0.7 0.8 0.7 0.5 0.5 0.7 0.9

Incidence M 0.3 0.2 0.3 0.6 0.8 0.9 0.7 0.2 0.3 0.6 0.4 0.4 0.4 0.4 0.4 0.3F 0.2 0.1 0.2 0.3 0.6 0.5 0.6 0.4 0.3 0.2 0.4 0.2 0.4 0.0 0.4 0.3P 0.2 0.1 0.3 0.5 0.7 0.6 0.7 0.3 0.3 0.4 0.4 0.3 0.4 0.2 0.4 0.3

Mortality M 0.1 0.2 0.1 0.3 0.0 0.3 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.1 0.3F 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.0P 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1

Incidence M 515.4 552.8 622.6 611.6 607.8 615.4 618.6 624.3 640.0 648.1 654.0 642.1 625.8 636.6 633.6 615.5F 359.2 381.5 413.9 439.5 443.9 413.6 427.1 439.3 439.0 430.8 443.0 451.1 446.7 436.5 451.1 453.8P 422.6 451.5 502.6 513.7 515.4 503.7 514.0 523.3 531.2 531.4 540.7 539.5 529.6 530.1 536.6 529.5

Mortality M 257.8 266.3 271.3 256.5 245.1 236.9 241.2 231.6 228.7 233.8 229.9 224.1 228.1 219.0 220.4 221.4F 147.4 150.2 154.2 149.5 148.8 140.7 144.1 145.3 135.8 138.5 137.1 134.7 135.4 133.1 135.3 134.1P 194.0 199.1 204.0 195.9 190.8 182.8 186.6 183.6 176.8 180.9 178.3 174.4 176.6 171.6 173.2 173.1











ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Inci

denc

eM

00

00

20

710

1710

2622

2218

1715

115

182

1.2

0.7

136

5.4

4.7

6.3

F0

00

00

01

43

13

62

109

611

965

0.6

0.2

445

1.5

1.2

1.9

P0

00

02

08

1420

1129

2824

2826

2122

1424

70.

90.

521

03.

43.

03.

9

Rate

Per

M0.

00.

00.

00.

01.

20.

04.

36.

510

.26.

517

.016

.217

.716

.622

.228

.731

.318

.37.

810

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.6

2.5

1.8

0.6

1.9

4.3

1.6

9.3

11.7

10.6

24.7

18.6

2.8

P0.

00.

00.

00.

00.

60.

02.

54.

55.

93.

69.

310

.29.

712

.916

.919

.327

.618

.55.

3

Mor

talit

yM

00

00

00

00

01

00

01

00

01

30.

10.

012

704

0.1

0.0

0.2

F0

00

00

00

00

10

00

00

00

01

0.0

0.0

3117

00.

00.

00.

2P

00

00

00

00

02

00

01

00

01

40.

00.

018

028

0.1

0.0

0.2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

00.

00.

90.

00.

00.

03.

70.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

60.

00.

00.

00.

50.

00.

00.

01.

30.

1

Inci

denc

eM

02

00

01

36

1634

7478

102

9752

4430

2756

63.

82.

343

16.2

14.9

17.6

F0

12

11

15

711

1718

3020

1829

1312

1319

91.

70.

812

95.

74.

96.

5P

03

21

12

813

2751

9210

812

211

581

5742

4076

52.

91.

665

10.8

10.1

11.6

Rate

Per

M0.

01.

30.

00.

00.

00.

61.

93.

99.

622

.348

.357

.382

.289

.268

.084

.285

.499

.024

.410

0,00

0F

0.0

0.7

1.4

0.7

0.6

0.6

3.1

4.5

6.4

10.9

11.4

21.6

16.1

16.7

37.6

23.0

27.0

26.8

8.5

P0.

01.

00.

70.

30.

30.

62.

54.

28.

016

.529

.639

.349

.153

.052

.852

.452

.852

.816

.4

Mor

talit

yM

00

00

02

11

17

721

2830

2727

2020

192

3.8

0.8

122

4.9

4.3

5.7

F0

00

00

00

00

12

56

120

410

1252

1.4

0.1

701

1.1

0.8

1.4

P0

00

00

21

11

89

2634

4227

3130

3224

42.

80.

521

02.

92.

63.

3

Rate

Per

M0.

00.

00.

00.

00.

01.

20.

60.

60.

64.

64.

615

.422

.627

.635

.351

.756

.973

.48.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.3

3.6

4.8

11.1

0.0

7.1

22.5

24.8

2.2

P0.

00.

00.

00.

00.

00.

60.

30.

30.

32.

62.

99.

513

.719

.417

.628

.537

.742

.35.

2

Inci

denc

eM

00

00

00

24

28

2524

2528

1215

16

152

1.0

0.7

149

4.4

3.8

5.2

F0

00

10

12

13

55

89

46

04

251

0.4

0.2

560

1.5

1.1

2.0

P0

00

10

14

55

1330

3234

3218

155

820

30.

80.

423

73.

02.

63.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

01.

22.

61.

25.

216

.317

.620

.125

.715

.728

.72.

822

.06.

610

0,00

0F

0.0

0.0

0.0

0.7

0.0

0.6

1.2

0.6

1.8

3.2

3.2

5.8

7.2

3.7

7.8

0.0

9.0

4.1

2.2

P0.

00.

00.

00.

30.

00.

31.

21.

61.

54.

29.

711

.613

.714

.811

.713

.86.

310

.64.

4

Mor

talit

yM

00

00

01

00

14

311

58

57

13

491.

00.

244

31.

41.

01.

8F

00

00

00

00

01

11

34

01

62

190.

50.

020

230.

40.

20.

6P

00

00

01

00

15

412

812

58

75

680.

80.

173

50.

90.

71.

1

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

00.

00.

62.

62.

08.

14.

07.

46.

513

.42.

811

.02.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.7

2.4

3.7

0.0

1.8

13.5

4.1

0.8

P0.

00.

00.

00.

00.

00.

30.

00.

00.

31.

61.

34.

43.

25.

53.

37.

48.

86.

61.

5

Inci

denc

eM

00

00

00

00

01

20

71

00

12

140.

10.

023

480.

40.

20.

7F

00

00

00

00

00

00

03

41

22

120.

10.

020

540.

20.

10.

4P

00

00

00

00

01

20

74

41

34

260.

10.

021

840.

30.

20.

5

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

71.

30.

05.

60.

90.

00.

02.

87.

30.

610

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.8

5.2

1.8

4.5

4.1

0.5

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

60.

02.

81.

82.

60.

93.

85.

30.

6

Mor

talit

yM

00

00

00

00

00

00

21

11

22

90.

20.

034

770.

20.

10.

4F

00

00

00

00

00

00

01

00

10

20.

10.

021

608

0.0

0.0

0.1

P0

00

00

00

00

00

02

21

13

211

0.1

0.0

6062

0.1

0.1

0.2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

60.

91.

31.

95.

77.

30.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

0.0

0.0

2.2

0.0

0.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

90.

70.

93.

82.

60.

2

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

C0

3 G

UM

C0

1,C

02

TO

NG

UE

C0

1-C

14

, C3

0-C

32

HEA

D A

ND

NEC

K

C0

0 L

IP

41


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

00

00

00

44

103

10

00

220.

10.

111

320.

70.

41.

0F

00

00

00

00

01

13

21

81

00

170.

10.

111

040.

50.

30.

8P

00

00

00

00

01

57

124

91

00

390.

10.

111

150.

60.

40.

8

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

62.

98.

12.

81.

30.

00.

00.

00.

910

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

2.2

1.6

0.9

10.4

1.8

0.0

0.0

0.7

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

31.

62.

54.

81.

85.

90.

90.

00.

00.

8

Mor

talit

yM

00

00

00

00

00

00

22

10

00

50.

10.

042

040.

10.

00.

3F

00

00

00

00

00

00

01

00

01

20.

10.

021

608

0.0

0.0

0.1

P0

00

00

00

00

00

02

31

00

17

0.1

0.0

7041

0.1

0.0

0.2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

61.

81.

30.

00.

00.

00.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

0.0

0.0

0.0

2.1

0.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

81.

40.

70.

00.

01.

30.

2

Inci

denc

eM

00

00

00

00

24

86

84

12

41

400.

30.

169

71.

20.

81.

6F

00

00

00

00

12

13

13

32

25

230.

20.

112

760.

50.

30.

8P

00

00

00

00

36

99

97

44

66

630.

20.

190

40.

90.

71.

1

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

01.

22.

65.

24.

46.

43.

71.

33.

811

.43.

71.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.3

0.6

2.2

0.8

2.8

3.9

3.5

4.5

10.3

1.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

91.

92.

93.

33.

63.

22.

63.

77.

57.

91.

4

Mor

talit

yM

00

00

00

01

00

03

13

22

31

160.

30.

115

550.

40.

20.

6F

00

00

00

00

00

01

02

02

05

100.

30.

032

720.

20.

10.

3P

00

00

00

01

00

04

15

24

36

260.

30.

021

130.

30.

20.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

60.

00.

00.

02.

20.

82.

82.

63.

88.

53.

70.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.0

1.9

0.0

3.5

0.0

10.3

0.4

P0.

00.

00.

00.

00.

00.

00.

00.

30.

00.

00.

01.

50.

42.

31.

33.

73.

87.

90.

6

Inci

denc

eM

01

00

00

00

11

03

19

27

47

360.

20.

168

60.

90.

61.

2F

00

10

10

14

31

56

13

11

13

320.

30.

195

21.

00.

71.

4P

01

10

10

14

42

59

212

38

510

680.

30.

180

30.

90.

71.

2

Rate

Per

M0.

00.

60.

00.

00.

00.

00.

00.

00.

60.

70.

02.

20.

88.

32.

613

.411

.425

.71.

610

0,00

0F

0.0

0.0

0.7

0.0

0.6

0.0

0.6

2.5

1.8

0.6

3.2

4.3

0.8

2.8

1.3

1.8

2.2

6.2

1.4

P0.

00.

30.

30.

00.

30.

00.

31.

31.

20.

61.

63.

30.

85.

52.

07.

46.

313

.21.

5

Mor

talit

yM

00

00

00

10

00

00

01

10

33

90.

20.

070

210.

20.

10.

4F

00

00

00

00

00

00

10

00

11

30.

10.

024

839

0.1

0.0

0.2

P0

00

00

01

00

00

01

11

04

412

0.1

0.0

1095

50.

10.

10.

2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

60.

00.

00.

00.

00.

00.

00.

91.

30.

08.

511

.00.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

2.2

2.1

0.1

P0.

00.

00.

00.

00.

00.

00.

30.

00.

00.

00.

00.

00.

40.

50.

70.

05.

05.

30.

3

Inci

denc

eM

00

00

00

01

812

1723

2016

73

22

111

0.8

0.4

230

3.4

2.8

4.1

F0

00

00

00

03

44

43

12

20

023

0.2

0.1

1041

0.7

0.5

1.1

P0

00

00

00

111

1621

2723

179

52

213

40.

50.

337

92.

11.

72.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

64.

87.

911

.116

.916

.114

.79.

25.

75.

77.

34.

810

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.8

2.6

2.5

2.9

2.4

0.9

2.6

3.5

0.0

0.0

1.0

P0.

00.

00.

00.

00.

00.

00.

00.

33.

25.

26.

89.

89.

37.

85.

94.

62.

52.

62.

9

Mor

talit

yM

00

00

00

00

03

33

62

43

34

310.

60.

184

20.

80.

61.

2F

00

00

00

00

00

01

02

00

11

50.

10.

077

810.

10.

00.

2P

00

00

00

00

03

34

64

43

45

360.

40.

115

370.

50.

30.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

02.

02.

02.

24.

81.

85.

25.

78.

514

.71.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.0

1.9

0.0

0.0

2.2

2.1

0.2

P0.

00.

00.

00.

00.

00.

00.

00.

00.

01.

01.

01.

52.

41.

82.

62.

85.

06.

60.

8

C0

7,C

08

PA

RO

TID

AN

D O

THER

& U

NSP

ECIF

IED

MA

JOR

SA

LIV

AR

Y G

LAN

DS

C0

5,C

06

PA

LATE

AN

D O

THER

& U

NSP

ECIF

IED

PA

RTS

OF

MO

UTH

C0

4 F

LOO

R O

F M

OU

TH

C0

9,C

10

TO

NSI

L A

ND

OR

OP

HA

RY

NX

51


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

01

00

01

11

01

01

04

11

01

130.

10.

118

570.

40.

20.

7F

00

00

00

01

12

11

00

00

00

60.

10.

051

810.

20.

10.

5P

01

00

01

12

13

12

04

11

01

190.

10.

027

380.

30.

20.

5

Rate

Per

M0.

00.

60.

00.

00.

00.

60.

60.

60.

00.

70.

00.

70.

03.

71.

31.

90.

03.

70.

610

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

1.3

0.6

0.7

0.0

0.0

0.0

0.0

0.0

0.0

0.3

P0.

00.

30.

00.

00.

00.

30.

30.

60.

31.

00.

30.

70.

01.

80.

70.

90.

01.

30.

4

Mor

talit

yM

00

00

01

00

00

00

21

03

01

80.

20.

022

580.

20.

10.

4F

00

00

00

00

00

00

01

00

00

10.

00.

021

608

0.0

0.0

0.2

P0

00

00

10

00

00

02

20

30

19

0.1

0.0

4182

0.1

0.1

0.2

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

00.

00.

00.

00.

00.

01.

60.

90.

05.

70.

03.

70.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

30.

00.

00.

00.

00.

00.

00.

80.

90.

02.

80.

01.

30.

2

Inci

denc

eM

00

00

00

00

01

33

611

72

53

410.

30.

261

11.

10.

81.

5F

00

00

00

10

00

10

12

21

10

90.

10.

024

160.

20.

10.

5P

00

00

00

10

01

43

713

93

63

500.

20.

197

80.

60.

50.

8

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

72.

02.

24.

810

.19.

23.

814

.211

.01.

810

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.6

0.0

0.8

1.9

2.6

1.8

2.2

0.0

0.4

P0.

00.

00.

00.

00.

00.

00.

30.

00.

00.

31.

31.

12.

86.

05.

92.

87.

54.

01.

1

Mor

talit

yM

00

00

00

00

00

11

15

22

41

170.

30.

115

120.

40.

20.

6F

00

00

00

00

00

00

00

01

01

20.

10.

011

290

0.0

0.0

0.1

P0

00

00

00

00

01

11

52

34

219

0.2

0.0

2682

0.2

0.1

0.3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

70.

84.

62.

63.

811

.43.

70.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.8

0.0

2.1

0.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

40.

42.

31.

32.

85.

02.

60.

4

Inci

denc

eM

00

00

00

00

00

11

43

31

10

140.

10.

115

150.

40.

20.

6F

00

00

00

00

00

00

10

00

10

20.

00.

024

839

0.0

0.0

0.2

P0

00

00

00

00

01

15

33

12

016

0.1

0.0

2875

0.2

0.1

0.3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

73.

22.

83.

91.

92.

80.

00.

610

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

2.2

0.0

0.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

42.

01.

42.

00.

92.

50.

00.

3

Mor

talit

yM

00

00

00

00

00

00

31

42

10

110.

20.

116

140.

30.

10.

5F

00

00

00

00

00

10

00

00

00

10.

00.

031

450

0.0

0.0

0.2

P0

00

00

00

00

01

03

14

21

012

0.1

0.0

3107

0.2

0.1

0.3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

40.

95.

23.

82.

80.

00.

510

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

01.

20.

52.

61.

81.

30.

00.

3

Inci

denc

eM

00

00

00

01

13

922

3336

3023

109

177

1.2

0.8

119

4.7

4.1

5.5

F0

00

00

00

12

12

36

710

89

1968

0.6

0.2

452

1.4

1.1

1.8

P0

00

00

00

23

411

2539

4340

3119

2824

50.

90.

519

03.

02.

73.

5

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

60.

62.

05.

916

.226

.633

.139

.344

.028

.533

.07.

610

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.2

0.6

1.3

2.2

4.8

6.5

13.0

14.2

20.2

39.2

2.9

P0.

00.

00.

00.

00.

00.

00.

00.

60.

91.

33.

59.

115

.719

.826

.128

.523

.937

.05.

3

Mor

talit

yM

00

00

00

00

21

816

2629

2125

1011

149

3.0

0.7

142

3.9

3.3

4.5

F0

00

00

00

01

13

34

811

516

2476

2.1

0.2

513

1.4

1.1

1.8

P0

00

00

00

03

211

1930

3732

3026

3522

52.

60.

422

42.

62.

33.

0

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

01.

20.

75.

211

.820

.926

.727

.547

.828

.540

.36.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

1.9

2.2

3.2

7.4

14.3

8.9

36.0

49.5

3.3

P0.

00.

00.

00.

00.

00.

00.

00.

00.

90.

63.

56.

912

.117

.120

.827

.632

.746

.24.

8

C1

2,C

13

PY

RIF

OR

M S

INU

S A

ND

HY

PO

PH

AR

YN

X

C1

5 O

ESO

PH

AG

US

C1

4 O

THER

& I

LL-D

EFIN

ED S

ITES

IN

LIP

,OR

AL

CA

VIT

Y &

PH

AR

YN

X

C1

1 N

ASO

PH

AR

YN

X

61


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

00

21

78

822

3241

3736

2624

244

1.7

1.1

946.

25.

57.

0F

00

01

10

13

46

810

514

1710

1118

109

0.9

0.4

254

2.7

2.2

3.2

P0

00

11

03

411

1416

3237

5554

4637

4235

31.

30.

713

84.

43.

94.

9

Rate

Per

M0.

00.

00.

00.

00.

00.

01.

20.

64.

25.

25.

216

.225

.837

.748

.468

.974

.088

.010

.510

0,00

0F

0.0

0.0

0.0

0.7

0.6

0.0

0.6

1.9

2.3

3.8

5.1

7.2

4.0

13.0

22.1

17.7

24.7

37.1

4.7

P0.

00.

00.

00.

30.

30.

00.

91.

33.

24.

55.

211

.614

.925

.435

.242

.346

.555

.57.

6

Mor

talit

yM

00

00

01

02

56

813

2319

1923

2424

167

3.3

0.6

156

4.2

3.6

4.9

F0

00

00

00

11

11

54

411

811

1562

1.7

0.2

483

1.2

0.9

1.6

P0

00

00

10

36

79

1827

2330

3135

3922

92.

60.

423

82.

62.

33.

0

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

01.

33.

03.

95.

29.

618

.517

.524

.944

.068

.388

.07.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.6

0.6

3.6

3.2

3.7

14.3

14.2

24.7

31.0

2.7

P0.

00.

00.

00.

00.

00.

30.

01.

01.

82.

32.

96.

510

.910

.619

.528

.544

.051

.54.

9

Inci

denc

eM

00

00

00

00

11

57

1219

129

106

820.

60.

328

72.

11.

72.

6F

00

00

00

00

36

36

86

47

45

520.

40.

248

31.

41.

01.

8P

00

00

00

00

47

813

2025

1616

1411

134

0.5

0.3

361

1.7

1.4

2.0

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

73.

35.

19.

717

.515

.717

.228

.522

.03.

510

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.8

3.8

1.9

4.3

6.4

5.6

5.2

12.4

9.0

10.3

2.2

P0.

00.

00.

00.

00.

00.

00.

00.

01.

22.

32.

64.

78.

111

.510

.414

.717

.614

.52.

9

Mor

talit

yM

00

00

00

00

01

01

33

93

25

270.

50.

183

10.

70.

41.

0F

00

00

00

00

00

11

11

42

35

180.

50.

116

920.

30.

20.

5P

00

00

00

00

01

12

44

135

510

450.

50.

111

180.

50.

40.

7

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

72.

42.

811

.85.

75.

718

.31.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.7

0.8

0.9

5.2

3.5

6.7

10.3

0.8

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

30.

71.

61.

88.

54.

66.

313

.21.

0

Inci

denc

eM

00

46

310

726

5348

111

123

179

239

248

224

187

114

1582

10.7

6.9

1541

.439

.443

.5F

00

56

1013

2116

3361

8682

110

175

159

185

167

201

1330

11.5

5.0

2031

.529

.933

.3P

00

912

1323

2842

8610

919

720

528

941

440

740

935

431

529

1211

.15.

917

36.4

35.1

37.7

Rate

Per

M0.

00.

02.

63.

81.

85.

94.

316

.931

.731

.472

.590

.414

4.2

219.

832

4.5

428.

753

2.5

418.

168

.210

0,00

0F

0.0

0.0

3.4

4.0

6.1

7.7

13.0

10.2

19.3

39.1

54.7

59.0

88.6

162.

020

6.4

327.

737

5.5

414.

857

.0P

0.0

0.0

3.0

3.9

3.9

6.8

8.7

13.5

25.4

35.3

63.5

74.5

116.

419

1.0

265.

237

6.3

444.

841

6.0

62.6

Mor

talit

yM

00

00

05

14

57

2934

5274

101

9488

8758

111

.52.

442

13.8

12.7

15.0

F0

00

01

34

58

1216

2534

4239

6374

125

451

12.5

1.4

739.

08.

29.

9P

00

00

18

59

1319

4559

8611

614

015

716

221

210

3211

.91.

954

11.3

10.7

12.1

Rate

Per

M0.

00.

00.

00.

00.

02.

90.

62.

63.

04.

618

.925

.041

.968

.013

2.1

179.

925

0.6

319.

125

.110

0,00

0F

0.0

0.0

0.0

0.0

0.6

1.8

2.5

3.2

4.7

7.7

10.2

18.0

27.4

38.9

50.6

111.

616

6.4

258.

019

.3P

0.0

0.0

0.0

0.0

0.3

2.4

1.6

2.9

3.8

6.2

14.5

21.4

34.6

53.5

91.2

144.

420

3.5

280.

022

.2

Inci

denc

eM

00

46

37

618

3127

6175

9413

116

814

812

479

982

6.7

4.3

2425

.423

.927

.1F

00

56

611

149

2033

4457

7112

112

014

614

616

897

78.

43.

628

22.1

20.7

23.5

P0

09

129

1820

2751

6010

513

216

525

228

829

427

024

719

597.

43.

926

23.8

22.7

24.8

Rate

Per

M0.

00.

02.

63.

81.

84.

13.

711

.718

.517

.739

.955

.175

.712

0.4

219.

828

3.2

353.

128

9.7

42.4

100,

000

F0.

00.

03.

44.

03.

66.

58.

75.

711

.721

.228

.041

.057

.211

2.0

155.

725

8.6

328.

334

6.7

41.9

P0.

00.

03.

03.

92.

75.

36.

28.

715

.119

.433

.848

.066

.411

6.2

187.

627

0.5

339.

232

6.2

42.1

Mor

talit

yM

00

00

04

02

45

1615

2844

5755

6162

353

7.0

1.4

748.

27.

49.

1F

00

00

11

43

812

1019

1926

3248

6694

343

9.5

1.0

996.

76.

07.

4P

00

00

15

45

1217

2634

4770

8910

312

715

669

68.

01.

284

7.4

6.9

8.0

Rate

Per

M0.

00.

00.

00.

00.

02.

40.

01.

32.

43.

310

.511

.022

.640

.574

.610

5.3

173.

722

7.4

15.2

100,

000

F0.

00.

00.

00.

00.

60.

62.

51.

94.

77.

76.

413

.715

.324

.141

.585

.014

8.4

194.

014

.7P

0.0

0.0

0.0

0.0

0.3

1.5

1.2

1.6

3.5

5.5

8.4

12.4

18.9

32.3

58.0

94.8

159.

620

6.0

15.0

C1

8 C

OLO

N

C1

8-C

20

,C2

18

CO

LOR

ECTA

L

C1

7 S

MA

LL I

NTE

STIN

E

C1

6 S

TOM

AC

H

71


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

03

18

2121

5047

8510

178

7562

3558

74.

02.

540

15.6

14.4

16.9

F0

00

04

27

712

2540

2338

5238

3821

3334

02.

91.

474

9.0

8.1

10.1

P0

00

04

58

1533

4690

7012

315

311

611

383

6892

73.

51.

952

12.2

11.4

13.0

Rate

Per

M0.

00.

00.

00.

00.

01.

80.

65.

212

.513

.832

.734

.568

.592

.910

2.1

143.

517

6.5

128.

425

.310

0,00

0F

0.0

0.0

0.0

0.0

2.4

1.2

4.3

4.5

7.0

16.0

25.4

16.5

30.6

48.1

49.3

67.3

47.2

68.1

14.6

P0.

00.

00.

00.

01.

21.

52.

54.

89.

714

.929

.025

.449

.570

.675

.610

4.0

104.

389

.819

.9

Mor

talit

yM

00

00

01

12

12

1318

2429

4338

2725

224

4.4

1.0

100

5.5

4.8

6.3

F0

00

00

20

20

05

615

157

158

2910

42.

90.

428

02.

21.

82.

7P

00

00

03

14

12

1824

3944

5053

3554

328

3.8

0.7

148

3.8

3.4

4.3

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

61.

30.

61.

38.

513

.219

.326

.756

.372

.776

.991

.79.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

1.2

0.0

1.3

0.0

0.0

3.2

4.3

12.1

13.9

9.1

26.6

18.0

59.8

4.5

P0.

00.

00.

00.

00.

00.

90.

31.

30.

30.

65.

88.

715

.720

.332

.648

.844

.071

.37.

1

Inci

denc

eM

00

00

00

00

11

23

59

52

22

320.

20.

172

90.

90.

61.

2F

00

00

00

01

27

68

65

43

31

460.

40.

255

91.

31.

01.

8P

00

00

00

01

38

811

1114

95

53

780.

30.

263

11.

10.

91.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

71.

32.

24.

08.

36.

53.

85.

77.

31.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.2

4.5

3.8

5.8

4.8

4.6

5.2

5.3

6.7

2.1

2.0

P0.

00.

00.

00.

00.

00.

00.

00.

30.

92.

62.

64.

04.

46.

55.

94.

66.

34.

01.

7

Mor

talit

yM

00

00

00

00

01

02

24

11

21

140.

30.

118

810.

40.

20.

6F

00

00

00

00

00

11

02

01

15

110.

30.

040

180.

20.

10.

4P

00

00

00

00

01

13

26

12

36

250.

30.

025

640.

30.

20.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

01.

51.

63.

71.

31.

95.

73.

70.

610

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.7

0.0

1.9

0.0

1.8

2.2

10.3

0.5

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

31.

10.

82.

80.

71.

83.

87.

90.

5

Inci

denc

eM

30

00

00

02

48

1945

3426

2716

1719

220

1.5

0.9

116

6.1

5.3

7.0

F1

00

00

01

11

58

138

1216

810

1498

0.8

0.4

276

2.4

2.0

2.9

P4

00

00

01

35

1327

5842

3843

2427

3331

81.

20.

616

44.

23.

84.

7

Rate

Per

M1.

80.

00.

00.

00.

00.

00.

01.

32.

45.

212

.433

.127

.423

.935

.330

.648

.469

.79.

510

0,00

0F

0.6

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.6

3.2

5.1

9.4

6.4

11.1

20.8

14.2

22.5

28.9

4.2

P1.

30.

00.

00.

00.

00.

00.

31.

01.

54.

28.

721

.116

.917

.528

.022

.133

.943

.66.

8

Mor

talit

yM

00

00

00

03

14

1023

2523

1823

1919

168

3.3

0.7

146

4.3

3.7

5.0

F0

00

00

01

02

26

1011

616

99

1587

2.4

0.3

307

2.0

1.6

2.5

P0

00

00

01

33

616

3336

2934

3228

3425

52.

90.

519

93.

12.

73.

5

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

01.

90.

62.

66.

516

.920

.121

.123

.644

.054

.169

.77.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

1.2

1.3

3.8

7.2

8.9

5.6

20.8

15.9

20.2

31.0

3.7

P0.

00.

00.

00.

00.

00.

00.

31.

00.

91.

95.

212

.014

.513

.422

.229

.435

.244

.95.

5

Inci

denc

eM

00

00

00

00

12

34

915

125

68

650.

40.

337

71.

71.

32.

1F

00

00

00

00

13

26

811

711

1613

780.

70.

337

61.

61.

32.

0P

00

00

00

00

25

510

1726

1916

2221

143

0.5

0.3

375

1.7

1.4

2.0

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

61.

32.

02.

97.

213

.815

.79.

617

.129

.32.

810

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.9

1.3

4.3

6.4

10.2

9.1

19.5

36.0

26.8

3.3

P0.

00.

00.

00.

00.

00.

00.

00.

00.

61.

61.

63.

66.

812

.012

.414

.727

.627

.73.

1

Mor

talit

yM

00

00

00

00

11

21

68

97

77

491.

00.

249

21.

20.

91.

6F

00

00

00

00

00

12

49

910

1216

631.

70.

246

51.

20.

91.

5P

00

00

00

00

11

33

1017

1817

1923

112

1.3

0.2

478

1.2

1.0

1.4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

71.

30.

74.

87.

411

.813

.419

.925

.72.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.4

3.2

8.3

11.7

17.7

27.0

33.0

2.7

P0.

00.

00.

00.

00.

00.

00.

00.

00.

30.

31.

01.

14.

07.

811

.715

.623

.930

.42.

4

C2

3,C

24

GA

LLB

LAD

DER

AN

D O

THER

& U

NSP

ECIF

IED

PA

RTS

OF

BIL

IAR

Y T

RA

CT

C2

2 L

IVER

& I

NTR

AH

EPA

TIC

BIL

E D

UC

TS

C2

1 A

NU

S &

AN

AL

CA

NA

L

C1

9,C

20

REC

TOSI

GM

OID

JU

NC

TIO

N A

ND

REC

TUM

81


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

00

04

48

1818

3232

5340

2928

266

1.8

1.2

856.

75.

97.

6F

00

00

00

12

55

618

3030

3022

2944

222

1.9

0.8

130

4.9

4.3

5.6

P0

00

00

01

69

1324

3662

6283

6258

7248

81.

91.

010

35.

85.

36.

3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

02.

62.

45.

211

.813

.225

.829

.469

.376

.682

.610

2.7

11.5

100,

000

F0.

00.

00.

00.

00.

00.

00.

61.

32.

93.

23.

812

.924

.227

.838

.939

.065

.290

.89.

5P

0.0

0.0

0.0

0.0

0.0

0.0

0.3

1.9

2.7

4.2

7.7

13.1

25.0

28.6

54.1

57.0

72.9

95.1

10.5

Mor

talit

yM

00

00

00

01

46

1313

3036

3440

3629

242

4.8

1.0

995.

95.

26.

7F

00

00

00

00

41

710

2135

2829

2550

210

5.8

0.8

132

4.4

3.8

5.0

P0

00

00

00

18

720

2351

7162

6961

7945

25.

20.

911

45.

14.

65.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

62.

43.

98.

59.

624

.233

.144

.576

.610

2.5

106.

410

.410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.3

0.6

4.5

7.2

16.9

32.4

36.3

51.4

56.2

103.

29.

0P

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.3

2.4

2.3

6.4

8.4

20.5

32.7

40.4

63.5

76.6

104.

39.

7

Inci

denc

eM

00

00

00

00

10

23

13

00

32

150.

10.

026

070.

40.

20.

6F

01

10

00

11

01

01

11

22

01

130.

10.

116

890.

40.

20.

7P

01

10

00

11

11

24

24

22

33

280.

10.

020

410.

40.

30.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

01.

32.

20.

82.

80.

00.

08.

57.

30.

610

0,00

0F

0.0

0.7

0.7

0.0

0.0

0.0

0.6

0.6

0.0

0.6

0.0

0.7

0.8

0.9

2.6

3.5

0.0

2.1

0.6

P0.

00.

30.

30.

00.

00.

00.

30.

30.

30.

30.

61.

50.

81.

81.

31.

83.

84.

00.

6

Mor

talit

yM

00

00

00

00

00

00

12

00

11

50.

10.

075

640.

10.

00.

3F

00

00

00

00

00

01

11

00

01

40.

10.

081

640.

10.

00.

3P

00

00

00

00

00

01

23

00

12

90.

10.

078

360.

10.

00.

2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

81.

80.

00.

02.

83.

70.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.8

0.9

0.0

0.0

0.0

2.1

0.2

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

40.

81.

40.

00.

01.

32.

60.

2

Inci

denc

eM

00

00

00

00

26

1210

2015

1813

93

108

0.7

0.5

203

3.0

2.4

3.6

F0

00

00

00

00

10

41

01

31

011

0.1

0.1

1829

0.3

0.1

0.5

P0

00

00

00

02

712

1421

1519

1610

311

90.

50.

336

91.

61.

31.

9

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

01.

23.

97.

87.

316

.113

.823

.624

.925

.611

.04.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

2.9

0.8

0.0

1.3

5.3

2.2

0.0

0.5

P0.

00.

00.

00.

00.

00.

00.

00.

00.

62.

33.

95.

18.

56.

912

.414

.712

.64.

02.

6

Mor

talit

yM

00

00

00

00

00

03

54

77

24

320.

60.

261

70.

80.

51.

1F

00

00

00

00

00

01

10

00

10

30.

10.

013

120

0.1

0.0

0.2

P0

00

00

00

00

00

46

47

73

435

0.4

0.1

1197

0.4

0.3

0.6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

24.

03.

79.

213

.45.

714

.71.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.8

0.0

0.0

0.0

2.2

0.0

0.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

52.

41.

84.

66.

43.

85.

30.

8

Inci

denc

eM

00

01

10

05

728

8395

171

245

244

196

151

137

1364

9.2

6.0

1734

.232

.436

.1F

00

00

04

22

922

6376

119

167

127

127

111

7790

67.

83.

827

21.8

20.4

23.2

P0

00

11

42

716

5014

617

129

041

237

132

326

221

422

708.

64.

921

27.7

26.5

28.8

Rate

Per

M0.

00.

00.

00.

60.

60.

00.

03.

24.

218

.354

.269

.813

7.7

225.

331

9.2

375.

143

0.0

502.

558

.810

0,00

0F

0.0

0.0

0.0

0.0

0.0

2.4

1.2

1.3

5.3

14.1

40.1

54.7

95.8

154.

616

4.8

225.

024

9.6

158.

938

.8P

0.0

0.0

0.0

0.3

0.3

1.2

0.6

2.3

4.7

16.2

47.0

62.2

116.

819

0.0

241.

729

7.2

329.

228

2.6

48.8

Mor

talit

yM

00

00

01

12

811

4372

111

195

212

170

156

148

1130

22.4

4.8

2127

.125

.528

.7F

01

00

00

11

513

3758

6510

592

100

8482

644

17.9

2.6

3914

.613

.515

.8P

01

00

01

23

1324

8013

017

630

030

427

024

023

017

7420

.53.

727

20.5

19.5

21.5

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

61.

34.

87.

228

.152

.989

.417

9.3

277.

432

5.4

444.

254

2.8

48.7

100,

000

F0.

00.

70.

00.

00.

00.

00.

60.

62.

98.

323

.541

.752

.397

.211

9.4

177.

218

8.9

169.

227

.6P

0.0

0.3

0.0

0.0

0.0

0.3

0.6

1.0

3.8

7.8

25.8

47.3

70.9

138.

419

8.1

248.

430

1.5

303.

738

.1

C2

5 P

AN

CR

EAS

C3

3,C

34

TR

AC

HEA

AN

D B

RO

NC

HU

S &

LU

NG

C3

2 L

AR

YN

X

C3

0,C

31

NA

SAL

CA

VIT

Y &

MID

DLE

EA

R A

ND

AC

CES

SOR

Y S

INU

SES

91


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

02

11

01

01

13

21

00

130.

10.

116

770.

40.

20.

7F

10

00

00

11

22

12

01

10

00

120.

10.

023

110.

40.

20.

8P

10

00

02

22

23

13

14

31

00

250.

10.

119

480.

40.

30.

6

Rate

Per

M0.

00.

00.

00.

00.

01.

20.

60.

60.

00.

70.

00.

70.

82.

82.

61.

90.

00.

00.

610

0,00

0F

0.6

0.0

0.0

0.0

0.0

0.0

0.6

0.6

1.2

1.3

0.6

1.4

0.0

0.9

1.3

0.0

0.0

0.0

0.5

P0.

30.

00.

00.

00.

00.

60.

60.

60.

61.

00.

31.

10.

41.

82.

00.

90.

00.

00.

5

Mor

talit

yM

00

00

01

00

10

01

10

00

00

40.

10.

073

380.

10.

00.

4F

00

00

00

01

00

00

02

00

00

30.

10.

080

370.

10.

00.

3P

00

00

01

01

10

01

12

00

00

70.

10.

076

900.

10.

00.

2

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

00.

00.

60.

00.

00.

70.

80.

00.

00.

00.

00.

00.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.0

0.0

1.9

0.0

0.0

0.0

0.0

0.1

P0.

00.

00.

00.

00.

00.

30.

00.

30.

30.

00.

00.

40.

40.

90.

00.

00.

00.

00.

2

Inci

denc

eM

01

23

20

11

32

14

32

00

22

290.

20.

111

601.

10.

71.

5F

01

11

01

10

00

02

14

10

12

160.

10.

119

090.

50.

30.

9P

02

34

21

21

32

16

46

10

34

450.

20.

114

440.

80.

61.

1

Rate

Per

M0.

00.

61.

31.

91.

20.

00.

60.

61.

81.

30.

72.

92.

41.

80.

00.

05.

77.

31.

310

0,00

0F

0.0

0.7

0.7

0.7

0.0

0.6

0.6

0.0

0.0

0.0

0.0

1.4

0.8

3.7

1.3

0.0

2.2

4.1

0.7

P0.

00.

61.

01.

30.

60.

30.

60.

30.

90.

60.

32.

21.

62.

80.

70.

03.

85.

31.

0

Mor

talit

yM

01

01

40

00

00

10

00

10

11

100.

20.

035

670.

40.

20.

7F

00

11

11

00

00

00

01

00

01

60.

20.

057

470.

30.

10.

6P

01

12

51

00

00

10

01

10

12

160.

20.

044

030.

30.

20.

5

Rate

Per

M0.

00.

60.

00.

62.

40.

00.

00.

00.

00.

00.

70.

00.

00.

01.

30.

02.

83.

70.

410

0,00

0F

0.0

0.0

0.7

0.7

0.6

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

0.0

0.0

0.0

2.1

0.3

P0.

00.

30.

30.

61.

50.

30.

00.

00.

00.

00.

30.

00.

00.

50.

70.

01.

32.

60.

3

Inci

denc

eM

10

04

1536

4562

9312

317

318

829

232

728

221

716

511

721

4014

.59.

012

60.6

58.1

63.2

F1

02

1026

5977

8611

313

216

514

413

015

810

711

577

107

1509

13.0

5.6

1844

.842

.647

.1P

20

214

4195

122

148

206

255

338

332

422

485

389

332

242

224

3649

13.9

7.3

1452

.450

.754

.1

Rate

Per

M0.

60.

00.

02.

58.

921

.227

.940

.355

.680

.511

3.0

138.

223

5.2

300.

736

9.0

415.

346

9.8

429.

192

.310

0,00

0F

0.6

0.0

1.4

6.7

15.8

34.9

47.8

54.8

66.0

84.7

104.

910

3.6

104.

714

6.2

138.

920

3.7

173.

122

0.8

64.7

P0.

60.

00.

74.

512

.328

.037

.947

.660

.982

.610

8.9

120.

716

9.9

223.

725

3.5

305.

430

4.1

295.

878

.5

Mor

talit

yM

00

00

01

23

67

1224

3339

3733

4149

287

5.7

1.1

957.

06.

37.

9F

00

00

00

41

36

1214

84

712

824

103

2.9

0.3

299

2.4

2.0

2.9

P0

00

00

16

49

1324

3841

4344

4549

7339

04.

50.

714

54.

64.

25.

1

Rate

Per

M0.

00.

00.

00.

00.

00.

61.

21.

93.

64.

67.

817

.626

.635

.948

.463

.211

6.7

179.

712

.410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

2.5

0.6

1.8

3.8

7.6

10.1

6.4

3.7

9.1

21.3

18.0

49.5

4.4

P0.

00.

00.

00.

00.

00.

31.

91.

32.

74.

27.

713

.816

.519

.828

.741

.461

.696

.48.

4

Inci

denc

eM

00

00

01

22

64

511

1514

1326

2724

150

1.0

0.6

178

3.6

3.0

4.2

F0

00

01

22

24

43

45

89

914

1683

0.7

0.3

377

1.9

1.5

2.4

P0

00

01

34

410

88

1520

2222

3541

4023

30.

90.

424

42.

72.

33.

1

Rate

Per

M0.

00.

00.

00.

00.

00.

61.

21.

33.

62.

63.

38.

112

.112

.917

.049

.876

.988

.06.

510

0,00

0F

0.0

0.0

0.0

0.0

0.6

1.2

1.2

1.3

2.3

2.6

1.9

2.9

4.0

7.4

11.7

15.9

31.5

33.0

3.6

P0.

00.

00.

00.

00.

30.

91.

21.

33.

02.

62.

65.

58.

110

.114

.332

.251

.552

.85.

0

Mor

talit

yM

00

00

00

00

01

40

28

55

106

410.

80.

170

60.

90.

71.

3F

00

00

00

00

10

01

00

42

39

200.

60.

119

930.

30.

20.

5P

00

00

00

00

11

41

28

97

1315

610.

70.

110

490.

60.

50.

8

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

72.

60.

01.

67.

46.

59.

628

.522

.01.

810

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.7

0.0

0.0

5.2

3.5

6.7

18.6

0.9

P0.

00.

00.

00.

00.

00.

00.

00.

00.

30.

31.

30.

40.

83.

75.

96.

416

.319

.81.

3

C4

4, M

87

2-M

879

MEL

AN

OM

A

C3

7, C

38

TH

YM

US,

HEA

RT,

MED

IAST

INU

M &

PLE

UR

A

C4

4 O

THER

SK

IN (

EXC

L B

CC

/SC

C)

C4

0,C

41

BO

NES

,JO

INTS

& A

RTI

CU

LAR

CA

RTI

LAG

ES

101


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

01

01

01

55

913

2023

1913

110

0.7

0.5

204

2.6

2.1

3.1

F0

00

00

00

02

00

13

19

43

225

0.2

0.1

834

0.6

0.4

0.9

P0

00

00

10

12

15

612

1429

2722

1513

50.

50.

333

21.

51.

31.

8

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

00.

60.

00.

73.

33.

77.

212

.026

.244

.054

.147

.74.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.2

0.0

0.0

0.7

2.4

0.9

11.7

7.1

6.7

4.1

1.1

P0.

00.

00.

00.

00.

00.

30.

00.

30.

60.

31.

62.

24.

86.

518

.924

.827

.619

.82.

9

Mor

talit

yM

00

00

01

00

00

14

517

1724

1521

105

2.1

0.5

218

2.3

1.9

2.8

F0

00

00

00

01

00

20

36

54

324

0.7

0.1

933

0.5

0.3

0.7

P0

00

00

10

01

01

65

2023

2919

2412

91.

50.

335

81.

31.

11.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

00.

00.

00.

00.

72.

94.

015

.622

.245

.942

.777

.04.

510

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

1.4

0.0

2.8

7.8

8.9

9.0

6.2

1.0

P0.

00.

00.

00.

00.

00.

30.

00.

00.

30.

00.

32.

22.

09.

215

.026

.723

.931

.72.

8

Inci

denc

eM

00

00

00

21

00

00

00

00

00

30.

00.

010

574

0.1

0.0

0.3

F0

00

00

00

00

00

00

20

00

02

0.0

0.0

1080

40.

10.

00.

2P

00

00

00

21

00

00

02

00

00

50.

00.

010

725

0.1

0.0

0.2

Rate

Per

M0.

00.

00.

00.

00.

00.

01.

20.

60.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.9

0.0

0.0

0.0

0.0

0.1

P0.

00.

00.

00.

00.

00.

00.

60.

30.

00.

00.

00.

00.

00.

90.

00.

00.

00.

00.

1

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

00.

0.

0.0

0.0

0.0

F0

00

00

00

00

00

00

00

00

00

0.0

0.0

.0.

00.

00.

0P

00

00

00

00

00

00

00

00

00

00.

00.

0.

0.0

0.0

0.0

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0

Inci

denc

eM

11

20

11

14

34

84

98

48

93

710.

50.

336

62.

11.

72.

7F

20

33

20

22

10

42

59

22

17

470.

40.

262

21.

61.

22.

1P

31

53

31

36

44

126

1417

610

1010

118

0.4

0.2

465

1.8

1.5

2.2

Rate

Per

M0.

60.

61.

30.

00.

60.

60.

62.

61.

82.

65.

22.

97.

27.

45.

215

.325

.611

.03.

110

0,00

0F

1.3

0.0

2.1

2.0

1.2

0.0

1.2

1.3

0.6

0.0

2.5

1.4

4.0

8.3

2.6

3.5

2.2

14.4

2.0

P0.

90.

31.

71.

00.

90.

30.

91.

91.

21.

33.

92.

25.

67.

83.

99.

212

.613

.22.

5

Mor

talit

yM

00

10

10

02

00

10

23

13

53

220.

40.

113

680.

60.

40.

9F

00

01

10

10

21

02

32

31

35

250.

70.

113

270.

60.

41.

0P

00

11

20

12

21

12

55

44

88

470.

50.

113

530.

60.

40.

8

Rate

Per

M0.

00.

00.

70.

00.

60.

00.

01.

30.

00.

00.

70.

01.

62.

81.

35.

714

.211

.00.

910

0,00

0F

0.0

0.0

0.0

0.7

0.6

0.0

0.6

0.0

1.2

0.6

0.0

1.4

2.4

1.9

3.9

1.8

6.7

10.3

1.1

P0.

00.

00.

30.

30.

60.

00.

30.

60.

60.

30.

30.

72.

02.

32.

63.

710

.110

.61.

0

Inci

denc

eM

10

00

01

00

01

20

12

12

10

120.

10.

118

280.

40.

20.

7F

02

00

20

00

11

13

28

13

33

300.

30.

190

20.

90.

61.

2P

12

00

21

00

12

33

310

25

43

420.

20.

112

060.

60.

50.

8

Rate

Per

M0.

60.

00.

00.

00.

00.

60.

00.

00.

00.

71.

30.

00.

81.

81.

33.

82.

80.

00.

510

0,00

0F

0.0

1.3

0.0

0.0

1.2

0.0

0.0

0.0

0.6

0.6

0.6

2.2

1.6

7.4

1.3

5.3

6.7

6.2

1.3

P0.

30.

60.

00.

00.

60.

30.

00.

00.

30.

61.

01.

11.

24.

61.

34.

65.

04.

00.

9

Mor

talit

yM

00

00

00

00

01

01

21

22

00

90.

20.

119

300.

30.

10.

5F

00

00

00

00

01

04

24

72

33

260.

70.

193

20.

60.

40.

9P

00

00

00

00

02

05

45

94

33

350.

40.

112

560.

40.

30.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

71.

60.

92.

63.

80.

00.

00.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

2.9

1.6

3.7

9.1

3.5

6.7

6.2

1.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

60.

01.

81.

62.

35.

93.

73.

84.

00.

8

C4

8 R

ETR

OP

ERIT

ON

EUM

& P

ERIT

ON

EUM

C4

7,C

49

CO

NN

ECTI

VE

TISS

UE,

PER

IPH

ERA

L N

ERV

ES

M9

14

KA

PO

SI S

AR

CO

MA

M9

05

MES

OTH

ELIO

MA

111


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

00

00

10

30

82

26

24

280.

20.

180

20.

70.

51.

0F

00

00

010

4298

233

371

446

379

400

452

292

215

164

170

3272

28.2

12.6

893

.790

.697

.0P

00

00

010

4298

234

371

449

379

408

454

294

221

166

174

3300

12.5

6.4

1647

.946

.349

.6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

02.

00.

06.

41.

82.

611

.55.

714

.71.

210

0,00

0F

0.0

0.0

0.0

0.0

0.0

5.9

26.1

62.5

136.

223

8.1

283.

627

2.6

322.

141

8.4

379.

038

0.9

368.

835

0.8

140.

3P

0.0

0.0

0.0

0.0

0.0

3.0

13.0

31.5

69.1

120.

214

4.7

137.

816

4.3

209.

419

1.6

203.

320

8.6

229.

870

.9

Mor

talit

yM

00

00

00

00

00

10

01

00

31

60.

10.

012

717

0.1

0.0

0.3

F0

00

00

02

912

1852

6158

6855

5367

9855

315

.41.

953

12.8

11.8

13.9

P0

00

00

02

912

1853

6158

6955

5370

9955

96.

51.

010

56.

76.

27.

3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

00.

90.

00.

08.

53.

70.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

1.2

5.7

7.0

11.5

33.1

43.9

46.7

62.9

71.4

93.9

150.

720

2.2

23.7

P0.

00.

00.

00.

00.

00.

00.

62.

93.

55.

817

.122

.223

.431

.835

.848

.888

.013

0.7

12.0

Inci

denc

eM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

27

822

4736

4852

112

119

129

160

121

8153

9010

879.

44.

224

30.5

28.7

32.3

P0

02

78

2247

3648

5211

211

912

916

012

181

5390

1087

4.1

n.a.

n.a.

n.a.

n.a.

n.a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

1.4

4.7

4.9

13.0

29.2

22.9

28.1

33.4

71.2

85.6

103.

914

8.1

157.

014

3.5

119.

218

5.7

46.6

P0.

00.

00.

72.

32.

46.

514

.611

.614

.216

.936

.143

.351

.973

.878

.874

.566

.611

8.9

23.4

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

01

02

46

612

2317

3539

2940

4379

336

9.3

1.1

927.

46.

68.

2P

00

01

02

46

612

2317

3539

2940

4379

336

3.9

n.a.

n.a.

n.a.

n.a.

n.a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.7

0.0

1.2

2.5

3.8

3.5

7.7

14.6

12.2

28.2

36.1

37.6

70.9

96.7

163.

014

.4P

0.0

0.0

0.0

0.3

0.0

0.6

1.2

1.9

1.8

3.9

7.4

6.2

14.1

18.0

18.9

36.8

54.0

104.

37.

2

Inci

denc

eM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

01

00

12

33

53

57

66

416

620.

50.

249

41.

51.

11.

9P

00

01

00

12

33

53

57

66

416

620.

2n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.7

0.0

0.0

0.6

1.3

1.8

1.9

3.2

2.2

4.0

6.5

7.8

10.6

9.0

33.0

2.7

P0.

00.

00.

00.

30.

00.

00.

30.

60.

91.

01.

61.

12.

03.

23.

95.

55.

021

.11.

3

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

00

00

01

11

00

11

510

200.

60.

039

480.

30.

20.

5P

00

00

00

00

01

11

00

11

510

200.

2n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.7

0.0

0.0

1.3

1.8

11.2

20.6

0.9

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

30.

40.

00.

00.

70.

96.

313

.20.

4

Inci

denc

eM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

519

2627

2611

1613

1211

78

33

187

1.6

0.7

151

6.4

5.6

7.4

P0

00

05

1926

2726

1116

1312

117

83

318

70.

7n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

3.0

11.3

16.1

17.2

15.2

7.1

10.2

9.4

9.7

10.2

9.1

14.2

6.7

6.2

8.0

P0.

00.

00.

00.

01.

55.

68.

18.

77.

73.

65.

24.

74.

85.

14.

67.

43.

84.

04.

0

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

01

14

13

76

29

04

36

471.

30.

262

41.

30.

91.

7P

00

00

01

14

13

76

29

04

36

470.

5n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.6

0.6

2.5

0.6

1.9

4.5

4.3

1.6

8.3

0.0

7.1

6.7

12.4

2.0

P0.

00.

00.

00.

00.

00.

30.

31.

30.

31.

02.

32.

20.

84.

20.

03.

73.

87.

91.

0

C5

3 C

ERV

IX U

TER

I

C5

1 V

ULV

A

C5

1-C

58

GY

NA

ECO

LOG

ICA

L

C5

0 B

REA

ST

121


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

00

73

917

4876

8710

562

4126

2350

44.

32.

147

13.6

12.5

14.9

P0

00

00

07

39

1748

7687

105

6241

2623

504

1.9

n.a.

n.a.

n.a.

n.a.

n.a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

4.3

1.9

5.3

10.9

30.5

54.7

70.1

97.2

80.5

72.6

58.5

47.5

21.6

P0.

00.

00.

00.

00.

00.

02.

21.

02.

75.

515

.527

.635

.048

.440

.437

.732

.730

.410

.8

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

00

10

21

42

127

1010

915

732.

00.

337

61.

61.

32.

0P

00

00

00

10

21

42

127

1010

915

730.

8n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

1.2

0.6

2.5

1.4

9.7

6.5

13.0

17.7

20.2

31.0

3.1

P0.

00.

00.

00.

00.

00.

00.

30.

00.

60.

31.

30.

74.

83.

26.

59.

211

.319

.81.

6

Inci

denc

eM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

26

33

94

917

4220

2229

3424

1732

273

2.4

1.0

987.

56.

68.

4P

00

26

33

94

917

4220

2229

3424

1732

273

1.0

n.a.

n.a.

n.a.

n.a.

n.a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

1.4

4.0

1.8

1.8

5.6

2.5

5.3

10.9

26.7

14.4

17.7

26.8

44.1

42.5

38.2

66.0

11.7

P0.

00.

00.

71.

90.

90.

92.

81.

32.

75.

513

.57.

38.

913

.422

.222

.121

.442

.35.

9

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

01

01

22

34

116

1921

1623

2035

164

4.6

0.6

173

3.6

3.1

4.2

P0

00

10

12

23

411

619

2116

2320

3516

41.

9n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.7

0.0

0.6

1.2

1.3

1.8

2.6

7.0

4.3

15.3

19.4

20.8

40.7

45.0

72.2

7.0

P0.

00.

00.

00.

30.

00.

30.

60.

60.

91.

33.

52.

27.

79.

710

.421

.225

.146

.23.

5

Inci

denc

eM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

00

40

14

17

38

122

316

610.

50.

249

81.

41.

11.

8P

00

00

00

40

14

17

38

122

316

610.

2n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

2.5

0.0

0.6

2.6

0.6

5.0

2.4

7.4

15.6

3.5

6.7

33.0

2.6

P0.

00.

00.

00.

00.

00.

01.

20.

00.

31.

30.

32.

51.

23.

77.

81.

83.

821

.11.

3

Mor

talit

yM

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.F

00

00

00

00

03

02

22

22

613

320.

90.

115

430.

60.

40.

8P

00

00

00

00

03

02

22

22

613

320.

4n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.9

0.0

1.4

1.6

1.9

2.6

3.5

13.5

26.8

1.4

P0.

00.

00.

00.

00.

00.

00.

00.

00.

01.

00.

00.

70.

80.

91.

31.

87.

517

.20.

7

Inci

denc

eM

00

00

00

01

2310

021

449

769

997

066

647

422

919

140

6427

.619

.16

108.

910

5.6

112.

3F

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.P

00

00

00

01

2310

021

449

769

997

066

647

422

919

140

6415

.4n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

613

.765

.513

9.8

365.

256

3.1

891.

987

1.4

907.

265

2.1

700.

517

5.3

100,

000

F0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0P

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.3

6.8

32.4

69.0

180.

728

1.5

447.

443

3.9

436.

128

7.7

252.

287

.4

Mor

talit

yM

00

00

00

00

12

414

2558

7798

136

221

636

12.6

1.9

5412

.912

.014

.0F

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.P

00

00

00

00

12

414

2558

7798

136

221

636

7.4

n.a.

n.a.

n.a.

n.a.

n.a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

61.

32.

610

.320

.153

.310

0.7

187.

638

7.3

810.

627

.410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

30.

61.

35.

110

.126

.850

.290

.217

0.9

291.

913

.7

C5

2,C

55

,C5

7,C

58

OTH

ER F

EMA

LE G

ENIT

AL

OR

GA

NS

C6

1 P

RO

STA

TE G

LAN

D

C5

6 O

VA

RY

C5

4 C

OR

PU

S U

TER

I

131


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

05

1129

3324

1712

65

51

20

00

150

1.0

0.5

209

6.0

5.1

7.0

F0

00

00

00

00

00

00

00

00

00

0.0

n.a.

n.a.

n.a.

n.a.

n.a.

P0

00

511

2933

2417

126

55

12

00

015

00.

6n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

03.

26.

617

.020

.515

.610

.27.

93.

93.

74.

00.

92.

60.

00.

00.

06.

510

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

01.

63.

38.

610

.27.

75.

03.

91.

91.

82.

00.

51.

30.

00.

00.

03.

2

Mor

talit

yM

00

00

00

00

00

00

11

00

00

20.

00.

011

595

0.1

0.0

0.2

F0

00

00

00

00

00

00

00

00

00

0.0

n.a.

n.a.

n.a.

n.a.

n.a.

P0

00

00

00

00

00

01

10

00

02

0.0

n.a.

n.a.

n.a.

n.a.

n.a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

90.

00.

00.

00.

00.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

40.

50.

00.

00.

00.

00.

0

Inci

denc

eM

00

00

00

10

10

23

33

44

50

260.

20.

187

80.

70.

41.

0F

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.P

00

00

00

10

10

23

33

44

50

260.

1n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

60.

00.

60.

01.

32.

22.

42.

85.

27.

714

.20.

01.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

30.

00.

30.

00.

61.

11.

21.

42.

63.

76.

30.

00.

6

Mor

talit

yM

00

00

00

00

01

01

01

21

20

80.

20.

029

250.

20.

10.

4F

00

00

00

00

00

00

00

00

00

00.

0n.

a.n.

a.n.

a.n.

a.n.

a.P

00

00

00

00

01

01

01

21

20

80.

1n.

a.n.

a.n.

a.n.

a.n.

a.

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

70.

00.

92.

61.

95.

70.

00.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

00.

40.

00.

51.

30.

92.

50.

00.

2

Inci

denc

eM

20

10

03

49

2036

5659

7261

6942

3424

492

3.3

2.1

4914

.112

.915

.4F

40

01

11

04

1716

1531

3930

2824

2127

259

2.2

1.0

102

7.0

6.1

7.9

P6

01

11

44

1337

5271

9011

191

9766

5551

751

2.9

1.5

6610

.59.

711

.2

Rate

Per

M1.

20.

00.

70.

00.

01.

82.

55.

812

.023

.636

.643

.458

.056

.190

.380

.496

.888

.021

.210

0,00

0F

2.6

0.0

0.0

0.7

0.6

0.6

0.0

2.5

9.9

10.3

9.5

22.3

31.4

27.8

36.3

42.5

47.2

55.7

11.1

P1.

90.

00.

30.

30.

31.

21.

24.

210

.916

.922

.932

.744

.742

.063

.260

.769

.167

.416

.1

Mor

talit

yM

00

00

00

00

34

711

1614

1817

2226

138

2.7

0.5

203

3.3

2.8

3.9

F0

00

00

00

00

22

35

97

812

2573

2.0

0.2

496

1.4

1.1

1.7

P0

00

00

00

03

69

1421

2325

2534

5121

12.

40.

329

02.

32.

02.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

01.

82.

64.

68.

112

.912

.923

.632

.562

.695

.46.

010

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.3

1.3

2.2

4.0

8.3

9.1

14.2

27.0

51.6

3.1

P0.

00.

00.

00.

00.

00.

00.

00.

00.

91.

92.

95.

18.

510

.616

.323

.042

.767

.44.

5

Inci

denc

eM

00

00

01

02

37

827

3840

5770

5864

375

2.5

1.5

658.

77.

99.

6F

00

00

00

00

14

44

1413

1816

2131

126

1.1

0.4

240

2.5

2.1

3.0

P0

00

00

10

24

1112

3152

5375

8679

9550

11.

91.

010

35.

55.

06.

0

Rate

Per

M0.

00.

00.

00.

00.

00.

60.

01.

31.

84.

65.

219

.830

.636

.874

.613

4.0

165.

223

4.7

16.2

100,

000

F0.

00.

00.

00.

00.

00.

00.

00.

00.

62.

62.

52.

911

.312

.023

.428

.347

.264

.05.

4P

0.0

0.0

0.0

0.0

0.0

0.3

0.0

0.6

1.2

3.6

3.9

11.3

20.9

24.4

48.9

79.1

99.3

125.

510

.8

Mor

talit

yM

00

00

00

00

02

25

619

1622

3350

155

3.1

0.5

219

3.2

2.7

3.8

F0

00

00

00

10

02

13

58

93

2254

1.5

0.2

556

1.0

0.7

1.3

P0

00

00

00

10

24

69

2424

3136

7220

92.

40.

331

72.

01.

72.

3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

01.

31.

33.

74.

817

.520

.942

.194

.018

3.4

6.7

100,

000

F0.

00.

00.

00.

00.

00.

00.

00.

60.

00.

01.

30.

72.

44.

610

.415

.96.

745

.42.

3P

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.0

0.6

1.3

2.2

3.6

11.1

15.6

28.5

45.2

95.1

4.5

C6

4-C

66

,C6

8 K

IDN

EY A

ND

OTH

ER R

ENA

L TR

AC

T

C6

0,C

63

PEN

IS A

ND

OTH

ER &

UN

SPEC

IFIE

D M

ALE

GEN

ITA

L O

RG

AN

S

C6

2 T

ESTI

S

C6

7 B

LAD

DER

141


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

10

00

01

00

42

38

1110

80

32

530.

40.

248

51.

61.

22.

1F

30

00

00

00

12

34

12

72

21

280.

20.

183

80.

90.

61.

3P

40

00

01

00

54

612

1212

152

53

810.

30.

261

41.

21.

01.

5

Rate

Per

M0.

60.

00.

00.

00.

00.

60.

00.

02.

41.

32.

05.

98.

99.

210

.50.

08.

57.

32.

310

0,00

0F

1.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.3

1.9

2.9

0.8

1.9

9.1

3.5

4.5

2.1

1.2

P1.

30.

00.

00.

00.

00.

30.

00.

01.

51.

31.

94.

44.

85.

59.

81.

86.

34.

01.

7

Mor

talit

yM

00

00

00

00

00

02

41

21

10

110.

20.

119

730.

30.

20.

5F

00

00

00

00

01

30

11

10

12

100.

30.

035

860.

30.

10.

5P

00

00

00

00

01

32

52

31

22

210.

20.

025

550.

30.

20.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

53.

20.

92.

61.

92.

80.

00.

510

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.9

0.0

0.8

0.9

1.3

0.0

2.2

4.1

0.4

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

31.

00.

72.

00.

92.

00.

92.

52.

60.

5

Inci

denc

eM

73

21

32

53

79

1517

2323

2113

97

170

1.2

0.7

143

5.4

4.7

6.3

F3

21

13

16

47

612

912

1421

511

812

61.

10.

521

33.

83.

24.

5P

105

32

63

117

1415

2726

3537

4218

2015

296

1.1

0.6

171

4.6

4.1

5.2

Rate

Per

M4.

31.

91.

30.

61.

81.

23.

11.

94.

25.

99.

812

.518

.521

.127

.524

.925

.625

.77.

310

0,00

0F

1.9

1.3

0.7

0.7

1.8

0.6

3.7

2.5

4.1

3.8

7.6

6.5

9.7

13.0

27.3

8.9

24.7

16.5

5.4

P3.

21.

61.

00.

61.

80.

93.

42.

34.

14.

98.

79.

514

.117

.127

.416

.625

.119

.86.

4

Mor

talit

yM

13

01

10

22

44

1314

2426

2015

57

142

2.8

0.6

157

4.2

3.5

4.9

F0

20

11

10

33

64

1312

2325

1212

812

63.

50.

518

73.

32.

84.

0P

15

02

21

25

710

1727

3649

4527

1715

268

3.1

0.6

171

3.7

3.3

4.2

Rate

Per

M0.

61.

90.

00.

60.

60.

01.

21.

32.

42.

68.

510

.319

.323

.926

.228

.714

.225

.76.

110

0,00

0F

0.0

1.3

0.0

0.7

0.6

0.6

0.0

1.9

1.8

3.8

2.5

9.4

9.7

21.3

32.4

21.3

27.0

16.5

5.4

P0.

31.

60.

00.

60.

60.

30.

61.

62.

13.

25.

59.

814

.522

.629

.324

.821

.419

.85.

8

Inci

denc

eM

00

11

25

710

1316

1811

1326

148

51

151

1.0

0.6

164

4.8

4.1

5.7

F0

13

311

1923

3346

4254

5740

3720

129

541

53.

61.

567

13.8

12.5

15.2

P0

14

413

2430

4359

5872

6853

6334

2014

656

62.

11.

195

9.3

8.6

10.1

Rate

Per

M0.

00.

00.

70.

61.

22.

94.

36.

57.

810

.511

.88.

110

.523

.918

.315

.314

.23.

76.

510

0,00

0F

0.0

0.7

2.1

2.0

6.7

11.3

14.3

21.0

26.9

26.9

34.3

41.0

32.2

34.2

26.0

21.3

20.2

10.3

17.8

P0.

00.

31.

31.

33.

97.

19.

313

.817

.418

.823

.224

.721

.329

.122

.218

.417

.67.

912

.2

Mor

talit

yM

00

00

00

00

11

11

01

31

00

90.

20.

021

280.

30.

10.

5F

00

00

00

00

10

10

00

10

21

60.

20.

079

430.

10.

00.

3P

00

00

00

00

21

21

01

41

21

150.

20.

033

840.

20.

10.

3

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

70.

70.

70.

00.

93.

91.

90.

00.

00.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.6

0.0

0.0

0.0

1.3

0.0

4.5

2.1

0.3

P0.

00.

00.

00.

00.

00.

00.

00.

00.

60.

30.

60.

40.

00.

52.

60.

92.

51.

30.

3

Inci

denc

eM

12

12

01

00

00

00

10

00

00

80.

10.

038

580.

50.

20.

9F

10

10

00

00

01

10

00

10

11

70.

10.

051

100.

30.

10.

5P

22

22

01

00

01

10

10

10

11

150.

10.

043

540.

40.

20.

6

Rate

Per

M0.

61.

30.

71.

30.

00.

60.

00.

00.

00.

00.

00.

00.

80.

00.

00.

00.

00.

00.

310

0,00

0F

0.6

0.0

0.7

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.0

0.0

0.0

1.3

0.0

2.2

2.1

0.3

P0.

60.

60.

70.

60.

00.

30.

00.

00.

00.

30.

30.

00.

40.

00.

70.

01.

31.

30.

3

Mor

talit

yM

10

00

00

00

01

00

00

00

00

20.

00.

015

731

0.1

0.0

0.4

F0

00

00

01

10

00

20

00

01

16

0.2

0.0

7418

0.2

0.1

0.3

P1

00

00

01

10

10

20

00

01

18

0.1

0.0

1000

30.

10.

10.

3

Rate

Per

M0.

60.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

00.

00.

00.

00.

00.

00.

00.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.0

0.0

0.0

1.4

0.0

0.0

0.0

0.0

2.2

2.1

0.3

P0.

30.

00.

00.

00.

00.

00.

30.

30.

00.

30.

00.

70.

00.

00.

00.

01.

31.

30.

2

C7

3 T

HY

RO

ID G

LAN

D

C7

0-C

72

BR

AIN

, MEN

ING

ES A

ND

OTH

ER C

ENTR

AL

NER

VO

US

SYST

EM

C6

9 E

YE

& A

DN

EXA

C7

4,C

75

AD

REN

AL

AN

D O

THER

EN

DO

CR

INE

GLA

ND

S

151


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

10

00

00

13

110

2221

3846

4552

5283

375

2.5

1.4

748.

98.

09.

9F

00

00

01

45

54

1519

2027

4038

4684

308

2.7

1.0

103

6.2

5.6

7.0

P1

00

00

15

86

1437

4058

7385

9098

167

683

2.6

1.2

867.

56.

98.

0

Rate

Per

M0.

60.

00.

00.

00.

00.

00.

61.

90.

66.

514

.415

.430

.642

.358

.999

.514

8.1

304.

416

.210

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.6

2.5

3.2

2.9

2.6

9.5

13.7

16.1

25.0

51.9

67.3

103.

417

3.3

13.2

P0.

30.

00.

00.

00.

00.

31.

62.

61.

84.

511

.914

.523

.433

.755

.482

.812

3.1

220.

514

.7

Mor

talit

yM

00

00

00

02

07

1013

1519

2033

4786

252

5.0

0.7

143

5.5

4.8

6.2

F0

00

00

01

14

36

612

1325

3432

7621

35.

90.

615

73.

83.

34.

4P

00

00

00

13

410

1619

2732

4567

7916

246

55.

40.

714

94.

54.

15.

0

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

01.

30.

04.

66.

59.

612

.117

.526

.263

.213

3.8

315.

410

.910

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

2.3

1.9

3.8

4.3

9.7

12.0

32.4

60.2

72.0

156.

89.

1P

0.0

0.0

0.0

0.0

0.0

0.0

0.3

1.0

1.2

3.2

5.2

6.9

10.9

14.8

29.3

61.6

99.3

213.

910

.0

Inci

denc

eM

15

812

518

616

2436

3249

6510

887

7159

4164

34.

42.

738

18.5

17.1

20.0

F1

31

46

1215

1417

2240

3952

6864

5953

3650

64.

42.

050

13.6

12.4

14.8

P2

89

1611

3021

3041

5872

8811

717

615

113

011

277

1149

4.4

2.4

4316

.015

.117

.0

Rate

Per

M0.

63.

15.

27.

63.

010

.63.

710

.414

.323

.620

.936

.052

.499

.311

3.8

135.

916

8.0

150.

427

.710

0,00

0F

0.6

2.0

0.7

2.7

3.6

7.1

9.3

8.9

9.9

14.1

25.4

28.1

41.9

62.9

83.1

104.

511

9.2

74.3

21.7

P0.

62.

63.

05.

23.

38.

96.

59.

712

.118

.823

.232

.047

.181

.298

.411

9.6

140.

710

1.7

24.7

Mor

talit

yM

00

00

10

11

16

85

1330

2319

2830

166

3.3

0.6

167

4.0

3.4

4.6

F0

00

00

00

00

02

35

1012

2020

3610

83.

00.

329

61.

91.

52.

2P

00

00

10

11

16

108

1840

3539

4866

274

3.2

0.5

214

2.9

2.5

3.2

Rate

Per

M0.

00.

00.

00.

00.

60.

00.

60.

60.

63.

95.

23.

710

.527

.630

.136

.479

.711

0.0

7.2

100,

000

F0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

32.

24.

09.

315

.635

.445

.074

.34.

6P

0.0

0.0

0.0

0.0

0.3

0.0

0.3

0.3

0.3

1.9

3.2

2.9

7.2

18.5

22.8

35.9

60.3

87.2

5.9

Inci

denc

eM

02

36

59

13

54

26

45

04

21

620.

40.

244

82.

41.

93.

1F

00

04

38

93

37

32

24

23

01

540.

50.

250

62.

01.

52.

7P

02

310

817

106

811

58

69

27

22

116

0.4

0.2

475

2.2

1.8

2.7

Rate

Per

M0.

01.

32.

03.

83.

05.

30.

61.

93.

02.

61.

34.

43.

24.

60.

07.

75.

73.

72.

710

0,00

0F

0.0

0.0

0.0

2.7

1.8

4.7

5.6

1.9

1.8

4.5

1.9

1.4

1.6

3.7

2.6

5.3

0.0

2.1

2.3

P0.

00.

61.

03.

22.

45.

03.

11.

92.

43.

61.

62.

92.

44.

21.

36.

42.

52.

62.

5

Mor

talit

yM

00

00

10

00

01

10

12

21

10

100.

20.

022

030.

30.

10.

5F

00

00

00

00

00

00

12

12

02

80.

20.

026

680.

20.

10.

3P

00

00

10

00

01

10

24

33

12

180.

20.

024

070.

20.

10.

4

Rate

Per

M0.

00.

00.

00.

00.

60.

00.

00.

00.

00.

70.

70.

00.

81.

82.

61.

92.

80.

00.

410

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

1.9

1.3

3.5

0.0

4.1

0.3

P0.

00.

00.

00.

00.

30.

00.

00.

00.

00.

30.

30.

00.

81.

82.

02.

81.

32.

60.

4

Inci

denc

eM

13

56

09

513

1932

3043

6110

387

6757

4058

13.

92.

541

16.1

14.8

17.5

F1

31

03

46

1114

1537

3750

6462

5653

3545

23.

91.

855

11.6

10.5

12.7

P2

66

63

1311

2433

4767

8011

116

714

912

311

075

1033

3.9

2.2

4713

.812

.914

.6

Rate

Per

M0.

61.

93.

33.

80.

05.

33.

18.

411

.421

.019

.631

.649

.194

.711

3.8

128.

216

2.3

146.

725

.110

0,00

0F

0.6

2.0

0.7

0.0

1.8

2.4

3.7

7.0

8.2

9.6

23.5

26.6

40.3

59.2

80.5

99.2

119.

272

.219

.4P

0.6

1.9

2.0

1.9

0.9

3.8

3.4

7.7

9.7

15.2

21.6

29.1

44.7

77.0

97.1

113.

213

8.2

99.0

22.2

Mor

talit

yM

00

00

00

11

15

75

1228

2118

2730

156

3.1

0.6

181

3.7

3.1

4.3

F0

00

00

00

00

02

34

811

1820

3410

02.

80.

333

31.

71.

42.

0P

00

00

00

11

15

98

1636

3236

4764

256

3.0

0.4

235

2.6

2.3

3.0

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

60.

60.

63.

34.

63.

79.

725

.727

.534

.476

.911

0.0

6.7

100,

000

F0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

32.

23.

27.

414

.331

.945

.070

.24.

3P

0.0

0.0

0.0

0.0

0.0

0.0

0.3

0.3

0.3

1.6

2.9

2.9

6.4

16.6

20.8

33.1

59.1

84.5

5.5

M9

59

,M9

67

-M97

2 N

ON

-HO

DG

KIN

LY

MP

HO

MA

M9

65

-M96

6 H

OD

GK

IN L

YM

PH

OM

A

M9

59

-M97

2 A

LL L

YM

PH

OM

AS

C2

6,C

39

,C7

6,C

77

,C8

0 O

THER

& I

LL-D

EFIN

ED S

ITES

AN

D U

NK

NO

WN

PR

IMA

RY

SIT

E

161


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

1011

311

45

57

1916

2830

4957

5644

4730

432

2.9

1.7

5812

.911

.714

.2F

148

43

22

24

87

1413

3328

3235

1439

262

2.3

1.0

967.

76.

88.

7P

2419

714

67

711

2723

4243

8285

8879

6169

694

2.6

1.4

7310

.29.

511

.0

Rate

Per

M6.

26.

92.

07.

02.

42.

93.

14.

511

.410

.518

.322

.039

.552

.473

.384

.213

3.8

110.

018

.610

0,00

0F

9.1

5.3

2.8

2.0

1.2

1.2

1.2

2.5

4.7

4.5

8.9

9.4

26.6

25.9

41.5

62.0

31.5

80.5

11.2

P7.

66.

12.

34.

51.

82.

12.

23.

58.

07.

513

.515

.633

.039

.257

.372

.776

.691

.114

.9

Mor

talit

yM

10

01

10

00

11

35

719

3621

2928

153

3.0

0.6

168

3.5

3.0

4.1

F1

10

02

11

34

12

77

817

2010

3411

93.

30.

423

42.

62.

13.

1P

21

01

31

13

52

512

1427

5341

3962

272

3.1

0.5

196

3.0

2.7

3.4

Rate

Per

M0.

60.

00.

00.

60.

60.

00.

00.

00.

60.

72.

03.

75.

617

.547

.140

.282

.610

2.7

6.6

100,

000

F0.

60.

70.

00.

01.

20.

60.

61.

92.

30.

61.

35.

05.

67.

422

.135

.422

.570

.25.

1P

0.6

0.3

0.0

0.3

0.9

0.3

0.3

1.0

1.5

0.6

1.6

4.4

5.6

12.5

34.5

37.7

49.0

81.9

5.8

Inci

denc

eM

911

27

14

02

510

1013

3236

2621

1812

219

1.5

0.9

111

7.1

6.1

8.0

F11

84

30

10

02

17

618

1613

165

1913

01.

10.

519

54.

33.

65.

1P

2019

610

15

02

711

1719

5052

3937

2331

349

1.3

0.7

142

5.6

5.1

6.3

Rate

Per

M5.

56.

91.

34.

40.

62.

40.

01.

33.

06.

56.

59.

625

.833

.134

.040

.251

.344

.09.

410

0,00

0F

7.1

5.3

2.8

2.0

0.0

0.6

0.0

0.0

1.2

0.6

4.5

4.3

14.5

14.8

16.9

28.3

11.2

39.2

5.6

P6.

36.

12.

03.

20.

31.

50.

00.

62.

13.

65.

56.

920

.124

.025

.434

.028

.940

.97.

5

Mor

talit

yM

00

01

00

00

00

12

18

1610

76

521.

00.

339

31.

20.

91.

6F

10

00

01

03

20

13

10

63

410

351.

00.

195

20.

80.

61.

1P

10

01

01

03

20

25

28

2213

1116

871.

00.

256

01.

00.

81.

2

Rate

Per

M0.

00.

00.

00.

60.

00.

00.

00.

00.

00.

00.

71.

50.

87.

420

.919

.119

.922

.02.

210

0,00

0F

0.6

0.0

0.0

0.0

0.0

0.6

0.0

1.9

1.2

0.0

0.6

2.2

0.8

0.0

7.8

5.3

9.0

20.6

1.5

P0.

30.

00.

00.

30.

00.

30.

01.

00.

60.

00.

61.

80.

83.

714

.312

.013

.821

.11.

9

Inci

denc

eM

10

13

31

24

125

1313

1517

179

1511

142

1.0

0.5

191

4.1

3.5

4.9

F3

00

02

12

45

65

613

1016

133

1110

00.

90.

423

52.

82.

33.

4P

40

13

52

48

1711

1819

2827

3322

1822

242

0.9

0.5

210

3.5

3.0

3.9

Rate

Per

M0.

60.

00.

71.

91.

80.

61.

22.

67.

23.

38.

59.

612

.115

.622

.217

.242

.740

.36.

110

0,00

0F

1.9

0.0

0.0

0.0

1.2

0.6

1.2

2.5

2.9

3.8

3.2

4.3

10.5

9.3

20.8

23.0

6.7

22.7

4.3

P1.

30.

00.

31.

01.

50.

61.

22.

65.

03.

65.

86.

911

.312

.521

.520

.222

.629

.15.

2

Mor

talit

yM

10

00

10

00

11

22

511

1510

1814

811.

60.

334

41.

91.

52.

3F

01

00

20

10

21

04

67

1014

514

671.

90.

335

61.

51.

21.

9P

11

00

30

10

32

26

1118

2524

2328

148

1.7

0.3

349

1.7

1.4

2.0

Rate

Per

M0.

60.

00.

00.

00.

60.

00.

00.

00.

60.

71.

31.

54.

010

.119

.619

.151

.351

.33.

510

0,00

0F

0.0

0.7

0.0

0.0

1.2

0.0

0.6

0.0

1.2

0.6

0.0

2.9

4.8

6.5

13.0

24.8

11.2

28.9

2.9

P0.

30.

30.

00.

00.

90.

00.

30.

00.

90.

60.

62.

24.

48.

316

.322

.128

.937

.03.

2

Inci

denc

eM

00

00

00

31

21

54

24

1214

124

640.

40.

334

31.

51.

22.

0F

00

00

00

00

10

21

21

24

67

260.

20.

113

520.

50.

30.

7P

00

00

00

31

31

75

45

1418

1811

900.

30.

255

41.

00.

81.

2

Rate

Per

M0.

00.

00.

00.

00.

00.

01.

90.

61.

20.

73.

32.

91.

63.

715

.726

.834

.214

.72.

810

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

1.3

0.7

1.6

0.9

2.6

7.1

13.5

14.4

1.1

P0.

00.

00.

00.

00.

00.

00.

90.

30.

90.

32.

31.

81.

62.

39.

116

.622

.614

.51.

9

Mor

talit

yM

00

00

00

00

00

01

10

51

36

170.

30.

020

010.

40.

20.

6F

00

00

00

00

00

10

00

02

19

130.

40.

047

860.

20.

10.

3P

00

00

00

00

00

11

10

53

415

300.

30.

028

150.

30.

20.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

80.

06.

51.

98.

522

.00.

710

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.0

3.5

2.2

18.6

0.6

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

40.

40.

03.

32.

85.

019

.80.

6

M9

94

OTH

ER S

PEC

IFIE

D L

EUK

AEM

IA

M9

84

-M99

3 M

YEL

OID

LEU

KA

EMIA

M9

82

-M98

3 L

YM

PH

OID

LEU

KA

EMIA

M9

80

-M99

4 A

LL L

EUK

AEM

IAS

171


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

01

00

00

00

00

00

10

23

70.

00.

010

300

0.2

0.1

0.3

F0

00

00

00

00

00

00

11

20

26

0.1

0.0

3469

0.1

0.0

0.2

P0

00

10

00

00

00

00

12

22

513

0.0

0.0

5091

0.1

0.1

0.2

Rate

Per

M0.

00.

00.

00.

60.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

30.

05.

711

.00.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

1.3

3.5

0.0

4.1

0.3

P0.

00.

00.

00.

30.

00.

00.

00.

00.

00.

00.

00.

00.

00.

51.

31.

82.

56.

60.

3

Mor

talit

yM

00

00

00

00

00

00

00

00

12

30.

10.

0.

0.1

0.0

0.1

F0

00

00

00

00

00

00

11

10

14

0.1

0.0

5007

0.1

0.0

0.2

P0

00

00

00

00

00

00

11

11

37

0.1

0.0

9839

0.1

0.0

0.1

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

87.

30.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

1.3

1.8

0.0

2.1

0.2

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

50.

70.

91.

34.

00.

2

Inci

denc

eM

00

00

00

00

010

616

2343

3726

2414

199

1.3

0.9

113

5.1

4.4

5.8

F0

00

00

00

13

17

1713

2113

1522

1612

91.

10.

521

52.

92.

43.

5P

00

00

00

01

311

1333

3664

5041

4630

328

1.2

0.7

148

4.0

3.5

4.4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

06.

53.

911

.818

.539

.548

.449

.868

.351

.38.

610

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

1.8

0.6

4.5

12.2

10.5

19.4

16.9

26.6

49.5

33.0

5.5

P0.

00.

00.

00.

00.

00.

00.

00.

30.

93.

64.

212

.014

.529

.532

.637

.757

.839

.67.

1

Mor

talit

yM

00

00

00

00

00

12

812

1712

813

731.

40.

330

91.

71.

32.

1F

00

00

00

00

11

13

43

88

1414

571.

60.

257

91.

10.

81.

4P

00

00

00

00

11

25

1215

2520

2227

130

1.5

0.2

404

1.4

1.1

1.6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

71.

56.

411

.022

.223

.022

.847

.73.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.6

0.6

2.2

3.2

2.8

10.4

14.2

31.5

28.9

2.4

P0.

00.

00.

00.

00.

00.

00.

00.

00.

30.

30.

61.

84.

86.

916

.318

.427

.635

.72.

8

Inci

denc

eM

00

01

00

00

02

05

1317

2334

2437

156

1.1

0.6

158

3.4

2.9

4.0

F0

00

00

00

03

01

37

1215

1218

2910

00.

90.

332

31.

91.

52.

3P

00

01

00

00

32

18

2029

3846

4266

256

1.0

0.5

214

2.6

2.3

2.9

Rate

Per

M0.

00.

00.

00.

60.

00.

00.

00.

00.

01.

30.

03.

710

.515

.630

.165

.168

.313

5.7

6.7

100,

000

F0.

00.

00.

00.

00.

00.

00.

00.

01.

80.

00.

62.

25.

611

.119

.521

.340

.559

.84.

3P

0.0

0.0

0.0

0.3

0.0

0.0

0.0

0.0

0.9

0.6

0.3

2.9

8.1

13.4

24.8

42.3

52.8

87.2

5.5

Mor

talit

yM

00

00

00

01

00

11

57

611

1423

691.

40.

248

41.

41.

11.

8F

00

00

10

00

01

10

22

23

919

401.

10.

115

090.

60.

50.

9P

00

00

10

01

01

21

79

814

2342

109

1.3

0.1

741

1.0

0.8

1.2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

60.

00.

00.

70.

74.

06.

47.

921

.139

.984

.43.

010

0,00

0F

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.0

0.6

0.6

0.0

1.6

1.9

2.6

5.3

20.2

39.2

1.7

P0.

00.

00.

00.

00.

30.

00.

00.

30.

00.

30.

60.

42.

84.

25.

212

.928

.955

.52.

3

Inci

denc

eM

00

00

01

23

54

1210

1617

1917

135

124

0.8

0.6

182

3.3

2.8

4.0

F0

00

02

00

16

35

713

56

88

569

0.6

0.3

381

1.8

1.4

2.3

P0

00

02

12

411

717

1729

2225

2521

1019

30.

70.

424

72.

62.

23.

0

Rate

Per

M0.

00.

00.

00.

00.

00.

61.

21.

93.

02.

67.

87.

312

.915

.624

.932

.537

.018

.35.

310

0,00

0F

0.0

0.0

0.0

0.0

1.2

0.0

0.0

0.6

3.5

1.9

3.2

5.0

10.5

4.6

7.8

14.2

18.0

10.3

3.0

P0.

00.

00.

00.

00.

60.

30.

61.

33.

22.

35.

56.

211

.710

.116

.323

.026

.413

.24.

1

Mor

talit

yM

00

00

00

00

00

01

06

35

47

260.

50.

110

130.

60.

40.

8F

00

00

00

00

00

01

12

12

310

200.

60.

024

350.

30.

20.

5P

00

00

00

00

00

02

18

47

717

460.

50.

114

430.

40.

30.

6

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

05.

53.

99.

611

.425

.71.

110

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.8

1.9

1.3

3.5

6.7

20.6

0.9

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

43.

72.

66.

48.

822

.51.

0

M9

95

-M99

6 C

HR

ON

IC M

YEL

OP

RO

LIFE

RA

TIV

E D

ISEA

SES

M9

98

MY

ELO

DY

SPLA

STIC

DIS

EASE

S

M9

73

MY

ELO

MA

/PLA

SMA

CEL

L TU

MO

UR

S

M9

80

UN

SPEC

IFIE

D L

EUK

AEM

IA

181


ICD

-O3/

SITE

Sex

0-4

5-9

10-

14 1

5-19

20-

24 2

5-29

30-

34 3

5-39

40-

44 4

5-49

50-

54 5

5-59

60-

64 6

5-69

70-

74 7

5-79

80-

8485

+To

tal

Perc

ent

Cum

Ra

te

Cum

Ri

sk

(1

in x

)

ASR

(Wor

ld)/

10

0,00

0Lo

wer

Li

mit

Upp

er

Lim

it

Tabl

e 5:

Can

cer

Inci

denc

e an

d M

orta

lity

by S

ite,

Sex

and

Age

Gro

up,

Que

ensl

and,

201

3

Inci

denc

eM

00

00

00

00

02

00

20

10

11

70.

00.

047

300.

20.

10.

4F

10

00

00

00

10

00

31

10

01

80.

10.

034

060.

30.

10.

5P

10

00

00

00

12

00

51

20

12

150.

10.

039

700.

20.

10.

4

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

01.

30.

00.

01.

60.

01.

30.

02.

83.

70.

310

0,00

0F

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

2.4

0.9

1.3

0.0

0.0

2.1

0.3

P0.

30.

00.

00.

00.

00.

00.

00.

00.

30.

60.

00.

02.

00.

51.

30.

01.

32.

60.

3

Mor

talit

yM

00

00

00

00

00

10

10

12

01

60.

10.

030

330.

10.

10.

3F

00

00

00

00

00

00

00

00

01

10.

00.

0.

0.0

0.0

0.1

P0

00

00

00

00

01

01

01

20

27

0.1

0.0

6219

0.1

0.0

0.2

Rate

Per

M0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

00.

80.

01.

33.

80.

03.

70.

310

0,00

0F

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.1

0.0

P0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

00.

40.

00.

71.

80.

02.

60.

2

Inci

denc

eM

2925

2447

4911

913

520

535

454

997

714

0920

4025

6321

6817

4712

6610

4214

748

100.

064

.12

400.

139

3.6

406.

6F

3218

2541

7614

825

432

859

280

111

0611

1612

4315

1412

2010

5492

510

9411

587

100.

044

.03

313.

430

7.7

319.

1P

6143

4988

125

267

389

533

946

1350

2083

2525

3283

4077

3388

2801

2191

2136

2633

510

0.0

53.9

235

5.0

350.

735

9.3

Rate

Per

M17

.915

.715

.729

.829

.269

.983

.813

3.2

211.

535

9.5

638.

310

35.4

1643

.323

56.6

2836

.533

43.5

3604

.938

21.7

636.

110

0,00

0F

20.8

12.0

17.2

27.3

46.2

87.7

157.

620

9.1

346.

051

4.0

703.

480

2.7

1000

.914

01.4

1583

.418

67.2

2080

.022

57.6

496.

7P

19.3

13.9

16.4

28.6

37.6

78.8

120.

717

1.5

279.

543

7.5

671.

291

7.8

1322

.018

80.6

2207

.525

76.8

2752

.928

20.8

566.

2

Mor

talit

yM

34

13

812

824

4584

191

300

476

704

757

737

768

925

5050

100.

019

.56

119.

411

6.1

122.

8F

14

14

78

2033

5985

185

261

308

422

428

462

495

818

3601

100.

012

.39

77.0

74.5

79.6

P4

82

715

2028

5710

416

937

656

178

411

2611

8511

9912

6317

4386

5110

0.0

15.8

796

.694

.698

.7

Rate

Per

M1.

82.

50.

71.

94.

87.

15.

015

.626

.955

.012

4.8

220.

538

3.4

647.

399

0.4

1410

.521

86.9

3392

.621

7.8

100,

000

F0.

62.

70.

72.

74.

34.

712

.421

.034

.554

.511

7.7

187.

724

8.0

390.

655

5.5

818.

511

13.1

1688

.115

4.4

P1.

32.

60.

72.

34.

55.

98.

718

.330

.754

.812

1.2

203.

931

5.7

519.

477

2.1

1103

.015

86.9

2301

.818

6.0

TOTA

L M

ALI

GN

AN

T N

EOP

LASM

S (C

00

-C8

0)

M9

74

-M97

6 O

THER

NEO

PLA

SMS

OF

LYM

PH

ATI

C &

HA

EMA

TOP

OIE

TIC

TIS

SUE

191


ICD-O3/SITE Sex 0-29 years 30-49 years 50-69 years 70 years plus All ages 0-29 years 30-49 years 50-69 years 70 years plus All agesC00 LIPCounts M 12 177 403 211 803 14 525 1366 943 2848

F 0 37 84 119 240 0 82 304 420 806P 12 214 487 330 1043 14 607 1670 1363 3654

Rate Per M 1.2 27.7 75.9 111.5 33.8 1.4 81.9 256.3 499.7 120.5100,000 F 0.0 5.7 15.1 50.4 9.2 0.0 12.5 55.5 179.9 30.9

P 0.6 16.6 45.3 78.8 21.2 0.7 46.9 155.3 323.9 74.1

C01-C14, C30-C32 HEAD AND NECKCounts M 16 195 1158 496 1865 29 321 2197 1407 3954

F 20 111 324 195 650 42 217 727 538 1524P 36 306 1482 691 2515 71 538 2924 1945 5478

Rate Per M 1.6 30.2 215.2 258.6 75.3 3.0 49.8 403.1 735.8 161.7100,000 F 2.2 17.0 60.3 87.0 25.7 4.4 33.2 133.7 235.0 59.2

P 1.9 23.5 137.4 167.0 49.9 3.7 41.4 267.8 466.8 108.7

C01,C02 TONGUECounts M 4 59 305 85 453 4 100 523 237 864

F 3 35 88 54 180 3 60 203 144 410P 7 94 393 139 633 7 160 726 381 1274

Rate Per M 0.4 9.2 57.3 43.8 18.1 0.4 15.5 96.5 122.4 34.8100,000 F 0.3 5.4 16.6 24.1 7.2 0.3 9.2 37.4 63.1 15.9

P 0.4 7.2 36.8 33.2 12.5 0.4 12.4 66.8 91.1 25.2

C03 GUMCounts M 0 4 31 31 66 0 6 51 55 112

F 1 1 13 23 38 2 6 32 52 92P 1 5 44 54 104 2 12 83 107 204

Rate Per M 0.0 0.6 5.8 16.4 2.8 0.0 0.9 9.3 29.0 4.7100,000 F 0.1 0.2 2.3 10.1 1.5 0.2 0.9 5.7 22.1 3.5

P 0.1 0.4 4.0 13.0 2.1 0.1 0.9 7.5 25.4 4.1

C04 FLOOR OF MOUTHCounts M 0 7 75 18 100 0 7 139 64 210

F 0 1 18 21 40 0 1 44 43 88P 0 8 93 39 140 0 8 183 107 298

Rate Per M 0.0 1.1 13.8 9.2 3.9 0.0 1.1 25.6 32.8 8.3100,000 F 0.0 0.2 3.3 10.2 1.6 0.0 0.2 8.0 20.7 3.5

P 0.0 0.6 8.5 9.7 2.7 0.0 0.6 16.8 26.4 5.9

C05,C06 PALATE AND OTHER & UNSPECIFIED PARTS OF MOUTHCounts M 0 9 61 31 101 0 22 126 87 235

F 2 13 44 28 87 5 22 93 80 200P 2 22 105 59 188 5 44 219 167 435

Rate Per M 0.0 1.4 11.3 16.1 4.1 0.0 3.4 23.0 45.4 9.6100,000 F 0.2 2.0 8.0 12.3 3.4 0.5 3.4 16.9 33.6 7.6

P 0.1 1.7 9.7 14.2 3.7 0.3 3.4 19.9 39.7 8.6

C07,C08 PAROTID AND OTHER & UNSPECIFIED MAJOR SALIVARY GLANDSCounts M 5 17 61 57 140 10 38 148 167 363

F 7 24 49 22 102 21 66 126 86 299P 12 41 110 79 242 31 104 274 253 662

Rate Per M 0.5 2.7 11.0 30.1 5.9 1.0 6.0 26.9 88.3 15.5100,000 F 0.7 3.7 9.1 9.1 4.0 2.2 10.2 23.3 35.9 11.8

P 0.6 3.2 10.0 18.9 4.9 1.6 8.1 25.1 59.9 13.4

C09,C10 TONSIL AND OROPHARYNXCounts M 0 59 290 50 399 1 78 519 138 736

F 0 13 55 15 83 0 16 100 34 150P 0 72 345 65 482 1 94 619 172 886

Rate Per M 0.0 9.1 55.0 25.6 15.8 0.1 12.0 97.2 71.6 29.2100,000 F 0.0 2.0 10.6 7.0 3.3 0.0 2.4 18.7 16.0 5.8

P 0.0 5.5 32.6 15.9 9.5 0.1 7.2 57.7 42.2 17.3

C11 NASOPHARYNXCounts M 5 18 25 6 54 7 32 69 23 131

F 2 11 6 1 20 4 18 24 7 53P 7 29 31 7 74 11 50 93 30 184

Rate Per M 0.5 2.8 5.0 3.0 2.3 0.7 5.0 13.4 11.9 5.5100,000 F 0.2 1.7 1.2 0.5 0.9 0.4 2.7 4.6 3.1 2.2

P 0.4 2.2 3.1 1.7 1.6 0.6 3.9 8.9 7.4 3.8

C12,C13 PYRIFORM SINUS AND HYPOPHARYNXCounts M 0 2 57 34 93 0 2 79 69 150

F 0 3 11 9 23 0 4 17 13 34P 0 5 68 43 116 0 6 96 82 184

Rate Per M 0.0 0.3 10.3 17.8 3.7 0.0 0.3 14.2 35.9 6.1100,000 F 0.0 0.5 2.1 4.2 0.9 0.0 0.6 3.2 6.1 1.4

P 0.0 0.4 6.2 10.6 2.3 0.0 0.5 8.7 20.2 3.7

C14 OTHER & ILL-DEFINED SITES IN LIP,ORAL CAVITY & PHARYNXCounts M 0 1 25 7 33 0 3 51 26 80

F 0 0 3 1 4 0 2 7 6 15P 0 1 28 8 37 0 5 58 32 95

Rate Per M 0.0 0.2 4.5 3.6 1.3 0.0 0.5 9.2 13.2 3.1100,000 F 0.0 0.0 0.6 0.4 0.2 0.0 0.3 1.3 2.6 0.6

P 0.0 0.1 2.5 2.0 0.7 0.0 0.4 5.2 7.7 1.8

C15 OESOPHAGUSCounts M 0 13 196 162 371 1 20 272 291 584

F 0 4 47 67 118 0 6 76 139 221P 0 17 243 229 489 1 26 348 430 805

Rate Per M 0.0 2.0 35.2 84.5 15.1 0.1 3.1 48.4 152.8 24.3100,000 F 0.0 0.6 8.4 30.3 4.6 0.0 0.9 13.6 61.4 8.5

P 0.0 1.3 21.7 55.7 9.7 0.0 2.0 30.9 103.6 16.0

Table 6: Limited duration (5-year and 25-year) Cancer Prevalence Site, Sex and Age Group, Queensland, 20135 year prevalence 25 year prevalence



ICD-O3/SITE Sex 0-29 years 30-49 years 50-69 years 70 years plus All ages 0-29 years 30-49 years 50-69 years 70 years plus All ages


C16 STOMACHCounts M 1 28 209 229 467 3 42 371 559 975

F 3 22 100 131 256 3 44 195 307 549P 4 50 309 360 723 6 86 566 866 1524

Rate Per M 0.1 4.3 37.4 121.0 19.6 0.3 6.5 65.8 298.3 41.9100,000 F 0.3 3.4 18.4 56.7 9.9 0.3 6.7 35.7 131.8 21.1

P 0.2 3.8 27.9 86.4 14.5 0.3 6.6 50.8 204.4 30.5

C17 SMALL INTESTINECounts M 2 26 130 93 251 3 38 220 196 457

F 2 28 86 66 182 2 42 152 165 361P 4 54 216 159 433 5 80 372 361 818

Rate Per M 0.2 4.0 23.7 49.2 10.4 0.3 5.8 40.3 103.7 19.2100,000 F 0.2 4.2 15.7 29.4 7.1 0.2 6.4 27.7 72.7 14.0

P 0.2 4.1 19.7 38.2 8.6 0.3 6.1 34.0 86.5 16.4

C18-C20,C218 COLORECTALCounts M 34 362 2497 2858 5751 39 560 4897 8097 13593

F 51 362 1715 2538 4666 66 610 3710 7468 11854P 85 724 4212 5396 10417 105 1170 8607 15565 25447

Rate Per M 3.5 56.4 452.1 1517.3 244.1 4.0 87.2 877.2 4309.3 589.2100,000 F 5.3 55.4 311.3 1102.3 179.4 6.9 93.2 666.3 3173.8 448.2

P 4.4 55.9 381.5 1293.8 210.3 5.4 90.2 771.6 3688.9 513.9

C18 COLONCounts M 30 197 1442 1983 3652 33 324 2745 5418 8520

F 43 214 1075 2047 3379 53 361 2303 5807 8524P 73 411 2517 4030 7031 86 685 5048 11225 17044

Rate Per M 3.1 30.7 259.6 1053.9 156.6 3.4 50.4 490.0 2887.4 373.5100,000 F 4.5 32.8 193.5 885.3 129.6 5.5 55.3 412.1 2453.0 321.3

P 3.8 31.7 226.5 963.1 142.5 4.5 52.9 451.0 2649.9 345.5

C19,C20 RECTOSIGMOID JUNCTION AND RECTUMCounts M 4 164 1066 908 2142 6 238 2177 2802 5223

F 8 141 616 507 1272 13 240 1364 1723 3340P 12 305 1682 1415 3414 19 478 3541 4525 8563

Rate Per M 0.4 25.5 194.5 480.9 89.4 0.6 37.0 391.4 1487.7 222.6100,000 F 0.8 21.6 113.1 224.7 49.3 1.3 36.6 246.2 747.6 127.4

P 0.6 23.5 153.7 343.1 68.5 1.0 36.8 318.7 1083.5 171.8

C21 ANUS & ANAL CANALCounts M 0 6 59 44 109 0 17 127 106 250

F 0 23 104 62 189 0 37 204 180 421P 0 29 163 106 298 0 54 331 286 671

Rate Per M 0.0 0.9 10.6 22.8 4.4 0.0 2.6 23.0 56.0 10.4100,000 F 0.0 3.5 19.0 27.4 7.2 0.0 5.6 37.0 78.3 16.0

P 0.0 2.2 14.8 25.1 5.8 0.0 4.1 30.0 67.8 13.3

C22 LIVER & INTRAHEPATIC BILE DUCTSCounts M 8 21 191 105 325 20 31 271 159 481

F 8 12 48 40 108 28 18 72 60 178P 16 33 239 145 433 48 49 343 219 659

Rate Per M 0.8 3.3 35.8 55.3 13.3 2.0 4.8 50.2 83.5 19.7100,000 F 0.9 1.8 8.9 18.3 4.3 3.0 2.8 13.2 27.1 7.1

P 0.8 2.5 22.3 35.2 8.7 2.5 3.8 31.6 52.7 13.2

C23,C24 GALLBLADDER AND OTHER & UNSPECIFIED PARTS OF BILIARY TRACTCounts M 0 9 63 55 127 0 11 110 123 244

F 0 8 45 60 113 0 9 67 129 205P 0 17 108 115 240 0 20 177 252 449

Rate Per M 0.0 1.4 11.4 29.2 5.3 0.0 1.7 19.6 65.1 10.2100,000 F 0.0 1.2 8.1 26.1 4.3 0.0 1.3 12.0 54.8 7.7

P 0.0 1.3 9.7 27.3 4.8 0.0 1.5 15.8 59.5 8.9

C25 PANCREASCounts M 2 25 132 112 271 2 31 169 165 367

F 3 26 111 102 242 4 36 154 151 345P 5 51 243 214 513 6 67 323 316 712

Rate Per M 0.2 3.9 24.1 58.4 11.3 0.2 4.8 30.7 86.6 15.4100,000 F 0.3 4.0 19.7 44.6 9.2 0.4 5.5 27.5 65.1 13.1

P 0.3 3.9 21.8 51.3 10.2 0.3 5.2 29.1 75.1 14.2

C30,C31 NASAL CAVITY & MIDDLE EAR AND ACCESSORY SINUSESCounts M 1 7 24 27 59 6 18 67 57 148

F 5 9 17 10 41 7 19 44 36 106P 6 16 41 37 100 13 37 111 93 254

Rate Per M 0.1 1.1 4.4 13.9 2.5 0.6 2.8 12.3 29.9 6.2100,000 F 0.6 1.4 3.0 4.4 1.6 0.8 2.9 8.0 15.0 4.1

P 0.3 1.2 3.7 8.5 2.0 0.7 2.8 10.1 21.6 5.1

C32 LARYNXCounts M 1 13 218 155 387 1 18 466 508 993

F 0 1 24 17 42 0 4 48 60 112P 1 14 242 172 429 1 22 514 568 1105

Rate Per M 0.1 2.0 39.6 81.5 15.8 0.1 2.8 83.1 267.5 41.3100,000 F 0.0 0.2 4.4 7.5 1.6 0.0 0.6 8.7 26.4 4.3

P 0.0 1.1 21.9 41.9 8.4 0.0 1.7 45.8 136.3 21.8

C33,C34 TRACHEA AND BRONCHUS & LUNGCounts M 6 75 833 934 1848 12 114 1134 1579 2839

F 7 64 747 652 1470 9 97 1069 1095 2270P 13 139 1580 1586 3318 21 211 2203 2674 5109

Rate Per M 0.6 11.6 148.5 492.9 77.4 1.2 17.7 202.0 834.2 120.8100,000 F 0.7 9.7 134.1 299.4 56.6 0.9 14.8 191.5 494.5 87.1

P 0.7 10.6 141.3 386.7 66.1 1.1 16.2 196.8 647.1 102.4





C37, C38 THYMUS, HEART,MEDIASTINUM & PLEURACounts M 8 6 18 11 43 17 23 41 26 107

F 3 9 13 5 30 8 15 26 19 68P 11 15 31 16 73 25 38 67 45 175

Rate Per M 0.8 1.0 3.2 5.7 1.8 1.7 3.7 7.5 13.6 4.5100,000 F 0.3 1.4 2.4 2.4 1.2 0.9 2.3 4.8 8.5 2.8

P 0.6 1.2 2.8 4.0 1.5 1.3 3.0 6.1 10.9 3.6

C40,C41 BONES,JOINTS & ARTICULAR CARTILAGESCounts M 39 22 18 12 91 85 100 68 44 297

F 23 13 16 9 61 57 69 65 33 224P 62 35 34 21 152 142 169 133 77 521

Rate Per M 4.0 3.4 3.3 6.6 3.9 8.7 15.8 12.7 23.7 13.0100,000 F 2.5 2.0 2.9 4.0 2.6 6.1 10.7 12.0 15.1 9.4

P 3.3 2.7 3.1 5.1 3.2 7.4 13.2 12.4 19.0 11.2

C44, M872-M879 MELANOMACounts M 228 1386 3831 3194 8639 360 3680 10494 9112 23646

F 308 1600 2658 1850 6416 466 4374 8696 6199 19735P 536 2986 6489 5044 15055 826 8054 19190 15311 43381

Rate Per M 23.2 216.9 703.7 1684.4 364.7 36.6 575.3 1929.5 4819.4 1001.2100,000 F 31.7 246.5 494.0 810.5 257.0 47.9 672.3 1615.9 2699.0 781.8

P 27.4 231.8 598.7 1207.5 307.2 42.2 624.3 1773.0 3641.9 881.1

C44 OTHER SKIN (EXCL BCC/SCC)Counts M 4 47 142 278 471 14 99 298 488 899

F 8 30 72 152 262 16 81 175 285 557P 12 77 214 430 733 30 180 473 773 1456

Rate Per M 0.4 7.4 25.5 150.0 20.9 1.4 15.5 54.5 262.9 39.7100,000 F 0.8 4.6 13.2 60.9 9.8 1.7 12.5 32.5 117.1 21.4

P 0.6 6.0 19.3 101.0 15.0 1.5 14.0 43.5 182.2 29.8

M905 MESOTHELIOMACounts M 0 2 59 80 141 0 3 63 86 152

F 0 3 16 23 42 0 5 20 27 52P 0 5 75 103 183 0 8 83 113 204

Rate Per M 0.0 0.3 10.5 41.8 5.9 0.0 0.5 11.2 45.1 6.4100,000 F 0.0 0.5 2.8 10.5 1.6 0.0 0.8 3.6 12.0 2.0

P 0.0 0.4 6.6 25.1 3.7 0.0 0.6 7.4 27.4 4.1

M914 KAPOSI SARCOMACounts M 0 11 10 5 26 0 26 31 18 75

F 0 0 1 2 3 0 0 3 5 8P 0 11 11 7 29 0 26 34 23 83

Rate Per M 0.0 1.7 1.9 2.6 1.1 0.0 4.1 6.1 9.4 3.3100,000 F 0.0 0.0 0.2 1.0 0.1 0.0 0.0 0.5 2.0 0.3

P 0.0 0.9 1.0 1.7 0.6 0.0 2.0 3.3 5.6 1.8

C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVESCounts M 26 41 87 61 215 72 112 251 171 606

F 28 32 72 47 179 76 103 195 136 510P 54 73 159 108 394 148 215 446 307 1116

Rate Per M 2.7 6.5 16.1 32.2 9.1 7.5 17.6 46.2 90.2 25.6100,000 F 3.0 5.0 13.0 20.1 7.1 8.1 15.9 35.7 59.0 20.5

P 2.8 5.7 14.6 25.8 8.1 7.8 16.7 40.9 73.0 22.9

C48 RETROPERITONEUM & PERITONEUMCounts M 8 6 21 15 50 10 12 33 25 80

F 9 4 44 31 88 13 10 87 69 179P 17 10 65 46 138 23 22 120 94 259

Rate Per M 0.8 0.9 4.0 8.0 2.1 1.0 1.9 6.2 13.2 3.4100,000 F 1.0 0.6 7.8 14.8 3.5 1.4 1.5 15.4 32.4 7.0

P 0.9 0.8 5.9 11.4 2.8 1.2 1.7 10.8 23.1 5.2

C50 BREASTCounts M 0 3 47 49 99 0 7 93 131 231

F 37 2507 7439 3840 13823 43 3908 19387 14105 37443P 37 2510 7486 3889 13922 43 3915 19480 14236 37674

Rate Per M 0.0 0.5 8.5 26.0 4.2 0.0 1.1 16.7 70.0 9.9100,000 F 3.8 381.4 1382.2 1726.8 542.9 4.4 593.3 3549.4 6290.7 1444.4

P 1.9 192.8 699.2 933.2 280.0 2.2 300.2 1791.3 3405.1 750.0

C51-C58 GYNAECOLOGICALCounts M 0 0 0 0 0 0 0 0 0 0

F 102 700 1972 1100 3874 145 1664 5143 3733 10685P 102 700 1972 1100 3874 145 1664 5143 3733 10685

Rate Per M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0100,000 F 10.7 108.1 359.7 497.2 152.3 15.1 255.4 939.3 1653.5 416.4

P 5.3 54.5 180.7 264.4 77.8 7.5 128.8 471.8 889.9 214.6

C51 VULVACounts M 0 0 0 0 0 0 0 0 0 0

F 2 35 111 90 238 2 70 254 214 540P 2 35 111 90 238 2 70 254 214 540

Rate Per M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0100,000 F 0.2 5.3 20.7 38.1 9.2 0.2 10.6 47.2 89.7 20.6

P 0.1 2.7 10.4 20.9 4.8 0.1 5.4 23.7 49.6 10.8

C53 CERVIX UTERICounts M 0 0 0 0 0 0 0 0 0 0

F 60 379 226 73 738 65 997 1375 426 2863P 60 379 226 73 738 65 997 1375 426 2863

Rate Per M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0100,000 F 6.2 58.9 43.0 33.3 31.6 6.7 153.4 261.1 190.9 117.1

P 3.1 29.7 21.7 17.7 16.0 3.3 77.4 131.5 102.2 59.5





C54 CORPUS UTERICounts M 0 0 0 0 0 0 0 0 0 0

F 1 147 1174 640 1962 2 242 2420 2305 4969P 1 147 1174 640 1962 2 242 2420 2305 4969

Rate Per M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0100,000 F 0.1 22.4 211.5 292.6 74.7 0.2 36.8 431.2 1024.5 188.3

P 0.1 11.3 106.2 154.9 38.2 0.1 18.6 216.2 551.0 97.8

C56 OVARYCounts M 0 0 0 0 0 0 0 0 0 0

F 37 128 419 242 826 72 298 986 675 2031P 37 128 419 242 826 72 298 986 675 2031

Rate Per M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0100,000 F 4.0 19.7 77.2 108.8 32.5 7.6 45.7 180.4 298.9 79.2

P 1.9 9.9 38.8 57.9 16.6 3.7 23.0 90.6 160.5 40.7

C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANSCounts M 0 0 0 0 0 0 0 0 0 0

F 2 25 78 63 168 4 74 185 145 408P 2 25 78 63 168 4 74 185 145 408

Rate Per M 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0100,000 F 0.2 3.9 14.1 28.1 6.6 0.4 11.4 33.8 64.0 16.0

P 0.1 2.0 7.1 15.0 3.4 0.2 5.8 17.0 34.3 8.2

C61 PROSTATE GLANDCounts M 2 301 9952 7874 18129 2 330 15806 21272 37410

F 0 0 0 0 0 0 0 0 0 0P 2 301 9952 7874 18129 2 330 15806 21272 37410

Rate Per M 0.2 46.2 1762.2 4100.7 730.4 0.2 50.6 2770.8 11218.0 1572.6100,000 F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

P 0.1 22.8 879.3 1923.8 353.3 0.1 25.0 1383.5 5134.7 743.0

C62 TESTISCounts M 184 442 90 13 729 265 1479 792 82 2618

F 0 0 0 0 0 0 0 0 0 0P 184 442 90 13 729 265 1479 792 82 2618

Rate Per M 18.6 69.9 18.1 6.8 32.8 26.9 232.6 157.8 41.9 115.4100,000 F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

P 9.4 34.7 9.0 3.1 16.3 13.6 115.4 78.2 19.6 57.2

C60,C63 PENIS AND OTHER & UNSPECIFIED MALE GENITAL ORGANSCounts M 1 9 41 42 93 4 17 92 124 237

F 0 0 0 0 0 0 0 0 0 0P 1 9 41 42 93 4 17 92 124 237

Rate Per M 0.1 1.4 7.6 22.5 4.0 0.4 2.6 17.1 66.6 10.3100,000 F 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

P 0.0 0.7 3.8 10.3 1.9 0.2 1.3 8.5 30.4 4.9

C64-C66,C68 KIDNEY AND OTHER RENAL TRACTCounts M 21 186 870 619 1696 64 283 1701 1586 3634

F 29 116 436 372 953 77 197 882 975 2131P 50 302 1306 991 2649 141 480 2583 2561 5765

Rate Per M 2.2 28.9 160.4 324.9 70.4 6.6 44.0 309.9 835.7 152.2100,000 F 3.1 17.6 80.0 164.9 37.1 8.3 30.0 160.9 423.7 82.2

P 2.6 23.2 120.0 239.2 53.2 7.4 36.9 235.2 613.5 115.7

C67 BLADDERCounts M 3 23 367 692 1085 9 70 854 1860 2793

F 1 12 111 209 333 2 40 250 637 929P 4 35 478 901 1418 11 110 1104 2497 3722

Rate Per M 0.3 3.5 65.4 371.0 47.5 0.9 10.9 152.0 995.0 123.4100,000 F 0.1 1.8 19.7 89.1 12.5 0.2 6.1 44.7 264.3 34.5

P 0.2 2.7 42.5 214.2 28.6 0.6 8.5 98.2 585.3 74.9

C69 EYE & ADNEXACounts M 9 21 78 51 159 50 50 238 168 506

F 7 14 47 26 94 46 51 138 106 341P 16 35 125 77 253 96 101 376 274 847

Rate Per M 0.9 3.3 14.3 26.4 6.5 5.2 7.8 43.5 88.4 21.0100,000 F 0.7 2.2 8.6 11.0 3.6 5.0 7.8 25.2 45.5 13.4

P 0.8 2.7 11.4 18.4 5.0 5.1 7.8 34.3 65.3 17.1

C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEMCounts M 76 110 122 34 342 164 259 259 70 752

F 54 89 91 36 270 113 201 216 62 592P 130 199 213 70 612 277 460 475 132 1344

Rate Per M 7.8 17.3 23.2 17.4 14.5 16.9 40.7 49.3 36.5 32.2100,000 F 5.8 13.7 17.3 16.5 11.4 12.1 31.1 41.0 28.0 24.9

P 6.8 15.5 20.2 16.9 13.0 14.5 35.9 45.1 31.7 28.5

C73 THYROID GLANDCounts M 29 169 291 117 606 40 362 704 312 1418

F 120 660 795 208 1783 193 1523 2339 744 4799P 149 829 1086 325 2389 233 1885 3043 1056 6217

Rate Per M 3.0 26.6 55.2 61.0 25.5 4.1 56.6 132.9 163.4 59.5100,000 F 12.3 101.9 151.4 96.6 74.0 19.8 234.2 441.0 338.5 195.4

P 7.6 64.6 103.7 79.3 50.0 11.9 146.2 288.1 255.4 128.2

C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDSCounts M 20 1 9 1 31 48 17 20 7 92

F 12 6 6 5 29 33 19 17 15 84P 32 7 15 6 60 81 36 37 22 176

Rate Per M 2.1 0.2 1.8 0.5 1.3 5.0 2.6 3.9 3.5 3.9100,000 F 1.3 0.9 1.1 2.4 1.2 3.5 2.9 3.1 6.8 3.6

P 1.7 0.5 1.4 1.5 1.3 4.3 2.8 3.5 5.4 3.8





C26,C39,C76,C77,C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITECounts M 7 38 250 279 574 12 80 511 614 1217

F 8 38 135 156 337 14 68 287 392 761P 15 76 385 435 911 26 148 798 1006 1978

Rate Per M 0.7 5.9 45.7 147.3 24.3 1.2 12.4 93.4 325.2 51.9100,000 F 0.8 5.8 24.7 66.5 12.9 1.5 10.4 52.0 166.7 29.0

P 0.8 5.9 35.2 103.4 18.3 1.3 11.4 72.6 238.1 39.7

M959-M972 ALL LYMPHOMASCounts M 171 315 989 842 2317 348 848 2154 1839 5189

F 123 251 730 733 1837 217 699 1695 1706 4317P 294 566 1719 1575 4154 565 1547 3849 3545 9506

Rate Per M 17.6 49.2 180.8 442.6 97.5 35.7 133.1 395.5 968.9 219.7100,000 F 12.8 38.7 133.3 326.8 72.6 22.5 107.8 308.6 749.6 169.8

P 15.3 43.9 156.9 379.1 84.5 29.2 120.3 351.9 846.3 193.6

M965-M966 HODGKIN LYMPHOMACounts M 83 73 56 29 241 153 320 202 72 747

F 88 81 49 26 244 147 332 168 67 714P 171 154 105 55 485 300 652 370 139 1461

Rate Per M 8.5 11.4 10.6 14.9 10.4 15.6 50.4 38.8 37.2 32.5100,000 F 9.1 12.6 9.4 12.1 10.5 15.2 51.6 32.5 30.8 30.9

P 8.8 12.0 10.0 13.2 10.4 15.4 51.0 35.6 33.4 31.6

M959,M967-M972 NON-HODGKIN LYMPHOMACounts M 89 242 933 813 2077 196 528 1952 1769 4445

F 35 170 681 707 1593 70 367 1528 1642 3607P 124 412 1614 1520 3670 266 895 3480 3411 8052

Rate Per M 9.2 37.8 170.2 427.6 87.2 20.2 82.6 356.7 932.7 187.4100,000 F 3.7 26.1 123.9 314.6 62.1 7.3 56.2 276.3 720.2 139.1

P 6.5 31.9 147.0 365.8 74.1 13.9 69.3 316.3 814.1 162.1

M980-M994 ALL LEUKAEMIASCounts M 167 156 607 560 1490 464 355 1250 1260 3329

F 126 94 323 377 920 413 250 765 931 2359P 293 250 930 937 2410 877 605 2015 2191 5688

Rate Per M 17.3 24.3 110.6 295.3 62.8 48.1 55.6 226.4 663.8 141.0100,000 F 13.8 14.4 58.8 162.4 36.2 44.6 38.5 139.3 403.6 93.8

P 15.6 19.3 84.6 225.1 49.2 46.4 47.0 182.7 524.9 116.6

M982-M983 LYMPHOID LEUKAEMIACounts M 119 49 387 353 908 355 119 775 870 2119

F 90 21 208 246 565 327 64 443 691 1525P 209 70 595 599 1473 682 183 1218 1561 3644

Rate Per M 12.4 7.6 69.7 185.1 37.8 36.9 18.8 138.3 458.2 89.5100,000 F 9.9 3.2 37.5 105.8 22.0 35.4 9.9 79.1 299.3 60.2

P 11.2 5.4 53.5 143.9 29.8 36.2 14.3 108.7 373.9 74.4

M984-M993 MYELOID LEUKAEMIACounts M 45 90 155 85 375 101 203 344 172 820

F 34 69 98 73 274 83 178 278 143 682P 79 159 253 158 649 184 381 622 315 1502

Rate Per M 4.6 14.1 28.9 44.3 15.8 10.4 31.8 64.1 89.6 34.5100,000 F 3.6 10.6 18.4 32.9 11.2 8.8 27.3 52.2 64.4 27.9

P 4.1 12.3 23.6 38.3 13.5 9.6 29.5 58.1 76.0 31.1

M994 OTHER SPECIFIED LEUKAEMIACounts M 1 17 64 120 202 3 27 129 213 372

F 1 4 15 56 76 2 8 38 94 142P 2 21 79 176 278 5 35 167 307 514

Rate Per M 0.1 2.6 11.9 64.7 9.0 0.3 4.2 23.6 113.2 16.2100,000 F 0.1 0.6 2.6 23.0 2.8 0.2 1.2 6.9 38.8 5.3

P 0.1 1.6 7.2 42.0 5.7 0.3 2.7 15.2 73.2 10.5

M980 UNSPECIFIED LEUKAEMIACounts M 2 0 1 3 6 5 6 2 6 19

F 1 0 2 2 5 1 0 6 3 10P 3 0 3 5 11 6 6 8 9 29

Rate Per M 0.2 0.0 0.2 1.7 0.3 0.5 0.9 0.4 3.3 0.9100,000 F 0.1 0.0 0.3 0.6 0.2 0.1 0.0 1.1 1.0 0.4

P 0.2 0.0 0.3 1.1 0.2 0.3 0.5 0.7 2.0 0.6

M973 MYELOMA/PLASMA CELL TUMOURSCounts M 1 39 292 281 613 2 53 434 459 948

F 1 18 183 220 422 1 24 313 363 701P 2 57 475 501 1035 3 77 747 822 1649

Rate Per M 0.1 6.0 52.2 147.9 25.5 0.2 8.2 77.5 241.2 39.6100,000 F 0.1 2.7 33.0 100.2 16.4 0.1 3.6 56.2 164.5 27.0

P 0.1 4.4 42.6 122.0 20.7 0.2 5.9 66.9 199.1 32.9

M998 MYELODYSPLASTIC DISEASESCounts M 2 8 103 291 404 5 23 172 444 644

F 5 8 71 181 265 11 14 133 317 475P 7 16 174 472 669 16 37 305 761 1119

Rate Per M 0.2 1.3 17.7 155.5 18.0 0.5 3.6 29.8 237.2 28.6100,000 F 0.5 1.2 12.6 75.1 9.9 1.2 2.1 24.1 130.7 17.7

P 0.4 1.2 15.2 110.3 13.5 0.8 2.9 27.0 177.5 22.5

M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASESCounts M 9 41 193 131 374 17 107 459 403 986

F 11 47 112 137 307 17 117 360 352 846P 20 88 305 268 681 34 224 819 755 1832

Rate Per M 0.9 6.4 35.8 68.6 15.5 1.8 16.7 83.9 211.2 41.3100,000 F 1.1 7.2 20.5 61.1 12.2 1.8 18.0 66.1 152.6 32.9

P 1.0 6.8 28.1 64.3 13.8 1.8 17.3 75.0 180.2 36.9





M974-M976 OTHER NEOPLASMS OF LYMPHATIC & HAEMATOPOIETIC TISSUECounts M 0 6 5 19 30 0 10 24 41 75

F 1 4 11 8 24 2 7 27 33 69P 1 10 16 27 54 2 17 51 74 144

Rate Per M 0.0 0.9 0.9 9.9 1.3 0.0 1.5 4.4 21.6 3.3100,000 F 0.1 0.6 2.0 3.3 0.9 0.2 1.1 5.0 14.1 2.6

P 0.1 0.8 1.5 6.3 1.1 0.1 1.3 4.7 17.5 2.9

TOTAL MALIGNANT NEOPLASMS (C00-C80)Counts M 1095 4285 23493 19654 48527 2167 9955 45023 47599 104744

F 1105 6875 18288 13198 39466 2101 14362 45520 38224 100207P 2200 11160 41781 32852 87993 4268 24317 90543 85823 204951

Rate Per M 112.2 669.3 4245.8 10323.0 2012.8 222.6 1556.0 8138.3 25137.0 4425.7100,000 F 115.8 1053.8 3373.9 5846.0 1553.4 220.8 2199.6 8355.0 16759.0 3903.2

P 114.1 863.3 3811.3 7917.3 1768.8 221.8 1881.0 8253.2 20515.0 4127.7



ICD-O3/SITE Sex N 1-year survival 5-year survival 10-year survival 15-year survival 20-year survival 25-year survivalC00 LIPPercent [95% CI] M 970 99.5 [ 98.3,100.3] 95.4 [ 92.6, 97.8] 88.4 [ 84.4, 92.0] 84.7 [ 79.9, 89.1] 80.3 [ 74.8, 85.5] 77.5 [ 71.1, 83.8]

F 289 99.3 [ 96.1,100.8] 94.5 [ 88.5, 99.1] 82.8 [ 75.0, 89.7] 70.8 [ 62.2, 78.9] 68.2 [ 58.7, 77.5] 57.8 [ 47.2, 68.7]P 1259 99.5 [ 98.4,100.2] 95.2 [ 92.7, 97.4] 87.0 [ 83.4, 90.3] 81.1 [ 77.0, 85.0] 77.1 [ 72.4, 81.7] 72.4 [ 66.9, 77.9]

C01-C14, C30-C32 HEAD AND NECKPercent [95% CI] M 3058 83.1 [ 81.6, 84.6] 60.9 [ 58.7, 63.0] 49.3 [ 46.7, 51.8] 40.1 [ 37.2, 43.0] 33.7 [ 30.4, 37.0] 29.6 [ 25.9, 33.6]

F 1015 86.3 [ 83.7, 88.6] 66.2 [ 62.5, 69.7] 55.3 [ 50.9, 59.6] 45.3 [ 40.3, 50.2] 36.6 [ 31.6, 41.9] 31.6 [ 26.0, 37.7]P 4073 83.9 [ 82.6, 85.2] 62.2 [ 60.3, 64.0] 50.8 [ 48.6, 53.0] 41.4 [ 38.9, 43.9] 34.3 [ 31.6, 37.2] 30.0 [ 26.9, 33.3]

C01,C02 TONGUEPercent [95% CI] M 707 83.8 [ 80.4, 86.6] 62.5 [ 57.9, 66.9] 53.6 [ 48.0, 59.1] 41.3 [ 34.7, 48.1] 33.2 [ 25.8, 41.3] 28.7 [ 20.2, 38.5]

F 282 86.7 [ 81.4, 90.6] 69.8 [ 62.9, 76.0] 60.8 [ 52.2, 68.8] 44.0 [ 34.3, 53.8] 37.8 [ 27.3, 49.1] **P 989 84.6 [ 81.9, 87.0] 64.7 [ 60.9, 68.4] 55.7 [ 51.1, 60.3] 42.0 [ 36.5, 47.6] 34.5 [ 28.4, 41.1] 28.0 [ 21.2, 35.7]

C03 GUMPercent [95% CI] M 101 86.1 [ 76.6, 92.4] 72.5 [ 58.7, 83.8] 71.0 [ 50.8, 88.6] ** ** **

F 63 86.4 [ 73.2, 93.8] 74.9 [ 58.8, 87.0] 62.6 [ 43.5, 79.5] ** ** **P 164 86.2 [ 79.0, 91.4] 73.4 [ 63.3, 82.0] 65.8 [ 52.1, 78.3] 46.8 [ 28.2, 66.4] ** **

C04 FLOOR OF MOUTHPercent [95% CI] M 167 88.1 [ 81.4, 92.6] 60.7 [ 51.6, 68.9] 41.3 [ 30.9, 51.7] 32.7 [ 22.8, 43.4] ** **

F 63 84.2 [ 70.8, 92.1] 53.6 [ 38.0, 67.4] 32.8 [ 18.8, 48.2] ** ** **P 230 87.0 [ 81.3, 91.2] 58.7 [ 50.9, 65.9] 39.2 [ 30.7, 47.8] 30.4 [ 22.3, 39.2] 19.1 [ 12.0, 27.9] **

C05,C06 PALATE AND OTHER & UNSPECIFIED PARTS OF MOUTHPercent [95% CI] M 196 74.6 [ 67.2, 80.8] 49.1 [ 40.9, 57.1] 38.7 [ 30.2, 47.4] 24.2 [ 16.1, 33.8] 18.7 [ 11.2, 28.2] **

F 135 84.9 [ 76.7, 90.5] 60.0 [ 49.7, 69.1] 48.6 [ 37.0, 60.0] 40.1 [ 27.7, 53.3] 30.2 [ 19.0, 43.3] 28.5 [ 16.6, 43.3]P 331 78.8 [ 73.4, 83.3] 53.5 [ 47.1, 59.6] 42.6 [ 35.7, 49.6] 30.4 [ 23.3, 38.2] 23.1 [ 16.5, 30.6] 19.8 [ 13.1, 27.9]

C07,C08 PAROTID AND OTHER & UNSPECIFIED MAJOR SALIVARY GLANDSPercent [95% CI] M 213 90.8 [ 85.0, 94.7] 71.7 [ 63.3, 79.1] 59.3 [ 49.1, 69.2] 53.7 [ 42.5, 65.0] ** **

F 135 96.5 [ 90.4, 99.2] 80.5 [ 70.5, 88.2] 75.6 [ 63.7, 85.5] 76.3 [ 62.8, 87.8] 71.4 [ 55.5, 85.7] **P 348 92.9 [ 88.9, 95.7] 75.0 [ 68.7, 80.6] 65.6 [ 57.8, 72.9] 62.3 [ 53.6, 70.8] 61.2 [ 51.2, 71.2] 62.0 [ 49.7, 74.5]

C09,C10 TONSIL AND OROPHARYNXPercent [95% CI] M 577 86.8 [ 83.4, 89.7] 69.9 [ 64.9, 74.4] 61.6 [ 55.1, 67.7] 54.0 [ 45.5, 62.3] 48.0 [ 36.9, 59.3] 47.2 [ 29.6, 66.6]

F 122 84.5 [ 75.9, 90.3] 64.4 [ 53.1, 74.0] 50.4 [ 37.4, 62.7] ** ** **P 699 86.4 [ 83.3, 89.1] 68.9 [ 64.4, 73.1] 59.4 [ 53.6, 65.0] 49.5 [ 41.8, 57.1] 42.5 [ 32.8, 52.6] 34.4 [ 21.6, 49.4]

C11 NASOPHARYNXPercent [95% CI] M 80 86.8 [ 76.2, 93.1] 64.9 [ 51.1, 75.9] 57.2 [ 42.4, 70.2] 54.2 [ 38.4, 68.7] 42.6 [ 25.7, 60.0] **

F 27 91.2 [ 68.4, 98.0] 68.6 [ 44.2, 84.5] ** ** ** **P 107 87.8 [ 79.1, 93.2] 66.0 [ 54.4, 75.5] 61.0 [ 48.5, 71.8] 57.1 [ 43.4, 69.4] 46.4 [ 31.8, 60.9] 44.4 [ 28.3, 61.0]

C12,C13 PYRIFORM SINUS AND HYPOPHARYNXPercent [95% CI] M 207 67.5 [ 60.0, 73.9] 32.2 [ 24.7, 40.0] 16.1 [ 10.2, 23.4] ** ** **

F 35 79.9 [ 59.5, 91.2] ** ** ** ** **P 242 69.1 [ 62.2, 75.1] 32.9 [ 25.7, 40.3] 17.4 [ 11.6, 24.4] ** ** **

C14 OTHER & ILL-DEFINED SITES IN LIP,ORAL CAVITY & PHARYNXPercent [95% CI] M 89 55.0 [ 43.1, 65.4] 35.9 [ 25.4, 46.8] ** ** ** **

F 17 ** ** ** ** ** **P 106 52.5 [ 41.8, 62.2] 32.6 [ 23.3, 42.4] ** ** ** **

C15 OESOPHAGUSPercent [95% CI] M 1064 52.0 [ 48.7, 55.1] 23.3 [ 20.2, 26.5] 18.4 [ 15.1, 21.9] 17.6 [ 14.0, 21.7] 15.1 [ 10.2, 21.2] **

F 363 47.7 [ 42.1, 53.1] 25.3 [ 20.6, 30.4] 20.7 [ 15.6, 26.3] 12.8 [ 8.1, 18.7] ** **P 1427 50.9 [ 48.1, 53.6] 24.1 [ 21.5, 26.8] 19.2 [ 16.4, 22.1] 16.4 [ 13.4, 19.7] 13.4 [ 9.9, 17.7] 9.4 [ 5.6, 14.9]

C16 STOMACHPercent [95% CI] M 1297 53.9 [ 50.9, 56.8] 27.6 [ 24.8, 30.6] 24.1 [ 21.1, 27.4] 22.1 [ 18.6, 26.0] 21.8 [ 17.5, 26.6] 25.3 [ 19.7, 31.6]

F 581 57.3 [ 52.7, 61.6] 32.2 [ 27.7, 36.8] 29.1 [ 24.3, 34.1] 24.1 [ 19.3, 29.5] 22.1 [ 16.9, 28.0] 22.5 [ 16.2, 29.8]P 1878 54.9 [ 52.4, 57.3] 29.1 [ 26.6, 31.5] 25.7 [ 23.1, 28.4] 22.6 [ 19.7, 25.7] 21.7 [ 18.4, 25.3] 24.0 [ 19.8, 28.6]

C17 SMALL INTESTINEPercent [95% CI] M 400 79.8 [ 74.9, 84.0] 60.2 [ 53.6, 66.4] 49.3 [ 41.1, 57.4] 43.0 [ 33.4, 53.1] ** **

F 265 81.9 [ 76.0, 86.6] 75.1 [ 67.7, 81.4] 63.4 [ 53.5, 72.6] 64.9 [ 53.3, 75.9] 54.6 [ 35.5, 74.3] **P 665 80.6 [ 77.0, 83.8] 66.4 [ 61.5, 71.0] 55.1 [ 48.8, 61.3] 51.7 [ 44.1, 59.4] 51.4 [ 41.5, 61.8] 52.8 [ 37.6, 69.6]

C18-C20,C218 COLORECTALPercent [95% CI] M 9239 86.4 [ 85.5, 87.2] 68.2 [ 66.9, 69.4] 61.2 [ 59.5, 62.8] 58.4 [ 56.3, 60.4] 55.8 [ 53.1, 58.4] 53.3 [ 49.7, 56.9]

F 7290 85.3 [ 84.4, 86.3] 69.8 [ 68.4, 71.2] 63.3 [ 61.5, 65.0] 59.5 [ 57.4, 61.6] 56.1 [ 53.6, 58.7] 52.6 [ 49.4, 55.9]P 16529 85.9 [ 85.3, 86.5] 68.9 [ 68.0, 69.8] 62.1 [ 60.9, 63.3] 58.9 [ 57.4, 60.3] 55.9 [ 54.0, 57.7] 52.9 [ 50.5, 55.3]

C18 COLONPercent [95% CI] M 5796 85.5 [ 84.4, 86.6] 68.6 [ 67.0, 70.2] 61.9 [ 59.8, 64.0] 58.7 [ 56.0, 61.4] 56.2 [ 52.8, 59.7] 53.7 [ 49.2, 58.3]

F 5326 83.9 [ 82.7, 85.0] 68.7 [ 67.1, 70.3] 62.6 [ 60.6, 64.7] 58.9 [ 56.4, 61.4] 55.3 [ 52.2, 58.3] 51.7 [ 48.0, 55.6]P 11122 84.8 [ 84.0, 85.5] 68.7 [ 67.5, 69.8] 62.3 [ 60.8, 63.7] 58.8 [ 57.0, 60.7] 55.7 [ 53.4, 58.0] 52.6 [ 49.7, 55.6]

Table 7: Relative Survival by Site, Sex and Follow up Interval, Queensland, 2009-20130-89 years at diagnosis



ICD-O3/SITE Sex N 1-year survival 5-year survival 10-year survival 15-year survival 20-year survival 25-year survival


C19,C20 RECTOSIGMOID JUNCTION AND RECTUMPercent [95% CI] M 3383 87.8 [ 86.4, 89.0] 67.6 [ 65.6, 69.6] 60.1 [ 57.6, 62.6] 58.0 [ 54.8, 61.1] 55.2 [ 51.1, 59.4] 52.7 [ 46.8, 58.9]

F 1878 88.9 [ 87.2, 90.5] 72.4 [ 69.7, 74.9] 64.8 [ 61.6, 67.9] 61.0 [ 57.1, 64.8] 58.3 [ 53.6, 63.1] 54.8 [ 48.6, 61.2]P 5261 88.2 [ 87.1, 89.2] 69.3 [ 67.7, 70.9] 61.8 [ 59.8, 63.8] 59.0 [ 56.6, 61.5] 56.3 [ 53.2, 59.4] 53.3 [ 49.0, 57.7]

C21 ANUS & ANAL CANALPercent [95% CI] M 178 81.6 [ 74.2, 87.3] 56.9 [ 47.4, 65.8] 51.2 [ 40.7, 61.5] 43.5 [ 32.0, 55.5] 38.9 [ 26.4, 52.8] **

F 268 91.6 [ 87.0, 94.8] 74.8 [ 67.5, 81.0] 67.3 [ 58.6, 75.3] 56.2 [ 44.0, 68.3] 53.5 [ 39.2, 68.3] **P 446 87.7 [ 83.7, 90.8] 67.7 [ 61.9, 73.0] 60.8 [ 54.0, 67.2] 51.1 [ 42.6, 59.7] 47.3 [ 37.5, 57.6] 40.7 [ 28.3, 54.7]

C22 LIVER & INTRAHEPATIC BILE DUCTSPercent [95% CI] M 1024 43.1 [ 39.8, 46.4] 17.7 [ 15.0, 20.6] 11.2 [ 8.7, 14.2] 10.2 [ 7.5, 13.5] 10.4 [ 7.4, 14.2] **

F 399 38.8 [ 33.7, 43.8] 15.5 [ 11.7, 19.8] 10.2 [ 6.8, 14.5] 8.3 [ 5.0, 12.7] 8.2 [ 4.9, 12.8] **P 1423 41.9 [ 39.1, 44.6] 17.1 [ 14.9, 19.5] 11.0 [ 8.8, 13.4] 9.5 [ 7.3, 12.1] 9.6 [ 7.2, 12.4] **

C23,C24 GALLBLADDER AND OTHER & UNSPECIFIED PARTS OF BILIARY TRACTPercent [95% CI] M 352 55.0 [ 49.1, 60.4] 26.2 [ 20.9, 31.9] 24.5 [ 18.6, 31.0] 22.2 [ 15.8, 29.6] 19.5 [ 12.3, 28.7] **

F 384 38.8 [ 33.6, 43.9] 15.0 [ 11.1, 19.4] 11.5 [ 7.9, 16.0] 11.0 [ 7.3, 15.9] 10.4 [ 6.2, 16.1] **P 736 46.5 [ 42.6, 50.3] 20.3 [ 17.0, 23.8] 17.3 [ 13.8, 21.1] 16.0 [ 12.4, 20.3] 14.6 [ 10.4, 19.6] 15.0 [ 10.0, 21.4]

C25 PANCREASPercent [95% CI] M 1353 28.3 [ 25.9, 30.8] 7.9 [ 6.4, 9.7] 5.0 [ 3.5, 6.9] 4.3 [ 2.8, 6.2] ** **

F 1170 30.1 [ 27.4, 32.8] 7.3 [ 5.7, 9.2] 5.8 [ 4.3, 7.7] 4.3 [ 2.8, 6.3] 4.3 [ 2.7, 6.5] **P 2523 29.1 [ 27.3, 30.9] 7.6 [ 6.5, 8.9] 5.4 [ 4.3, 6.7] 4.3 [ 3.3, 5.7] 4.3 [ 3.1, 5.8] 4.5 [ 2.9, 6.5]

C30,C31 NASAL CAVITY & MIDDLE EAR AND ACCESSORY SINUSESPercent [95% CI] M 99 83.2 [ 73.0, 90.2] 60.8 [ 48.2, 72.0] 54.5 [ 40.5, 67.7] 55.1 [ 39.3, 70.6] ** **

F 61 88.0 [ 73.8, 95.2] 70.9 [ 54.2, 83.6] 55.2 [ 36.7, 72.1] 56.7 [ 36.5, 75.5] 55.7 [ 33.1, 78.3] **P 160 84.8 [ 77.1, 90.4] 64.6 [ 54.7, 73.3] 54.9 [ 43.8, 65.5] 55.6 [ 43.1, 67.8] 55.5 [ 40.7, 70.5] 50.4 [ 34.1, 67.9]

C32 LARYNXPercent [95% CI] M 622 86.4 [ 82.9, 89.3] 63.0 [ 58.0, 67.7] 50.4 [ 45.1, 55.8] 41.4 [ 35.5, 47.4] 35.1 [ 28.9, 41.8] 30.5 [ 23.6, 38.4]

F 75 85.9 [ 74.1, 92.9] 63.9 [ 50.1, 75.5] 50.0 [ 34.8, 64.6] ** ** **P 697 86.3 [ 83.1, 89.1] 63.1 [ 58.4, 67.5] 50.5 [ 45.4, 55.5] 40.5 [ 35.0, 46.2] 33.4 [ 27.7, 39.5] 30.1 [ 23.7, 37.2]

C33,C34 TRACHEA AND BRONCHUS & LUNGPercent [95% CI] M 7003 38.7 [ 37.5, 40.0] 14.1 [ 13.2, 15.1] 9.5 [ 8.6, 10.5] 6.6 [ 5.7, 7.5] 5.7 [ 4.8, 6.7] 5.1 [ 4.1, 6.3]

F 4518 47.3 [ 45.8, 48.9] 19.0 [ 17.7, 20.3] 14.0 [ 12.7, 15.4] 10.4 [ 9.0, 11.8] 9.2 [ 7.8, 10.9] 8.2 [ 6.5, 10.2]P 11521 42.1 [ 41.1, 43.1] 16.0 [ 15.2, 16.8] 11.3 [ 10.5, 12.1] 8.0 [ 7.2, 8.8] 7.0 [ 6.2, 7.9] 6.3 [ 5.3, 7.3]

C37, C38 THYMUS, HEART,MEDIASTINUM & PLEURAPercent [95% CI] M 68 76.0 [ 62.3, 85.5] 60.6 [ 45.9, 72.9] 37.5 [ 22.0, 53.7] 34.3 [ 19.5, 50.8] ** **

F 42 80.3 [ 62.6, 90.5] 65.7 [ 45.6, 80.6] 53.5 [ 33.0, 71.5] 47.4 [ 26.6, 67.4] ** **P 110 77.6 [ 67.4, 85.1] 62.0 [ 50.2, 72.1] 45.4 [ 33.0, 57.5] 41.3 [ 29.0, 53.9] 33.4 [ 21.5, 46.6] **

C40,C41 BONES,JOINTS & ARTICULAR CARTILAGESPercent [95% CI] M 144 85.5 [ 77.7, 90.9] 61.8 [ 52.1, 70.3] 54.7 [ 44.7, 63.9] 49.8 [ 39.4, 59.7] 49.8 [ 38.9, 60.3] 47.5 [ 36.2, 58.6]

F 95 93.1 [ 84.5, 97.2] 71.2 [ 59.1, 80.5] 65.7 [ 53.2, 76.1] 59.6 [ 46.4, 71.2] 59.1 [ 45.3, 71.4] 58.8 [ 44.4, 72.1]P 239 88.5 [ 83.1, 92.4] 65.5 [ 58.1, 72.1] 58.9 [ 51.1, 66.0] 53.6 [ 45.5, 61.3] 53.4 [ 44.9, 61.6] 51.8 [ 42.9, 60.5]

C44, M872-M879 MELANOMAPercent [95% CI] M 11119 98.3 [ 97.9, 98.7] 91.4 [ 90.4, 92.3] 87.9 [ 86.6, 89.2] 85.5 [ 83.8, 87.1] 83.9 [ 81.8, 85.9] 83.3 [ 80.8, 85.9]

F 7781 99.0 [ 98.7, 99.4] 95.0 [ 94.1, 95.8] 92.3 [ 91.1, 93.4] 90.9 [ 89.4, 92.3] 89.2 [ 87.3, 91.0] 87.5 [ 85.3, 89.7]P 18900 98.6 [ 98.3, 98.9] 92.9 [ 92.2, 93.5] 89.7 [ 88.8, 90.6] 87.8 [ 86.7, 88.9] 86.1 [ 84.7, 87.5] 85.0 [ 83.4, 86.7]

C44 OTHER SKIN (EXCL BCC/SCC)Percent [95% CI] M 777 89.6 [ 86.6, 92.2] 65.1 [ 60.0, 69.9] 55.6 [ 48.9, 62.1] 46.4 [ 38.3, 54.8] 48.0 [ 39.0, 57.5] 44.5 [ 34.5, 55.5]

F 367 88.8 [ 84.3, 92.2] 75.6 [ 68.8, 81.7] 66.4 [ 58.0, 74.4] 60.8 [ 50.8, 70.5] 53.5 [ 42.2, 65.0] 52.8 [ 39.9, 66.3]P 1144 89.4 [ 86.9, 91.5] 68.5 [ 64.4, 72.3] 59.2 [ 54.0, 64.3] 51.4 [ 45.1, 57.8] 50.0 [ 43.0, 57.2] 47.5 [ 39.5, 55.9]

M905 MESOTHELIOMAPercent [95% CI] M 631 43.5 [ 39.4, 47.5] 4.7 [ 2.9, 7.0] ** ** ** **

F 146 50.2 [ 41.4, 58.5] ** ** ** ** **P 777 44.7 [ 41.0, 48.4] 5.3 [ 3.6, 7.5] ** ** ** **

M914 KAPOSI SARCOMAPercent [95% CI] M 39 88.9 [ 71.7, 96.3] 82.7 [ 63.9, 93.5] 80.4 [ 58.3, 93.9] 71.5 [ 42.8, 92.2] ** **

F 6 ** ** ** ** ** **P 45 90.7 [ 75.6, 97.2] 78.2 [ 59.8, 90.2] 71.7 [ 50.0, 87.3] 60.7 [ 35.7, 82.1] ** **

C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVESPercent [95% CI] M 351 81.3 [ 76.2, 85.5] 61.9 [ 55.2, 68.1] 59.0 [ 51.7, 65.9] 52.9 [ 45.1, 60.5] 50.4 [ 41.8, 59.1] 51.1 [ 41.2, 61.3]

F 273 86.7 [ 81.5, 90.7] 66.2 [ 59.0, 72.6] 64.2 [ 56.4, 71.2] 59.9 [ 51.4, 68.0] 56.2 [ 46.7, 65.4] 53.7 [ 42.4, 64.9]P 624 83.7 [ 80.1, 86.7] 63.8 [ 58.9, 68.3] 60.9 [ 55.6, 65.9] 55.5 [ 49.8, 61.2] 52.5 [ 46.1, 58.9] 52.2 [ 44.8, 59.6]

C48 RETROPERITONEUM & PERITONEUMPercent [95% CI] M 71 83.4 [ 70.9, 91.2] 60.9 [ 45.8, 73.9] ** ** ** **

F 190 80.1 [ 73.0, 85.6] 34.3 [ 27.2, 41.6] 25.2 [ 18.5, 32.5] 19.7 [ 12.9, 27.8] ** **P 261 81.0 [ 75.0, 85.7] 40.6 [ 33.9, 47.2] 27.4 [ 21.0, 34.4] 22.0 [ 15.4, 29.6] ** **





C50 BREASTPercent [95% CI] M 130 97.2 [ 90.6,100.3] 93.0 [ 82.6,100.5] 80.9 [ 65.6, 94.2] 66.6 [ 47.6, 85.3] 64.7 [ 40.3, 90.8] **

F 17421 98.0 [ 97.7, 98.3] 90.7 [ 90.0, 91.3] 85.0 [ 84.1, 85.9] 79.7 [ 78.5, 80.8] 74.1 [ 72.5, 75.5] 68.9 [ 66.9, 70.9]P 17551 98.0 [ 97.7, 98.3] 90.7 [ 90.0, 91.3] 85.0 [ 84.1, 85.8] 79.6 [ 78.5, 80.8] 74.0 [ 72.5, 75.5] 68.8 [ 66.8, 70.8]

C51-C58 GYNAECOLOGICALPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 5707 88.8 [ 87.8, 89.7] 71.1 [ 69.6, 72.5] 64.4 [ 62.6, 66.1] 61.1 [ 59.2, 63.1] 57.4 [ 55.2, 59.6] 54.5 [ 52.1, 57.0]P . n.a. n.a. n.a. n.a. n.a. n.a.

C51 VULVAPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 328 89.5 [ 85.0, 92.8] 74.8 [ 68.0, 80.8] 64.5 [ 55.9, 72.4] 60.1 [ 50.4, 69.6] 48.5 [ 37.6, 59.7] 44.5 [ 32.3, 57.8]P . n.a. n.a. n.a. n.a. n.a. n.a.

C53 CERVIX UTERIPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 1046 89.1 [ 86.8, 91.0] 74.3 [ 71.0, 77.3] 69.8 [ 66.3, 73.1] 67.4 [ 63.7, 70.9] 64.8 [ 60.9, 68.6] 62.7 [ 58.6, 66.7]P . n.a. n.a. n.a. n.a. n.a. n.a.

C54 CORPUS UTERIPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 2602 95.0 [ 93.9, 95.9] 84.3 [ 82.3, 86.2] 80.2 [ 77.6, 82.7] 76.1 [ 72.7, 79.4] 69.8 [ 65.3, 74.2] 64.4 [ 58.7, 70.1]P . n.a. n.a. n.a. n.a. n.a. n.a.

C56 OVARYPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 1446 79.1 [ 76.6, 81.3] 48.6 [ 45.5, 51.6] 37.5 [ 34.4, 40.7] 35.1 [ 31.8, 38.4] 33.8 [ 30.4, 37.3] 32.4 [ 28.6, 36.3]P . n.a. n.a. n.a. n.a. n.a. n.a.

C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANSPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 285 80.1 [ 74.3, 84.8] 54.0 [ 47.0, 60.5] 45.0 [ 37.7, 52.2] 40.2 [ 32.4, 48.2] 35.8 [ 27.5, 44.6] 32.9 [ 24.0, 42.6]P . n.a. n.a. n.a. n.a. n.a. n.a.

C61 PROSTATE GLANDPercent [95% CI] M 23572 98.3 [ 98.0, 98.6] 93.2 [ 92.6, 93.8] 85.9 [ 84.7, 87.0] 75.6 [ 73.6, 77.5] 63.3 [ 60.3, 66.3] 55.7 [ 50.1, 61.6]

F . n.a. n.a. n.a. n.a. n.a. n.a.P . n.a. n.a. n.a. n.a. n.a. n.a.

C62 TESTISPercent [95% CI] M 895 98.7 [ 97.6, 99.4] 98.1 [ 96.6, 99.2] 98.3 [ 96.5, 99.7] 97.3 [ 94.7, 99.2] 95.5 [ 92.2, 98.2] 94.8 [ 90.5, 98.2]


C60,C63 PENIS AND OTHER & UNSPECIFIED MALE GENITAL ORGANSPercent [95% CI] M 144 87.3 [ 79.5, 92.6] 71.4 [ 60.0, 81.2] 65.9 [ 52.4, 78.4] 59.6 [ 44.3, 74.8] 56.6 [ 39.8, 74.2] 63.0 [ 42.5, 85.0]


C64-C66,C68 KIDNEY AND OTHER RENAL TRACTPercent [95% CI] M 2517 86.1 [ 84.5, 87.7] 70.5 [ 68.0, 72.8] 61.7 [ 58.6, 64.7] 54.4 [ 50.6, 58.1] 48.2 [ 43.6, 53.0] 43.1 [ 37.2, 49.3]

F 1443 84.3 [ 82.0, 86.4] 69.9 [ 66.8, 72.9] 58.8 [ 54.9, 62.6] 53.3 [ 48.8, 57.8] 47.5 [ 42.1, 53.1] 44.2 [ 37.6, 51.1]P 3960 85.5 [ 84.1, 86.7] 70.3 [ 68.4, 72.1] 60.6 [ 58.2, 63.0] 54.0 [ 51.1, 56.9] 48.0 [ 44.4, 51.6] 43.6 [ 39.2, 48.2]

C67 BLADDERPercent [95% CI] M 1942 79.6 [ 77.3, 81.6] 53.6 [ 50.7, 56.5] 44.7 [ 41.5, 47.9] 37.6 [ 34.2, 41.1] 33.8 [ 30.1, 37.7] 34.0 [ 29.5, 38.8]

F 638 71.6 [ 67.5, 75.4] 48.1 [ 43.2, 52.8] 42.2 [ 37.1, 47.5] 38.9 [ 33.3, 44.6] 37.6 [ 31.5, 44.2] 33.9 [ 27.1, 41.4]P 2580 77.5 [ 75.6, 79.4] 52.2 [ 49.7, 54.7] 44.1 [ 41.3, 46.8] 37.9 [ 35.0, 40.9] 34.9 [ 31.7, 38.2] 33.9 [ 30.1, 38.0]

C69 EYE & ADNEXAPercent [95% CI] M 222 97.7 [ 93.5, 99.8] 80.9 [ 73.0, 87.3] 76.9 [ 67.6, 85.1] 71.5 [ 60.8, 81.4] 65.5 [ 53.5, 77.3] 62.4 [ 48.3, 76.6]

F 134 95.9 [ 89.5, 98.8] 72.6 [ 63.0, 80.5] 61.6 [ 51.5, 70.8] 57.2 [ 46.3, 67.6] 54.7 [ 42.9, 66.2] 45.7 [ 33.3, 58.6]P 356 97.0 [ 93.8, 98.9] 77.3 [ 71.4, 82.5] 70.0 [ 63.2, 76.3] 65.1 [ 57.5, 72.4] 61.0 [ 52.6, 69.3] 54.7 [ 45.2, 64.5]

C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEMPercent [95% CI] M 1016 52.1 [ 48.8, 55.3] 24.0 [ 21.2, 26.9] 19.3 [ 16.6, 22.1] 16.5 [ 13.9, 19.3] 15.7 [ 13.0, 18.6] 13.9 [ 11.1, 17.1]

F 744 49.4 [ 45.6, 53.2] 25.5 [ 22.2, 29.0] 21.3 [ 18.1, 24.8] 18.9 [ 15.7, 22.4] 15.5 [ 12.3, 18.9] 14.7 [ 11.5, 18.3]P 1760 51.0 [ 48.4, 53.4] 24.7 [ 22.5, 26.9] 20.1 [ 18.0, 22.3] 17.5 [ 15.5, 19.7] 15.6 [ 13.5, 17.8] 14.2 [ 12.1, 16.5]

C73 THYROID GLANDPercent [95% CI] M 759 96.5 [ 94.6, 97.9] 93.7 [ 90.5, 96.3] 90.4 [ 85.7, 94.4] 85.0 [ 78.4, 90.8] 85.8 [ 77.5, 93.3] 88.0 [ 76.8, 98.0]

F 2183 98.3 [ 97.5, 98.8] 98.1 [ 97.0, 99.0] 97.7 [ 96.1, 99.0] 96.9 [ 94.5, 98.9] 94.3 [ 90.7, 97.5] 94.0 [ 89.1, 98.3]P 2942 97.8 [ 97.1, 98.4] 97.0 [ 95.9, 98.0] 95.9 [ 94.3, 97.4] 94.1 [ 91.7, 96.2] 92.1 [ 88.8, 95.2] 92.4 [ 87.9, 96.4]

C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDSPercent [95% CI] M 47 87.4 [ 71.8, 94.9] 63.2 [ 44.7, 77.5] 51.2 [ 31.4, 68.6] 49.5 [ 29.9, 67.3] 44.1 [ 25.6, 62.2] **

F 53 82.0 [ 66.7, 90.9] 59.4 [ 43.4, 72.5] 53.3 [ 37.0, 67.8] 35.5 [ 19.6, 52.6] ** **P 100 84.5 [ 74.5, 91.0] 61.2 [ 49.4, 71.3] 52.3 [ 39.7, 63.8] 43.2 [ 30.7, 55.4] 40.3 [ 27.9, 52.8] 36.3 [ 23.6, 49.9]





C26,C39,C76,C77,C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITEPercent [95% CI] M 1689 36.8 [ 34.3, 39.3] 26.2 [ 23.8, 28.7] 23.6 [ 21.0, 26.3] 23.6 [ 20.6, 26.8] 21.7 [ 18.2, 25.6] 20.3 [ 16.0, 25.2]

F 1138 27.3 [ 24.6, 30.1] 17.1 [ 14.8, 19.4] 14.8 [ 12.5, 17.2] 12.7 [ 10.4, 15.3] 11.9 [ 9.4, 14.7] **P 2827 33.0 [ 31.1, 34.8] 22.4 [ 20.7, 24.1] 19.9 [ 18.1, 21.7] 18.7 [ 16.7, 20.8] 17.4 [ 15.1, 19.8] 17.1 [ 14.5, 20.0]

M959-M972 ALL LYMPHOMASPercent [95% CI] M 3351 87.3 [ 85.9, 88.6] 75.7 [ 73.6, 77.6] 68.1 [ 65.5, 70.6] 61.3 [ 58.1, 64.5] 57.7 [ 53.9, 61.6] 55.1 [ 50.5, 59.7]

F 2474 89.4 [ 87.8, 90.7] 81.6 [ 79.5, 83.6] 72.2 [ 69.4, 75.0] 66.3 [ 62.9, 69.7] 60.2 [ 56.0, 64.3] 53.5 [ 48.5, 58.6]P 5825 88.2 [ 87.2, 89.1] 78.2 [ 76.7, 79.6] 69.8 [ 67.9, 71.7] 63.5 [ 61.2, 65.8] 58.7 [ 55.9, 61.6] 54.2 [ 50.8, 57.6]

M965-M966 HODGKIN LYMPHOMAPercent [95% CI] M 327 90.6 [ 86.3, 93.7] 83.2 [ 77.6, 87.6] 80.3 [ 73.9, 85.7] 78.2 [ 71.0, 84.3] 74.4 [ 66.3, 81.5] 68.1 [ 59.0, 76.4]

F 300 91.9 [ 87.8, 94.8] 88.1 [ 82.9, 91.9] 83.8 [ 77.5, 88.8] 78.3 [ 71.0, 84.3] 76.4 [ 68.6, 82.9] 74.8 [ 66.1, 82.3]P 627 91.3 [ 88.4, 93.5] 85.5 [ 81.8, 88.6] 82.0 [ 77.6, 85.8] 78.1 [ 73.1, 82.5] 75.2 [ 69.6, 80.1] 71.1 [ 64.8, 76.9]

M959,M967-M972 NON-HODGKIN LYMPHOMAPercent [95% CI] M 3024 87.0 [ 85.5, 88.4] 74.8 [ 72.6, 76.9] 66.6 [ 63.7, 69.3] 58.9 [ 55.4, 62.5] 55.3 [ 50.8, 59.7] 53.8 [ 48.3, 59.4]

F 2174 89.0 [ 87.3, 90.5] 80.7 [ 78.4, 82.9] 70.5 [ 67.3, 73.5] 64.5 [ 60.7, 68.3] 56.9 [ 52.1, 61.8] 48.3 [ 42.3, 54.4]P 5198 87.8 [ 86.7, 88.8] 77.3 [ 75.7, 78.9] 68.2 [ 66.1, 70.3] 61.3 [ 58.7, 63.9] 55.9 [ 52.6, 59.2] 50.9 [ 46.9, 55.1]

M980-M994 ALL LEUKAEMIASPercent [95% CI] M 2446 81.0 [ 79.1, 82.8] 64.8 [ 62.3, 67.2] 53.8 [ 50.8, 56.7] 45.7 [ 42.3, 49.1] 39.8 [ 35.9, 43.8] 37.5 [ 32.9, 42.2]

F 1539 78.7 [ 76.2, 80.9] 65.2 [ 62.2, 68.0] 56.3 [ 52.9, 59.7] 50.3 [ 46.5, 54.2] 45.0 [ 40.6, 49.5] 41.7 [ 36.5, 47.1]P 3985 80.1 [ 78.6, 81.5] 65.0 [ 63.1, 66.8] 54.9 [ 52.6, 57.1] 47.7 [ 45.1, 50.2] 42.0 [ 39.1, 45.0] 39.2 [ 35.8, 42.8]

M982-M983 LYMPHOID LEUKAEMIAPercent [95% CI] M 1258 94.8 [ 93.0, 96.2] 83.3 [ 80.1, 86.1] 68.5 [ 64.2, 72.6] 57.6 [ 52.4, 62.7] 47.8 [ 41.8, 54.1] 45.8 [ 38.9, 52.9]

F 788 94.0 [ 91.6, 95.8] 86.1 [ 82.5, 89.3] 75.5 [ 70.6, 80.1] 66.7 [ 60.7, 72.5] 59.1 [ 52.0, 66.2] 55.2 [ 46.6, 63.9]P 2046 94.5 [ 93.1, 95.6] 84.4 [ 82.1, 86.6] 71.4 [ 68.2, 74.5] 61.4 [ 57.4, 65.2] 52.6 [ 48.0, 57.3] 49.9 [ 44.5, 55.4]

M984-M993 MYELOID LEUKAEMIAPercent [95% CI] M 819 60.9 [ 57.1, 64.6] 42.4 [ 38.4, 46.4] 37.3 [ 33.1, 41.5] 33.2 [ 28.7, 37.9] 32.5 [ 27.4, 37.7] 30.3 [ 23.9, 37.1]

F 583 61.0 [ 56.5, 65.3] 43.5 [ 38.9, 48.1] 37.6 [ 32.9, 42.4] 34.3 [ 29.4, 39.3] 30.9 [ 25.7, 36.4] 27.9 [ 21.9, 34.4]P 1402 61.0 [ 58.1, 63.8] 42.8 [ 39.8, 45.8] 37.4 [ 34.2, 40.5] 33.7 [ 30.3, 37.1] 31.6 [ 27.9, 35.4] 28.8 [ 24.3, 33.5]

M994 OTHER SPECIFIED LEUKAEMIAPercent [95% CI] M 348 80.2 [ 74.8, 84.8] 52.6 [ 45.5, 59.5] 40.4 [ 32.5, 48.6] 31.8 [ 23.5, 41.0] 26.1 [ 17.2, 36.8] **

F 152 74.2 [ 65.1, 81.5] 48.4 [ 38.2, 58.3] 35.4 [ 24.3, 47.6] ** ** **P 500 78.4 [ 73.9, 82.4] 51.3 [ 45.5, 57.0] 38.8 [ 32.3, 45.6] 32.8 [ 25.7, 40.6] 27.9 [ 19.7, 37.4] 24.1 [ 14.9, 35.8]

M980 UNSPECIFIED LEUKAEMIAPercent [95% CI] M 21 54.1 [ 28.0, 75.3] ** ** ** ** **

F 16 ** ** ** ** ** **P 37 41.0 [ 23.7, 57.9] ** ** ** ** **

M973 MYELOMA/PLASMA CELL TUMOURSPercent [95% CI] M 992 85.5 [ 82.7, 88.0] 53.9 [ 49.6, 58.0] 32.6 [ 27.8, 37.7] 22.9 [ 18.0, 28.4] 21.6 [ 15.7, 28.6] **

F 667 85.1 [ 81.7, 88.0] 53.8 [ 48.9, 58.6] 33.5 [ 28.3, 39.0] 22.8 [ 17.8, 28.3] 17.0 [ 11.5, 23.7] **P 1659 85.3 [ 83.2, 87.3] 53.9 [ 50.7, 57.0] 33.0 [ 29.4, 36.7] 22.9 [ 19.3, 26.7] 19.2 [ 15.0, 24.0] **

M998 MYELODYSPLASTIC DISEASESPercent [95% CI] M 837 75.0 [ 71.4, 78.3] 38.9 [ 34.6, 43.2] 21.3 [ 17.4, 25.5] 15.0 [ 11.0, 19.6] 13.1 [ 8.5, 19.3] **

F 475 77.7 [ 73.1, 81.8] 43.9 [ 38.3, 49.5] 28.7 [ 23.4, 34.3] 22.0 [ 16.3, 28.5] ** **P 1312 76.0 [ 73.2, 78.6] 40.8 [ 37.4, 44.2] 24.1 [ 21.0, 27.5] 17.8 [ 14.4, 21.5] 13.6 [ 9.6, 18.5] **

M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASESPercent [95% CI] M 530 92.6 [ 89.3, 95.1] 76.0 [ 70.9, 80.6] 62.9 [ 56.9, 68.7] 55.9 [ 49.1, 62.6] 44.6 [ 36.5, 53.1] 30.4 [ 20.4, 42.2]

F 419 94.8 [ 91.6, 97.1] 83.4 [ 78.2, 87.9] 71.8 [ 65.4, 77.8] 56.6 [ 49.3, 63.8] 40.9 [ 33.0, 49.1] 22.8 [ 15.2, 32.0]P 949 93.6 [ 91.4, 95.4] 79.3 [ 75.7, 82.6] 66.9 [ 62.5, 71.1] 56.2 [ 51.2, 61.1] 42.4 [ 36.7, 48.3] 25.8 [ 19.5, 33.0]

M974-M976 OTHER NEOPLASMS OF LYMPHATIC & HAEMATOPOIETIC TISSUEPercent [95% CI] M 45 81.7 [ 64.6, 91.9] 74.4 [ 54.7, 89.3] 46.1 [ 29.1, 63.8] ** ** **

F 39 82.3 [ 63.5, 92.4] 78.5 [ 57.2, 92.5] 50.2 [ 31.0, 69.0] ** ** **P 84 82.0 [ 70.2, 89.8] 76.2 [ 62.3, 87.1] 47.8 [ 34.8, 60.8] 29.9 [ 18.3, 43.7] ** **

TOTAL MALIGNANT NEOPLASMS (C00-C80)Percent [95% CI] M 80212 82.5 [ 82.2, 82.8] 68.6 [ 68.2, 69.0] 61.9 [ 61.3, 62.4] 56.6 [ 55.9, 57.3] 52.5 [ 51.7, 53.4] 50.6 [ 49.5, 51.7]

F 60430 84.7 [ 84.4, 85.1] 71.6 [ 71.2, 72.1] 65.9 [ 65.3, 66.4] 61.7 [ 61.1, 62.4] 58.0 [ 57.2, 58.7] 54.8 [ 53.9, 55.7]P 140642 83.5 [ 83.3, 83.7] 69.9 [ 69.6, 70.2] 63.6 [ 63.3, 64.0] 59.0 [ 58.5, 59.5] 55.1 [ 54.5, 55.7] 52.5 [ 51.8, 53.1]



ICD-O3/SITE Sex N At diagnosis1 year after

diagnosis3 years after


diagnosis 7 years after


diagnosisC00 LIPPercent [95% CI] M 1754 94.9 [ 92.9, 96.6] 94.2 [ 92.2, 96.2] 92.8 [ 90.7, 94.9] 92.6 [ 90.4, 94.8] 92.9 [ 90.6, 95.2] 94.5 [ 92.1, 96.8]

F 533 93.0 [ 89.0, 96.3] 91.2 [ 87.3, 95.0] 90.6 [ 86.5, 94.7] 90.2 [ 86.1, 94.4] 88.0 [ 83.5, 92.4] 88.8 [ 83.9, 93.7]P 2287 94.4 [ 92.6, 96.0] 93.5 [ 91.7, 95.2] 92.3 [ 90.4, 94.2] 92.0 [ 90.1, 94.0] 91.8 [ 89.7, 93.8] 93.2 [ 91.0, 95.3]

C01-C14, C30-C32 HEAD AND NECKPercent [95% CI] M 5235 58.9 [ 57.3, 60.5] 67.8 [ 65.9, 69.8] 77.4 [ 75.3, 79.6] 78.6 [ 76.2, 81.0] 80.7 [ 78.1, 83.4] 81.7 [ 78.5, 84.8]

F 1730 66.1 [ 63.3, 68.7] 74.9 [ 71.8, 78.0] 82.2 [ 78.9, 85.5] 84.2 [ 80.7, 87.7] 84.8 [ 80.9, 88.7] 83.0 [ 78.6, 87.5]P 6965 60.7 [ 59.3, 62.1] 69.7 [ 68.0, 71.3] 78.7 [ 76.9, 80.5] 80.1 [ 78.1, 82.1] 81.9 [ 79.7, 84.1] 82.1 [ 79.5, 84.7]

C01,C02 TONGUEPercent [95% CI] M 1092 61.5 [ 57.9, 65.0] 70.6 [ 66.3, 74.8] 83.0 [ 78.3, 87.6] 84.3 [ 79.2, 89.5] 86.4 [ 80.6, 92.1] 82.5 [ 75.3, 89.7]

F 456 67.3 [ 62.0, 72.2] 77.1 [ 71.0, 83.2] 85.6 [ 79.5, 91.8] 88.3 [ 81.9, 94.7] 87.7 [ 80.3, 95.0] 74.2 [ 64.8, 83.7]P 1548 63.3 [ 60.3, 66.1] 72.6 [ 69.1, 76.1] 83.9 [ 80.1, 87.6] 85.8 [ 81.7, 89.8] 86.8 [ 82.3, 91.4] 79.2 [ 73.5, 85.0]

C03 GUMPercent [95% CI] M 158 61.1 [ 50.6, 70.7] 72.3 [ 59.2, 85.4] 89.0 [ 74.2,103.8] 90.4 [ 72.9,107.8] 92.7 [ 75.4,110.1] 74.3 [ 52.7, 95.8]

F 106 73.3 [ 61.6, 82.8] 82.2 [ 69.3, 95.1] 88.2 [ 74.3,102.0] 87.4 [ 73.3,101.5] 95.8 [ 82.3,109.4] 95.8 [ 75.1,116.5]P 264 66.2 [ 58.5, 73.2] 76.8 [ 67.5, 86.0] 88.5 [ 78.4, 98.6] 88.7 [ 77.7, 99.6] 94.4 [ 83.6,105.1] 83.9 [ 68.1, 99.7]

C04 FLOOR OF MOUTHPercent [95% CI] M 284 55.2 [ 48.5, 61.6] 61.1 [ 53.3, 68.8] 68.3 [ 59.5, 77.2] 69.4 [ 60.1, 78.8] 81.0 [ 70.3, 91.7] 72.6 [ 59.8, 85.3]

F 114 57.0 [ 45.8, 67.0] 63.0 [ 51.3, 74.7] 70.1 [ 57.0, 83.3] 67.5 [ 52.4, 82.6] 65.5 [ 49.0, 82.0] 84.9 [ 65.6,104.2]P 398 55.7 [ 50.0, 61.1] 61.8 [ 55.3, 68.2] 69.1 [ 61.8, 76.4] 69.1 [ 61.2, 77.0] 76.3 [ 67.3, 85.3] 76.6 [ 66.1, 87.2]

C05,C06 PALATE AND OTHER & UNSPECIFIED PARTS OF MOUTHPercent [95% CI] M 371 48.6 [ 42.7, 54.3] 59.1 [ 51.8, 66.3] 70.4 [ 62.1, 78.7] 72.1 [ 62.6, 81.6] 75.7 [ 64.7, 86.7] 68.3 [ 55.5, 81.0]

F 235 62.4 [ 54.7, 69.5] 69.7 [ 60.6, 78.8] 75.6 [ 65.7, 85.6] 79.6 [ 68.8, 90.4] 82.9 [ 71.4, 94.4] 87.7 [ 75.3,100.0]P 606 53.9 [ 49.2, 58.4] 63.3 [ 57.6, 68.9] 72.4 [ 66.1, 78.8] 75.0 [ 67.8, 82.2] 78.6 [ 70.6, 86.7] 77.7 [ 68.7, 86.7]

C07,C08 PAROTID AND OTHER & UNSPECIFIED MAJOR SALIVARY GLANDSPercent [95% CI] M 409 68.2 [ 62.1, 73.9] 75.1 [ 68.6, 81.6] 81.6 [ 74.3, 88.8] 86.6 [ 78.7, 94.4] 85.0 [ 76.4, 93.6] 89.5 [ 80.1, 98.9]

F 243 82.7 [ 75.7, 88.5] 84.6 [ 77.9, 91.3] 91.1 [ 84.3, 97.9] 96.3 [ 89.7,103.0] 97.5 [ 91.0,104.0] 94.5 [ 86.8,102.1]P 652 73.6 [ 68.9, 77.8] 78.7 [ 73.9, 83.5] 85.5 [ 80.3, 90.6] 90.6 [ 85.2, 96.0] 90.4 [ 84.7, 96.1] 91.8 [ 85.6, 98.0]

C09,C10 TONSIL AND OROPHARYNXPercent [95% CI] M 915 65.6 [ 61.7, 69.2] 74.1 [ 69.7, 78.6] 82.3 [ 77.2, 87.3] 82.4 [ 76.4, 88.3] 85.1 [ 78.2, 92.0] 88.6 [ 80.0, 97.2]

F 197 63.6 [ 55.2, 71.0] 75.8 [ 66.0, 85.6] 77.7 [ 67.0, 88.3] 77.2 [ 64.9, 89.5] 71.7 [ 55.3, 88.2] 69.5 [ 49.7, 89.2]P 1112 65.2 [ 61.7, 68.5] 74.4 [ 70.4, 78.5] 81.4 [ 76.8, 86.0] 81.3 [ 76.0, 86.7] 82.6 [ 76.1, 89.0] 84.9 [ 76.9, 93.0]

C11 NASOPHARYNXPercent [95% CI] M 139 61.3 [ 51.7, 69.7] 70.6 [ 59.6, 81.6] 83.9 [ 73.2, 94.7] 83.6 [ 72.5, 94.7] 91.0 [ 80.3,101.6] 94.8 [ 82.4,107.1]

F 50 69.6 [ 52.3, 82.0] 73.0 [ 56.8, 89.2] 76.5 [ 59.8, 93.1] 88.4 [ 71.9,104.9] 92.0 [ 76.2,107.7] 86.1 [ 68.4,103.7]P 189 63.4 [ 55.1, 70.6] 71.2 [ 62.0, 80.3] 81.9 [ 72.9, 91.0] 84.9 [ 75.6, 94.2] 91.2 [ 82.3,100.1] 91.9 [ 81.5,102.3]

C12,C13 PYRIFORM SINUS AND HYPOPHARYNXPercent [95% CI] M 351 31.5 [ 26.0, 37.2] 45.1 [ 37.0, 53.2] 57.9 [ 47.2, 68.6] 56.9 [ 44.7, 69.0] 52.0 [ 39.8, 64.2] 65.6 [ 49.1, 82.0]

F 62 34.9 [ 21.5, 49.0] 49.0 [ 29.3, 68.6] 57.5 [ 33.0, 82.1] 63.1 [ 34.5, 91.7] 73.3 [ 37.7,108.8] **P 413 32.0 [ 26.9, 37.3] 45.7 [ 38.2, 53.2] 58.1 [ 48.2, 67.9] 58.0 [ 46.7, 69.2] 54.8 [ 43.1, 66.4] 65.2 [ 50.3, 80.1]

C14 OTHER & ILL-DEFINED SITES IN LIP,ORAL CAVITY & PHARYNXPercent [95% CI] M 183 35.1 [ 27.7, 42.8] 51.6 [ 39.9, 63.4] 60.8 [ 47.6, 74.1] 50.0 [ 34.8, 65.1] 50.1 [ 33.6, 66.6] 80.3 [ 56.5,104.2]

F 28 ** ** ** ** ** **P 211 33.8 [ 27.0, 40.8] 50.8 [ 39.9, 61.7] 60.3 [ 47.8, 72.8] 52.6 [ 38.7, 66.5] 50.5 [ 35.4, 65.7] 77.6 [ 57.1, 98.1]

C15 OESOPHAGUSPercent [95% CI] M 1812 20.7 [ 18.5, 22.9] 40.1 [ 35.7, 44.5] 70.3 [ 63.3, 77.3] 76.6 [ 68.8, 84.3] 86.7 [ 78.5, 94.9] 91.9 [ 81.4,102.3]

F 693 22.7 [ 19.3, 26.3] 42.9 [ 36.3, 49.5] 66.2 [ 56.4, 76.0] 69.3 [ 58.5, 80.0] 68.0 [ 55.2, 80.9] 75.3 [ 60.4, 90.1]P 2505 21.3 [ 19.5, 23.1] 41.0 [ 37.3, 44.6] 68.9 [ 63.2, 74.6] 74.0 [ 67.8, 80.3] 80.5 [ 73.5, 87.5] 86.3 [ 77.7, 94.8]

C16 STOMACHPercent [95% CI] M 2396 28.2 [ 26.2, 30.4] 52.7 [ 48.8, 56.5] 77.7 [ 72.6, 82.8] 84.7 [ 79.2, 90.2] 86.1 [ 79.9, 92.2] 96.2 [ 89.2,103.3]

F 1080 30.5 [ 27.4, 33.6] 53.6 [ 48.2, 59.0] 79.5 [ 73.1, 86.0] 87.7 [ 81.0, 94.3] 86.5 [ 79.8, 93.1] 86.7 [ 79.0, 94.5]P 3476 28.9 [ 27.2, 30.7] 53.0 [ 49.8, 56.1] 78.4 [ 74.4, 82.4] 85.8 [ 81.5, 90.0] 86.2 [ 81.6, 90.8] 92.3 [ 87.1, 97.6]

C17 SMALL INTESTINEPercent [95% CI] M 604 59.9 [ 54.8, 64.8] 75.2 [ 68.8, 81.5] 85.3 [ 78.5, 92.1] 87.2 [ 79.3, 95.1] 86.7 [ 77.8, 95.6] 86.6 [ 75.4, 97.9]

F 437 68.6 [ 62.9, 73.9] 80.1 [ 73.1, 87.1] 85.7 [ 78.9, 92.4] 87.2 [ 79.0, 95.3] 90.3 [ 81.6, 98.9] 101.2 [ 92.1,110.2]P 1041 63.7 [ 59.9, 67.3] 77.3 [ 72.6, 82.0] 85.4 [ 80.6, 90.2] 87.1 [ 81.4, 92.8] 88.1 [ 81.7, 94.4] 92.2 [ 84.3,100.1]

C18-C20,C218 COLORECTALPercent [95% CI] M 16301 67.0 [ 66.1, 67.9] 76.2 [ 75.1, 77.3] 85.7 [ 84.5, 86.8] 91.1 [ 89.8, 92.4] 93.3 [ 91.8, 94.7] 95.7 [ 94.0, 97.4]

F 12909 68.8 [ 67.8, 69.8] 79.8 [ 78.6, 81.0] 88.1 [ 86.9, 89.3] 91.4 [ 90.1, 92.7] 93.2 [ 91.8, 94.6] 94.2 [ 92.6, 95.8]P 29210 67.8 [ 67.1, 68.5] 77.8 [ 77.0, 78.6] 86.8 [ 85.9, 87.6] 91.2 [ 90.3, 92.2] 93.2 [ 92.2, 94.2] 95.0 [ 93.8, 96.2]

C18 COLONPercent [95% CI] M 10175 67.0 [ 65.8, 68.2] 77.2 [ 75.8, 78.7] 86.5 [ 85.0, 88.1] 91.4 [ 89.7, 93.1] 93.0 [ 91.1, 94.9] 95.0 [ 92.8, 97.2]

F 9321 68.4 [ 67.1, 69.5] 80.8 [ 79.3, 82.2] 89.1 [ 87.6, 90.5] 91.8 [ 90.2, 93.3] 93.2 [ 91.5, 94.9] 93.8 [ 91.8, 95.7]P 19496 67.7 [ 66.8, 68.5] 78.9 [ 77.9, 80.0] 87.8 [ 86.7, 88.8] 91.6 [ 90.4, 92.7] 93.1 [ 91.8, 94.4] 94.4 [ 92.9, 95.8]

Table 8: Conditional 5-year Relative Survival by Site, Sex and Years after Diagnosis, Queensland, 2004-20130-89 years at diagnosis








diagnosis


C19,C20 RECTOSIGMOID JUNCTION AND RECTUMPercent [95% CI] M 6023 67.2 [ 65.7, 68.7] 74.6 [ 72.9, 76.3] 84.4 [ 82.6, 86.3] 90.7 [ 88.7, 92.7] 93.8 [ 91.6, 96.0] 96.8 [ 94.1, 99.4]

F 3440 69.7 [ 67.8, 71.6] 77.2 [ 75.1, 79.4] 85.7 [ 83.5, 87.9] 90.5 [ 88.2, 92.8] 92.9 [ 90.4, 95.4] 95.5 [ 92.6, 98.4]P 9463 68.1 [ 66.9, 69.3] 75.6 [ 74.2, 76.9] 84.9 [ 83.5, 86.3] 90.6 [ 89.1, 92.2] 93.4 [ 91.8, 95.1] 96.3 [ 94.3, 98.2]

C21 ANUS & ANAL CANALPercent [95% CI] M 310 56.7 [ 49.8, 63.3] 66.2 [ 58.3, 74.1] 83.1 [ 74.6, 91.5] 86.6 [ 77.5, 95.7] 89.1 [ 80.1, 98.1] 89.4 [ 78.1,100.7]

F 460 74.6 [ 69.3, 79.3] 78.7 [ 72.9, 84.5] 87.1 [ 80.8, 93.3] 89.1 [ 82.5, 95.8] 93.5 [ 85.4,101.6] 86.6 [ 76.2, 96.9]P 770 67.3 [ 63.1, 71.3] 73.9 [ 69.1, 78.6] 85.6 [ 80.5, 90.6] 87.9 [ 82.5, 93.3] 91.7 [ 85.7, 97.7] 87.8 [ 80.2, 95.4]

C22 LIVER & INTRAHEPATIC BILE DUCTSPercent [95% CI] M 1655 16.6 [ 14.6, 18.8] 33.2 [ 28.5, 37.8] 52.6 [ 45.1, 60.1] 66.2 [ 56.9, 75.5] 81.2 [ 70.1, 92.3] 91.5 [ 80.1,102.8]

F 636 14.6 [ 11.8, 17.8] 37.8 [ 30.0, 45.6] 64.0 [ 51.9, 76.2] 73.2 [ 59.0, 87.4] 85.3 [ 70.5,100.1] 86.5 [ 69.6,103.4]P 2291 16.1 [ 14.4, 17.9] 34.4 [ 30.5, 38.4] 55.7 [ 49.3, 62.1] 68.0 [ 60.2, 75.8] 82.6 [ 73.7, 91.5] 89.7 [ 80.2, 99.2]

C23,C24 GALLBLADDER AND OTHER & UNSPECIFIED PARTS OF BILIARY TRACTPercent [95% CI] M 590 26.1 [ 22.0, 30.4] 43.7 [ 36.7, 50.7] 73.8 [ 63.4, 84.1] 84.9 [ 73.8, 96.0] 86.6 [ 74.9, 98.3] 91.1 [ 78.4,103.7]

F 653 16.5 [ 13.5, 19.9] 39.1 [ 31.5, 46.7] 65.8 [ 54.7, 76.9] 75.6 [ 63.1, 88.0] 81.9 [ 69.0, 94.8] 96.2 [ 81.4,111.1]P 1243 21.0 [ 18.4, 23.7] 41.6 [ 36.5, 46.8] 70.1 [ 62.5, 77.7] 80.4 [ 72.1, 88.8] 84.3 [ 75.6, 93.0] 93.4 [ 83.7,103.1]

C25 PANCREASPercent [95% CI] M 2395 6.5 [ 5.5, 7.7] 23.1 [ 19.1, 27.2] 53.3 [ 43.8, 62.8] 70.6 [ 59.0, 82.3] 79.8 [ 66.4, 93.3] 84.8 [ 70.0, 99.6]

F 2016 6.5 [ 5.4, 7.8] 21.9 [ 18.0, 25.9] 57.1 [ 47.7, 66.5] 73.1 [ 61.6, 84.6] 81.5 [ 70.1, 92.9] 84.7 [ 70.8, 98.5]P 4411 6.5 [ 5.8, 7.4] 22.5 [ 19.7, 25.4] 55.3 [ 48.6, 62.0] 71.9 [ 63.7, 80.1] 80.6 [ 71.8, 89.4] 84.5 [ 74.4, 94.7]

C30,C31 NASAL CAVITY & MIDDLE EAR AND ACCESSORY SINUSESPercent [95% CI] M 173 61.9 [ 52.7, 70.2] 70.9 [ 60.7, 81.1] 80.4 [ 69.9, 90.9] 85.2 [ 73.1, 97.4] 84.8 [ 72.0, 97.7] 94.8 [ 80.3,109.2]

F 102 71.4 [ 59.4, 81.1] 78.3 [ 66.1, 90.4] 81.8 [ 69.2, 94.5] 81.2 [ 68.0, 94.5] 90.4 [ 75.9,104.8] 92.1 [ 76.1,108.0]P 275 65.3 [ 58.1, 71.8] 73.6 [ 65.7, 81.5] 81.0 [ 72.9, 89.2] 83.9 [ 74.9, 92.8] 87.3 [ 77.7, 96.9] 93.3 [ 82.6,104.1]

C32 LARYNXPercent [95% CI] M 1160 64.3 [ 60.8, 67.6] 69.4 [ 65.5, 73.3] 76.5 [ 72.4, 80.7] 77.9 [ 73.4, 82.3] 80.1 [ 75.2, 85.1] 81.0 [ 75.4, 86.5]

F 137 62.9 [ 52.9, 71.7] 73.0 [ 62.0, 84.0] 87.0 [ 75.0, 99.0] 80.6 [ 67.5, 93.7] 70.8 [ 56.1, 85.6] 72.2 [ 56.3, 88.1]P 1297 64.1 [ 60.8, 67.2] 69.7 [ 66.1, 73.4] 77.5 [ 73.6, 81.4] 78.1 [ 73.9, 82.3] 79.2 [ 74.5, 83.9] 80.1 [ 74.8, 85.3]

C33,C34 TRACHEA AND BRONCHUS & LUNGPercent [95% CI] M 12730 12.8 [ 12.2, 13.5] 31.2 [ 29.6, 32.9] 58.3 [ 55.4, 61.3] 68.6 [ 65.0, 72.2] 72.8 [ 68.7, 77.0] 75.1 [ 70.2, 80.1]

F 7664 17.4 [ 16.5, 18.4] 36.1 [ 34.1, 38.1] 62.3 [ 59.0, 65.6] 73.6 [ 69.6, 77.6] 74.5 [ 69.9, 79.1] 78.6 [ 73.2, 84.1]P 20394 14.5 [ 14.0, 15.1] 33.2 [ 31.9, 34.5] 60.0 [ 57.8, 62.2] 70.7 [ 68.0, 73.4] 73.5 [ 70.4, 76.6] 76.6 [ 72.9, 80.3]

C37, C38 THYMUS, HEART,MEDIASTINUM & PLEURAPercent [95% CI] M 106 57.8 [ 46.7, 67.7] 70.8 [ 56.8, 84.8] 75.6 [ 62.7, 88.5] 80.9 [ 68.2, 93.6] 95.8 [ 83.5,108.2] 94.8 [ 84.9,104.7]

F 77 61.3 [ 47.7, 72.7] 71.8 [ 56.0, 87.6] 82.9 [ 68.3, 97.5] 86.2 [ 71.7,100.7] 85.6 [ 69.2,102.0] 95.9 [ 78.6,113.3]P 183 59.3 [ 50.9, 67.0] 71.2 [ 60.7, 81.7] 78.5 [ 68.8, 88.3] 83.3 [ 73.7, 92.8] 92.2 [ 82.7,101.8] 95.0 [ 86.1,103.9]

C40,C41 BONES,JOINTS & ARTICULAR CARTILAGESPercent [95% CI] M 256 63.4 [ 56.5, 69.7] 71.2 [ 63.8, 78.7] 84.6 [ 77.3, 91.9] 91.5 [ 84.6, 98.4] 93.0 [ 86.8, 99.3] 94.1 [ 87.9,100.2]

F 179 68.3 [ 60.4, 75.1] 76.0 [ 68.0, 84.1] 89.3 [ 81.8, 96.8] 91.3 [ 84.6, 98.0] 93.2 [ 86.5, 99.9] 93.4 [ 86.2,100.6]P 435 65.5 [ 60.3, 70.2] 73.4 [ 67.9, 78.8] 86.8 [ 81.5, 92.0] 91.4 [ 86.5, 96.2] 93.1 [ 88.5, 97.6] 93.9 [ 89.2, 98.6]

C44, M872-M879 MELANOMAPercent [95% CI] M 18377 91.9 [ 91.2, 92.5] 92.6 [ 91.9, 93.3] 94.4 [ 93.6, 95.1] 96.0 [ 95.2, 96.7] 96.8 [ 96.0, 97.6] 97.2 [ 96.3, 98.1]

F 12988 95.2 [ 94.6, 95.8] 95.4 [ 94.7, 96.0] 96.5 [ 95.9, 97.2] 97.4 [ 96.7, 98.1] 97.8 [ 97.1, 98.5] 98.3 [ 97.6, 99.1]P 31365 93.3 [ 92.8, 93.7] 93.8 [ 93.3, 94.3] 95.3 [ 94.8, 95.8] 96.6 [ 96.1, 97.1] 97.3 [ 96.7, 97.8] 97.7 [ 97.1, 98.3]

C44 OTHER SKIN (EXCL BCC/SCC)Percent [95% CI] M 1170 63.6 [ 59.7, 67.5] 69.6 [ 65.2, 74.1] 81.2 [ 75.7, 86.8] 84.3 [ 78.0, 90.6] 84.0 [ 76.9, 91.2] 89.1 [ 81.6, 96.6]

F 584 75.2 [ 70.1, 79.9] 82.8 [ 77.2, 88.4] 87.7 [ 81.9, 93.5] 87.4 [ 80.9, 93.8] 87.9 [ 80.7, 95.2] 89.1 [ 80.8, 97.5]P 1754 67.6 [ 64.5, 70.6] 74.2 [ 70.7, 77.7] 83.7 [ 79.7, 87.8] 85.6 [ 81.0, 90.2] 85.7 [ 80.5, 90.8] 89.2 [ 83.6, 94.8]

M905 MESOTHELIOMAPercent [95% CI] M 1117 4.5 [ 3.2, 6.1] 7.4 [ 4.6, 10.3] ** ** ** **

F 239 ** 13.7 [ 7.0, 20.5] ** ** ** **P 1356 5.0 [ 3.7, 6.5] 8.8 [ 6.2, 11.5] 21.7 [ 13.0, 30.3] ** 46.9 [ 24.6, 69.1] **

M914 KAPOSI SARCOMAPercent [95% CI] M 62 76.6 [ 62.3, 86.7] 90.6 [ 76.8,104.4] 93.2 [ 80.4,106.0] 87.9 [ 72.7,103.0] 87.3 [ 69.5,105.1] 86.0 [ 66.9,105.2]

F 10 ** ** ** ** ** **P 72 74.3 [ 60.6, 84.6] 87.2 [ 73.8,100.7] 87.5 [ 74.2,100.8] 86.9 [ 71.5,102.2] 83.9 [ 67.1,100.7] 83.5 [ 65.2,101.9]

C47,C49 CONNECTIVE TISSUE, PERIPHERAL NERVESPercent [95% CI] M 597 61.3 [ 56.5, 65.7] 73.6 [ 68.2, 79.1] 92.6 [ 87.7, 97.6] 95.5 [ 91.0,100.0] 93.7 [ 89.2, 98.1] 94.8 [ 89.2,100.5]

F 476 65.3 [ 60.1, 70.1] 74.1 [ 68.4, 79.7] 84.6 [ 78.9, 90.2] 91.3 [ 86.1, 96.5] 96.5 [ 91.5,101.5] 91.3 [ 85.3, 97.2]P 1073 63.1 [ 59.6, 66.4] 73.9 [ 69.9, 77.8] 89.0 [ 85.2, 92.7] 93.5 [ 90.1, 97.0] 94.8 [ 91.5, 98.2] 93.2 [ 89.0, 97.3]

C48 RETROPERITONEUM & PERITONEUMPercent [95% CI] M 120 60.4 [ 48.8, 70.7] 70.3 [ 57.1, 83.5] 67.9 [ 52.1, 83.6] 58.5 [ 39.2, 77.8] 49.1 [ 25.7, 72.5] **

F 370 35.6 [ 30.4, 41.0] 41.6 [ 35.2, 48.0] 58.1 [ 48.7, 67.4] 68.1 [ 56.5, 79.6] 72.7 [ 59.2, 86.2] 75.1 [ 57.7, 92.5]P 490 40.9 [ 36.0, 45.8] 47.7 [ 41.8, 53.6] 60.5 [ 52.4, 68.5] 65.7 [ 55.8, 75.6] 66.3 [ 54.4, 78.2] 71.8 [ 56.5, 87.1]








diagnosis


C50 BREASTPercent [95% CI] M 234 88.2 [ 80.5, 94.4] 86.4 [ 78.8, 94.0] 88.8 [ 80.4, 97.3] 85.8 [ 76.2, 95.5] 90.4 [ 79.4,101.4] 79.9 [ 65.5, 94.2]

F 29160 89.9 [ 89.4, 90.3] 90.3 [ 89.8, 90.8] 91.7 [ 91.2, 92.2] 93.2 [ 92.6, 93.8] 93.4 [ 92.8, 94.1] 93.3 [ 92.6, 94.1]P 29394 89.8 [ 89.4, 90.3] 90.3 [ 89.8, 90.8] 91.7 [ 91.1, 92.2] 93.1 [ 92.5, 93.7] 93.4 [ 92.8, 94.0] 93.3 [ 92.5, 94.0]

C51-C58 GYNAECOLOGICALPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 9685 70.2 [ 69.1, 71.2] 77.6 [ 76.4, 78.9] 86.4 [ 85.2, 87.6] 91.0 [ 89.8, 92.2] 93.7 [ 92.6, 94.9] 95.3 [ 94.1, 96.6]P 9685 n.a. n.a. n.a. n.a. n.a. n.a.

C51 VULVAPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 523 73.5 [ 68.4, 78.1] 80.4 [ 74.9, 86.0] 85.2 [ 79.6, 90.8] 86.6 [ 80.5, 92.8] 86.2 [ 79.7, 92.6] 93.7 [ 86.7,100.6]P 523 n.a. n.a. n.a. n.a. n.a. n.a.

C53 CERVIX UTERIPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 1846 74.7 [ 72.4, 76.8] 82.3 [ 79.9, 84.8] 90.7 [ 88.7, 92.8] 93.8 [ 91.9, 95.6] 95.7 [ 94.1, 97.4] 96.2 [ 94.6, 97.8]P 1846 n.a. n.a. n.a. n.a. n.a. n.a.

C54 CORPUS UTERIPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 4283 83.5 [ 82.0, 84.9] 87.7 [ 86.2, 89.3] 92.9 [ 91.3, 94.5] 95.0 [ 93.3, 96.7] 95.7 [ 93.8, 97.5] 95.8 [ 93.5, 98.0]P 4283 n.a. n.a. n.a. n.a. n.a. n.a.

C56 OVARYPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 2532 47.5 [ 45.2, 49.6] 56.7 [ 54.0, 59.4] 70.2 [ 67.0, 73.3] 80.4 [ 77.2, 83.7] 88.4 [ 85.2, 91.5] 93.4 [ 90.3, 96.5]P 2532 n.a. n.a. n.a. n.a. n.a. n.a.

C52,C55,C57,C58 OTHER FEMALE GENITAL ORGANSPercent [95% CI] M . n.a. n.a. n.a. n.a. n.a. n.a.

F 501 54.6 [ 49.5, 59.5] 63.2 [ 57.0, 69.4] 74.1 [ 67.5, 80.6] 83.2 [ 76.0, 90.3] 91.9 [ 85.2, 98.5] 94.4 [ 87.4,101.5]P 501 n.a. n.a. n.a. n.a. n.a. n.a.

C61 PROSTATE GLANDPercent [95% CI] M 39278 92.0 [ 91.5, 92.5] 92.2 [ 91.7, 92.8] 91.7 [ 91.0, 92.3] 90.2 [ 89.4, 91.1] 88.2 [ 87.1, 89.3] 86.9 [ 85.3, 88.4]

F . n.a. n.a. n.a. n.a. n.a. n.a.P 39278 n.a. n.a. n.a. n.a. n.a. n.a.

C62 TESTISPercent [95% CI] M 1514 97.6 [ 96.4, 98.5] 98.8 [ 97.7, 99.8] 99.4 [ 98.6,100.3] 100.0 [ 99.2,100.9] 100.0 [ 99.1,101.0] 99.3 [ 98.1,100.4]


C60,C63 PENIS AND OTHER & UNSPECIFIED MALE GENITAL ORGANSPercent [95% CI] M 227 76.7 [ 68.4, 83.8] 84.5 [ 75.6, 93.4] 93.3 [ 83.7,102.9] 90.1 [ 80.8, 99.4] 86.7 [ 76.7, 96.7] 91.0 [ 80.1,102.0]


C64-C66,C68 KIDNEY AND OTHER RENAL TRACTPercent [95% CI] M 4209 70.6 [ 68.7, 72.4] 80.5 [ 78.4, 82.7] 85.5 [ 83.3, 87.8] 87.5 [ 85.0, 90.0] 88.4 [ 85.6, 91.1] 90.3 [ 87.0, 93.6]

F 2401 68.0 [ 65.6, 70.3] 78.8 [ 76.0, 81.6] 85.0 [ 82.2, 87.9] 85.5 [ 82.4, 88.6] 87.7 [ 84.4, 91.0] 89.0 [ 85.1, 92.9]P 6610 69.6 [ 68.2, 71.0] 79.9 [ 78.2, 81.6] 85.3 [ 83.6, 87.1] 86.8 [ 84.8, 88.7] 88.1 [ 86.0, 90.3] 89.8 [ 87.3, 92.3]

C67 BLADDERPercent [95% CI] M 3710 56.0 [ 53.9, 58.0] 65.3 [ 62.9, 67.7] 75.6 [ 72.9, 78.2] 79.9 [ 77.1, 82.8] 81.2 [ 78.2, 84.2] 82.4 [ 79.0, 85.9]

F 1163 51.0 [ 47.6, 54.4] 67.9 [ 63.4, 72.4] 79.6 [ 75.1, 84.2] 83.1 [ 78.5, 87.7] 85.0 [ 80.1, 89.9] 83.7 [ 78.1, 89.2]P 4873 54.8 [ 53.0, 56.5] 65.9 [ 63.8, 68.0] 76.5 [ 74.2, 78.8] 80.7 [ 78.3, 83.1] 82.1 [ 79.5, 84.7] 82.7 [ 79.8, 85.7]

C69 EYE & ADNEXAPercent [95% CI] M 393 82.0 [ 76.5, 86.7] 82.6 [ 77.4, 87.9] 88.5 [ 82.9, 94.1] 91.8 [ 86.2, 97.3] 92.5 [ 86.6, 98.4] 95.3 [ 89.2,101.5]

F 269 81.4 [ 75.1, 86.7] 79.6 [ 73.5, 85.6] 81.6 [ 75.1, 88.0] 85.5 [ 78.9, 92.2] 91.9 [ 85.5, 98.3] 93.1 [ 85.9,100.4]P 662 81.7 [ 77.7, 85.4] 81.3 [ 77.3, 85.2] 85.5 [ 81.2, 89.7] 89.1 [ 84.8, 93.4] 92.3 [ 87.9, 96.6] 94.4 [ 89.7, 99.1]

C70-C72 BRAIN, MENINGES AND OTHER CENTRAL NERVOUS SYSTEMPercent [95% CI] M 1846 23.2 [ 21.2, 25.3] 45.5 [ 41.6, 49.5] 72.2 [ 67.1, 77.3] 79.2 [ 74.2, 84.1] 81.5 [ 76.2, 86.7] 86.4 [ 80.9, 91.9]

F 1272 25.4 [ 22.9, 27.9] 51.1 [ 46.1, 56.0] 73.4 [ 67.9, 78.9] 82.6 [ 77.0, 88.1] 86.0 [ 80.6, 91.3] 88.2 [ 82.6, 93.7]P 3118 24.1 [ 22.5, 25.7] 47.8 [ 44.7, 50.9] 72.7 [ 69.0, 76.5] 80.6 [ 76.9, 84.3] 83.4 [ 79.7, 87.2] 87.2 [ 83.2, 91.1]

C73 THYROID GLANDPercent [95% CI] M 1215 93.0 [ 90.5, 95.0] 94.9 [ 92.4, 97.5] 95.8 [ 93.2, 98.4] 95.4 [ 92.4, 98.3] 95.3 [ 92.0, 98.5] 94.6 [ 90.4, 98.7]

F 3557 97.9 [ 97.1, 98.6] 99.4 [ 98.5,100.2] 99.0 [ 98.2, 99.9] 99.0 [ 98.0, 99.9] 98.9 [ 97.8,100.0] 99.4 [ 98.1,100.7]P 4772 96.7 [ 95.9, 97.5] 98.3 [ 97.4, 99.2] 98.3 [ 97.4, 99.2] 98.1 [ 97.1, 99.2] 98.1 [ 97.0, 99.3] 98.4 [ 97.0, 99.8]

C74,C75 ADRENAL AND OTHER ENDOCRINE GLANDSPercent [95% CI] M 76 57.6 [ 44.2, 69.2] 62.1 [ 48.2, 76.0] 78.9 [ 64.2, 93.5] 84.9 [ 69.7,100.1] 90.2 [ 79.6,100.8] 100.0 [ 95.0,104.9]

F 100 58.7 [ 47.4, 68.6] 66.7 [ 53.2, 80.2] 85.0 [ 71.8, 98.3] 84.1 [ 70.9, 97.3] 83.2 [ 67.6, 98.8] 81.3 [ 65.4, 97.2]P 176 58.1 [ 49.5, 65.8] 64.5 [ 54.8, 74.2] 81.9 [ 72.0, 91.8] 84.2 [ 74.2, 94.2] 88.1 [ 79.3, 96.9] 92.5 [ 85.1, 99.9]








diagnosis


C26,C39,C76,C77,C80 OTHER & ILL-DEFINED SITES AND UNKNOWN PRIMARY SITEPercent [95% CI] M 3012 24.5 [ 22.8, 26.2] 69.6 [ 65.1, 74.1] 84.3 [ 80.0, 88.6] 87.1 [ 82.4, 91.8] 90.2 [ 85.2, 95.2] 100.1 [ 94.7,105.5]

F 2158 17.1 [ 15.5, 18.8] 63.0 [ 57.5, 68.4] 82.5 [ 77.1, 87.8] 86.7 [ 81.3, 92.1] 87.0 [ 81.0, 92.9] 88.0 [ 81.3, 94.7]P 5170 21.3 [ 20.1, 22.6] 67.0 [ 63.6, 70.5] 83.6 [ 80.3, 86.9] 86.9 [ 83.4, 90.5] 88.9 [ 85.0, 92.7] 94.9 [ 90.7, 99.2]

M959-M972 ALL LYMPHOMASPercent [95% CI] M 5507 74.4 [ 72.9, 75.9] 83.2 [ 81.4, 85.0] 87.8 [ 86.0, 89.6] 90.1 [ 88.2, 92.0] 90.8 [ 88.7, 93.0] 89.8 [ 87.3, 92.4]

F 4210 78.5 [ 76.8, 80.1] 87.6 [ 85.8, 89.5] 88.8 [ 87.0, 90.6] 87.9 [ 85.9, 90.0] 89.0 [ 86.8, 91.3] 91.7 [ 89.2, 94.2]P 9717 76.2 [ 75.1, 77.3] 85.2 [ 83.9, 86.4] 88.2 [ 87.0, 89.5] 89.1 [ 87.7, 90.5] 90.0 [ 88.5, 91.6] 90.7 [ 88.9, 92.5]

M965-M966 HODGKIN LYMPHOMAPercent [95% CI] M 541 82.8 [ 78.7, 86.3] 89.3 [ 85.2, 93.4] 90.8 [ 87.2, 94.5] 94.2 [ 90.5, 97.9] 95.5 [ 91.9, 99.2] 97.1 [ 93.8,100.4]

F 489 89.0 [ 85.3, 91.9] 94.8 [ 91.4, 98.3] 96.9 [ 94.1, 99.7] 95.8 [ 93.0, 98.7] 96.9 [ 94.1, 99.8] 95.5 [ 92.2, 98.8]P 1030 85.7 [ 82.9, 88.0] 91.9 [ 89.1, 94.6] 93.7 [ 91.3, 96.0] 95.0 [ 92.6, 97.4] 96.2 [ 93.9, 98.5] 96.3 [ 94.0, 98.6]

M959,M967-M972 NON-HODGKIN LYMPHOMAPercent [95% CI] M 4966 73.5 [ 71.8, 75.1] 82.4 [ 80.5, 84.3] 87.4 [ 85.4, 89.3] 89.4 [ 87.2, 91.6] 89.9 [ 87.4, 92.4] 88.0 [ 84.9, 91.1]

F 3721 77.1 [ 75.3, 78.8] 86.6 [ 84.5, 88.6] 87.5 [ 85.4, 89.5] 86.5 [ 84.2, 88.8] 87.4 [ 84.8, 90.0] 90.7 [ 87.6, 93.7]P 8687 75.0 [ 73.8, 76.2] 84.2 [ 82.8, 85.6] 87.4 [ 86.0, 88.8] 88.1 [ 86.5, 89.7] 88.7 [ 86.9, 90.5] 89.2 [ 87.1, 91.4]

M980-M994 ALL LEUKAEMIASPercent [95% CI] M 4170 63.7 [ 61.9, 65.5] 75.8 [ 73.5, 78.0] 81.1 [ 78.9, 83.4] 82.5 [ 80.0, 85.1] 84.0 [ 81.1, 86.8] 84.2 [ 80.8, 87.6]

F 2636 64.8 [ 62.6, 67.0] 80.1 [ 77.4, 82.8] 86.4 [ 83.9, 88.9] 85.5 [ 82.8, 88.3] 85.4 [ 82.3, 88.4] 87.7 [ 84.1, 91.2]P 6806 64.2 [ 62.8, 65.6] 77.5 [ 75.8, 79.2] 83.3 [ 81.6, 85.0] 83.8 [ 81.9, 85.7] 84.6 [ 82.5, 86.6] 85.7 [ 83.3, 88.2]

M982-M983 LYMPHOID LEUKAEMIAPercent [95% CI] M 2178 81.8 [ 79.4, 84.0] 83.3 [ 80.8, 85.8] 83.8 [ 81.0, 86.6] 82.7 [ 79.5, 85.8] 82.8 [ 79.2, 86.3] 82.2 [ 77.7, 86.6]

F 1348 85.3 [ 82.6, 87.8] 87.9 [ 85.1, 90.8] 88.8 [ 85.8, 91.7] 86.0 [ 82.6, 89.4] 85.6 [ 81.8, 89.4] 88.0 [ 83.5, 92.5]P 3526 83.2 [ 81.5, 84.9] 85.2 [ 83.3, 87.1] 85.9 [ 83.8, 87.9] 84.1 [ 81.8, 86.4] 84.0 [ 81.4, 86.6] 84.8 [ 81.6, 88.0]

M984-M993 MYELOID LEUKAEMIAPercent [95% CI] M 1379 39.2 [ 36.3, 42.1] 64.6 [ 59.9, 69.3] 81.1 [ 76.3, 85.8] 85.2 [ 80.5, 89.8] 87.7 [ 82.7, 92.7] 89.6 [ 84.1, 95.2]

F 1005 43.1 [ 39.7, 46.5] 70.3 [ 65.0, 75.6] 84.3 [ 79.5, 89.1] 86.2 [ 81.5, 90.9] 87.2 [ 82.2, 92.1] 87.8 [ 81.9, 93.6]P 2384 40.9 [ 38.7, 43.1] 67.0 [ 63.5, 70.6] 82.5 [ 79.2, 85.9] 85.6 [ 82.3, 88.9] 87.4 [ 83.9, 91.0] 88.7 [ 84.6, 92.7]

M994 OTHER SPECIFIED LEUKAEMIAPercent [95% CI] M 576 55.2 [ 49.7, 60.5] 62.6 [ 56.0, 69.3] 65.5 [ 57.9, 73.1] 75.1 [ 66.0, 84.3] 81.0 [ 70.5, 91.5] 83.0 [ 71.4, 94.6]

F 251 47.0 [ 39.2, 54.6] 59.0 [ 48.6, 69.4] 73.2 [ 60.7, 85.7] 79.1 [ 63.3, 94.8] 72.9 [ 54.2, 91.5] 85.4 [ 64.1,106.6]P 827 52.6 [ 48.1, 57.0] 61.5 [ 55.9, 67.1] 67.4 [ 60.9, 74.0] 76.1 [ 68.2, 84.0] 79.0 [ 70.0, 88.1] 83.4 [ 73.2, 93.7]

M980 UNSPECIFIED LEUKAEMIAPercent [95% CI] M 37 ** ** 91.6 [ 51.7,131.5] 82.2 [ 54.7,109.7] 102.7 [ 79.0,126.5] 98.0 [ 65.9,130.2]

F 32 ** ** ** ** ** **P 69 ** 46.7 [ 24.6, 68.9] 78.4 [ 47.4,109.4] 70.1 [ 44.8, 95.4] 82.0 [ 57.0,107.0] 84.4 [ 46.4,122.3]

M973 MYELOMA/PLASMA CELL TUMOURSPercent [95% CI] M 1612 49.7 [ 46.6, 52.8] 52.6 [ 49.0, 56.3] 53.7 [ 49.1, 58.2] 57.4 [ 51.5, 63.3] 65.1 [ 57.5, 72.7] 76.4 [ 66.3, 86.5]

F 1124 50.2 [ 46.7, 53.7] 54.2 [ 50.1, 58.4] 58.3 [ 53.3, 63.3] 64.6 [ 58.4, 70.8] 72.3 [ 64.8, 79.7] 71.2 [ 61.1, 81.3]P 2736 50.0 [ 47.6, 52.3] 53.3 [ 50.6, 56.1] 55.8 [ 52.4, 59.1] 60.7 [ 56.4, 65.0] 68.5 [ 63.2, 73.9] 74.1 [ 66.9, 81.2]

M998 MYELODYSPLASTIC DISEASESPercent [95% CI] M 1518 40.4 [ 37.3, 43.6] 48.5 [ 44.4, 52.6] 56.7 [ 51.2, 62.2] 55.9 [ 48.9, 62.8] 57.9 [ 49.0, 66.7] 75.2 [ 61.8, 88.7]

F 890 43.6 [ 39.6, 47.5] 50.9 [ 46.0, 55.8] 57.3 [ 51.3, 63.2] 66.5 [ 58.8, 74.1] 77.4 [ 68.2, 86.5] 78.8 [ 66.0, 91.6]P 2408 41.6 [ 39.2, 44.1] 49.5 [ 46.3, 52.6] 57.0 [ 52.9, 61.1] 60.4 [ 55.2, 65.5] 66.6 [ 60.1, 73.0] 77.2 [ 67.8, 86.5]

M995-M996 CHRONIC MYELOPROLIFERATIVE DISEASESPercent [95% CI] M 1008 78.1 [ 74.6, 81.4] 80.9 [ 77.3, 84.5] 81.4 [ 77.5, 85.2] 82.4 [ 78.1, 86.6] 82.1 [ 77.2, 86.9] 83.9 [ 77.9, 90.0]

F 774 84.6 [ 80.9, 87.9] 85.7 [ 82.0, 89.5] 84.5 [ 80.6, 88.4] 83.8 [ 79.4, 88.2] 83.7 [ 78.9, 88.5] 82.1 [ 76.3, 87.9]P 1782 81.0 [ 78.4, 83.3] 83.0 [ 80.4, 85.7] 82.8 [ 80.0, 85.6] 83.0 [ 80.0, 86.1] 82.8 [ 79.4, 86.2] 83.0 [ 78.8, 87.2]

M974-M976 OTHER NEOPLASMS OF LYMPHATIC & HAEMATOPOIETIC TISSUEPercent [95% CI] M 91 78.7 [ 66.3, 88.8] 80.8 [ 68.3, 93.3] 76.5 [ 63.6, 89.5] 68.7 [ 53.7, 83.6] 73.1 [ 56.0, 90.1] 72.8 [ 50.4, 95.2]

F 78 75.7 [ 62.0, 86.6] 85.0 [ 71.1, 98.9] 77.0 [ 63.8, 90.2] 72.4 [ 56.2, 88.6] 75.3 [ 57.6, 93.0] 77.7 [ 53.0,102.3]P 169 77.5 [ 68.5, 85.1] 82.6 [ 73.3, 92.0] 76.7 [ 67.4, 86.1] 70.2 [ 59.1, 81.2] 74.0 [ 61.7, 86.3] 74.4 [ 57.4, 91.5]

TOTAL MALIGNANT NEOPLASMS (C00-C80)Percent [95% CI] M 137104 67.2 [ 66.8, 67.5] 80.3 [ 79.9, 80.7] 87.4 [ 87.0, 87.8] 89.4 [ 88.9, 89.8] 90.2 [ 89.7, 90.7] 91.4 [ 90.8, 92.0]

F 103063 70.8 [ 70.4, 71.1] 82.5 [ 82.1, 82.9] 89.2 [ 88.9, 89.6] 91.8 [ 91.4, 92.1] 92.9 [ 92.5, 93.3] 93.7 [ 93.3, 94.2]P 240167 68.7 [ 68.5, 69.0] 81.3 [ 81.0, 81.5] 88.3 [ 88.0, 88.5] 90.6 [ 90.3, 90.8] 91.6 [ 91.3, 91.9] 92.6 [ 92.2, 93.0]



APPENDIX 1: GUIDELINES FOR RELEASE OF INFORMATION QUEENSLAND CANCER REGISTRY

The Public Health Act 2005, provides the following:

Division 4 Confidentiality237 Definitions for div 4In this division relevant person means the following—(a) a person who is, or was, the chief executive;(b) a person who is, or was, involved in the administration of this part, including, for example, a health service

employee or a public service employee, but not including a contractor or an employee of a contractor;(c) a person who was involved in the administration or enforcement of the repealed provisions.

238 Confidentiality of information(1) A relevant person must not, whether directly or indirectly, disclose confidential information.(2) The Health Services Act 1991, section 62A, does not apply to a relevant person in relation to confidential

information.

239 Disclosure under an Act or another lawSection 238(1) does not apply if the disclosure of the confidential information by a relevant person is authorised under an Act or another law.

244 Disclosure to Commonwealth, another State or Commonwealth or State entity(1) Section 238(1) does not apply to the disclosure of confidential information by the chief executive if—

(a) the disclosure is to the Commonwealth or another State, or an entity of the Commonwealth or another State and the disclosure—

(i) is required or allowed under an agreement—(A) between Queensland and the Commonwealth, State or entity; and(B) prescribed under a regulation for this paragraph; and

(ii) is considered by the chief executive to be in the public interest; or(b) the disclosure is to an entity of the State and the disclosure—

(i) is required or allowed under an agreement—(A) between the chief executive and the entity; and(B) prescribed under a regulation for this paragraph; and

(ii) is considered by the chief executive to be in the public interest.(2) The Commonwealth, a State or entity that receives confidential information under an agreement under

subsection (1)—(a) must not give it to anyone else unless allowed to do so by the agreement or in writing by the chief

executive; and(b) must ensure the confidential information is used only for the purpose for which it was given under

the agreement.

Disclosure by contractorSection 248 does not apply to the disclosure of confidential information by the contractor or an employee of the contractor if the disclosure—(a) is made in the performance of functions under this part; or(b) is made in a form that does not identify any person; or(c) is made to the chief executive, at the written request of the chief executive stating the chief executive

considers the disclosure is necessary for ensuring the proper administration of this part; or(d) is made to a person or entity to which the chief executive may make the disclosure under section 242, 243 or

244, if the chief executive authorises the contractor, in writing, to disclose the information; or(e) is for the purpose of giving information under chapter 6, part 4, division 2 for research, if the chief executive

authorises the contractor, in writing, to disclose the information; or(f) is authorised under an Act or another law.

Statistical information in an aggregate form may be obtained by contacting the Queensland Cancer Registry.



APPENDIX 1: GUIDELINES FOR RELEASE OF INFORMATION QUEENSLAND CANCER REGISTRY

The Public Health Act 2005, provides the following:

Division 4 Confidentiality237 Definitions for div 4In this division relevant person means the following—(a) a person who is, or was, the chief executive;(b) a person who is, or was, involved in the administration of this part, including, for example, a health service

employee or a public service employee, but not including a contractor or an employee of a contractor;(c) a person who was involved in the administration or enforcement of the repealed provisions.

238 Confidentiality of information(1) A relevant person must not, whether directly or indirectly, disclose confidential information.(2) The Health Services Act 1991, section 62A, does not apply to a relevant person in relation to confidential

information.

239 Disclosure under an Act or another lawSection 238(1) does not apply if the disclosure of the confidential information by a relevant person is authorised under an Act or another law.

244 Disclosure to Commonwealth, another State or Commonwealth or State entity(1) Section 238(1) does not apply to the disclosure of confidential information by the chief executive if—

(a) the disclosure is to the Commonwealth or another State, or an entity of the Commonwealth or another State and the disclosure—

(i) is required or allowed under an agreement—(A) between Queensland and the Commonwealth, State or entity; and(B) prescribed under a regulation for this paragraph; and

(ii) is considered by the chief executive to be in the public interest; or(b) the disclosure is to an entity of the State and the disclosure—

(i) is required or allowed under an agreement—(A) between the chief executive and the entity; and(B) prescribed under a regulation for this paragraph; and

(ii) is considered by the chief executive to be in the public interest.(2) The Commonwealth, a State or entity that receives confidential information under an agreement under

subsection (1)—(a) must not give it to anyone else unless allowed to do so by the agreement or in writing by the chief

executive; and(b) must ensure the confidential information is used only for the purpose for which it was given under

the agreement.

Disclosure by contractorSection 248 does not apply to the disclosure of confidential information by the contractor or an employee of the contractor if the disclosure—(a) is made in the performance of functions under this part; or(b) is made in a form that does not identify any person; or(c) is made to the chief executive, at the written request of the chief executive stating the chief executive

considers the disclosure is necessary for ensuring the proper administration of this part; or(d) is made to a person or entity to which the chief executive may make the disclosure under section 242, 243 or

244, if the chief executive authorises the contractor, in writing, to disclose the information; or(e) is for the purpose of giving information under chapter 6, part 4, division 2 for research, if the chief executive

authorises the contractor, in writing, to disclose the information; or(f) is authorised under an Act or another law.

Statistical information in an aggregate form may be obtained by contacting the Queensland Cancer Registry.



Medical researchers wishing to obtain information on individual patients from the Cancer Registry should complete an application under the Public Health Act 2005 and forward to the Registrar of the Queensland Cancer Registry. The research proposal must also have received ethical approval and set out the aims and methods of the research. The application will be submitted to the Queensland Health Data Custodian for approval by the Director General of Queensland Health. If the application is approved then the researcher will be granted access to Cancer Registry data under the terms of the application approved under the Public Health Act 2005.

Before information concerning a live patient is released to any researcher, the latter must sign a declaration that any such information will not be used to contact patients, other than the researcher’s own patients, without first obtaining permission from each patient’s own medical practitioner.

The data set collected for each cancer includes:-• patient name(s)• usual residential address (at diagnosis and at last contact)• date of birth/age• occupation• country of birth• sex• indigenous status• marital status• date of last contact• institution of last contact• treating doctor• date of diagnosis• site of cancer• cancer histology• differentiation• basis of diagnosis• laterality• date of death• cause of death

Further information is collected for: -

Breast cancer –• tumour size• size complete• number of nodes• number of positive nodes• nodes complete

Melanoma –• thickness• ulceration• Clark’s level



APPENDIX 2: QUEENSLAND CANCER REGISTRY NOTIFICATION FORM



APPENDIX 3: CANCER REPORTING DEFINITIONS AND CALCULATION OF STATISTICS

Rates per 100,000 are calculated by dividing the number of cases in each five year age and sex stratum by the Australian Bureau of Statistics estimated resident population1 for that stratum and multiplying the product by 100,000.

Age-standardised rates are calculated by summing the products of the age-specific rates with either the World Standard Population strata (1960) or the Australian age-specific population distribution in 2001 (see Appendix 4). They provide a rate that is independent of the age structure of the population of interest and are therefore useful in making comparisons between different populations and time periods.

Conditional survival is the probability of surviving an additional y years given that the person has already survived x years.2 It is calculated by dividing the relative survival (see ‘Relative Survival’ below) at (x+y) years after diagnosis by the relative survival at x years after diagnosis, while confidence intervals were calculated using a variation of Greenwood’s formula.3

In the conditional survival tables (pages 57 to 60), the ‘at diagnosis’ column shows the percentage of patients who are expected to survive for at least 5 years after diagnosis. The ‘1 year after diagnosis’ column shows the percentage of patients who will survive for another 5 years, given they have already survived 1 year, and similarly for the other columns. Therefore, if the ‘10 years after diagnosis’ column was 94.2 [93.3, 95.2] then 94.2% of patients who have already survived for 10 years are expected to survive for at least another 5 years.

N represents the initial number of ‘at risk’ cases and ‘**’ means estimates were too unreliable to be included (ie. the standard error was greater than 25% of the estimate).

Confidence intervals: All statistical estimates are calculated with some degree of imprecision. The level of accuracy is typically reported in terms of a confidence interval, which specifies a range of values in which the true data point is expected to occur with a given level of certainty. For example, a 5-year survival rate may be estimated as 88.5% with a 95% confidence interval of 87.9%-89.2%. This means that there is a 95% probability that the true survival rate will be somewhere between 87.9% and 89.2%.

Cumulative rates are calculated for ages 0-79 in this report. The cumulative rate is used as an estimate of the risk of developing or dying of cancer up to the age of 79, and is expressed as a percentage (i.e., rate per 100 population).

Cumulative Rate (0-79) = 5 * (sum of age-specific rates for ages 0-79)*100/ 100,000

Cumulative risk is another measure of risk derived from the cumulative rate. It is more precise, as it takes into account the removal of persons from the population of interest who have already been diagnosed or died from cancer. Expressed as a '1 in n' proportion, it is calculated as follows:

n = 1/(1-e-cumulative rate/100)

This report calculates the cumulative risk up to the age of 79 years as an approximation of lifetime risk. The calculation assumes that the person experiences the current age-specific risk rates up to the age of 79, and is unable to factor in individual risk factors such as smoking etc.

Incidence is defined as the occurrence of new cancers in a defined population during a specified time period. For the purposes of this report, 2013 incidence, for example, is based on those cancers notified to the registry which were first diagnosed between 1 January 2013 and 31 December 2013 for residents of Queensland.

Limited duration prevalence reports the number of people still alive at a given point in time (ie. 31st December 2013) who were diagnosed within a specific time period. In this report limited duration prevalence estimates arepresented for people diagnosed within 5 years and 25 years. Rates are age-standardised to the Australian standard population.



APPENDIX 3: CANCER REPORTING DEFINITIONS AND CALCULATION OF STATISTICS

Rates per 100,000 are calculated by dividing the number of cases in each five year age and sex stratum by the Australian Bureau of Statistics estimated resident population1 for that stratum and multiplying the product by 100,000.

Age-standardised rates are calculated by summing the products of the age-specific rates with either the World Standard Population strata (1960) or the Australian age-specific population distribution in 2001 (see Appendix 4). They provide a rate that is independent of the age structure of the population of interest and are therefore useful in making comparisons between different populations and time periods.

Conditional survival is the probability of surviving an additional y years given that the person has already survived x years.2 It is calculated by dividing the relative survival (see ‘Relative Survival’ below) at (x+y) years after diagnosis by the relative survival at x years after diagnosis, while confidence intervals were calculated using a variation of Greenwood’s formula.3

In the conditional survival tables (pages 57 to 60), the ‘at diagnosis’ column shows the percentage of patients who are expected to survive for at least 5 years after diagnosis. The ‘1 year after diagnosis’ column shows the percentage of patients who will survive for another 5 years, given they have already survived 1 year, and similarly for the other columns. Therefore, if the ‘10 years after diagnosis’ column was 94.2 [93.3, 95.2] then 94.2% of patients who have already survived for 10 years are expected to survive for at least another 5 years.

N represents the initial number of ‘at risk’ cases and ‘**’ means estimates were too unreliable to be included (ie. the standard error was greater than 25% of the estimate).

Confidence intervals: All statistical estimates are calculated with some degree of imprecision. The level of accuracy is typically reported in terms of a confidence interval, which specifies a range of values in which the true data point is expected to occur with a given level of certainty. For example, a 5-year survival rate may be estimated as 88.5% with a 95% confidence interval of 87.9%-89.2%. This means that there is a 95% probability that the true survival rate will be somewhere between 87.9% and 89.2%.

Cumulative rates are calculated for ages 0-79 in this report. The cumulative rate is used as an estimate of the risk of developing or dying of cancer up to the age of 79, and is expressed as a percentage (i.e., rate per 100 population).

Cumulative Rate (0-79) = 5 * (sum of age-specific rates for ages 0-79)*100/ 100,000

Cumulative risk is another measure of risk derived from the cumulative rate. It is more precise, as it takes into account the removal of persons from the population of interest who have already been diagnosed or died from cancer. Expressed as a '1 in n' proportion, it is calculated as follows:

n = 1/(1-e-cumulative rate/100)

This report calculates the cumulative risk up to the age of 79 years as an approximation of lifetime risk. The calculation assumes that the person experiences the current age-specific risk rates up to the age of 79, and is unable to factor in individual risk factors such as smoking etc.

Incidence is defined as the occurrence of new cancers in a defined population during a specified time period. For the purposes of this report, 2013 incidence, for example, is based on those cancers notified to the registry which were first diagnosed between 1 January 2013 and 31 December 2013 for residents of Queensland.

Limited duration prevalence reports the number of people still alive at a given point in time (ie. 31st December 2013) who were diagnosed within a specific time period. In this report limited duration prevalence estimates arepresented for people diagnosed within 5 years and 25 years. Rates are age-standardised to the Australian standard population.


Prevalence estimates are based on people rather than individual cancers. Therefore prevalence for all cancers combined excludes multiple primary cancers diagnosed in the same person, while prevalence for specific cancer sites excludes multiple primary cancers on the same site for the same person.

Mortality is based on those deaths notified to the registry for persons who died from cancer during a specified time period and who usually resided in Queensland at the time of diagnosis of any notifiable cancer (not necessarily the cancer leading to the death). This means that mortality information is not directly comparable withdeath data released from the Australian Bureau of Statistics (which is based on the State where the death was registered).

Multiple Primary Tumours: Incidence reflects the number of primary tumours rather than the number of individuals with cancer. The Queensland Cancer Registry records multiple primary cancers in the same person, of which only the first instance in each topographic site is reported for incidence purposes according to the rules of the International Agency for Research on Cancer and International Association of Cancer Registries. In brief, these rules state that:

• The recognition of the existence of one or more primary tumours does not depend on time. Hence synchronous and metachronous multiple lesions are not distinguished as the definitions are frequently arbitrary.

• A primary cancer is one that originates in a primary site or tissue and is thus not an extension, a recurrence, nor a metastasis of a pre-existing tumour.

• Only one tumour shall be recognised in an organ or pair of organs or tissue (as defined by the three-digit rubric of the ICD-O-3 topography) unless of ‘different’ histology. Some 3-digit topography codes are combined as single groups for this purpose, such as trachea (C33) and lung (C34).

A histologically ‘different’ cancer in the same organ is counted as a new tumour. There are twelve defined groups of malignant neoplasms considered to be histologically ‘different’ based on the first three digits of the ICDO morphology code, and incidence reporting of multiple tumours is based upon these groups.4

Relative survival compares the survival of people who have a particular disease or condition against the expected survival of a comparable group from the general population, taking into account age, sex and year of diagnosis. The 5-year relative survival estimate can be interpreted as the proportion of cancer patients alive 5 years after diagnosis in the hypothetical situation where the cancer in question is the only possible cause of death.5 For instance, a 5-year relative survival estimate of 75% indicates that 75% of people diagnosed with that cancer could expect to live for at least 5 years, ignoring the impact of other causes of death. This means that these cancer patients have a higher risk of mortality compared to that of the general population (of comparable age and gender). The method does not require knowledge of the specific cause of death, only knowledge of whether the patient has died.

Relative survival estimates can be calculated using either period or cohort methods.6 The period method has been used in this report, as it is recognised as providing more up-to-date survival estimates.7 Under the period method, the group of cancer patients included in the survival calculations are selected based on whether they are living with a diagnosis of cancer in the "at risk" period, which for this report is 2009-2013. In contrast, the cohort method is defined by the time of diagnosis. We included all patients diagnosed up to 31st December 2013.

Patients who were still alive at 31st December 2013 were considered censored. Persons aged 90 years and over at time of diagnosis have been excluded from the calculation of survival estimates, as have those whose cancer diagnosis was based on death certificate or autopsy, or those with a survival time of zero days or less.

A suite of computer programs developed by Paul Dickman from the Karolinska Institutet in Sweden8 were used to generate the relative survival estimates, using the actuarial method for calculating observed survival and the Ederer II method5 for calculating expected survival. Expected survival was based on the total Queensland mortality data obtained from the Australian Bureau of Statistics,9 incorporating three year moving averages to minimise the effects of year to year variation. The proportion of deaths for Queensland residents at ages 85-89years was based on unit record file mortality data to 2011,10,11 and then Australian proportions were applied for 2012 and 2013.12



To interpret the relative survival tables, ‘N’ represents the initial number of 'at risk' cases and ‘**’ means estimates were too unreliable to be included (typically when the standard error was greater than 25% of the estimate).

References:

1. Australian Bureau of Statistics, 2015. Australian Demographic Statistics. Table 53 Estimated Resident Population by single year of age, Queensland. (Catalogue number 3101.0). ABS: Canberra.

2. Baade PD, Youlden DR, Chambers SK, 2011. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust, 194(2):73-77.

3. Skuladottir H, Olsen JH, 2003. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol, 21(16):3035-3040.

4. Fritz A, Percy C, Jack A, et al., eds. 2000. ICDO 3rd edition. WHO: Geneva.5. Ederer F, Axtell LM, Cutler SJ, 1961. The relative survival rate: a statistical methodology. NCI Monogr,

6:101-121.6. Brenner H, 2002. Long-term survival rates of cancer patients achieved by the end of the 20th century: a

period analysis. Lancet, 360(9340):1131-1135.7. Brenner H, Gefeller O, Hakulinen T, 2004. Period analysis for 'up-to-date' cancer survival data: theory,

empirical evaluation, computation realisation and applications. Eur J Cancer, 40:326-335.8. Dickman PW, 2004. Estimating and modelling relative survival using SAS. Retrieved 24 July 2007, from

http://www.pauldickman.com/rsmodel/sas_colon/.9. Australian Bureau of Statistics, 2014. Deaths, Australia, 2013. Table 11.3 Deaths, Year of occurrence, Age

at death, Queensland 2003-2013 (Catalogue number 3302.0). ABS: Canberra.10. Australian Bureau of Statistics, 2007. Unit record mortality data for Queensland by State of usual

residence, 1982-2005. (unpublished data). ABS: Canberra11. Registries of Births, Deaths and Marriages, the Coroners and the National Coronial Information System,

2014. Unit record mortality data for Australia by State of usual residence, 2006-2011 (unpublished data). Australian Coordinating Registry: Canberra

12. Australian Bureau of Statistics, 2014. Deaths, Australia, 2013. Table 21.1 Deaths, Sex, Age (single years), Australia, 2003 to 2013. (Catalogue number 3302.0). ABS: Canberra.



To interpret the relative survival tables, ‘N’ represents the initial number of 'at risk' cases and ‘**’ means estimates were too unreliable to be included (typically when the standard error was greater than 25% of the estimate).

References:

1. Australian Bureau of Statistics, 2015. Australian Demographic Statistics. Table 53 Estimated Resident Population by single year of age, Queensland. (Catalogue number 3101.0). ABS: Canberra.

2. Baade PD, Youlden DR, Chambers SK, 2011. When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust, 194(2):73-77.

3. Skuladottir H, Olsen JH, 2003. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol, 21(16):3035-3040.

4. Fritz A, Percy C, Jack A, et al., eds. 2000. ICDO 3rd edition. WHO: Geneva.5. Ederer F, Axtell LM, Cutler SJ, 1961. The relative survival rate: a statistical methodology. NCI Monogr,

6:101-121.6. Brenner H, 2002. Long-term survival rates of cancer patients achieved by the end of the 20th century: a

period analysis. Lancet, 360(9340):1131-1135.7. Brenner H, Gefeller O, Hakulinen T, 2004. Period analysis for 'up-to-date' cancer survival data: theory,

empirical evaluation, computation realisation and applications. Eur J Cancer, 40:326-335.8. Dickman PW, 2004. Estimating and modelling relative survival using SAS. Retrieved 24 July 2007, from

http://www.pauldickman.com/rsmodel/sas_colon/.9. Australian Bureau of Statistics, 2014. Deaths, Australia, 2013. Table 11.3 Deaths, Year of occurrence, Age

at death, Queensland 2003-2013 (Catalogue number 3302.0). ABS: Canberra.10. Australian Bureau of Statistics, 2007. Unit record mortality data for Queensland by State of usual

residence, 1982-2005. (unpublished data). ABS: Canberra11. Registries of Births, Deaths and Marriages, the Coroners and the National Coronial Information System,

2014. Unit record mortality data for Australia by State of usual residence, 2006-2011 (unpublished data). Australian Coordinating Registry: Canberra

12. Australian Bureau of Statistics, 2014. Deaths, Australia, 2013. Table 21.1 Deaths, Sex, Age (single years), Australia, 2003 to 2013. (Catalogue number 3302.0). ABS: Canberra.


APPENDIX 4: AGE DISTRIBUTION OF STANDARD POPULATIONS

Age group ‘Australia 2001’ Population structure – Total 100,000‘Aust 2001’ ‘World’

0-4 1,282,357 6600 12,0005-9 1,351,664 7000 10,00010-14 1,353,177 7000 9,00015-19 1,352,745 7000 9,00020-24 1,302,412 6700 8,00025-29 1,407,081 7200 8,00030-34 1,466,615 7500 6,00035-39 1,492,204 7700 6,00040-44 1,479,257 7600 6,00045-49 1,358,594 7000 6,00050-54 1,300,777 6700 5,00055-59 1,008,799 5200 4,00060-64 822,024 4200 4,00065-69 682,513 3500 3,00070-74 638,380 3300 2,00075-79 519,356 2700 1,00080-84 330,050 1700 50085+ 265,235 1400 500

All ages 19,413,240 100,000 100,000



APPENDIX 5: INDICES OF DATA QUALITY, QUEENSLAND, 2012 AND 2013

Three commonly used indices of data quality are tabulated on the following page. These are defined in Cancer Incidence in Five Continents Vol V1 as follows:

• Histological Verification (HV%) – the proportion of cases registered which had histological verification of diagnosis.

• Death Certificate Only (DCO%)– the proportion of cases registered for which no information was available other than a statement on the death certificate that the deceased died from or with cancer.

• Mortality to Incidence Ratio (M/I%) – the comparison of the number of deaths attributed to a specific cancer in a defined population with the number of cases of the same cancer registered during the same period in the same population.

1 Muir C, Waterhouse J, Mack T, et al. Cancer Incidence in Five Continents Vol V, IARC Scientific Publication No 88. Lyon: International Agency for Research on Cancer, 1987 (p45).



APPENDIX 5: INDICES OF DATA QUALITY, QUEENSLAND, 2012 AND 2013

Three commonly used indices of data quality are tabulated on the following page. These are defined in Cancer Incidence in Five Continents Vol V1 as follows:

• Histological Verification (HV%) – the proportion of cases registered which had histological verification of diagnosis.

• Death Certificate Only (DCO%)– the proportion of cases registered for which no information was available other than a statement on the death certificate that the deceased died from or with cancer.

• Mortality to Incidence Ratio (M/I%) – the comparison of the number of deaths attributed to a specific cancer in a defined population with the number of cases of the same cancer registered during the same period in the same population.

1 Muir C, Waterhouse J, Mack T, et al. Cancer Incidence in Five Continents Vol V, IARC Scientific Publication No 88. Lyon: International Agency for Research on Cancer, 1987 (p45).

Indices of Data Quality by Selected Site and Sex, Queensland, 2012 and 2013ICD-O3/SITE

MALES 2012 2013 2012 2013 2012 2013 2012 2013 2012 2013C00 Lip 178 182 1 3 100 100 0.0 0.0 1 2C01,C02 Tongue 124 152 43 49 99 98 0.8 0.7 35 32C09,C10 Tonsil and Oropharynx 118 111 17 31 97 99 0.0 0.0 14 28C15 Oesophagus 226 177 155 149 96 95 0.0 0.6 69 84C16 Stomach 249 244 175 167 95 95 1.2 0.8 70 68C18 Colon 1070 982 342 353 96 95 0.8 1.1 32 36C19,C20 Rectosigmoid Junction and Rectum 587 587 207 224 97 97 0.2 0.2 35 38C22 Liver & Intrahepatic Bile Ducts 212 220 143 168 44 41 0.5 1.8 67 76C23,C24 Gallbladder and Other & Unspecified Parts of Biliary Tract 69 65 50 49 77 86 0.0 1.5 72 75C25 Pancreas 272 266 233 242 71 69 2.2 2.6 86 91C26, C39,C76,C77,C80 Other & Ill-defined Sites and Unknown Primary Site 329 375 218 252 72 70 5.2 8.8 66 67C32 Larynx 111 108 48 32 95 94 1.8 0.9 43 30C33,C34 Trachea and Bronchus & Lung 1356 1364 1047 1130 83 84 1.8 2.4 77 83C44, M872-M879 Melanoma 1998 2140 213 287 99 99 0.1 0.0 11 13C44 Other Skin (Excl BCC/SCC) 144 150 27 41 99 99 0.0 0.0 19 27C61 Prostate Gland 4147 4064 659 636 95 96 0.7 0.5 16 16C62 Testis 142 150 6 2 98 99 0.0 0.0 4 1C64-C66,C68 Kidney and Other Renal Tract 500 492 152 138 87 90 1.2 1.6 30 28C67 Bladder 366 375 143 155 90 87 1.6 0.5 39 41C70-C72 Brain, Meninges and Other Central Nervous System 164 170 140 142 84 84 0.0 1.2 85 84C73 Thyroid Gland 124 151 15 9 98 99 0.0 0.7 12 6M905 Mesothelioma 138 110 130 105 88 97 0.0 0.0 94 95M959,M967-M972 Non-Hodgkin Lymphoma 599 581 125 156 96 97 0.5 0.2 21 27M973 Myeloma/Plasma Cell Tumours 194 199 72 73 94 95 1.0 1.5 37 37M982-M983 Lymphoid Leukaemia 227 219 58 52 99 96 0.4 0.5 26 24M984-M993 Myeloid Leukaemia 150 142 84 81 97 98 0.0 0.0 56 57Total Malignant Neoplasms (C00-C80) 14723 14748 4852 5050 92 92 0.8 1.0 33 34

FEMALESC00 Lip 44 65 3 1 100 100 0.0 0.0 7 2C01,C02 Tongue 51 51 24 19 96 98 2.0 0.0 47 37C09,C10 Tonsil and Oropharynx 29 23 6 5 93 91 0.0 0.0 21 22C15 Oesophagus 72 68 50 76 92 93 0.0 0.0 69 112C16 Stomach 127 109 68 62 87 87 2.4 1.8 54 57C18 Colon 918 977 324 343 91 93 1.2 1.3 35 35C19,C20 Rectosigmoid Junction and Rectum 352 340 110 104 97 96 0.3 0.9 31 31C22 Liver & Intrahepatic Bile Ducts 86 98 67 87 52 44 1.2 6.1 78 89C23,C24 Gallbladder and Other & Unspecified Parts of Biliary Tract 90 78 63 63 78 78 0.0 5.1 70 81C25 Pancreas 260 222 220 210 68 67 2.3 4.5 85 95C26, C39,C76,C77,C80 Other & Ill-defined Sites and Unknown Primary Site 263 308 201 213 55 60 8.0 11.4 76 69C32 Larynx 7 11 7 3 86 100 0.0 0.0 100 27C33,C34 Trachea and Bronchus & Lung 840 906 659 644 82 86 2.7 2.2 78 71C44, M872-M879 Melanoma 1428 1509 96 103 99 99 0.1 0.1 7 7C44 Other Skin (Excl BCC/SCC) 80 83 10 20 100 100 0.0 0.0 13 24C50 Breast 3143 3272 512 553 98 99 0.6 0.6 16 17C53 Cervix Uteri 207 187 48 47 97 98 0.5 0.0 23 25C54 Corpus Uteri 476 504 88 73 98 98 0.6 0.8 18 14C56 Ovary 282 273 154 164 89 92 2.5 0.7 55 60C64-C66,C68 Kidney and Other Renal Tract 276 259 91 73 82 87 3.6 2.7 33 28C67 Bladder 124 126 74 54 81 87 3.2 1.6 60 43C70-C72 Brain, Meninges and Other Central Nervous System 152 126 110 126 80 75 1.3 0.8 72 100C73 Thyroid Gland 359 415 13 6 99 100 0.0 0.0 4 1M905 Mesothelioma 33 25 27 24 97 96 0.0 0.0 82 96M959,M967-M972 Non-Hodgkin Lymphoma 419 452 80 100 95 98 1.0 0.0 19 22M973 Myeloma/Plasma Cell Tumours 146 129 65 57 92 95 3.4 1.6 45 44M982-M983 Lymphoid Leukaemia 136 130 36 35 91 95 0.0 2.3 26 27M984-M993 Myeloid Leukaemia 120 100 54 67 95 97 3.3 0.0 45 67Total Malignant Neoplasms (C00-C80) 11251 11587 3506 3601 92 93 1.2 1.3 31 31

Incidence Mortality HV% DCO% M/I%


Queensland Cancer Registry Cancer Council QueenslandLocked Bag No 1450Spring Hill Qld 4004Telephone (07) 3634 5333Facsimile (07) 3259 8590email [email protected]

1501

10 Ca

ncer in

QLD R

eport

82-13

_v01

Documents

Cancer in Queensland€¦ · and nursing homes throughout Queensland. The work of all people concerned is appreciated and grateful thanks are extended to them for their continued